Clinical trial NCT02713178
Conditions: Pain
Sponsor: Pacira Pharmaceuticals, Inc
Start date: 2016-06-03; Completion date: 2017-06-30
Enrollment: 232 participants; Allocation: RANDOMIZED; Intervention model: PARALLEL

Brief summary:
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study in 232 adult subjects undergoing primary unilateral TKA under general or spinal anesthesia.

Detailed description:
On Day 0, eligible subjects will be randomized in a 1:1:1 ratio to receive a single dose of either EXPAREL 133 mg in 10 mL expanded in volume with 10 mL of normal saline for a total volume of 20 mL (Group 1); EXPAREL 266 mg in 20 mL (Group 2); or placebo 20 mL (Group 3). Study drug (EXPAREL or placebo) will be administered in a blinded manner via an ultrasound guided single-dose femoral nerve block at least 1 hour prior to surgery. Prior to placement of the prosthesis, 8 mL of bupivacaine hydrochloride (HCl) (0.5%) diluted with 8 mL of normal saline will be administered by the surgeon as a periarticular infiltration to the posterior capsule (8 mL medially and 8 mL laterally).

Postsurgical assessments will include pain intensity scores using a 10-cm visual analog scale (VAS); total postsurgical opioid consumption; overall benefit of analgesia score (OBAS) questionnaire; subject satisfaction with overall analgesia using a 5-point Likert scale; neurological assessment; sensory function assessment; motor function assessment; the study physical therapy assessments (ie, timed walk, timed up and go, and stair climbing tests); discharge readiness; unscheduled phone calls or office visits related to pain; 12-lead ECGs; vital sign measurements; and clinical laboratory tests. Adverse events will be recorded from the time the informed consent form (ICF) is signed through postsurgical Day 29.

Follow-up visits will be scheduled for all subjects on postsurgical Days 6 and 10. A follow-up phone call will be made on postsurgical Day 29.

Pharmacokinetic (PK) parameters will be estimated from plasma bupivacaine measurements using non-compartmental analysis based on the sampling schedule of baseline (prior to the nerve block) through postsurgical Day 10.

Arms: arm 1: Single dose of 133 mg (10 mL) EXPAREL (bupivacaine liposome injectable suspension) expanded in volume with 10 mL of normal saline for a total volume of 20 mL. arm 2: Single dose of 266 mg (20 mL) EXPAREL (bupivacaine liposome injectable suspension). arm 3: Normal saline (20 mL).
Interventions: intervention 1: bupivacaine liposome injectable suspension intervention 2: Placebo
Intervention descriptions: intervention 1: bupivacaine liposome injectable suspension 133 mg expanded with normal saline to 20 mL or 266 mg in 20 mL intervention 2: Normal saline.

Protocol documents:
Prot_001.pdf: 
 
 
Clinical Study Protocol  
Amendment 3 
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the 
Efficacy, Safety, and Pharmacokinetics of Femoral Nerve Block with EXPAREL for 
Postsurgical Analgesia in Subjects Undergoing Total Knee Arthroplasty 
 
 
 
 
 
 
 
Confidentiality Statement 
The information contained in this document is confidential and the property of Pacira Pharmaceuticals, Inc.  
It should not be reproduced, revealed, or sent to third parties other than Institutional Review Boards/Independent 
Ethics Committees and the Investigator’s research support staff participating in the conduct of the study without 
the prior written authorization of Pacira Pharmaceuticals, Inc. 
 
Protocol No.: 402-C-326  
EudraCT No.: 2015-005179-25 
IND No.: 69,198 
Study Phase: Phase 3 
Study Drug: EXPAREL® (bupivacaine liposome injectable suspension) 
Date: 07 November 2016 (Amendment 3) 
28 September 2016 (Amendment 2)  
15 February 2016 (Amendment 1) 
16 November 2015 (Original) 
Investigator(s) or Study Site(s): Multicenter study in the US and Europe 
Sponsor: Pacira Pharmaceuticals, Inc. 
5 Sylvan Way 
Parsippany, NJ  07054 
Telephone: (973) 254-3560 


Pacira Pharmaceuticals, Inc. 
402-C-326 (FNB TKA) 
EXPAREL®  
Clinical Study Protocol Amendment 3 
 
1. 
SIGNATURE PAGE 
 
 
 
 
 
 
 
 
 
CONFIDENTIAL 
2 of 88 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
402-C-326 (FNB TKA) 
EXPAREL®  
Clinical Study Protocol Amendment 3 
 
2. 
SYNOPSIS 
Name of Sponsor/Company: 
Pacira Pharmaceuticals, Inc. 
5 Sylvan Way 
Parsippany, NJ  07054 
(973) 254-3560 
Individual Study Table Referring 
to Part of the Dossier 
Volume: 
Page: 
 
(For National Authority Use Only) 
Name of Finished Product: 
EXPAREL (bupivacaine liposome 
injectable suspension) 
Name of Active Ingredient: 
Bupivacaine, 1.3%, 13.3 mg/mL 
Title of Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, 
Safety, and Pharmacokinetics of Femoral Nerve Block with EXPAREL for Postsurgical Analgesia in Subjects 
Undergoing Total Knee Arthroplasty 
Principal Investigator(s): To be determined 
Study Center(s): Multicenter study in the US and Europe 
Publications (Reference): None 
Objectives: Primary Objective: The primary objective of this study is to evaluate the magnitude and duration of 
the analgesic effect achieved following single-dose injection femoral nerve block with EXPAREL in subjects 
undergoing primary unilateral total knee arthroplasty (TKA). 
Secondary Objectives: The secondary objectives of this study are to further assess the efficacy, safety, and 
pharmacokinetic (PK) profiles of EXPAREL as well as the onset and duration of sensory and motor function 
blockade following administration for analgesia in subjects undergoing primary unilateral TKA. 
Methodology: This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study in 
approximately 231 adult subjects undergoing primary unilateral TKA under general or spinal anesthesia.   
Screening 
Subjects will be screened within 30 days prior to study drug administration.  During the Screening visit, which 
must take place at least 1 day prior to surgery, subjects will be assessed for past or present neurologic, cardiac, 
and general medical conditions that in the opinion of the Investigator would preclude them from study 
participation.  After the informed consent form (ICF) is signed, the patient’s eligibility for participation in the 
study will be confirmed and demographic and baseline characteristics will be recorded. A medical history, 
surgical history, neurological assessment, sensory and motor function assessments, the study physical therapy 
assessments (ie, timed walk, timed up and go, and stair climbing tests), physical examination, 12-lead 
electrocardiogram (ECG), vital sign measurements, urine drug screen, blood alcohol test, clinical laboratory tests 
(hematology, chemistry, and urinalysis), and urine pregnancy test for women of childbearing potential will be 
conducted.   
Day of Surgery 
On Day 0, eligible subjects will be randomized in a 1:1:1 ratio to receive a single dose of either EXPAREL 
133 mg in 10 mL expanded in volume with 10 mL of normal saline for a total volume of 20 mL (Group 1); 
EXPAREL 266 mg in 20 mL (Group 2); or placebo 20 mL (Group 3).  Subjects may receive acetaminophen/ 
paracetamol up to 1000 mg orally (PO) or intravenously (IV) every 8 hours (q8h) (maximum total daily dose of 
3000 mg) prior to surgery. 
Study drug (EXPAREL or placebo) will be administered in a blinded manner via an ultrasound guided single-
dose femoral nerve block at least 1 hour prior to surgery.  A confirmatory photo of the ultrasound nerve block 
needle placement will be obtained.  Use of tourniquets and drains, if used, will be recorded.  Prior to placement 
of the prosthesis, 8 mL of bupivacaine HCl (0.5%) diluted with 8 mL of normal saline will be administered by 
the surgeon as a periarticular infiltration to the posterior capsule (8 mL medially and 8 mL laterally).  The use 
of opioids (other than ultrashort-acting opioids [ie, fentanyl, sufentanil, or remifentanil]), acetaminophen/ 
paracetamol, ketorolac, or other non-steroidal anti-inflammatory drugs (NSAIDs), and local anesthetics other 
 
 
CONFIDENTIAL 
3 of 88 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
402-C-326 (FNB TKA) 
EXPAREL®  
Clinical Study Protocol Amendment 3 
 
Name of Sponsor/Company: 
Pacira Pharmaceuticals, Inc. 
5 Sylvan Way 
Parsippany, NJ  07054 
(973) 254-3560 
Individual Study Table Referring 
to Part of the Dossier 
Volume: 
Page: 
 
(For National Authority Use Only) 
Name of Finished Product: 
EXPAREL (bupivacaine liposome 
injectable suspension) 
Name of Active Ingredient: 
Bupivacaine, 1.3%, 13.3 mg/mL 
than the study drug will not be permitted intraoperatively, except for emergency use to treat an adverse event 
(AE). Subjects will be required to remain at the hospital facility through postsurgical Day 4. 
Postsurgical Rescue Medication 
Subjects should only receive rescue medication upon request for pain control, as needed.  Postsurgical rescue 
medication will consist of PO immediate-release oxycodone (initiating at 5-10 mg every 4 hours [q4h] or as 
needed [PRN]).  If a subject cannot tolerate PO medication, IV morphine (2.5-5 mg) or hydromorphone (0.5-1 
mg) may be administered q4h or PRN.  Patient-controlled analgesia (PCA) is not permitted.  Postsurgically, 
all subjects will receive the following scheduled medications until hospital discharge: 
• Acetaminophen/paracetamol up to 1000 mg PO or IV every 8 hours (q8h) unless contraindicated.  The total 
daily dose of acetaminophen/paracetamol should not exceed 3000 mg.  
• Cyclobenzaprine (eg, Flexeril®) 10 mg PO x1 dose (PRN at the surgeon’s discretion) 
No other analgesic agents, including NSAIDs, are permitted through 108 hours (postsurgical Day 4).  After 
108 hours, the analgesic regimen may be adjusted for each subject individually as deemed appropriate by the 
physician responsible for the postsurgical care.     
Postsurgical Assessments 
Postsurgical assessments will include : 
• Pain intensity scores using a 10-cm visual analog 
scale (VAS; Appendix 1) 
• Total postsurgical opioid consumption 
• Overall benefit of analgesia score (OBAS) 
questionnaire (Appendix 2) 
• Subject satisfaction with overall analgesia using a 
5-point Likert scale (Appendix 3) 
• Neurological assessment (Appendix 4) 
• Sensory function assessment (as measured by cold, 
pinprick, and light touch testing; Appendix 5) 
• Motor function assessment (Appendix 6) 
• Physical therapy assessments (ie, timed walk, timed 
up and go, and stair climbing tests; Appendix 9) 
• Discharge readiness (Appendix 7) 
• Unscheduled phone calls or office visits related to 
pain 
• 12-lead ECGs (ECGs must be read within 2 hours) 
• Vital sign measurements 
• Clinical laboratory tests (hematology, chemistry, and 
urinalysis; Appendix 8) 
At timepoints when multiple assessments coincide, the pain intensity assessment will be conducted first and the 
blood draw for PK analysis will be conducted second, as applicable.   
Adverse events will be recorded from the time the ICF is signed through postsurgical Day 29.  If a cardiac or 
neurological AE of special interest (AESI), fall, or serious AE (SAE) occurs during the study, an unscheduled PK 
blood sample must be collected.  In addition, a 12-lead ECG, vital signs, and any appropriate clinical laboratory 
tests must be conducted.  If conducted, the ECG must be read within 2 hours. 
Cardiac AESIs include chest pain (angina, myocardial infarction), abnormal/irregular heart rate (bradycardia, 
tachycardia, extrasystoles), and shortness of breath requiring intervention.  Neurologic AESIs include altered 
mental status/altered sensorium, rigidity, dysarthria, seizure, tremors, metallic taste, tinnitus, perioral numbness, 
visual disturbance, severe or worsening dizziness, and dizziness beyond 72 hours postdose.  Additionally, the 
following events are of special interest if they persist or occur beyond 72-hours postdose: hyperesthesia, muscular 
twitching, and tingling/paresthesia. 
Follow-up visits will be scheduled for all subjects on postsurgical Days 6 and 10.  A follow-up phone call will be 
made on postsurgical Day 29 to all subjects who received study drug to assess for AEs. 
 
 
CONFIDENTIAL 
4 of 88 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
402-C-326 (FNB TKA) 
EXPAREL®  
Clinical Study Protocol Amendment 3 
 
Name of Sponsor/Company: 
Pacira Pharmaceuticals, Inc. 
5 Sylvan Way 
Parsippany, NJ  07054 
(973) 254-3560 
Individual Study Table Referring 
to Part of the Dossier 
Volume: 
Page: 
 
(For National Authority Use Only) 
Name of Finished Product: 
EXPAREL (bupivacaine liposome 
injectable suspension) 
Name of Active Ingredient: 
Bupivacaine, 1.3%, 13.3 mg/mL 
Pharmacokinetic Assessment 
A population PK analysis will be utilized to limit the number of blood draws.  A total of 7 PK samples will be 
collected from each subject for this study. All subjects will have PK samples taken at baseline and upon arrival at 
the PACU.  An additional 5 blood samples will be collected at the assigned time windows, spanning from 
24 hours postdose to postsurgical Day 6. There are two PK collection sequences for this study and a subject can 
only be randomized to one sequence. The PK schedule sequence will be indicated for each subject at the time of 
randomization and will also be noted on the randomization confirmation.   Subjects in Sequence 1 will have 
samples taken at 24, 56, 68, 80, and 108 hours.  Subjects in Sequence 2 will have samples taken at 48, 60, 76, 96 
hours, and Day 6. 
Blood samples for PK analysis may be drawn using a properly maintained indwelling cannula (PICC line) at the 
discretion of the Investigator.  Blood samples will be collected from all subjects to maintain the treatment double-
blind.  Blood samples from the subjects randomized to placebo will be analyzed through the 24-hour timepoint.   
Interim PK Analysis 
A blinded interim PK analysis was completed after 30 subjects completed the assessments through postsurgical 
Day 10. All of the plasma samples from the subjects who received EXPAREL were analyzed and the plasma 
samples from the subjects randomized to placebo were analyzed through the 24-hour timepoint.  Enrollment 
continued while the interim PK data were analyzed.  The goal of this blinded analysis was to determine the 
appropriateness of the PK timepoints selected and make recommendations to keep, remove, or revise them in 
order to fully characterize the PK profile.   
The results of this analysis showed a median Tmax of 60 hours for the 133 mg EXPAREL group and a median 
Tmax of 78 hours for the 266 mg EXPAREL group. These data informed the changes to the PK collection schedule 
contained in this protocol amendment. 
In addition, the safety assessment timepoints, including the neurological exam, vital signs, and ECG were 
adjusted based on the interim PK data. 
Number of Subjects (Planned): Approximately 231 subjects (77 subjects per treatment group) are planned for 
enrollment in this study in order to have at least 225 evaluable subjects. 
Eligibility Criteria: 
Inclusion Criteria:  
1. Male or female, at least 18 years of age at Screening. 
2. Scheduled to undergo primary unilateral TKA under general or spinal anesthesia. 
3. American Society of Anesthesiologists (ASA) physical status 1, 2, or 3.  
4. Female subject must be surgically sterile; or at least 2 years postmenopausal; or have a monogamous partner 
who is surgically sterile; or practicing double-barrier contraception; or practicing abstinence (must agree to 
use double-barrier contraception in the event of sexual activity); or using an insertable, injectable, 
transdermal, or combination oral contraceptive approved by the FDA for greater than 2 months prior to 
Screening and commit to the use of an acceptable form of birth control for the duration of the study and for 
30 days after completion of the study. 
5. Able to demonstrate sensory function by exhibiting sensitivity to cold, pinprick, and light touch. 
6. Able to provide informed consent, adhere to the study visit schedule, and complete all study assessments. 
 
 
CONFIDENTIAL 
5 of 88 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
402-C-326 (FNB TKA) 
EXPAREL®  
Clinical Study Protocol Amendment 3 
 
Name of Sponsor/Company: 
Pacira Pharmaceuticals, Inc. 
5 Sylvan Way 
Parsippany, NJ  07054 
(973) 254-3560 
Individual Study Table Referring 
to Part of the Dossier 
Volume: 
Page: 
 
(For National Authority Use Only) 
Name of Finished Product: 
EXPAREL (bupivacaine liposome 
injectable suspension) 
Name of Active Ingredient: 
Bupivacaine, 1.3%, 13.3 mg/mL 
Exclusion Criteria: 
1. Currently pregnant, nursing, or planning to become pregnant during the study or within 1 month after study 
drug administration.   
2. Planned concurrent surgical procedure (eg, bilateral TKA). 
3. Concurrent painful physical condition that may require analgesic treatment (such as an NSAID or opioid) in 
the postsurgical period for pain that is not strictly related to the knee surgery and which may confound the 
postsurgical assessments (eg, significant pain from other joints including the non-index knee joint, chronic 
neuropathic pain, concurrent or prior contralateral TKA, concurrent foot surgery). 
4. Previous open knee surgery on the knee being considered for TKA.  Prior arthroscopy is permitted. 
5. History of hypersensitivity or idiosyncratic reaction to amide-type local anesthetics. 
6. Contraindication to any one of the following: bupivacaine, oxycodone, morphine, or hydromorphone. 
7. Use of any of the following medications within the times specified before surgery: long-acting opioid 
medication or NSAIDs (except for low-dose aspirin used for cardioprotection) within 3 days, or any opioid 
medication within 24 hours. 
8. Initiation of treatment with any of the following medications within 1 month of study drug administration or 
if the medication(s) are being given to control pain: selective serotonin reuptake inhibitors (SSRIs), selective 
norepinephrine reuptake inhibitors (SNRIs), gabapentin, pregabalin (Lyrica®), or duloxetine (Cymbalta®).  
If a subject is taking one of these medications for a reason other than pain control, he or she must be on a 
stable dose for at least 1 month prior to study drug administration.   
9. Current use of systemic glucocorticosteroids within 1 month of enrollment in this study. 
10. Use of dexmedetomidine HCl (Precedex®) within 3 days of study drug administration. 
11. History of impaired kidney function, poorly controlled chronic respiratory disease, rheumatoid arthritis, 
coagulopathy, or loss of sensation in extremities. 
12. Impaired kidney function (eg, serum creatinine level >2 mg/dL [176.8 µmol/L] or blood urea nitrogen level 
>50 mg/dL [17.9 mmol/L]) or impaired liver function (eg, serum aspartate aminotransferase [AST] level 
>3 times the upper limit of normal (ULN) or serum alanine aminotransferase [ALT] level >3 times the ULN. 
13. Uncontrolled anxiety, psychiatric, or neurological disorder that might interfere with study assessments. 
14. Any chronic neuromuscular deficit effecting the peripheral nerves or muscles of the surgical extremity. 
15. Any chronic condition or disease that would compromise neurological or vascular assessments. 
16. Malignancy in the last 2 years, with the exception of non-metastatic basal cell or squamous cell carcinoma of 
the skin or localized carcinoma in situ of the cervix. 
17. Suspected or known history of drug or alcohol abuse within the previous year. 
18. Body weight <50 kg (110 pounds) or a body mass index >44 kg/m2. 
19. Previous participation in an EXPAREL study. 
20. Administration of an investigational drug within 30 days or 5 elimination half-lives of such investigational 
drug, whichever is longer, prior to study drug administration, or planned administration of another 
investigational product or procedure during the subject’s participation in this study. 
 
 
CONFIDENTIAL 
6 of 88 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
402-C-326 (FNB TKA) 
EXPAREL®  
Clinical Study Protocol Amendment 3 
 
Name of Sponsor/Company: 
Pacira Pharmaceuticals, Inc. 
5 Sylvan Way 
Parsippany, NJ  07054 
(973) 254-3560 
Individual Study Table Referring 
to Part of the Dossier 
Volume: 
Page: 
 
(For National Authority Use Only) 
Name of Finished Product: 
EXPAREL (bupivacaine liposome 
injectable suspension) 
Name of Active Ingredient: 
Bupivacaine, 1.3%, 13.3 mg/mL 
Test Product, Dose, Mode of Administration, and Lot Number: 
Name: EXPAREL (bupivacaine liposome injectable suspension)  
Active ingredient: Bupivacaine 1.3%, 13.3 mg/mL 
Dosage: Single dose of either 133 mg (10 mL) expanded in volume with 10 mL of normal saline for a total 
volume of 20 mL (Group 1), or 266 mg in 20 mL (Group 2)  
Lot number: To be determined 
Mode of administration: Preoperative femoral nerve block 
Reference Product, Dose, Mode of Administration, and Lot Number:  
Name: Placebo (normal saline) 
Active ingredient: Not applicable 
Dosage: 20 mL (Group 3) 
Lot number: Commercial product to be provided by Pacira. 
Mode of administration: Preoperative femoral nerve block  
Duration of Subject Participation in Study:  
Participation will begin at the signing of the ICF.  No more than 30 days should pass between signing of the ICF 
and the administration of study drug.  The time from study drug administration through the end of participation is 
30 ± 3 days.  Therefore, subjects may participate in the study for up to 63 days. 
Efficacy Assessments:  
The following efficacy measurements will be assessed at the times specified after the beginning of the femoral 
nerve block with study drug: 
• 
Pain intensity scores using the VAS at baseline (on Day 0 prior to the nerve block and prior to any 
premedication); upon arrival at the PACU, every 15 minutes while in the PACU, and prior to PACU 
discharge; at 6, 12, 24, 36, 48, 60, 72, 84, 96, and 108 hours; and immediately prior to each 
administration of rescue pain medication through 108 hours (see Appendix 1). 
• 
Date, time of administration, and amount of all opioid rescue medication taken through 108 hours. 
• 
The OBAS questionnaire at 24 and 72 hours, and on postsurgical Day 10 (see Appendix 2). 
• 
Subject satisfaction with overall analgesia (using a 5-point Likert scale) at 24 and 72 hours, and 
postsurgical Day 10 (see Appendix 3). 
• 
Discharge readiness at 12, 24, 36, 48, 60, 72, 84, and 96 hours or until the subject is determined to be 
discharge ready, whichever occurs first (see Appendix 7). 
• 
Unscheduled phone calls or office visits related to pain after discharge through postsurgical Day 10. 
 
 
CONFIDENTIAL 
7 of 88 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
402-C-326 (FNB TKA) 
EXPAREL®  
Clinical Study Protocol Amendment 3 
 
Name of Sponsor/Company: 
Pacira Pharmaceuticals, Inc. 
5 Sylvan Way 
Parsippany, NJ  07054 
(973) 254-3560 
Individual Study Table Referring 
to Part of the Dossier 
Volume: 
Page: 
 
(For National Authority Use Only) 
Name of Finished Product: 
EXPAREL (bupivacaine liposome 
injectable suspension) 
Name of Active Ingredient: 
Bupivacaine, 1.3%, 13.3 mg/mL 
Efficacy Endpoints: 
The efficacy endpoints listed below will be assessed based on the efficacy measurements conducted at the times 
specified after the beginning of the femoral nerve block with study drug. 
Primary Endpoint: 
The primary endpoint is area under the curve (AUC) of the VAS pain intensity scores through 72 hours. 
Secondary Endpoints: 
The following secondary endpoints will be analyzed in the following order  
1. Total postsurgical opioid consumption (in IV morphine equivalents) through 72 hours.  
2. Percentage of opioid-free subjects through 72 hours.  
3. Time to first opioid rescue through 72 hours. 
Tertiary Endpoints:  
• 
The AUC of the VAS pain intensity scores through 12, 24, 48, and 96 hours. 
• 
The AUC of the VAS pain intensity scores from 24-48, 48-72 hours, and 72-96 hours. 
• 
VAS pain intensity scores at each assessed timepoint. 
• 
Proportion of subjects who are pain free (defined as a VAS pain intensity score of ≤1.5 without prior 
rescue medication use) at each assessed timepoint.  
• 
Sum of the pain intensity scores (SPIS) through 24, 48, 72, and 96 hours. 
• 
SPIS from 24-48, 48-72, and 72-96 hours. 
• 
Total opioid consumption in IV morphine equivalents through 24, 48, and 96 hours. 
• 
Total opioid consumption in IV morphine equivalents from 24-48, 48-72, and 72-96 hours. 
• 
Percentage of opioid-free subjects through 24, 48, and 96 hours. 
• 
The OBAS total score at 24 and 72 hours, and postsurgical Day 10. 
• 
Physical therapy assessments (ie, timed walk, timed up and go, and stair climbing tests) will be 
conducted at Screening; once postsurgically on Day 0; at 8:00 am (±2 hours) and 8:00 pm (±2 hours) 
from postsurgical Day 1 through hospital discharge; and once on postsurgical Day 10.   
• 
Subject satisfaction with overall analgesia (using a 5-point Likert scale) at 24 and 72 hours, and 
postsurgical Day 10.  
• 
Proportion of subjects meeting Modified Postanesthesia Discharge Scoring System (MPADSS) criteria 
for discharge readiness at 12, 24, 36, 48, 60, 72, 84, and 96 hours. 
• 
Number of unscheduled phone calls or office visits related to pain after discharge through postsurgical 
Day 10. 
 
 
CONFIDENTIAL 
8 of 88 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
402-C-326 (FNB TKA) 
EXPAREL®  
Clinical Study Protocol Amendment 3 
 
Name of Sponsor/Company: 
Pacira Pharmaceuticals, Inc. 
5 Sylvan Way 
Parsippany, NJ  07054 
(973) 254-3560 
Individual Study Table Referring 
to Part of the Dossier 
Volume: 
Page: 
 
(For National Authority Use Only) 
Name of Finished Product: 
EXPAREL (bupivacaine liposome 
injectable suspension) 
Name of Active Ingredient: 
Bupivacaine, 1.3%, 13.3 mg/mL 
Pharmacokinetic Assessments:  
A population PK analysis will be utilized to limit the number of blood draws.  A total of 7 PK samples will be 
collected from each subject for this study. All subjects will have PK samples taken at baseline and upon arrival at 
the PACU.  An additional 5 blood samples will be collected at the assigned time windows shown in Table 2, 
spanning from 24 hours postdose to postsurgical Day 6. There are two PK collection sequences for this study and 
a subject can only be randomized to one sequence. The PK schedule sequence will be indicated for each subject 
at the time of randomization and will also be noted on the randomization confirmation.  Subjects in Sequence 1 
will have samples taken at 24, 56, 68, 80, and 108 hours.  Subjects in Sequence 2 will have samples taken at 48, 
60, 76, 96 hours, and Day 6. 
Pharmacokinetic Endpoints:  
The following PK parameters will be determined:  
• 
Area under the plasma concentration-versus-time curve from time 0 to the last collection time after drug 
administration (AUC0-tlast). 
• 
Area under the plasma concentration-versus-time curve from time 0 extrapolated to infinity after drug 
administration (AUC0-∞). 
• 
Maximum plasma concentration (Cmax). 
• 
Time to maximum plasma concentration (Tmax). 
• 
The apparent terminal elimination rate constant (λz). 
• 
The apparent terminal elimination half-life (t1/2el). 
Safety Assessments:  
The following safety measurements will be conducted at the specified timepoints after the beginning of the 
femoral nerve block with study drug: 
• 
Clinical laboratory tests (hematology, chemistry, and urinalysis) at baseline (on Day 0 prior to the nerve 
block) and on postsurgical Day 10 (see Appendix 8). 
• 
Vital signs (resting heart rate and blood pressure) at baseline (on Day 0 prior to the nerve block); every 5 
minutes during performance of the block and up to 30 minutes after the end of the injection and then 
every 15 minutes until entering the operating room; upon arrival at the PACU; at 6, 9, 12, 24, 36, 48, 56, 
60, 64, 68, 72, 76, 80, 84, 96, and 108 hours; and on postsurgical Days 6 and 10. 
• 
12-lead ECG recordings at baseline (on Day 0 prior to the nerve block); upon arrival at the PACU; 
at 6, 9, 12, 24, 36, 48, 56, 60, 64, 68, 72, 76, 80, 84, 96, and 108 hours; and on postsurgical Days 6 
and 10.  Note: The ECG must be read within 2 hours. 
• 
Neurological assessment at baseline (on Day 0 prior to the nerve block); upon arrival at the PACU;  
at 6, 9, 12, 24, 36, 48, 56, 60, 64, 68, 72, 76, 80, 84, 96, and 108 hours; and on postsurgical Days 6 
and 10 (see Appendix 4).  
• 
Sensory function assessment (as measured by cold, pinprick, and light touch testing) at baseline 
(on Day 0 prior to the nerve block); at approximately 15, 30, and 45 minutes prior to the OR; prior to 
discharge from the PACU; at 6, 9, 12, 18, 24, 36, 48, 60, 72, 84, 96, and 108 hours; and at hospital 
discharge (see Appendix 5).  If there is a sensory deficit at time of hospital discharge, sensory function 
will again be assessed on Day 6. If there continues to be a sensory deficit on Day 6, sensory function 
will again be assessed on Day 10. If there continues to be a sensory deficit on Day 10, the sensory deficit 
 
 
CONFIDENTIAL 
9 of 88 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
402-C-326 (FNB TKA) 
EXPAREL®  
Clinical Study Protocol Amendment 3 
 
Name of Sponsor/Company: 
Pacira Pharmaceuticals, Inc. 
5 Sylvan Way 
Parsippany, NJ  07054 
(973) 254-3560 
Individual Study Table Referring 
to Part of the Dossier 
Volume: 
Page: 
 
(For National Authority Use Only) 
Name of Finished Product: 
EXPAREL (bupivacaine liposome 
injectable suspension) 
Name of Active Ingredient: 
Bupivacaine, 1.3%, 13.3 mg/mL 
will be recorded as an AE and the physician will assess the subject for other etiologies that may explain 
the persistent deficit.  The subject will return for unscheduled visit(s) at the Investigator's discretion 
through postsurgical Day 29 or until sensory function has returned to baseline, whichever occurs first. 
• 
Degree of motor nerve block (angle of flexion [active and passive] and angle of extension [active and 
passive]) at baseline (on Day 0 prior to the nerve block); at approximately 15, 30, and 45 minutes prior 
to the OR; prior to discharge from the PACU; at 6, 9, 12, 18, 24, 36, 48, 60, 72, 84, 96, and 108 hours; 
and at hospital discharge (see Appendix 6).  If there is a motor function deficit at time of hospital 
discharge, motor function will again be assessed on Day 6. If there continues to be a motor function 
deficit on Day 6,  motor function will again be assessed on Day 10. If there continues to be a motor 
function deficit on Day 10, the motor function deficit will be recorded as an AE and the physician will 
assess the subject for other etiologies that may explain the persistent deficit.  The subject will return for 
unscheduled visit(s) at the Investigator's discretion through postsurgical Day 29 or until motor function 
has returned to baseline, whichever occurs first. 
The following criteria (Paauwe 2008) will be used to determine if a subject has achieved a level of 
clinically meaningful physical rehabilitation or “return to baseline”:  
1. Active flexion angle ≥80°. 
2. Active extension angle ≤10°. 
If a subject demonstrates a motor function deficit at Baseline, the subject will be considered to have 
returned to baseline if, at 108 hours (or before), the following two criteria are met: 
1. The active flexion measurement is no more than 10° less than the Baseline measurement 
AND 
2. The active extension angle is no more than 10° greater than the Baseline measurement 
• 
Adverse events from the time the ICF is signed through postsurgical Day 29. 
Safety Endpoints: 
The following safety endpoints will be assessed based on the safety measurements conducted at the specified 
timepoints: 
• 
Change from baseline in clinical laboratory data at each assessed timepoint. 
• 
Change from baseline in vital signs (resting heart rate and blood pressure) at each assessed timepoint. 
• 
Change from baseline in ECG data at each assessed timepoint. 
• 
Summary of neurological assessments (proportion of subjects who are oriented, and proportion of 
subjects who have any of the neurologic events). 
• 
Cold sensation at each assessed timepoint. 
• 
Pinprick sensation at each assessed timepoint. 
• 
Light touch sensation at each assessed timepoint. 
• 
Change from baseline in motor function (flexion [active and passive] and extension [active and passive]) 
at each assessed timepoint. 
• 
Incidence of treatment-emergent AEs (TEAEs) and SAEs through postsurgical Day 29. 
 
 
CONFIDENTIAL 
10 of 88 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
402-C-326 (FNB TKA) 
EXPAREL®  
Clinical Study Protocol Amendment 3 
 
Name of Sponsor/Company: 
Pacira Pharmaceuticals, Inc. 
5 Sylvan Way 
Parsippany, NJ  07054 
(973) 254-3560 
Individual Study Table Referring 
to Part of the Dossier 
Volume: 
Page: 
 
(For National Authority Use Only) 
Name of Finished Product: 
EXPAREL (bupivacaine liposome 
injectable suspension) 
Name of Active Ingredient: 
Bupivacaine, 1.3%, 13.3 mg/mL 
Statistical Methods:  
A comprehensive statistical analysis plan will be developed for this study.  Demographic and baseline 
characteristics will be summarized descriptively by treatment group.  Efficacy data will be summarized by 
treatment group.  EXPAREL will be compared with placebo using analysis of variance (ANOVA) with treatment 
as the main effect for the primary efficacy endpoint of AUC of the VAS pain intensity scores through 72 hours.   
A graphical multiplicity procedure will be used to provide strong control of the type 1 error across the eight key 
null hypotheses, ie, for the null hypotheses corresponding to the two primary pairwise treatment group 
comparisons (EXPAREL dosage arms versus placebo) in combination with each of the four (primary and three 
secondary) endpoints of greatest interest.  Other efficacy endpoints will be analyzed using ANOVA, chi-square 
tests, and Gehan-Wilcoxon tests, as appropriate.  Safety endpoints will be summarized descriptively by treatment 
group.  The PK parameters will be calculated using non-compartmental analysis and summarized for each 
treatment group.  
Sample Size 
The sample size was estimated based on the results of a Phase-3 study of  EXPAREL versus placebo in patients 
undergoing TKA where the means (standard deviation [SD]) AUC of the NRS-R pain intensity scores through 72 
hours were 420 (169) and 514 (160) for the EXPAREL and placebo groups, respectively.  Assuming a 2.5% two-
sided alpha, common SD of 170 and a 3% drop-out rate, a sample size of 77 subjects per treatment group will 
have at least 80% power to detect a difference of 100 in at least one of the active treatment groups.Approximately 
231 subjects (77 subjects per treatment group) are planned for enrollment in this study in order to have at least 
225 evaluable subjects. 
 
 
CONFIDENTIAL 
11 of 88 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
 
402-C-326 (FNB TKA) 
EXPAREL®  
                                            Clinical Study Protocol Amendment 3 
 
 
Table 1:  Time and Events Schedule of Study Procedures - Screening Visit Through PACU Discharge 
 
 
Screen 
Visit** 
D0 
Preop Dosing 
15 min  
30 min 
45 min 
OR 
PACU 
Arrival 
Every 
15 min 
up to 
PACU 
Discharge 
PACU 
Discharge 
Time 
Window 
Within 
30 days 
 
 
±5 min 
±5 min 
±5 min 
 
 
 
Obtain signed ICF 
X 
 
 
 
 
 
 
 
 
 
Assess/confirm eligibility 
X 
X3 
 
 
 
 
 
 
 
 
Record medical and surgical history 
X 
X3 
 
 
 
 
 
 
 
 
Record demographics and baseline characteristics 
X 
 
 
 
 
 
 
 
 
 
Conduct pregnancy test for WOCBP 
X 
X3 
 
 
 
 
 
 
 
 
Perform physical examination 
X 
 
 
 
 
 
 
 
 
 
Urine drug screen and blood alcohol test (Screening) or urine drug screen 
and alcohol breath test (Day 0 Preop)1 
X 
X3 
 
 
 
 
 
 
 
 
Clinical labs (hematology, chemistry, and urinalysis)2 
X 
X3 
 
 
 
 
 
 
 
 
Perform neurological assessment 
X 
X3 
 
 
 
 
 
X 
 
 
Measure vital signs (heart rate and blood pressure)4 
X 
X3 
From the beginning of dosing, assess vital 
signs every 5 mins up to 30 mins after 
completion of the injection then every 15 
mins (±5 mins) until OR 
 
X 
 
 
Perform 12-lead ECG recordings5 
X 
X3 
 
 
 
 
 
X 
 
 
Perform sensory function assessment6 
X 
X3 
 
X 
X 
X 
 
 
 
X 
Conduct motor function assessment7 
X 
X3 
 
X 
X 
X 
 
 
 
X 
Record VAS pain intensity scores8 
 
X3 
 
 
 
 
 
X 
X 
X 
Collect PK blood sample; record date and time9 
 
X3 
 
 
 
 
 
X 
 
 
Randomize subject, prepare study drug 
 
X3 
 
 
 
 
 
 
 
 
Administer blinded study drug via FNB at least 1 hour prior to surgery; 
record start and stop times 
 
 
X 
 
 
 
 
 
 
 
Take photo of ultrasound NB needle placement 
 
 
X 
 
 
 
 
 
 
 
Administer 8 mL of bupivacaine HCl (0.5%) diluted with 8 mL normal 
saline to posterior capsule prior to placement of prosthesis; record time  
 
 
 
 
 
 
X 
 
 
 
Record start and end time of tourniquet use and maximum pressure 
(mmHg) used 
 
 
 
 
 
 
X 
 
 
 
Record date and time of insertion of drain(s), if used 
 
 
 
 
 
 
X 
 
 
 
Record intraoperative opioids administered & doses 
 
 
 
 
 
 
X 
 
 
 
Record surgery start and stop times 
 
 
 
 
 
 
X 
 
 
 
Record date and time of removal of drain(s), if used 
 
 
 
 
 
 
 
 
 
 
Complete OBAS questionnaire 
 
 
 
 
 
 
 
 
 
 
 
 
CONFIDENTIAL 
12 of 88 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
 
402-C-326 (FNB TKA) 
EXPAREL®  
                                            Clinical Study Protocol Amendment 3 
 
Abbreviations: AE = adverse event; D = day; ECG = electrocardiogram; FNB = femoral nerve block; h = hours; ICF = informed consent form; min = minutes; NB = nerve block; OBAS = 
overall benefit of analgesia score; OR = operating room; PACU = post-anesthesia care unit; PK = pharmacokinetic; Preop = preoperative; VAS = visual analog scale; WOCBP = women of 
childbearing potential. 
* 
Postsurgical safety, efficacy, and PK assessments will be conducted at the timepoints specified after the beginning of the femoral nerve block with study drug.  At timepoints when 
multiple assessments coincide, the pain intensity assessment will be conducted first and the blood draw for PK analysis will be conducted second, as applicable. 
** The Screening visit must take place at least 1 day prior to surgery. 
 
1 
A blood alcohol test will be conducted at Screening, and an alcohol breath test will be conducted on Day 0.   
2 
Also conduct clinical laboratory tests if a subject experiences an AE of special interest (AESI; ie, cardiac AE, neurological AE, or fall), or a serious AE (SAE); see footnote 9. 
3 
Prior to the FNB with study drug. 
4 
Vital signs will be measured after the subject has rested in a supine position for at least 5 minutes.  Also measure vital signs if a subject experiences an AE (ie, cardiac AE, neurological 
AE, or fall), or an SAE; see footnote 9. 
5 
Also conduct a 12-lead ECG if a subject experiences an AESI (ie, cardiac AE, neurological AE, or fall), or an SAE; see footnote 9. ECGs must be read within 2 hours. 
6 
Sensory function will be assessed using cold, pinprick, and light touch testing.  If there is a sensory deficit at time of hospital discharge, sensory function will be assessed again on 
postsurgical Day 6.  If there continues to be a sensory deficit on Day 6,  sensory function will again be assessed on Day 10. If there continues to be a sensory deficit on Day 10, the 
sensory deficit will be recorded as an AE and the physician will assess the subject for other etiologies that may explain the persistent deficit.  The subject will return for unscheduled 
visit(s) at the Investigator's discretion through postsurgical Day 29 or until sensory function has returned to baseline, whichever occurs first. 
7 
The motor function assessments include flexion (active and passive) and extension (active and passive).  If there is a motor function deficit at time of hospital discharge, motor function 
will be assessed again on postsurgical Day 6.  If there continues to be a motor function deficit on Day 6,  motor function will again be assessed on Day 10. If there continues to be a 
motor function deficit on Day 10, the motor function deficit will be recorded as an AE and the physician will assess the subject for other etiologies that may explain the persistent 
deficit.  The subject will return for unscheduled visit(s) at the Investigator's discretion through postsurgical Day 29 or until motor function has returned to baseline, whichever occurs 
first.   
8 
The preoperative pain intensity assessment must be conducted prior to administration of any premedication.  Also record VAS pain intensity score immediately prior to each 
administration of rescue pain medication through 108 hours.   
9 
If a cardiac AE or neurological AESI, fall, or SAE occurs during the study, an unscheduled PK blood sample must be collected.  In addition, a 12-lead ECG, vital signs, and any 
appropriate clinical laboratory tests must be conducted.  If conducted, the ECG must be read within 2 hours. Cardiac AESIs include chest pain (angina, myocardial infarction), 
abnormal/irregular heart rate (bradycardia, tachycardia, extrasystoles), and shortness of breath requiring intervention.  Neurologic AESIs include altered mental status/altered 
sensorium, rigidity, dysarthria, seizure, tremors, metallic taste, tinnitus, perioral numbness, visual disturbance, severe or worsening dizziness, or any dizziness beyond 72 hours 
postdose.  Additionally, the following events are of special interest if they persist or occur beyond 72-hours postdose: hyperesthesia, muscular twitching, and tingling/paresthesia. 
10 
Physical therapy assessments (ie, timed walk, timed up and go, and stair climbing tests) will be conducted at Screening;  once postsurgically on Day 0; q12h from postsurgical Day 1 
through hospital discharge; and on postsurgical Day 10.  Preemptive use of opioids or NSAIDs prior to the physical therapy assessment is not permitted. 
11 
Instruct subject to discontinue prohibited medications.  Record date and time of all medications starting at least 30 days prior to study drug administration through 108 hours after study 
drug administration.  Record all analgesics taken through postsurgical Day 29.  Record medications administered for treatment of an AE through postsurgical Day 29. 
12 
Assess vital signs every 5 mins during performance of the nerve block 
 
Perform physical therapy assessments; record date and time10 
X 
 
 
 
 
 
 
 
 
 
Subject satisfaction with postsurgical pain control 
 
 
 
 
 
 
 
 
 
 
Assess discharge readiness; record date and time 
 
 
 
 
 
 
 
 
 
 
Record date and time of actual discharge 
 
 
 
 
 
 
 
 
 
 
Document any unscheduled phone calls or office visits related to pain 
after discharge 
 
 
 
 
 
 
 
 
 
 
Record prior and concomitant medications, including all analgesics11 
 
 
 
 
 
 
 
 
 
 
Record AEs beginning at the time ICF is signed2,4, 5,9 
 
 
 
 
 
 
 
 
 
 
 
 
CONFIDENTIAL 
13 of 88 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
 
402-C-326 (FNB TKA) 
EXPAREL®  
                                            Clinical Study Protocol Amendment 3 
 
Table 2: Time and Events Schedule of Study Procedures - 6 Hours Through Day 29 
 
 
6h 
9h 
12h 
18h 
24h 
36h 
48h 
56h 
60h 
64h 
68h 
72h 
76h 
80h 
84h 
96h 108h D6 
Visit 
D10 
Visit 
D29 
Call 
Time 
Window 
±30 
min 
±30 
min 
±30 
min 
±30 
min ±1h ±1h 
±1h 
±2h 
±2h ±2h 
±2h 
±2h 
±2h ±2h 
±2h ±4h 
±6h 
±1d 
±1d 
±3d 
Obtain signed ICF 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assess/confirm eligibility 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Record medical and surgical history 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Record demographics and baseline characteristics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conduct pregnancy test for WOCBP 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Perform physical examination 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
Urine drug screen and blood alcohol test1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clinical labs (hematology, chemistry, and urinalysis)2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
Perform neurological assessment 
X 
X 
X 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
Measure vital signs (heart rate and blood pressure)4 
X 
X 
X 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
Perform 12-lead ECG recordings5 
X 
X 
X 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
Perform sensory function assessment6 
X 
X 
X 
X 
X 
X 
X 
 
X 
 
 
X 
 
 
X 
X 
X 
X12 X12 
 
Conduct motor function assessment7 
X 
X 
X 
X 
X 
X 
X 
 
X 
 
 
X 
 
 
X 
X 
X 
X13 X13 
 
Record VAS pain intensity scores8 
X 
 
X 
 
X 
X 
X 
 
X 
 
 
X 
 
 
X 
X 
X 
 
 
 
Collect PK blood sample; record date and time9 
 
 
 
 
S1 
 
S2 
S1 
S2 
 
S1 
 
S2 
S1 
 
S2 
S1 
S2 
 
 
Randomize subject, prepare study drug 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Administer blinded study drug via FNB at least 1 hour prior to 
surgery; record start and stop times 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Take photo of ultrasound NB needle placement 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Administer 8 mL of bupivacaine HCl (0.5%) diluted with 8 
mL normal saline to posterior capsule prior to placement of 
prosthesis; record time  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Record start and end time of tourniquet use and maximum 
pressure (mmHg) used 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Record date and time of insertion of drain(s), if used 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Record intraoperative opioids administered & doses 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Record surgery start and stop times 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Record date and time of removal of drain(s), if used 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Complete OBAS questionnaire 
 
 
 
 
X 
 
 
 
 
 
 
X 
 
 
 
 
 
 
X 
 
Perform physical therapy assessments once postsurgically on 
Day 0, each day at 8:00 am (±2h) and 8:00 pm (±2h) from 
Day 1 until hospital discharge, and once on Day 10; record 
date and time10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
Subject satisfaction with postsurgical pain control 
 
 
 
 
X 
 
 
 
 
 
 
X 
 
 
 
 
 
 
X 
 
 
 
CONFIDENTIAL 
14 of 88 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
 
402-C-326 (FNB TKA) 
EXPAREL®  
                                            Clinical Study Protocol Amendment 3 
 
Abbreviations: AE = adverse event; D = day; ECG = electrocardiogram; FNB = femoral nerve block; h = hours; ICF = informed consent form; min = minutes; NB = nerve block; OBAS = 
overall benefit of analgesia score; OR = operating room; PACU = post-anesthesia care unit; PK = pharmacokinetic; Preop = preoperative; S1 =  PK Sequence 1; S2 = PK Sequence 2; VAS = 
visual analog scale; WOCBP = women of childbearing potential. 
* 
Postsurgical safety, efficacy, and PK assessments will be conducted at the timepoints specified after the beginning of the femoral nerve block with study drug.  At timepoints when 
multiple assessments coincide, the pain intensity assessment will be conducted first and the blood draw for PK analysis will be conducted second, as applicable. 
** The Screening visit must take place at least 1 day prior to surgery. 
 
1 
A blood alcohol test will be conducted at Screening, and an alcohol breath test will be conducted on Day 0.   
2 
Also conduct clinical laboratory tests if a subject experiences an AE of special interest (AESI; ie, cardiac AE, neurological AE, or fall), or a serious AE (SAE); see footnote 9. 
3 
Prior to the FNB with study drug. 
4 
Vital signs will be measured after the subject has rested in a supine position for at least 5 minutes.  Also measure vital signs if a subject experiences an AE (ie, cardiac AE, neurological 
AE, or fall), or an SAE; see footnote 9. 
5 
Also conduct a 12-lead ECG if a subject experiences an AESI (ie, cardiac AE, neurological AE, or fall), or an SAE; see footnote 9. ECGs must be read within 2 hours 
6 
Sensory function will be assessed using cold, pinprick, and light touch testing.  If there is a sensory deficit at time of hospital discharge, sensory function will be assessed again on 
postsurgical Day 6.  If there continues to be a sensory deficit on Day 6,  sensory function will again be assessed on Day 10. If there continues to be a sensory deficit on Day 10, the 
sensory deficit will be recorded as an AE and the physician will assess the subject for other etiologies that may explain the persistent deficit.  The subject will return for unscheduled 
visit(s) at the Investigator's discretion through postsurgical Day 29 or until sensory function has returned to baseline, whichever occurs first. 
7 
The motor function assessments include flexion (active and passive) and extension (active and passive).  If there is a motor function deficit at time of hospital discharge, motor function 
will be assessed again on postsurgical Day 6.  If there continues to be a motor function deficit on Day 6,  motor function will again be assessed on Day 10. If there continues to be a 
motor function deficit on Day 10, the motor function deficit will be recorded as an AE and the physician will assess the subject for other etiologies that may explain the persistent 
deficit.  The subject will return for unscheduled visit(s) at the Investigator's discretion through postsurgical Day 29 or until motor function has returned to baseline, whichever occurs 
first. See Section 13.1.6 for the criteria used to determine “return to baseline” for motor function. 
8 
The preoperative pain intensity assessment should be conducted prior to administration of any premedication.  Also record VAS pain intensity score immediately prior to each 
administration of rescue pain medication through 108 hours.   
9 
If a cardiac AE or neurological AESI, fall, or SAE occurs during the study, an unscheduled PK blood sample must be collected.  In addition, a 12-lead ECG, vital signs, and any 
appropriate clinical laboratory tests must be conducted.  If conducted, the ECG must be read within 2 hours.  Cardiac AESIs include chest pain (angina, myocardial infarction), 
abnormal/irregular heart rate (bradycardia, tachycardia, extrasystoles), and shortness of breath requiring intervention.  Neurologic AESIs include altered mental status/altered 
sensorium, rigidity, dysarthria, seizure, tremors, metallic taste, tinnitus, perioral numbness, visual disturbance, severe or worsening dizziness, and dizziness beyond 72 hours postdose.  
Additionally, the following events are of special interest if they persist or occur beyond 72-hours postdose: hyperesthesia, muscular twitching, and tingling/paresthesia. 
10 
Physical therapy assessments (ie, timed walk, timed up and go, and stair climbing tests) will be conducted once before surgery, once postsurgically on Day 0; q12h from postsurgical 
Day 1 through hospital discharge; and on postsurgical Day 10.  Preemptive use of opioids or NSAIDs prior to the physical therapy assessment is not permitted. 
11 
Instruct subject to discontinue prohibited medications.  Record date and time of all medications starting at least 30 days prior to study drug administration through 108 hours after study 
drug administration.  Record all analgesics taken through postsurgical Day 29.  Record medications administered for treatment of an AE through postsurgical Day 29. 
12 
Sensory function will be assessed at Day 6 only if there was a sensory deficit noted at hospital discharge.  Likewise, sensory function will be assessed at Day 10 only if there was a 
sensory deficit noted on Day 6.  If there continues to be a sensory deficit on Day 10, sensory deficit will be recorded as an AE and the physician will assess the subject for other 
Assess discharge readiness; record date and time 
 
 
X 
 
X 
X 
X 
 
X 
 
 
X 
 
 
X 
X 
 
 
 
 
Record date and time of actual discharge 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
X 
X 
 
Document any unscheduled phone calls or office visits related 
to pain after discharge 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
X 
 
Record prior and concomitant medications, including all 
analgesics11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Record AEs beginning at the time ICF is signed2,7, 8,9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONFIDENTIAL 
15 of 88 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
 
402-C-326 (FNB TKA) 
EXPAREL®  
                                            Clinical Study Protocol Amendment 3 
 
etiologies that may explain the persistent deficit.  The subject will return for unscheduled visit(s) at the Investigator's discretion through postsurgical Day 29 or until sensory function 
has returned to baseline, whichever occurs first. 
13 
Motor function will be assessed at Day 6 only if there was a motor function deficit noted at hospital discharge.  Likewise, motor function will be assessed at Day 10 only if there was a 
motor function deficit noted on Day 6.  If there continues to be a motor function deficit on Day 10, the motor function deficit will be recorded as an AE and the physician will assess the 
subject for other etiologies that may explain the persistent deficit.  The subject will return for unscheduled visit(s) at the Investigator's discretion through postsurgical Day 29 or until 
motor function has returned to baseline, whichever occurs first.  See Section 13.1.6 for the criteria used to determine “return to baseline” for motor function. 
 
 
 
 
Table 3: Time and Events Schedule of Study Procedures – Scheduled Pharmacokinetic Samples Blood Draws 
Note: If a cardiac AE or neurological AESI, fall, or SAE occurs during the study, an unscheduled PK blood sample must be collected.  In addition, a 12-lead ECG, vital signs, and any 
appropriate clinical laboratory tests must be conducted.  If conducted, the ECG must be read within 2 hours.  Cardiac AESIs include chest pain (angina, myocardial infarction), 
abnormal/irregular heart rate (bradycardia, tachycardia, extrasystoles), and shortness of breath requiring intervention.  Neurologic AESIs include altered mental status/altered sensorium, 
rigidity, dysarthria, seizure, tremors, metallic taste, tinnitus, perioral numbness, visual disturbance, severe or worsening dizziness, and dizziness beyond 72 hours postdose.  Additionally, the 
following events are of special interest if they persist or occur beyond 72-hours postdose: hyperesthesia, muscular twitching, and tingling/paresthesia. 
 
 
6h 
9h 
12h 
18h 
24h 
36h 
48h 
56h 
60h 
64h 
68h 
72h 
76h 
80h 
84h 
96h 108h D6 
Visit 
D10 
Visit 
D29 
Call 
Time 
Window 
±30 
min 
±30 
min 
±30 
min 
±30 
min ±1h ±1h 
±1h 
±2h 
±2h ±2h 
±2h 
±2h 
±2h ±2h 
±2h ±4h 
±6h 
±1d 
±1d 
±3d 
Sequence 1 (S1):  Collect PK blood sample; record date 
and time 
 
 
 
 
S1 
 
 
S1 
 
 
S1 
 
 
S1 
 
 
S1 
 
 
 
Sequence 2 (S2):  Collect PK blood sample; record date 
and time 
 
 
 
 
 
 
S2 
 
S2 
 
 
 
S2 
 
 
S2 
 
S2 
 
 
 
 
CONFIDENTIAL 
16 of 88 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
 
            402-C-326 (FNB TKA) 
EXPAREL® 
 
 
          Clinical Study Protocol Amendment 3 
 
3. 
TABLE OF CONTENTS  
1. 
SIGNATURE PAGE ....................................................................................................2 
2. 
SYNOPSIS ...................................................................................................................3 
3. 
TABLE OF CONTENTS ...........................................................................................17 
4. 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS.............................22 
4.1. 
List of Abbreviations ..................................................................................................22 
4.2. 
Definition of Terms ....................................................................................................23 
5. 
ETHICS ......................................................................................................................24 
5.1. 
Institutional Review Board/Independent Ethics Committee ......................................24 
5.2. 
Ethical Conduct of the Study ......................................................................................24 
5.3. 
Subject Information and Consent ...............................................................................24 
6. 
INVESTIGATORS AND STUDY ADMINISTRATION STRUCTURE .................24 
7. 
INTRODUCTION ......................................................................................................25 
7.1. 
Indication ....................................................................................................................25 
7.2. 
Current Therapies/Treatments ....................................................................................25 
7.3. 
EXPAREL (bupivacaine liposome injectable suspension) .........................................26 
7.3.1. 
Summary of Human Experience with EXPAREL ......................................................27 
7.4. 
Postmarketing Exposure .............................................................................................30 
8. 
OBJECTIVES .............................................................................................................30 
8.1. 
Primary Objectives .....................................................................................................30 
8.2. 
Secondary Objectives .................................................................................................30 
9. 
STUDY DESIGN AND PLAN ..................................................................................31 
9.1. 
Study Design ...............................................................................................................31 
9.1.1. 
Duration of the Study and Subject Participation ........................................................33 
9.1.2. 
Study Stopping Rules .................................................................................................33 
9.2. 
Discussion of Study Design ........................................................................................34 
10. 
STUDY POPULATION .............................................................................................36 
10.1. 
Inclusion Criteria ........................................................................................................36 
10.2. 
Exclusion Criteria .......................................................................................................36 
10.3. 
Removal of Subjects from Therapy or Assessment ....................................................37 
10.3.1. 
Withdrawal Secondary to Adverse Events .................................................................37 
10.3.2. 
Voluntary or Study Investigator Withdrawal .............................................................38 
 
 
 
CONFIDENTIAL 
17 of 88 
 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
 
            402-C-326 (FNB TKA) 
EXPAREL® 
 
 
          Clinical Study Protocol Amendment 3 
 
11. 
TREATMENTS ..........................................................................................................38 
11.1. 
Treatment to be Administered ....................................................................................38 
11.1.1. 
Administration Technique ..........................................................................................39 
11.1.2. 
Study Drug Administration Considerations................................................................39 
11.2. 
Identity of Investigational Product(s) .........................................................................39 
11.2.1. 
Description of EXPAREL ..........................................................................................39 
11.2.2. 
Description of Reference Product ...............................................................................40 
11.2.3. 
Description of Diluents ...............................................................................................40 
11.3. 
Method of Assigning Subjects to Treatment ..............................................................40 
11.3.1. 
Randomization Scheme ..............................................................................................40 
11.3.2. 
Randomization Procedures .........................................................................................40 
11.3.3. 
Replacement of Subjects .............................................................................................40 
11.4. 
Selection of Doses in the Study ..................................................................................40 
11.5. 
Blinding ......................................................................................................................41 
11.5.1. 
Blinding Procedures ....................................................................................................41 
11.5.2. 
Unblinding Procedures ...............................................................................................42 
11.6. 
Prior and Concomitant Therapy and Medications ......................................................42 
11.6.1. 
Before Study Drug Administration .............................................................................42 
11.6.2. 
During Surgery ...........................................................................................................43 
11.6.3. 
After Surgery ..............................................................................................................43 
11.7. 
Treatment Compliance ................................................................................................44 
11.8. 
Accountability of Study Drug .....................................................................................44 
12. 
STUDY ENDPOINTS AND MEASUREMENTS ....................................................44 
12.1. 
Efficacy Assessments .................................................................................................44 
12.2. 
Efficacy Endpoints ......................................................................................................45 
12.3. 
Pharmacokinetic Analysis ..........................................................................................46 
12.4. 
Pharmacokinetic Endpoints ........................................................................................46 
12.5. 
Safety Assessments .....................................................................................................47 
12.6. 
Safety Endpoints .........................................................................................................48 
12.7. 
Appropriateness of Measures .....................................................................................48 
13. 
STUDY PROCEDURES ............................................................................................48 
13.1. 
Instructions for Conducting Procedures and Measures ..............................................48 
13.1.1. 
Pain Intensity Assessments .........................................................................................49 
 
 
 
CONFIDENTIAL 
18 of 88 
 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
 
            402-C-326 (FNB TKA) 
EXPAREL® 
 
 
          Clinical Study Protocol Amendment 3 
 
13.1.2. 
Overall Benefit of Analgesia Score Questionnaire .....................................................49 
13.1.3. 
Subject Satisfaction with Postsurgical Pain Control ..................................................49 
13.1.4. 
Neurological Assessment ............................................................................................49 
13.1.5. 
Sensory Function Assessment ....................................................................................49 
13.1.6. 
Motor Nerve Block Assessment .................................................................................50 
13.1.7. 
Clinical Laboratory Tests ...........................................................................................51 
13.1.8. 
Vital Signs ..................................................................................................................51 
13.1.9. 
Physical Examination .................................................................................................51 
13.1.10. 
Electrocardiogram .......................................................................................................51 
13.1.11. 
Physical Therapy Assessments ...................................................................................51 
13.1.12. 
Adverse Events of Special Interest .............................................................................52 
13.2. 
Screening Procedures ..................................................................................................53 
13.3. 
Baseline Procedures (Day 0 - Prior to Study Drug Administration) ..........................53 
13.4. 
Baseline Procedures (Time 0) .....................................................................................54 
13.5. 
Approximately 15, 30, and 45 Minutes After Study Drug Administration ................54 
13.6. 
Intraoperative Procedures ...........................................................................................54 
13.7. 
Upon Arrival at the Post-Anesthesia Care Unit ..........................................................55 
13.8. 
Prior to PACU Discharge ...........................................................................................55 
13.9. 
Postsurgical Assessments through Hour 108 ..............................................................56 
13.10. 
Postsurgical Day 6 Visit .............................................................................................57 
13.11. 
Postsurgical Day 10 Visit ...........................................................................................57 
13.12. 
Unscheduled Visit(s) ..................................................................................................58 
13.13. 
Postsurgical Day 29 Phone Call .................................................................................58 
14. 
ADVERSE EVENT REPORTING ............................................................................58 
14.1. 
Adverse Events ...........................................................................................................58 
14.1.1. 
Definitions ..................................................................................................................58 
14.1.2. 
Recording Adverse Events .........................................................................................59 
14.1.3. 
Severity of Adverse Events ........................................................................................60 
14.1.4. 
Relationship of Adverse Events to Study Drug ..........................................................60 
14.1.5. 
Outcome of Adverse Events .......................................................................................61 
14.1.6. 
Action Taken with Subject due to an Adverse Event .................................................61 
14.2. 
Serious Adverse Events ..............................................................................................61 
14.2.1. 
Definition of a Serious Adverse Event .......................................................................61 
 
 
 
CONFIDENTIAL 
19 of 88 
 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
 
            402-C-326 (FNB TKA) 
EXPAREL® 
 
 
          Clinical Study Protocol Amendment 3 
 
14.2.2. 
Reporting Serious Adverse Events .............................................................................62 
15. 
STATISTICAL METHODS .......................................................................................63 
15.1. 
Study Hypothesis ........................................................................................................63 
15.2. 
Study Endpoints ..........................................................................................................63 
15.3. 
Determination of Sample Size ....................................................................................63 
15.4. 
Analysis Populations ..................................................................................................63 
15.5. 
Handling Subject Dropouts and Discontinuations ......................................................63 
15.6. 
Statistical Analyses .....................................................................................................64 
15.6.1. 
Baseline Characteristics ..............................................................................................64 
15.6.2. 
Study Compliance .......................................................................................................64 
15.6.3. 
Efficacy Analyses .......................................................................................................64 
15.6.4. 
Pharmacokinetic Analyses ..........................................................................................65 
15.6.5. 
Safety Analyses ..........................................................................................................65 
15.7. 
Significance Testing ...................................................................................................66 
15.8. 
Interim Pharmacokinetic Analysis ..............................................................................68 
16. 
REFERENCES ...........................................................................................................69 
17. 
INVESTIGATOR AGREEMENT .............................................................................71 
18. 
APPENDICES ............................................................................................................72 
Appendix 1: Subject’s Reported Pain Intensity ..........................................................................73 
Appendix 2: Overall Benefit of Analgesia Score (OBAS) Questionnaire ..................................74 
Appendix 3: Subject Satisfaction with Postsurgical Pain Control (Likert Scale) .......................75 
Appendix 4: Neurological Assessment .......................................................................................76 
Appendix 5: Sensory Function Assessment (Cold, Pinprick, and Light Touch Tests) ...............77 
Appendix 6: Motor Function Assessment ...................................................................................80 
Appendix 7: Discharge Readiness...............................................................................................81 
Appendix 8: Clinical Laboratory Tests .......................................................................................82 
Appendix 9: Physical Therapy Assessments ...............................................................................83 
 
 
 
 
CONFIDENTIAL 
20 of 88 
 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
 
            402-C-326 (FNB TKA) 
EXPAREL® 
 
 
          Clinical Study Protocol Amendment 3 
 
LIST OF TABLES 
Table 1:  Time and Events Schedule of Study Procedures - Screening Visit Through 
PACU Discharge ......................................................................................................................12 
Table 2: Time and Events Schedule of Study Procedures - 6 Hours Through Day 29............14 
Table 3: Time and Events Schedule of Study Procedures – Scheduled 
Pharmacokinetic Samples Blood Draws ..................................................................................16 
 
 
 
 
CONFIDENTIAL 
21 of 88 
 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
 
            402-C-326 (FNB TKA) 
EXPAREL® 
 
 
          Clinical Study Protocol Amendment 3 
 
4. 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS 
4.1. 
List of Abbreviations 
AE 
Adverse event 
AESI 
Adverse event of special interest 
ANOVA 
Analysis of variance 
AUC 
Area under the curve 
AUC0-tlast 
Area under the plasma concentration-versus-time curve from the time of 
administration to the time of the last quantifiable concentration  
AUC0-∞ 
Area under the plasma concentration-versus-time curve from the time of 
administration extrapolated to infinity 
BDR 
Blinded Data Review 
CFR 
Code of Federal Regulations 
CI 
Confidence interval 
Cmax 
The maximum observed plasma concentration obtained directly from the 
experimental data without interpolation 
CRF 
Case Report Form 
Ctlast 
Time of the last quantifiable concentration 
ECG 
Electrocardiogram 
FDA 
Food and Drug Administration 
GCP 
Good Clinical Practice 
ICF 
Informed consent form 
ICH 
International Conference on Harmonisation 
IEC 
Independent Ethics Committee 
IND 
Investigational New Drug 
IRB 
Institutional Review Board 
IV 
Intravenous 
LS 
Least squares 
MPADSS 
Modified Postanesthesia Discharge Scoring System 
NDA 
New Drug Application 
NRS 
Numeric rating scale  
NRS-R 
Numeric rating scale at rest 
NSAIDs 
Non-steroidal anti-inflammatory drugs 
 
 
 
CONFIDENTIAL 
22 of 88 
 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
 
            402-C-326 (FNB TKA) 
EXPAREL® 
 
 
          Clinical Study Protocol Amendment 3 
 
OBAS 
Overall benefit of analgesia score 
PACU 
Post-anesthesia care unit 
PCA 
Patient-controlled analgesia 
PK 
Pharmacokinetic 
PO 
Oral 
PRN 
As needed 
PT 
Preferred term 
PTAE 
Pretreatment adverse event 
q4h 
Every 4 hours 
q8h 
Every 8 hours 
SAE 
Serious adverse event 
SAP 
Statistical analysis plan 
SD 
Standard deviation 
SNRI 
Selective norepinephrine reuptake inhibitor 
SPIS 
Sum of the pain intensity scores 
SSRI 
Selective serotonin reuptake inhibitor 
λz 
The apparent terminal elimination rate constant 
t1/2el 
The apparent terminal elimination half-life 
TEAE 
Treatment-emergent adverse event 
TKA 
Total knee arthroplasty 
Tmax 
The time to maximum plasma concentration  
ULN 
Upper limit of normal 
US 
United States (of America) 
VAS 
Visual analog scale 
4.2. 
Definition of Terms 
Pharmacokinetic (PK) terms are defined in Section 12.4. 
 
 
 
CONFIDENTIAL 
23 of 88 
 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
 
            402-C-326 (FNB TKA) 
EXPAREL® 
 
 
          Clinical Study Protocol Amendment 3 
 
5. 
ETHICS 
5.1. 
Institutional Review Board/Independent Ethics Committee 
Prior to screening subjects into this study, each study site will obtain the approval of an 
Institutional Review Board (IRB)/Independent Ethics Committee (IEC) that complies with the 
International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) and/or the 
United States (US) Food and Drug Administration (FDA) Title 21 Code of Federal Regulations 
(CFR) Part 56.  For study sites with IECs that comply with ICH GCP, but not US FDA 21 CFR 
Part 56, a waiver request will be submitted to FDA.  If granted, then FDA’s letter documenting 
the waiver will be provided to the Investigator to be maintained with the signed Investigator 
statement (Form FDA 1572) in the Investigator's study binder.  Attention is directed to the basic 
elements that are required to be incorporated into the informed consent form (ICF) under 21 CFR 
Part 50.25 and ICH GCP. 
5.2. 
Ethical Conduct of the Study 
This study will be conducted in accordance with the clinical research guidelines established by 
the FDA Title 21 CFR, Parts 50, 54, 56, and 312, the Directive 2001/20/EC of the European 
Parliament and of the Council of 04 April 2001 and amendments, the Commission Directive 
2005/28/EC of 08 April 2005 and amendments, and the ICH GCP.  Study documents will be 
maintained in accordance with applicable regulations. 
5.3. 
Subject Information and Consent 
Before a subject undergoes any study-specific screening procedures, the Investigator or designee 
will thoroughly explain to the subject the purpose of the study, the associated procedures, and 
any expected effects and potential adverse reactions.  A copy of the IRB- or IEC-approved ICF 
will be provided to the subject, who will be given sufficient time and opportunity to inquire 
about the details of the study and decide whether or not to participate.  The subject, and the study 
staff with whom he or she discusses the ICF, will sign and date the ICF.  A photocopy of the 
signed ICF will be given to the subject. 
The Investigator will explain to the subject that he or she is completely free to decline entry into 
the study and may withdraw from the study at any time, for any reason, without risking his or her 
medical care.  Similarly, the Investigator and/or Pacira Pharmaceuticals, Inc. (Pacira) is free to 
withdraw the subject at any time for safety or administrative reasons.  Any other requirements 
necessary for the protection of the human rights of the subject will also be explained, according 
to the current ICH GCP (E6) and the Declaration of Helsinki (1964, and as amended through 
2013). 
6. 
INVESTIGATORS AND STUDY ADMINISTRATION 
STRUCTURE 
Information regarding the Investigators, sites, laboratories, and other service providers is 
available upon request to the IRB/IECs and regulatory agencies. 
 
 
 
CONFIDENTIAL 
24 of 88 
 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
 
            402-C-326 (FNB TKA) 
EXPAREL® 
 
 
          Clinical Study Protocol Amendment 3 
 
7. 
INTRODUCTION 
7.1. 
Indication 
EXPAREL® was developed to provide a prolonged period of decreased pain and decreased 
opioid use with a single dose administration without the use of indwelling catheters.  It is 
indicated for use as an analgesic injected into the surgical site for postsurgical pain relief. 
Effective postsurgical pain control is a critical element in patient recovery following surgery, 
as the majority of patients may experience significant pain, particularly in the first few days.  
Improved postsurgical pain management contributes to better healing, faster patient mobilization, 
shortened hospital stays, and reduced healthcare costs (American Society of Anesthesiologists 
Task Force on Pain Management 1995). 
7.2. 
Current Therapies/Treatments 
Current modalities of postsurgical analgesic treatment include wound infiltration and nerve block 
with local anesthetic agents, usually combined with the systemic administration of analgesics 
(multimodal therapy).  Multimodal therapy usually includes opioid medications, nonsteroidal 
anti-inflammatory drugs (NSAIDs), and/or acetaminophen provided through a variety of routes 
including intravenous (IV), transdermal patch, and oral (PO) administration.  Opioids are widely 
used and considered some of the most powerful analgesics; however, they also have considerable 
drawbacks including time and resources required for monitoring opioid-related side effects.  
A reduction in the use of postoperative opioids is desirable to decrease the incidence and severity 
of opioid-induced adverse effects, such as respiratory depression, nausea, vomiting, constipation, 
somnolence, pruritus, and urinary retention.   
Total knee arthroplasty (TKA) is a common surgical procedure that causes postsurgical pain of 
considerable intensity and duration.  While the standard analgesic medications administered prior 
to the TKA procedure and used to provide analgesic relief immediately after surgery can vary, 
most experts agree that multimodal pain control has become the standard of care.  In TKA, 
that may include local and regional analgesic techniques (ie, neuraxial blocks, peripheral 
nerve blocks, and wound infiltration) combined with acetaminophen and an NSAID or a 
cyclooxygenase-2 selective inhibitor with opioids reserved as rescue analgesics.  This approach 
has been shown to significantly reduce opioid requirements and opioid-related adverse events 
(AEs).  It is clear that opioid-related AEs increase perioperative morbidity, including delay in 
ambulation and participation in rehabilitation therapy programs.  Also, analgesic adjuncts, such 
as dexamethasone (single intraoperative dose) and gabapentinoids (ie, gabapentin and 
pregabalin) may provide further benefit (Joshi 2015).  Following surgery, additional analgesic 
treatment often includes opioids.  Therefore, TKA was selected as an appropriate pain model for 
investigating a sustained-release formulation of bupivacaine, which has the potential to 
overcome the limitation reported in previous studies with regard to the duration of the analgesic 
effect obtained with commercially-available products. 
With over 70 million surgeries performed annually in the US, postoperative pain is a ubiquitous 
condition among our population.  While it is a predictable component of the postoperative 
process, such pain is often poorly managed, resulting in clinical and physiological changes that 
 
 
 
CONFIDENTIAL 
25 of 88 
 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
 
            402-C-326 (FNB TKA) 
EXPAREL® 
 
 
          Clinical Study Protocol Amendment 3 
 
increase morbidity and mortality (inability to ambulate early, etc.), diminish quality of life, 
and extend length of stay, thereby increasing hospital expenditures (Oderda 2007) and reducing 
patient satisfaction.  Effective relief of acute pain with minimal opioid complications, on the 
other hand, may improve clinical outcomes, avoid complications (like delay in regaining bowel 
function or an inability to tolerate liquid and solid oral intake, etc.), and conserve healthcare 
resources.  As such, the Joint Commission on Accreditation of Healthcare Organizations requires 
that all healthcare facilities practice adequate pain management and monitor opioid-related AEs 
(Apfelbaum 2003). 
Opioid analgesics have long been established to be the most effective agents used for the 
management of moderate to severe postoperative pain, and are currently considered the mainstay 
of treatment.  Adverse events related to opioid administration (eg, nausea, vomiting, ileus, 
confusion), however, represent one important reason that there is a need to develop opioid-
sparing strategies.  Indeed, fear of gastrointestinal side effects such as nausea and vomiting, 
as well as respiratory depression, present major limitations for the widespread use of opioid 
analgesics (Chernin 2001 and Viscusi 2009).  Furthermore, management of opioid-related events 
often requires medical attention (eg, opioid antagonists, antiemetic agents) and increased 
pharmacy/nursing time, which may raise healthcare expenses (Carroll 1994).   
7.3. 
EXPAREL (bupivacaine liposome injectable suspension) 
Bupivacaine is one of the longer-acting local anesthetics, but even so it has a limited duration 
of action after local administration, usually reported as less than 8 hours.  EXPAREL (Pacira 
Pharmaceuticals, Inc., Parsippany, NJ) is a bupivacaine liposome injectable suspension.  
It consists of microscopic spherical, multivesicular liposomes (DepoFoam® drug delivery 
system), organized in a honeycomb-like structure comprising numerous non-concentric internal 
aqueous chambers containing a bupivacaine base at a concentration of 13.3 mg/mL.  Each 
chamber is separated from adjacent chambers by lipid membranes.  The lipids (phospholipids, 
cholesterol, and triglycerides) are naturally occurring or close analogs of endogenous lipids.  
Bupivacaine is slowly released from the DepoFoam particles by a complex mechanism involving 
reorganization of the barrier lipid membranes and subsequent diffusion of the drug over an 
extended period of time.  A small amount of extra-liposomal bupivacaine (ie, not bound within 
the DepoFoam particles) enables EXPAREL to have a similar onset of action to standard 
bupivacaine HCl.  Because of this, EXPAREL has been noted in wound infiltration studies to 
have a bimodal curve (Apseloff 2013), with an initial peak at approximately 0-2 hours and a 
second peak at approximately 24-48 hours (Hu 2013).  
EXPAREL was approved by the US FDA in 2011 for administration into the surgical site to 
produce postsurgical analgesia.  The active ingredient (bupivacaine) and inactive ingredient 
(DepoFoam) of EXPAREL are each contained, though separately, in FDA-approved products: 
• 
Bupivacaine HCl solution, a well-characterized anesthetic/analgesic, with more than 
35 years of its use in the US. 
• 
DepoFoam, a liposomal extended-release formulation contained in the marketed 
product DepoCyt® (1999).  The form of DepoFoam used in each of the products – 
DepoCyt and EXPAREL – has a slightly different mixture of lipid components.   
 
 
 
CONFIDENTIAL 
26 of 88 
 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
 
            402-C-326 (FNB TKA) 
EXPAREL® 
 
 
          Clinical Study Protocol Amendment 3 
 
7.3.1. 
Summary of Human Experience with EXPAREL 
7.3.1.1. 
Wound Infiltration New Drug Application (NDA)  
During the original clinical development program (wound infiltration), Pacira conducted 
21 clinical studies and one observational follow-up study to investigate EXPAREL (formerly 
known as SKY0402™).  Across these studies, a total of 1307 human subjects received 
EXPAREL at doses ranging from 10-750 mg (or 9-665 mg free base) and by various routes: 
local administration into the surgical wound, subcutaneous, perineural, and epidural.  The 
investigational drug product has been well tolerated and the reported AEs occurred at a similar 
rate as the corresponding bupivacaine HCl controls in the active comparator studies.   
In doses up to 665 mg of EXPAREL, no signal of any of the central nervous system or 
cardiovascular system AEs observed with high doses of bupivacaine HCl solution have been 
observed.  Two thorough QTc studies have been conducted; EXPAREL did not cause significant 
QTc prolongation even at the highest dose evaluated.   
Across all studies, the types of treatment-emergent adverse events (TEAEs) reported and the 
incidence rates generally were similar between the EXPAREL All Doses group (all doses 
combined) and the bupivacaine HCl group.  The incidence rate for each of the three most 
common TEAEs (nausea, constipation, and vomiting) was lower in the EXPAREL All Doses 
group than in the bupivacaine HCl group.   
EXPAREL was demonstrated to produce statistically significant and clinically meaningful 
analgesia in two pivotal placebo-controlled Phase 3 studies (SKY0402-C-317 and SKY0402-
C-316) involving both orthopedic and soft tissue procedures over 36 and 72 hours, respectively.  
In addition to meeting their primary endpoints (area under the curve [AUC] of the numeric rating 
scale [NRS] at rest [NRS-R] pain intensity scores through 72 hours [Study SKY0402-C-316] and 
through 24 hours [Study SKY0402-C-317]), key secondary endpoints also were met, 
demonstrating prolonged analgesia and reduction of opioid use by various measures (percentage 
of subjects who received no supplementary opioid medication; total amount of postoperative 
consumption of opioid medication; and time to first use of opioid medication).  The robust nature 
of the efficacy results in both pivotal studies SKY0402-C-316 and SKY0402-C-317 was 
demonstrated across subgroups of subjects with various prognostic features and across 
demographic subgroups.   
An analysis was performed to compare the incidence of opioid-related AEs between the 
EXPAREL and bupivacaine HCl groups in all bupivacaine-controlled, parallel-group wound 
infiltration studies (SIMPLE TKA 311, SKY0402-C-208, SIMPLE Hemorrhoidectomy 312, 
SKY0402-C-209, SKY0402-C-207, SKY0402-C-201, and SIMPLE Breast Augmentation 315).  
There was a statistically significantly lower incidence of opioid-related AEs in the EXPAREL 
≤300 mg group compared to the bupivacaine HCl group through 72 hours postdose.  This was 
consistent with the statistically significantly lower total postoperative consumption of opioids 
in the EXPAREL ≤300 mg group through 72 hours postdose.  Fewer subjects in the EXPAREL 
≤300 mg group had at least one opioid-related AE compared to the bupivacaine HCl group 
(25.6% versus 45.6%; p<0.0001).  The total opioid medication administered (adjusted geometric 
mean) through 72 hours postdose was statistically significantly lower in the EXPAREL ≤300 mg 
group (7.94 mg) compared to the bupivacaine HCl group (15.84 mg); p<0.0001.  The EXPAREL 
>300 mg group did not show a statistically significant advantage favoring EXPAREL; the mean 
 
 
 
CONFIDENTIAL 
27 of 88 
 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
 
            402-C-326 (FNB TKA) 
EXPAREL® 
 
 
          Clinical Study Protocol Amendment 3 
 
(standard deviation [SD]) of the average number of opioid-related AEs per subject was 
0.58 (0.522), and the total opioid medication administered (adjusted geometric mean) through 
72 hours postdose was 22.82 mg in the EXPAREL >300 mg group. 
Please see the EXPAREL Full Prescribing Information for safety information regarding the use 
of EXPAREL for the treatment of postsurgical pain in the setting of wound infiltration. 
7.3.1.2. 
Nerve Block Supplemental NDA 
A total of 335 human subjects received EXPAREL as a nerve block over six clinical studies 
(SKY0402-002, SKY0402-C-111, SKY0402-C-203, SKY0402-C-211, 402-C-322, and 
402-C-323) utilizing three different surgical models (femoral nerve block, intercostal nerve 
block, and ankle nerve block).  Doses administered ranged from 2 mg to 310 mg.  The data from 
three of these studies (SKY0402-002, SKY0402-C-203, and SKY0402-C-211) were included in 
the wound infiltration NDA as well as the nerve block supplemental NDA.   
Phase 3 Nerve Block Studies 
Study 402-C-322 was a Phase 3, multicenter, randomized, double-blind, parallel-group, placebo-
controlled study to investigate the efficacy and safety of EXPAREL (total of 266 mg in 20 mL) 
divided into three equal doses in three syringes of approximately 88 mg in 6.6 mL volume per 
nerve and administered to each of three nerve segments (index nerve, nerve above, and nerve 
below) compared with saline placebo nerve block.  The primary objective was to evaluate the 
efficacy of intercostal nerve block using EXPAREL compared with placebo in subjects 
undergoing posterolateral thoracotomy. 
Intercostal nerve block with EXPAREL was well tolerated in subjects undergoing posterolateral 
thoracotomy.  However, the study did not meet its primary efficacy endpoint: there was no 
statistically significant difference in the mean AUC of the NRS-R pain intensity scores through 
72 hours between subjects in the EXPAREL group and in the placebo group although a treatment 
effect was evident through 12 to 24 hours based upon a post hoc analysis. 
Fifty-six subjects (59.6%) in the EXPAREL group and 46 subjects (50.5%) in the placebo group 
experienced one or more TEAEs.  Most of the TEAEs were mild or moderate in severity.  
Three subjects (3.2%) in the EXPAREL group and no subjects in the placebo group experienced 
a TEAE that were assessed by the Investigator as related to study drug.  Twelve subjects (12.8%) 
in the EXPAREL group and 9 subjects (9.9%) in the placebo group experienced one or more 
treatment-emergent serious AEs (SAEs).  Two of these subjects in the EXPAREL group and 
four of these subjects in the placebo group died.  None of the SAEs or deaths was assessed by the 
Investigator as related to study drug.  Two subjects (2.1%) in the EXPAREL group and seven 
subjects (7.4%) in the placebo group were withdrawn from the study due to an AE. 
Study 402-C-323 was a Phase 2/3, multicenter, randomized, double-blind, parallel-group, 
placebo-controlled, dose-ranging study in subjects undergoing primary unilateral TKA under 
general or spinal anesthesia.  The primary objectives of Part 1 were to (1) evaluate three dose 
levels of EXPAREL versus placebo with respect to the magnitude and duration of the analgesic 
effect achieved following single dose injection femoral nerve block with EXPAREL, and 
(2) select a single therapeutic dose of EXPAREL from the three dose levels to be tested in Part 2. 
 
 
 
CONFIDENTIAL 
28 of 88 
 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
 
            402-C-326 (FNB TKA) 
EXPAREL® 
 
 
          Clinical Study Protocol Amendment 3 
 
The primary objective of Part 2 was to compare the magnitude and duration of the analgesic 
effect of single injection femoral nerve block of a single dose level of EXPAREL (selected from 
Part 1) with placebo (preservative-free normal saline for injection). 
Femoral nerve block with EXPAREL at 67 mg, 133 mg, and 266 mg was well tolerated in 
subjects undergoing TKA.  There were no discernible safety differences across the treatment 
groups.  There was a dose response in EXPAREL-treated subjects.  A dose of 266 mg was 
selected for Part 2. 
Part 2 of the study met its primary efficacy endpoint: the difference in the AUC of the NRS-R 
pain intensity scores through 72 hours between the EXPAREL group and the placebo group was 
statistically significant.  Additionally, the difference in the total postsurgical opioid consumption 
(mg) through 72 hours between the EXPAREL 266 mg group and the placebo group was 
statistically significant indicating lower opioid consumption in the EXPAREL group.   
In Part 1, there were no discernible safety differences across the treatment groups.  In Part 2, 
the incidences of TEAEs and treatment-emergent SAEs were similar between the EXPAREL 
266 mg group and the placebo group.  There were no deaths or withdrawals due to an AE during 
the study. 
During Part 2 of the study, three subjects experienced a fall; each subject was in the EXPAREL 
266 mg group.  Each of the three subjects was able to complete the 20-meter walk test at 
24 hours, 72 hours, and on Day 30.  The rate of inpatient falls in study 402-C-323, 1.8%, was 
very similar to the overall incidence of inpatient falls in TKA patients (between 1% and 2%). 
The 20-meter walk test was used to determine whether there was any significant degree of motor 
blockade with use of EXPAREL.  The percentage of subjects who were able to complete the 
walk test at 24 hours and 72 hours did not differ significantly across the EXPAREL and placebo 
groups in Part 1.  In Part 2, the percentage of subjects who were able to complete the walk test 
was comparable between EXPAREL 266 mg and placebo groups at 24 hours (53.0% vs. 58.5%, 
respectively) and 72 hours (83.1% vs. 92.6%, respectively).  This suggested a lack of significant 
motor blockade with EXPAREL.  This is confirmed by physician satisfaction with return of 
sensory/motor function.  
Pooled Nerve Block Safety Data 
In the All Studies pool, 335 subjects received EXPAREL (All Doses), 33 subjects received 
bupivacaine HCl, and 207 subjects received placebo. 
Overall, 184/335 subjects (54.9%) in the EXPAREL All Doses group, 15/35 subjects (45.5%) in 
the bupivacaine HCl group, and 99/207 subjects (47.8%) in the placebo group experienced at 
least one TEAE in a preferred term (PT) that had an incidence of ≥2%.  The incidence and types 
of TEAEs (PTs) were similar between the EXPAREL All Doses group and the placebo group. 
In the EXPAREL All Doses group, the TEAEs reported with an incidence ≥2% were anemia 
(5.1%), bradycardia (2.1%), sinus tachycardia (2.1%), constipation (13.4%), feeling cold (3.3%), 
local swelling (2.1%), pyrexia (20.3%), procedural hypotension (5.1%), body temperature 
increased (2.4%), headache (4.5%), hypoesthesia (7.8%), paresthesia (2.1%), urinary retention 
(4.2%), and pruritus (12.2%). 
 
 
 
CONFIDENTIAL 
29 of 88 
 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
 
            402-C-326 (FNB TKA) 
EXPAREL® 
 
 
          Clinical Study Protocol Amendment 3 
 
In the EXPAREL 266 mg group, the TEAEs reported with an incidence ≥2% were anemia 
(5.7%), sinus tachycardia (2.4%), constipation (18.1%), feeling cold (4.8%), local swelling 
(2.9%), pyrexia (24.3%), procedural hypotension (6.2%), body temperature increased (3.8%), 
mobility decreased (2.9%), headache (3.3%), hypoesthesia (2.4%), urinary retention (5.7%), 
and pruritus (16.7%). 
In the bupivacaine HCl group (N=33 subjects), the TEAEs reported with an incidence ≥2% were 
abdominal pain (3.0%), diarrhea (6.1%), flatulence (3.0%), chills (3.0%), injection site 
discomfort (3.0%), injection site erythema (9.1%), pyrexia (6.1%), drug hypersensitivity (3.0%), 
procedural hypotension (3.0%), back pain (6.1%), joint swelling (3.0%), headache (6.1%), 
hypoesthesia (24.2%), paresthesia (12.1%), nasal congestion (3.0%), and oropharyngeal pain 
(3.0%). 
In the placebo group, the TEAEs reported with an incidence ≥2% were anemia (3.9%), 
constipation (16.9%), feeling cold (3.9%), local swelling (2.4%), pyrexia (18.8%), procedural 
hypotension (2.9%), mobility decreased (2.4%), headache (3.4%), urinary retention (2.9%), and 
pruritus (15.9%). 
There were 17 TEAEs (anemia, bradycardia, sinus tachycardia, constipation, diarrhea, feeling 
cold, injection site erythema, pyrexia, postoperative wound infection, procedural hypotension, 
back pain, cluster headache, hypoesthesia, paresthesia, urinary retention, and pruritus) that 
occurred at an incidence of ≥5% in the EXPAREL 266 mg group where the incidence was 
greater in the EXPAREL group than in the placebo group. 
Please refer to the Investigator’s Brochure for additional information regarding the completed 
studies.   
7.4. 
Postmarketing Exposure 
As of June 2016, more than 2 million patients have received EXPAREL in the postmarketing 
setting.  
8. 
OBJECTIVES 
8.1. 
Primary Objectives 
The primary objective of this study is to evaluate the magnitude and duration of the analgesic 
effect achieved following single-dose injection femoral nerve block with EXPAREL in subjects 
undergoing primary unilateral TKA.  
8.2. 
Secondary Objectives 
The secondary objectives of this study are to further assess the efficacy, safety, and PK profile of 
EXPAREL as well as the onset and duration of sensory and motor function blockade following 
administration for analgesia in subjects undergoing primary unilateral TKA. 
 
 
 
CONFIDENTIAL 
30 of 88 
 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
 
            402-C-326 (FNB TKA) 
EXPAREL® 
 
 
          Clinical Study Protocol Amendment 3 
 
9. 
STUDY DESIGN AND PLAN 
9.1. 
Study Design 
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study in 
approximately 231 adult subjects undergoing primary unilateral TKA under general or spinal 
anesthesia.   
Subjects will be screened within 30 days prior to study drug administration.  During the 
Screening visit, which must take place at least 1 day prior to surgery, subjects will be assessed 
for past or present neurologic, cardiac, and general medical conditions that in the opinion of the 
Investigator would preclude them from study participation.  After the ICF is signed, the patient’s 
eligibility for participation in the study will be confirmed and demographic and baseline 
characteristics will be recorded. A medical history, surgical history, neurological assessment, 
sensory and motor function assessments, the study physical therapy assessments (ie, timed walk, 
timed up and go, and stair climbing tests), physical examination, 12-lead electrocardiogram 
(ECG), vital sign measurements, urine drug screen, blood alcohol test, clinical laboratory tests 
(hematology, chemistry, and urinalysis), and urine pregnancy test for women of childbearing 
potential will be conducted. 
On Day 0, eligible subjects will be randomized in a 1:1:1 ratio to receive a single dose of either 
EXPAREL 133 mg in 10 mL expanded in volume with 10 mL of normal saline for a total 
volume of 20 mL (Group 1); EXPAREL 266 mg in 20 mL (Group 2); or placebo 20 mL 
(Group 3).  Subjects may receive acetaminophen/paracetamol up to 1000 mg PO or IV every 
8 hours (q8h) (maximum total daily dose of 3000 mg) prior to surgery. 
Study drug (EXPAREL or placebo) will be administered in a blinded manner via an ultrasound 
guided single-dose femoral nerve block at least 1 hour prior to surgery.  A confirmatory photo 
of the ultrasound nerve block needle placement will be obtained.  Use of tourniquets and drains, 
if used, will be recorded.  Prior to placement of the prosthesis, 8 mL of bupivacaine HCl (0.5%) 
diluted with 8 mL of normal saline will be administered by the surgeon as a periarticular 
infiltration to the posterior capsule (8 mL medially and 8 mL laterally).  The use of opioids 
(other than ultrashort-acting opioids [ie, fentanyl, sufentanil, or remifentanil]), acetaminophen/ 
paracetamol, ketorolac, or other NSAIDs, and local anesthetics other than the study drug will not 
be permitted intraoperatively, except for emergency use to treat an adverse event (AE).   
Subjects will be required to remain at the hospital facility through postsurgical Day 4. 
Postsurgical Rescue Medication 
Subjects should only receive rescue medication upon request for pain control, as needed.  
Postsurgical rescue medication will consist of PO immediate-release oxycodone (initiating at 5-
10 mg every 4 hours [q4h] or as needed [PRN]).  If a subject cannot tolerate PO medication, 
IV morphine (2.5-5 mg) or hydromorphone (0.5-1 mg) may be administered q4h or PRN. 
Patient-controlled analgesia (PCA) is not permitted.  Postsurgically, all subjects will receive 
the following scheduled medications until hospital discharge: 
• Acetaminophen/paracetamol up to 1000 mg PO or IV every 8 hours (q8h) unless 
contraindicated.  The total daily dose of acetaminophen is not to exceed 3000 mg.  
 
 
 
CONFIDENTIAL 
31 of 88 
 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
 
            402-C-326 (FNB TKA) 
EXPAREL® 
 
 
          Clinical Study Protocol Amendment 3 
 
• Cyclobenzaprine (eg, Flexeril®) 10 mg PO x1 dose (PRN at the surgeon’s discretion) 
No other analgesic agents, including NSAIDs, are permitted through 108 hours.  After 108 hours, 
the analgesic regimen may be adjusted for each subject individually as deemed appropriate by 
the physician responsible for the postsurgical care. 
Postsurgical Assessments   
Postsurgical assessments will include pain intensity scores using a 10-cm visual analog scale 
(VAS) (see Appendix 1); total postsurgical opioid consumption; overall benefit of analgesia 
score (OBAS) questionnaire (see Appendix 2); subject satisfaction with overall analgesia using 
a 5-point Likert scale (see Appendix 3); neurological assessment (see Appendix 4); sensory 
function assessment (as measured by cold, pinprick, and light touch testing; see Appendix 5); 
degree of motor nerve block (see Appendix 6); physical therapy assessments (ie, timed walk, 
timed up and go, and stair climbing tests; Appendix 9); discharge readiness (see Appendix 7); 
unscheduled phone calls or office visits related to pain; 12-lead ECGs; vital sign measurements; 
and clinical laboratory tests (hematology, chemistry, and urinalysis; see Appendix 8).  At 
timepoints when multiple assessments coincide, the pain intensity assessment will be conducted 
first and the blood draw for PK analysis will be collected second, as applicable.   
Adverse events will be recorded from the time the ICF is signed through postsurgical Day 29.  
If a cardiac or neurological AE of special interest (AESI), fall, or SAE occurs during the study, 
an unscheduled PK blood sample must be collected.  In addition, a 12-lead ECG, vital signs, and 
any appropriate clinical laboratory tests must be conducted.  If conducted, the ECG must be read 
within 2 hours.   
Cardiac AESIs include chest pain (angina, myocardial infarction), abnormal/irregular heart rate 
(bradycardia, tachycardia, extrasystoles), and shortness of breath requiring intervention.  
Neurologic AESIs include altered mental status/altered sensorium, rigidity, dysarthria, seizure, 
tremors, metallic taste, tinnitus, perioral numbness, visual disturbance, severe or worsening 
dizziness, and any dizziness beyond 72 hours postdose.  Additionally, the following events are of 
special interest if they persist or occur beyond 72-hours postdose:hyperesthesia, muscular 
twitching, and tingling/paresthesia. 
Follow-up visits will be scheduled for all subjects on postsurgical Days 6 and 10.  A follow-up 
phone call will be made on postsurgical Day 29 to all subjects who received study drug to assess 
for AEs. 
Pharmacokinetic Assessment 
A population PK analysis will be utilized to limit the number of blood draws.  A total of 7 PK 
samples will be collected from each subject for this study. All subjects will have PK samples 
taken at baseline and upon arrival at the PACU.  An additional 5 blood samples will be collected 
at the assigned time windows, spanning from 24 hours postdose to postsurgical Day 6. There are 
two PK collection sequences for this study and a subject can only be randomized to one 
sequence. The PK schedule sequence will be indicated for each subject at the time of 
randomization and will also be noted on the randomization confirmation.    Subjects in Sequence 
1 will have samples taken at 24, 56, 68, 80, and 108 hours.  Subjects in Sequence 2 will have 
samples taken at 48, 60, 76, and 96 hours, and Day 6. 
 
 
 
CONFIDENTIAL 
32 of 88 
 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
 
            402-C-326 (FNB TKA) 
EXPAREL® 
 
 
          Clinical Study Protocol Amendment 3 
 
Blood samples for PK analysis may be drawn using a properly maintained indwelling cannula 
(PICC line) at the discretion of the Investigator.  Blood samples will be collected from all 
subjects to maintain the treatment double-blind.  Blood samples from the subjects randomized to 
placebo will be analyzed through the 24-hour timepoint.     
Interim PK Analysis 
A blinded interim PK analysis was completed after 30 subjects completed the assessments 
through postsurgical Day 10. All of the plasma samples from the subjects who received 
EXPAREL were analyzed and the plasma samples from the subjects randomized to placebo were 
analyzed through the 24-hour timepoint.  Enrollment continued while the interim PK data were 
analyzed.  The goal of this blinded analysis was to determine the appropriateness of the PK 
timepoints selected and make recommendations to keep, remove, or revise them in order to fully 
characterize the PK profile.   
The results of this analysis showed a median Tmax of 60 hours for the 133 mg EXPAREL group 
and a median Tmax of 78 hours for the 266 mg EXPAREL group. These data informed the 
changes to the PK collection schedule contained in this protocol amendment. 
In addition, the safety assessment timepoints, including the neurological exam, vital signs, and 
ECG were adjusted based on the interim PK data. 
9.1.1. 
Duration of the Study and Subject Participation  
Participation will begin at the signing of the ICF.  No more than 30 days should pass between 
signing of the ICF and the administration of EXPAREL.  The time from study drug 
administration through the end of participation is 30 ± 3 days.  Therefore, subjects may 
participate in the study for up to 63 days. 
9.1.2. 
Study Stopping Rules 
If Pacira, the Investigator, or officials from regulatory authorities discover conditions during the 
study that indicate that the study or study site should be terminated, this action may be taken 
after Pacira has consulted with appropriate regulatory authorities and notified the Investigator(s). 
Blinded Data Review (BDR) of the subject data will be conducted by an independent Safety 
Monitor Committee after the first 30 subjects have completed Day 29 and subsequently after 
every 30 subjects have completed Day 29. The independent Safety Monitors will communicate 
their review findings to the Pacira Medical Management and Biostatistics team and records will 
be maintained.  
The outcome of the BDR process will be the trigger for prompting the Safety Stopping Rules 
based on the incidence rate of serious or severe AE based on the following rules: 
• 
Incidence rate of severe or serious AESIs as defined by the protocol including cardiac 
AESIs and neurologic AESIs exceeding 5% and in at least 5 subjects  
• 
Incidence rate of severe dizziness exceeding 10% and in at least 5 subjects  
• 
Incidence rate of severe or serious AEs regardless of relationship to study drug 
exceeding 20% and in at least 10 subjects   
 
 
 
CONFIDENTIAL 
33 of 88 
 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
 
            402-C-326 (FNB TKA) 
EXPAREL® 
 
 
          Clinical Study Protocol Amendment 3 
 
The study will be halted and an unblinded review of the data and a relative risk data analysis will 
occur if the study stopping rule is triggered. If the relative risk is greater than 2, the next step will 
be one of the following actions: 
• 
Permanently stop the study. 
• 
Revise eligibility criteria to exclude subjects who appear to be at higher risk for a 
particular AE. 
In addition to the study stopping rules described above, any death will be thoroughly reviewed 
and appropriate action taken.  
9.2. 
Discussion of Study Design 
EXPAREL is approved for infiltration into a surgical site.  This Phase 3, multicenter, 
randomized, double-blind, placebo-controlled study is designed to further evaluate the efficacy, 
safety, and pharmacokinetics of femoral nerve block with EXPAREL for postsurgical analgesia 
in subjects undergoing TKA.  The double-blind study design is intended to avoid potential bias 
resulting from subject or Investigator knowledge of the assigned treatment. 
In the femoral nerve block study 402-C-323, the time to first opioid use was similar across the 
treatment groups likely due to pain in the posterior portion of the knee, which is enervated by the 
sciatic nerve.  Although the femoral nerve block is well-suited for surgery on the anterior thigh 
and knee, quadriceps tendon repair, and postoperative pain management after femur and knee 
surgery, it is often combined with a block of the sciatic nerve in order to achieve analgesia of 
nearly the entire lower extremity.  As this study, similar to 402-C-323, involves blockade of only 
the femoral nerve, prior to the placement of the prosthesis, an additional 8 mL of bupivacaine 
HCl (0.5%) diluted with 8 mL of normal saline will be administered by the surgeon as a 
periarticular infiltration to the posterior capsule (8 mL medially and 8 mL laterally).  This 
amount is consistent with the amount of study drug placed into the posterior capsule in prior 
EXPAREL studies (eg, study 402-C-208). 
In the femoral nerve block study 402-C-323, following a blinded review of the initial plasma 
samples from 13 subjects who received the 266 mg dose of EXPAREL, it was apparent that in 
some subjects the last plasma sample collected contained the highest bupivacaine concentration, 
and that it could not be definitively determined whether their time to maximum plasma 
concentration (Tmax) occurred prior to 72 hours, at 72 hours, or later.  Therefore, in the current 
study, the PK sampling period was extended through postsurgical Day 10 with more frequent PK 
blood draws scheduled between 60-84 hours for the first 30 subjects.  An interim assessment of 
the PK data from these subjects was then conducted and the protocol amended to revise the PK 
and safety assessment timepoints. 
EXPAREL was developed in nerve block as an analgesic and not an anesthetic.  It does not 
produce a dense, consistent sensory blockade as would be required for anesthesia; this is 
reflected in the current package insert.  There is no expectation of a complete or sustained block.  
Consistent with analgesia but not anesthesia, significant sensory blockade occurred very 
infrequently in the nerve block program.  In study 402-C-323, the return of motor function was 
assessed using a validated 20-meter walk test that is commonly used in clinical practice and has 
been used in numerous clinical trials.  The validation of this method was performed with the use 
of a walker or cane only to ensure subject safety.  The percentage of subjects able to complete 
 
 
 
CONFIDENTIAL 
34 of 88 
 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
 
            402-C-326 (FNB TKA) 
EXPAREL® 
 
 
          Clinical Study Protocol Amendment 3 
 
the 20-meter walk test was comparable between the EXPAREL and placebo groups at 24 hours, 
72 hours, and on Day 30.   
As there is no single universally clinically accepted validated outcomes instrument for motor 
testing, two motor tests of the muscles impacted by the nerve block will be undertaken.  
The degree of motor nerve block (angle of flexion [active and passive] and angle of extension 
[active and passive]) will be assessed at baseline (on Day 0 prior to the nerve block); at 
approximately 15, 30, and 45 minutes; prior to PACU discharge; at 6, 9, 12, 18, 24, 36, 48, 60, 
72, 84, 96, and 108 hours; and at hospital discharge.   
Similarly, there is no universally clinically accepted validated outcomes instrument for sensory 
testing.  Prior experience with EXPAREL (Study 402-C-203) utilized warm threshold, cool 
threshold, and vibratory sensation as well as pinprick testing.  In the current study, the subject’s 
sensitivity to cold, pinprick, and light touch in the proximal and distal part of innervated 
dermatomes that express the anterior femoral cutaneous nerve (L2/L3) and saphenous nerve (L4) 
will be assessed with their eyes closed at baseline (on Day 0 prior to the nerve block); 
at approximately 15, 30, and 45 minutes; prior to PACU discharge; at 6, 9, 12, 18, 24, 36, 48, 60, 
72, 84, 96, and 108 hours; and at hospital discharge.   
If there is a sensory and/or motor function deficit at the time of hospital discharge, sensory 
and/or motor function will again be assessed on Day 6. If there continues to be a sensory and/or 
motor function deficit on Day 6, sensory and/or motor function will again be assessed on Day 10. 
If there continues to be a sensory and/or motor function deficit on Day 10, the sensory and/or 
motor function deficit will be recorded as an AE and the physician will assess the subject for 
other etiologies that may explain the persistent deficit(s).  The subject will return for 
unscheduled visit(s) at the Investigator's discretion through postsurgical Day 29 or until sensory 
and/or motor function has returned to baseline, whichever occurs first.  See Section 13.1.6 for the 
criteria used to determine “return to baseline” for motor function.  
All subjects will receive an opioid analgesic(s) to control breakthrough postsurgical pain, as 
needed. 
If a cardiac or neurological AESI, fall, or SAE occurs during the study, an unscheduled PK blood 
sample must be collected.  In addition, a 12-lead ECG, vital signs, and any appropriate clinical 
laboratory tests must be conducted.  If conducted, the ECG must be read within 2 hours.  Cardiac 
AESIs include chest pain (angina, myocardial infarction), abnormal/irregular heart rate 
(bradycardia, tachycardia, extrasystoles), and shortness of breath requiring intervention.  
Neurologic AESIs include altered mental status/altered sensorium, rigidity, dysarthria, seizure, 
tremors, metallic taste, tinnitus, perioral numbness, visual disturbance, severe or worsening 
dizziness, and any dizziness beyond 72 hours postdose.  Additionally, the following events are of 
special interest if they persist or occur beyond 72-hours postdose: hyperesthesia, muscular 
twitching, and tingling/ paresthesia. 
 
 
 
CONFIDENTIAL 
35 of 88 
 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
 
            402-C-326 (FNB TKA) 
EXPAREL® 
 
 
          Clinical Study Protocol Amendment 3 
 
10. 
STUDY POPULATION 
10.1. 
Inclusion Criteria 
Subjects eligible for study entry must meet all of the following criteria: 
1. Male or female, at least 18 years of age at Screening. 
2. Scheduled to undergo primary unilateral TKA under general or spinal anesthesia. 
3. American Society of Anesthesiologists (ASA) physical status 1, 2, or 3.  
4. Female subject must be surgically sterile; or at least 2 years postmenopausal; or have a 
monogamous partner who is surgically sterile; or practicing double-barrier contraception; or 
practicing abstinence (must agree to use double-barrier contraception in the event of sexual 
activity); or using an insertable, injectable, transdermal, or combination oral contraceptive 
approved by the FDA for greater than 2 months prior to Screening and commit to the use of 
an acceptable form of birth control for the duration of the study and for 30 days after 
completion of the study. 
5. Able to demonstrate sensory function by exhibiting sensitivity to cold, pinprick, and light 
touch. 
6. Able to provide informed consent, adhere to the study visit schedule, and complete all study 
assessments. 
10.2. 
Exclusion Criteria 
A subject will not be eligible for the study if he or she meets any of the following criteria:  
1. Currently pregnant, nursing, or planning to become pregnant during the study or within 
1 month after study drug administration.   
2. Planned concurrent surgical procedure (eg, bilateral TKA). 
3. Concurrent painful physical condition that may require analgesic treatment (such as an 
NSAID or opioid) in the postsurgical period for pain that is not strictly related to the knee 
surgery and which may confound the postsurgical assessments (eg, significant pain from 
other joints including the non-index knee joint, chronic neuropathic pain, concurrent or prior 
contralateral TKA, concurrent foot surgery). 
4. Previous open knee surgery on the knee being considered for TKA.  Prior arthroscopy is 
permitted. 
5. History of hypersensitivity or idiosyncratic reaction to amide-type local anesthetics. 
6. Contraindication to any one of the following: bupivacaine, oxycodone, morphine, or 
hydromorphone. 
7. Use of any of the following medications within the times specified before surgery: long-
acting opioid medication or NSAIDs (except for low-dose aspirin used for cardioprotection) 
within 3 days, or any opioid medication within 24 hours. 
 
 
 
CONFIDENTIAL 
36 of 88 
 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
 
            402-C-326 (FNB TKA) 
EXPAREL® 
 
 
          Clinical Study Protocol Amendment 3 
 
8. Initiation of treatment with any of the following medications within 1 month of study drug 
administration or if the medication(s) are being given to control pain: selective serotonin 
reuptake inhibitors (SSRIs), selective norepinephrine reuptake inhibitors (SNRIs), 
gabapentin, pregabalin (Lyrica®), or duloxetine (Cymbalta®).  If a subject is taking one of 
these medications for a reason other than pain control, he or she must be on a stable dose for 
at least 1 month prior to study drug administration.   
9. Current use of systemic glucocorticosteroids within 1 month of enrollment in this study. 
10. Use of dexmedetomidine HCl (Precedex®) within 3 days prior to study drug administration. 
11. History of impaired kidney function, poorly controlled chronic respiratory disease, 
rheumatoid arthritis, coagulopathy, or loss of sensation in extremities. 
12. Impaired kidney function (eg, serum creatinine level >2 mg/dL [176.8 µmol/L] or blood urea 
nitrogen level >50 mg/dL [17.9 mmol/L]) or impaired liver function (eg, serum aspartate 
aminotransferase [AST] level >3 times the upper limit of normal (ULN) or serum alanine 
aminotransferase [ALT] level >3 times the ULN. 
13. Uncontrolled anxiety, psychiatric, or neurological disorder that might interfere with study 
assessments. 
14. Any chronic neuromuscular deficit effecting the peripheral nerves or muscles of the surgical 
extremity. 
15. Any chronic condition or disease that would compromise neurological or vascular 
assessments. 
16. Malignancy in the last 2 years, with the exception of non-metastatic basal cell or squamous 
cell carcinoma of the skin or localized carcinoma in situ of the cervix. 
17. Suspected or known history of drug or alcohol abuse within the previous year. 
18. Body weight <50 kg (110 pounds) or a body mass index >44 kg/m2. 
19. Previous participation in an EXPAREL study. 
20. Administration of an investigational drug within 30 days or 5 elimination half-lives of such 
investigational drug, whichever is longer, prior to study drug administration, or planned 
administration of another investigational product or procedure during the subject’s 
participation in this study. 
10.3. 
Removal of Subjects from Therapy or Assessment 
Every reasonable effort should be made to maintain subject compliance and participation in the 
study.  Reasons for discontinuation of any subject from the study will be recorded. 
If a subject who withdraws from the study has an ongoing AE, every effort must be made to 
follow such events until satisfactory resolution is obtained, or further follow-up is otherwise no 
longer warranted. 
10.3.1. 
Withdrawal Secondary to Adverse Events 
If a subject experiences an AE that renders him or her incapable of continuing with the 
remaining study assessments, then he or she will be discontinued from further participation in the 
 
 
 
CONFIDENTIAL 
37 of 88 
 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
 
            402-C-326 (FNB TKA) 
EXPAREL® 
 
 
          Clinical Study Protocol Amendment 3 
 
study.  A final evaluation should be performed so that the subject’s study participation can be 
terminated in a safe and orderly manner. 
10.3.2. 
Voluntary or Study Investigator Withdrawal 
Subjects are free to discontinue from the study at any time, without prejudice to future treatment.  
Nevertheless, subjects will be encouraged to complete at least the study safety assessments.  
In addition, a subject may be discontinued from the study if he or she refuses to comply with 
study procedures.  Reasons for discontinuation from the study will be recorded. 
If a subject is discontinued by the Investigator or voluntarily withdraws from the study after 
receiving study drug, the subject will be asked to complete a final evaluation so that he or she 
can be withdrawn in a safe and orderly manner.  In the final evaluation, vital signs (heart rate and 
blood pressure), sensory function, motor function, physical therapy assessments, and any 
changes in the subject's health status will be recorded.   
After termination from the study, the subject may be followed for safety including monitoring of 
AEs through postsurgical Day 29.   
11. 
TREATMENTS  
11.1. 
Treatment to be Administered 
Study Drug 
Subjects will receive a single dose of either EXPAREL 133 mg expanded in volume with 10 mL 
of normal saline to achieve a total volume of 20 mL (Group 1), EXPAREL 266 mg in 20 mL 
(Group 2), or placebo (normal saline, 20 mL) according to the randomization schedule.  Study 
drug administration will be performed in a blinded manner (see Section 11.5.1).   
Bupivacaine HCl 
In addition to the study drug, prior to the placement of the prosthesis, 8 mL of bupivacaine HCl 
(0.5%) diluted with 8 mL of normal saline will be administered by the surgeon as a periarticular 
infiltration to the posterior capsule (8 mL medially and 8 mL laterally).   
Postsurgical Rescue Medication 
Subjects should only receive rescue medication upon request for pain control, as needed.  
Postsurgical rescue medication will consist of PO immediate-release oxycodone (initiating at 5-
10 mg q4h or PRN).  If a subject cannot tolerate PO medication, IV morphine (2.5-5 mg) or 
hydromorphone (0.5-1 mg) may be administered q4h or PRN.  PCA is not permitted.  
Postsurgically, all subjects will receive the following scheduled medications until hospital 
discharge: 
• Acetaminophen/paracetamol up to 1000 mg PO or IV q8h unless contraindicated.  The total 
daily dose of acetaminophen is not to exceed 3000 mg.  
• Cyclobenzaprine (eg, Flexeril®) 10 mg PO x1 dose (PRN at the surgeon’s discretion) 
No other analgesic agents, including NSAIDs, are permitted through 108 hours.  After 108 hours, 
the analgesic regimen may be adjusted for each subject individually as deemed appropriate by 
 
 
 
CONFIDENTIAL 
38 of 88 
 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
 
            402-C-326 (FNB TKA) 
EXPAREL® 
 
 
          Clinical Study Protocol Amendment 3 
 
the physician responsible for the postsurgical care.  All analgesic use must be recorded through 
postsurgical Day 29. 
11.1.1. 
Administration Technique  
Study Drug 
Study drug (EXPAREL or placebo) will be administered under ultrasound guidance by the 
anesthesiologist into the femoral nerve as described below (adopted from Mariano 2009).  
A confirmatory photo of the ultrasound nerve block needle placement will be obtained.   
Subjects will have their femoral nerve located by ultrasound guidance alone.  The recommended 
method is as follows: With a linear array transducer in a sterile sleeve, the femoral nerve will be 
identified in a transverse (short-axis) view at the inguinal crease.  In a transverse view, the 
internal appearance of the peripheral nerve bundle is a mixture of hypoechoic neural tissue 
(fascicles) and hyperechoic connective tissue (perineurium and epineurium).  Once the optimal 
image of the femoral nerve is obtained, a local anesthetic skin wheal will be raised lateral to the 
ultrasound transducer.  A needle will be inserted through the skin wheal and directed medially in 
plane beneath the ultrasound transducer toward the femoral nerve.  The study drug (total volume 
of 20 mL) will be injected posterior to the femoral nerve via the needle.   
Bupivacaine HCl 
Posterior capsule: bupivacaine HCl should be infiltrated primarily into the peripheral aspects, 
behind the medial and lateral condyles.  Do not inject too deeply into the central portion of the 
posterior capsule to avoid puncturing the popliteal vessels.  Keeping the knee in a flexed position 
will help the vessels relax and pull away from the capsule. 
11.1.2. 
Study Drug Administration Considerations 
Since there is a potential risk of severe adverse effects associated with the administration of 
bupivacaine, the study sites must be equipped to manage subjects with any evidence of cardiac 
toxicity.   
EXPAREL may not be administered to a subject if it has been held in a syringe for more than 
4 hours after preparation.  In order to prevent the study drug from settling, gently inverting and 
re-inverting the syringe several times prior to administration is recommended.  No agents are to 
be admixed with EXPAREL.  
11.2. 
Identity of Investigational Product(s) 
11.2.1. 
Description of EXPAREL 
EXPAREL is formulated as a sterile, non-pyrogenic, white to off-white, preservative-free, 
homogeneous suspension of bupivacaine encapsulated into multivesicular lipid-based particles 
(the DepoFoam drug delivery system).  Bupivacaine is present at a nominal concentration of 
13.3 mg/mL.  EXPAREL will be provided in 20 mL, 1.3% (13.3 mg/mL) single-use, clear glass 
vials.  EXPAREL vials should be stored refrigerated between 2°C to 8°C (36°F to 46°F). 
 
 
 
CONFIDENTIAL 
39 of 88 
 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
 
            402-C-326 (FNB TKA) 
EXPAREL® 
 
 
          Clinical Study Protocol Amendment 3 
 
11.2.2. 
Description of Reference Product 
Placebo will consist of normal saline for injection.  Subjects in the placebo group will receive 
20 mL of placebo.  
11.2.3. 
Description of Diluents 
Normal saline for injection will be added to the 133 mg (10 mL) dose of EXPAREL to achieve a 
total volume of 20 mL.   
11.3. 
Method of Assigning Subjects to Treatment 
11.3.1. 
Randomization Scheme 
Approximately 231 subjects (77 per treatment group) are planned for enrollment.  Subjects will 
be randomized in a 1:1:1 ratio to receive a single-dose injection femoral nerve block with 
EXPAREL 133 mg, EXPAREL 266 mg, or placebo. 
The randomization code will be generated by a centralized randomization system, which will 
also be used to communicate subject randomizations to study sites.  All randomized subjects will 
have both a unique subject identifier and a unique random code identifier.  No subject or random 
code identifiers are to be reused once assigned.  
11.3.2. 
Randomization Procedures 
Once a subject is identified as being qualified for the study per the eligibility criteria (see 
Section 10.1 and Section 10.2), and is at the study site for surgery, the unblinded research 
pharmacist or designee will obtain a randomization assignment.  The subject will be considered 
randomized into the study once the study treatment assignment is received. 
11.3.3. 
Replacement of Subjects 
Subjects who are randomized but are withdrawn from the study before receiving study drug or 
do not undergo the surgical procedure may be replaced.  Once assigned, subject numbers will not 
be reused; subjects enrolled to replace those who withdraw will be assigned a unique subject 
number and randomized to treatment according to the procedures outlined above. 
11.4. 
Selection of Doses in the Study 
During the clinical development of EXPAREL, single doses ranging from 2 mg to 665 mg have 
been safely administered via various routes.  Pharmacokinetic studies have shown that because 
EXPAREL releases bupivacaine gradually as the lipid structure breaks down, administration of 
EXPAREL 266 mg results in a maximum plasma concentration (Cmax) equivalent to that seen 
with standard bupivacaine HCl 100 mg.   
Pacira conducted a Phase 2/3, multicenter, randomized, double-blind, parallel-group, placebo-
controlled, dose-ranging study in subjects undergoing primary unilateral TKA under general or 
spinal anesthesia (Study 402-C-323).  Three dose levels of EXPAREL versus placebo were 
evaluated with respect to the magnitude and duration of the analgesic effect achieved following 
single-dose injection femoral nerve block with EXPAREL.   
 
 
 
CONFIDENTIAL 
40 of 88 
 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
 
            402-C-326 (FNB TKA) 
EXPAREL® 
 
 
          Clinical Study Protocol Amendment 3 
 
Femoral nerve block with EXPAREL at 67 mg, 133 mg, and 266 mg was well tolerated in 
subjects undergoing TKA; there were no discernible safety differences across the treatment 
groups.  The primary endpoint was the AUC of the NRS-R pain intensity scores through 
72 hours.  The least squares (LS) mean AUC of the NRS-R pain intensity scores was 533.4 in the 
EXPAREL 67 mg group, 427.2 in the EXPAREL 133 mg group, 436.2 in the EXPAREL 266 mg 
group, and 530.5 in the placebo group.  The difference between the LS mean for the EXPAREL 
67 mg group and the placebo group was not statistically significant (p=0.9494); however, the 
differences between the other groups (EXPAREL 133 mg and EXPAREL 266 mg) and the 
placebo group were statistically significant (p=0.0237 and p=0.0386, respectively).  The two 
EXPAREL doses that were significantly superior to placebo for the primary endpoint, 133 mg 
and 266 mg, were selected for the current study. 
The most common volume of local anesthetic administered in the majority of femoral nerve 
blocks is 10 to 20 mL (Nader 2013), and previous studies with EXPAREL have used a range of 
concentrations in 20 mL. 
11.5. 
Blinding 
11.5.1. 
Blinding Procedures 
EXPAREL and placebo are visually distinguishable; therefore, to maintain the double-blind 
study design, only unblinded study personnel who are NOT involved with protocol-specific, 
postsurgical assessments may prepare and administer the study drug.  Staff members conducting 
study-specific, postsurgical assessments and the subjects will remain blinded to the assigned 
treatment throughout the study.  If a subject experiences an SAE, Pacira will not automatically 
unblind the subject’s treatment, unless it is necessary to manage treatment of the SAE.  
Expedited SAEs will be unblinded by Pacira for regulatory reporting purposes. 
At each site, only the designated unblinded pharmacist will receive unblinded randomization 
assignments and be responsible for preparing study drug.  
Assignment of blinded and unblinded responsibilities regarding the preparation of study drug 
should take into account that EXPAREL must be administered within 4 hours of opening 
the vial. 
The individuals preparing and administering study drug will not be allowed to perform any of the 
study assessments or reveal the assigned study treatment to any other members of the study team 
at any time.  Syringes containing study drug will need to be gently inverted several times to re-
suspend any settling of the study drug that may have occurred prior to administration.  The 
administration of study drug will be recorded using the minimal amount of information 
necessary to avoid unblinding staff who will be participating in blinded procedures (see 
Pharmacy Manual for additional details). 
No crossover will be permitted between the blinded and unblinded study site personnel during 
the study period.  The assignment of site monitors will also be segregated.  Blinded monitors will 
review case report forms (CRFs), clinic charts, and all other study-related documents that do not 
disclose the allocation of study treatment.  Care should be taken in recording and review of 
operating room records to not record information in an unblinded fashion.  Pharmacy or any 
other clinic records providing unblinded information (eg, randomization, study drug preparation, 
 
 
 
CONFIDENTIAL 
41 of 88 
 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
 
            402-C-326 (FNB TKA) 
EXPAREL® 
 
 
          Clinical Study Protocol Amendment 3 
 
study drug accountability, study drug administration) will be reviewed by specialized unblinded 
monitors who will notify Pacira of treatment noncompliance. 
11.5.2. 
Unblinding Procedures 
Subject treatment assignments should not be unblinded during the study by blinded study 
personnel.  The Investigator will have the ability to unblind a subject through the randomization 
system if he or she feels that subject safety warrants such unblinding.  However, the Investigator 
should discuss the safety issues with the Medical Monitor before attempting such unblinding, if 
possible.  Any unblinding will be documented through immediate notification of the Pacira study 
team and the Investigator within the interactive response technology (IRT) system used for 
randomization.  The reason for unblinding will be documented.  Any accidental unblinding 
events (ie, through mishaps in the operating room or miscommunication among study staff) must 
be reported to Pacira immediately.  
Any unblinding performed through the randomization system will be recorded as a transaction 
and the appropriate study personnel will be notified that such a transaction occurred. 
Any incidence(s) of unblinding will be noted in the clinical study report with a full discussion of 
the events leading to the decision to unblind. 
11.6. 
Prior and Concomitant Therapy and Medications 
All medications taken within 30 days prior to study drug administration through 108 hours after 
study drug administration or until the subject is withdrawn from the study, whichever is sooner, 
will be recorded on the CRF.  All analgesic use must be recorded through postsurgical Day 29. 
Additionally, any medications administered in association with an AE will be recorded through 
postsurgical Day 29.   
11.6.1. 
Before Study Drug Administration 
Permitted Prior Medications  
• 
Low-dose aspirin for cardioprotection. 
• 
Acetaminophen/paracetamol up to 1000 mg PO or IV q8h (maximum total daily dose 
of 3000 mg) is permitted.   
• 
1-2 mg of midazolam (Versed) pre-op 
Restricted Prior Medications and Therapy 
• 
Systemic glucocorticosteroids are prohibited within 1 month of enrollment in this 
study. 
• 
Initiation of treatment with any of the following medications is prohibited within 1 
month of study drug administration or if the medication(s) are being given to control 
pain: SSRIs, SNRIs, gabapentin, pregabalin (Lyrica), or duloxetine (Cymbalta).  If a 
subject is taking one of these medications for a reason other than pain control, he or 
she must be on a stable dose for at least 1 month prior to study drug administration. 
• 
Long-acting opioid medications or NSAIDs (except for low-dose aspirin used for 
cardioprotection) are not permitted within 3 days of study drug administration. 
 
 
 
CONFIDENTIAL 
42 of 88 
 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
 
            402-C-326 (FNB TKA) 
EXPAREL® 
 
 
          Clinical Study Protocol Amendment 3 
 
• 
Dexmedetomidine HCl (Precedex) use is not permitted within 3 days of study drug 
administration. 
• 
No opioid medications are permitted within 24 hours of study drug administration.   
• 
Use of an investigational product within 30 days or 5 elimination half-lives of such 
investigational drug, whichever is longer, prior to study drug administration, or 
planned administration of another investigational product or procedure during the 
subject’s participation in this study is not permitted. 
11.6.2. 
During Surgery 
Permitted 
• 
Ultra-short acting opioids (ie, fentanyl, sufentanil, or remifentanil) will be permitted 
during surgery. 
• 
Single-dose administration of ondansetron or metoclopramide may be used intra-
operatively for nausea/vomiting prevention.  If not available or contraindicated, a 
single dose of dexamethasone 10 mg IV may be administered. 
Restricted 
• 
No drugs are to be admixed with study drug (eg, epinephrine, dexamethasone, 
clonidine). 
• 
Lidocaine and other local anesthetics will not be permitted to be locally administered 
during surgery because they are known to interact with EXPAREL resulting in the 
displacement of bupivacaine and elevated plasma levels. 
• 
Intrathecal opioids. 
• 
The use of long-acting opioids (eg, morphine, hydromorphone HCl), acetaminophen/ 
paracetamol, ketorolac, or other NSAIDs will not be permitted intraoperatively except 
for emergency use to treat an AE.   
11.6.3. 
After Surgery 
Permitted 
• 
The permitted rescue medication is oxycodone (initiating at 5-10 mg q4h or PRN).  If 
a subject cannot tolerate PO medication, IV morphine (2.5-5 mg) or hydromorphone 
(0.5-1 mg) may be administered q4h or PRN.   
Postsurgically, all subjects will receive the following scheduled medications until hospital 
discharge: 
• 
Acetaminophen/paracetamol up to 1000 mg PO or IV q8h unless 
contraindicated.  The total daily dose of acetaminophen is not to exceed 3000 mg.  
• 
Cyclobenzaprine (eg, Flexeril®) 10 mg PO x1 dose (PRN at the surgeon’s discretion) 
Restricted 
• 
No other analgesics, including fentanyl, are permitted within 108 hours after study 
drug administration. 
 
 
 
CONFIDENTIAL 
43 of 88 
 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
 
            402-C-326 (FNB TKA) 
EXPAREL® 
 
 
          Clinical Study Protocol Amendment 3 
 
• 
PCA is not permitted.   
• 
Dexmedetomidine HCl (Precedex) use is prohibited. 
• 
Anesthetics in the "caine" family, which may interfere with the bupivacaine PK 
profile, are prohibited through postsurgical Day 10. 
For study purposes, it is important to standardize pain management modalities during the first 
108 hours following study drug administration.  Therefore, the study staff must adhere closely to 
the treatment options and requirements noted in the protocol.  After 108 hours, the analgesic 
regimen may be adjusted for each subject individually as deemed appropriate by the physician 
responsible for the postsurgical care. 
All postsurgical analgesics administered must be documented through postsurgical Day 29.  
11.7. 
Treatment Compliance 
Not applicable, since study drug (EXPAREL or placebo) will be administered preoperatively by 
the study staff. 
11.8. 
Accountability of Study Drug 
Any shipment of EXPAREL for the study will contain an investigational drug transmittal and 
receipt form to assist the Investigator or designee (eg, pharmacist) in maintaining current and 
accurate inventory records.  At a minimum, the pharmacist or designee will maintain accurate 
records demonstrating dates and units of drug received, lot numbers, subjects to whom drug was 
administered, and accounts of any drug destroyed accidentally or deliberately.  The Investigator 
must retain vials containing used, unused, or expired EXPAREL for return or destruction, as 
instructed by Pacira, following confirmation of drug accountability data by an unblinded study 
monitor.  A record of drug return or destruction will be maintained and provided to Pacira.  
Inventory records must be readily available for inspection by the unblinded study monitor and 
appropriate regulatory authorities at any time.  A copy of the inventory records, drug 
accountability information, and notice of return or destruction will be returned to Pacira at the 
end of the study.  Only authorized personnel identified by the Investigator will have the ability to 
access and administer the drug. 
12. 
STUDY ENDPOINTS AND MEASUREMENTS 
12.1. 
Efficacy Assessments 
The following efficacy measurements will be assessed at the times specified after the beginning 
of the femoral nerve block with study drug: 
• 
Pain intensity scores using the VAS at baseline (on Day 0 prior to the nerve block and 
prior to any premedication); upon arrival at the PACU, every 15 minutes while in the 
PACU, and prior to PACU discharge; at 6, 12, 24, 36, 48, 60, 72, 84, 96, and 108 hours; 
and immediately prior to each administration of rescue pain medication through 108 
hours (see Appendix 1). 
 
 
 
CONFIDENTIAL 
44 of 88 
 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
 
            402-C-326 (FNB TKA) 
EXPAREL® 
 
 
          Clinical Study Protocol Amendment 3 
 
• 
Date, time of administration, and amount of all opioid rescue medication taken through 
108 hours. 
• 
The OBAS questionnaire at 24 and 72 hours, and on postsurgical Day 10 (see 
Appendix 2).   
• 
Physical therapy assessments (ie, timed walk, timed up and go, and stair climbing tests) 
will be conducted once postsurgically on Day 0; at 8:00 am (±2 hrs) and 8:00 pm (±2 hrs) 
from postsurgical Day 1 through hospital discharge; and on postsurgical Day 10 
(Appendix 9).  Preemptive use of opioids or NSAIDs prior to the physical therapy 
assessment is not permitted. 
• 
Subject satisfaction with overall analgesia (using a 5-point Likert scale) at 24 and 
72 hours, and postsurgical Day 10 (see Appendix 3). 
• 
Discharge readiness at 12, 24, 36, 48, 60, 72, 84, and 96 hours or until the subject is 
determined to be discharge ready, whichever occurs first (see Appendix 7). 
• 
Unscheduled phone calls or office visits related to pain after discharge through 
postsurgical Day 10. 
12.2. 
Efficacy Endpoints 
The efficacy endpoints listed below will be assessed based on the efficacy measurements 
conducted at the times specified after the beginning of the femoral nerve block with study drug. 
Primary Endpoint: 
The primary endpoint is AUC of the VAS pain intensity scores through 72 hours. 
Secondary Endpoints: 
The following secondary endpoints will be analyzed in the following order: 
1. Total postsurgical opioid consumption (in IV morphine equivalents) through 72 hours.  
2. Percentage of opioid-free subjects through 72 hours.  
3. Time to first opioid rescue through 72 hours. 
Tertiary Endpoints:  
• 
The AUC of the VAS pain intensity scores through 12, 24, 48, and 96 hours. 
• 
The AUC of the VAS pain intensity scores from 24-48, 48-72, and 72-96 hours. 
• 
VAS pain intensity scores at each assessed timepoint. 
• 
Proportion of subjects who are pain free (defined as a VAS pain intensity score of 
≤1.5 without prior rescue medication use) at each assessed timepoint.  
• 
Sum of the pain intensity scores (SPIS) through 24, 48, 72, and 96 hours. 
• 
SPIS from 24-48, 48-72, and 72-96 hours. 
• 
Total opioid consumption in IV morphine equivalents through 24, 48, and 96 hours. 
 
 
 
CONFIDENTIAL 
45 of 88 
 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
 
            402-C-326 (FNB TKA) 
EXPAREL® 
 
 
          Clinical Study Protocol Amendment 3 
 
• 
Total opioid consumption in IV morphine equivalents from 24-48, 48-72, and 
72-96 hours. 
• 
Percentage of opioid-free subjects through 24, 48, and 96 hours. 
• 
The OBAS total score at 24 and 72 hours, and postsurgical Day 10. 
• 
Physical therapy assessments (ie, timed walk, timed up and go, and stair climbing 
tests) will be conducted once postsurgically on Day 0; at 8:00 am (±2 hrs) and 
8:00 pm (±2 hrs) from postsurgical Day 1 through hospital discharge; and once on 
postsurgical Day 10.   
• 
Subject satisfaction with overall analgesia (using a 5-point Likert scale) at 24 and 
72 hours, and postsurgical Day 10.  
• 
Proportion of subjects meeting Modified Postanesthesia Discharge Scoring System 
(MPADSS) criteria for discharge readiness at 12, 24, 36, 48, 60, 72, 84, and 96 hours. 
• 
Number of unscheduled phone calls or office visits related to pain after discharge 
through postsurgical Day 10. 
12.3. 
Pharmacokinetic Analysis  
A population PK analysis will be utilized to limit the number of blood draws.  A total of 7 PK 
samples will be collected for this study. All subjects will have PK samples taken at baseline and 
upon arrival at the PACU.  An additional 5 blood samples will be collected at the assigned time 
windows, spanning from 24 hours postdose to postsurgical Day 6.  There are two PK collection 
sequences for this study and a subject can only be randomized to one sequence.  The PK 
schedule sequence will be indicated for each subject at the time of randomization and will also 
be noted on the randomization confirmation.  Subjects in Sequence 1 will have samples taken at 
24, 56, 68, 80, and 108 hours.  Subjects in Sequence 2 will have samples taken at 48, 60, 76, and 
96 hours, and Day 6. 
Blood samples for PK analysis may be drawn using a properly maintained indwelling cannula 
(PICC line) at the discretion of the Investigator.  Blood samples will be collected from all 
subjects to maintain the treatment double-blind.  Blood samples from the subjects randomized to 
placebo will be analyzed through the 24-hour timepoint.     
12.4. 
Pharmacokinetic Endpoints 
Pharmacokinetic parameters will be estimated from the plasma bupivacaine measurements using 
non-compartmental analysis.  The following parameters will be determined: 
AUC0-tlast 
The area under the plasma concentration-versus-time curve from the time of 
administration to the time of the last quantifiable concentration calculated using 
the log-linear trapezoidal rule. 
AUC0-∞  
The area under the plasma concentration-versus-time curve from the time of 
administration extrapolated to infinity.  The residual area from the time of the last 
quantifiable concentration (Ctlast) to infinity is to be calculated using the 
approximation: AUCt-∞ = Ctlast/λz.   
Cmax  
The maximum observed plasma concentration obtained directly from the 
experimental data without interpolation. 
 
 
 
CONFIDENTIAL 
46 of 88 
 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
 
            402-C-326 (FNB TKA) 
EXPAREL® 
 
 
          Clinical Study Protocol Amendment 3 
 
Tmax  
The time to maximum plasma concentration (Cmax). 
λz  
The apparent terminal elimination rate constant determined by log-linear 
regression of the terminal log-linear segment of the plasma concentration-versus-
time curve. 
t1/2el 
The apparent terminal elimination half-life calculated as 0.693/λz. 
12.5. 
Safety Assessments 
The following safety assessments will be conducted at the times specified after the beginning of 
the femoral nerve block with study drug: 
• 
Clinical laboratory tests (hematology, chemistry, and urinalysis) at baseline (on Day 0 
prior to the nerve block) and on postsurgical Day 10 (see Appendix 8). 
• 
Vital signs (resting heart rate and blood pressure) at baseline (on Day 0 prior to the nerve 
block); every 5 minutes during performance of the block up to 30 minutes; and  every 15 
minutes after the block until entering the operating room; upon arrival at the PACU; at 6, 
9, 12, 24, 36, 48, 56, 60, 64, 68, 72, 76, 80, 84, 96, and 108 hours; and on postsurgical 
Days 6 and 10. 
• 
12-lead ECG recordings at baseline (on Day 0 prior to the nerve block); upon arrival at 
the PACU; at 6, 9, 12, 24, 36, 48, 56, 60, 64, 68, 72, 76, 80, 84, 96, and 108 hours; and 
on postsurgical Days 6 and 10.  Note: ECGs must be read within 2 hours. 
• 
Neurological assessment at baseline (on Day 0 prior to the nerve block); upon arrival at 
the PACU; at 6, 9, 12, 24, 36, 48, 56, 60, 64, 68, 72, 76, 80, 84, 96, and 108 hours; and 
on postsurgical Days 6 and 10 (see Appendix 4).  
• 
Sensory function assessment (as measured by cold, pinprick, and light touch testing) at 
baseline (on Day 0 prior to the nerve block); at approximately 15, 30, and 45 minutes 
after the nerve block; prior to discharge from the PACU; and at 6, 9, 12, 18, 24, 36, 48, 
60, 72, 84, 96, and 108 hours; and hospital discharge (see Appendix 5).  If there is a 
sensory deficit at time of hospital discharge, sensory function will again be assessed on 
Day 6. If there continues to be a sensory deficit on Day 6, sensory function will again be 
assessed on Day 10. If there continues to be a sensory deficit on Day 10, the sensory 
deficit will be recorded as an AE and the physician will assess the subject for other 
etiologies that may explain the persistent deficit. The subject will return for unscheduled 
visit(s) at the Investigator's discretion through postsurgical Day 29 or until the sensory 
function has returned to baseline, whichever occurs first. 
• 
Degree of motor nerve block (angle of flexion [active and passive] and angle of extension 
[active and passive]) at baseline (on Day 0 prior to the nerve block); at approximately 
15, 30, and 45 minutes after the nerve block; prior to discharge from the PACU; and at 6, 
9, 12, 18, 24, 36, 48, 60, 72, 84, 96, and 108 hours; and hospital discharge (see 
Appendix 6). If there is a motor function deficit at time of hospital discharge, motor 
function will again be assessed on Day 6. If there continues to be a motor function deficit 
on Day 6,  motor function will again be assessed on Day 10.  If there continues to be a 
motor function deficit on Day 10, the motor function deficit will be recorded as an AE 
and the physician will assess the subject for other etiologies that may explain the 
persistent deficit.  The subject will return for unscheduled visit(s) at the Investigator's 
 
 
 
CONFIDENTIAL 
47 of 88 
 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
 
            402-C-326 (FNB TKA) 
EXPAREL® 
 
 
          Clinical Study Protocol Amendment 3 
 
discretion through postsurgical Day 29 or until the motor function has returned to 
baseline, whichever occurs first. See Section 13.1.6 for the criteria used to determine 
“return to baseline” for motor function. 
• 
Adverse events from the time the ICF is signed through Day 29. 
12.6. 
Safety Endpoints 
The following safety endpoints will be assessed based on the safety measurements conducted at 
the specified timepoints: 
• 
Change from baseline in clinical laboratory data at each assessed timepoint. 
• 
Change from baseline in vital signs (resting heart rate and blood pressure) at each 
assessed timepoint. 
• 
Change from baseline in ECG data at each assessed timepoint. 
• 
Summary of neurological assessments (proportion of subjects who are oriented, and 
proportion of subjects who have any of the neurologic events). 
• 
Cold sensation at each assessed timepoint. 
• 
Pinprick sensation at each assessed timepoint. 
• 
Light touch sensation at each assessed timepoint. 
• 
Change from baseline in motor function (flexion [active and passive] and extension 
[active and passive]) at each assessed timepoint. 
• 
Incidence of TEAEs and SAEs through postsurgical Day 29. 
12.7. 
Appropriateness of Measures  
Endpoints selected for this study were based on validated methodologies and other well 
established clinical measurements used in peer-reviewed studies in both the peer reviewed 
literature and at regulatory authorities.  Measurements were further refined in this study based on 
previous nerve block experience with EXPAREL including the Phase 2/3 femoral nerve block 
study 402-C-323 in TKA and feedback from the FDA.   
13. 
STUDY PROCEDURES 
A time and events schedule for all study procedures is provided in Table 1, Table 2, and Table 3. 
13.1. 
Instructions for Conducting Procedures and Measures 
All safety, efficacy, and PK assessments conducted after baseline will be timed from the 
beginning of the femoral nerve block with study drug.   
At timepoints when multiple assessments coincide, the pain intensity assessment will be 
conducted first and the blood draw for PK analysis will be collected second, as applicable.   
 
 
 
CONFIDENTIAL 
48 of 88 
 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
 
            402-C-326 (FNB TKA) 
EXPAREL® 
 
 
          Clinical Study Protocol Amendment 3 
 
Day 0 is defined as the day on which study drug is administered.  The beginning of surgery is 
defined as the time of the first incision.  The end of surgery is defined as the time of the last 
suture.  Postsurgical is defined as after the end of surgery.   
Postsurgical analgesia and collection of study data through the primary endpoint will take place 
under the supervision of study staff. 
13.1.1. 
Pain Intensity Assessments 
Pain intensity will be assessed using the VAS (Carlsson 1983, McCormack 1988, and 
Scott 1976) at baseline (on Day 0 prior to the nerve block and prior to any premedication); upon 
arrival at the PACU, every 15 minutes while in the PACU, and prior to PACU discharge; at 6, 
12, 24, 36, 48, 60, 72, 84, 96, and 108 hours; and immediately prior to each administration of 
rescue pain medication through 108 hours (see Appendix 1).   
If ice or passive extenders are used, these must be stopped at least 15 minutes prior to the pain 
intensity assessment.  If subjects are in immobilizers, these must be removed at least 15 minutes 
prior to the pain intensity assessment. 
13.1.2. 
Overall Benefit of Analgesia Score Questionnaire 
The OBAS questionnaire will be completed at 24 and 72 hours, and on postsurgical Day 10 
(see Appendix 2). 
13.1.3. 
Subject Satisfaction with Postsurgical Pain Control 
The subject’s satisfaction with postsurgical pain control will be assessed using the Likert Scale 
at 24 and 72 hours, and on postsurgical Day 10 (see Appendix 3). 
13.1.4. 
Neurological Assessment 
A neurological assessment will be conducted at Screening; baseline (on Day 0 prior to the nerve 
block); upon arrival at the PACU; at 6, 9, 12, 24, 36, 48, 56, 60, 64, 68, 72, 76, 80, 84, 96, and 
108 hours; and on postsurgical Days 6 and 10.  The examination will include the subject's 
orientation.  Additionally, the subject will be asked whether he or she is experiencing any 
numbness of the lips, the tongue, or around the mouth; a metallic taste in the mouth; vision 
problems; hearing problems; or muscle twitching (see Appendix 4).  If the subject answers "yes" 
to any of these questions, the event should be recorded as an AE and additional safety procedures 
must be conducted (see Section 13.1.12). 
13.1.5. 
Sensory Function Assessment 
Sensory function (as measured by cold, pinprick, and light touch sensation) will be assessed at 
Screening; baseline (on Day 0 prior to the nerve block); at approximately 15, 30, and 45 minutes 
after the nerve block; prior to discharge from the PACU; and at 6, 9, 12, 18, 24, 36, 48, 60, 72, 
84, 96, and 108 hours; and hospital discharge (see Appendix 5).  If there is a sensory deficit at 
time of hospital discharge, sensory function will again be assessed on Day 6. If there continues to 
be a sensory deficit on Day 6, sensory function will again be assessed on Day 10. If there 
continues to be a sensory deficit on Day 10, the sensory deficit will be recorded as an AE and the 
physician will assess the subject for other etiologies that may explain the persistent deficit. The 
 
 
 
CONFIDENTIAL 
49 of 88 
 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
 
            402-C-326 (FNB TKA) 
EXPAREL® 
 
 
          Clinical Study Protocol Amendment 3 
 
subject will return for unscheduled visit(s) at the Investigator's discretion through postsurgical 
Day 29 or until the sensory function has returned to baseline, whichever occurs first.   
The assessors will be deemed to be qualified if the following three conditions are met: 
1. They are a licensed or certified medical professionals (physician, nurse, physical 
therapist, etc), 
2. They have prior experience completing the assessment being conducted or have similar 
relevant experience, 
3. They have participated  and completed the 326 protocol specific training on the study 
assessment through either one of the following: 
a. Participation at the Investigator Meeting 
OR 
b. Completed the Pacira Pharmaceuticals ComplianceWire Training (the study 
specific Learning Management System) including review of the slide deck and 
training videos. 
13.1.6. 
Motor Nerve Block Assessment 
The motor nerve block assessment (angle of flexion [active and passive] and angle of extension 
[active and passive]) will be assessed at Screening; baseline (on Day 0 prior to the nerve block); 
at approximately 15, 30, and 45 minutes after the nerve block; prior to discharge from the 
PACU; at 6, 9, 12, 18, 24, 36, 48, 60, 72, 84, 96, and 108 hours; and at hospital discharge 
(see Appendix 6).  If there is a motor function deficit at time of hospital discharge, motor 
function will again be assessed on Day 6. If there continues to be a motor function deficit on Day 
6, motor function will again be assessed on Day 10.  If there continues to be a motor function 
deficit on Day 10, the motor function deficit will be recorded as an AE and the physician will 
assess the subject for other etiologies that may explain the persistent deficit. The subject will 
return for unscheduled visit(s) at the Investigator’s discretion through postsurgical Day 29 or 
until the motor function has returned to baseline, whichever occurs first. 
The assessors will be deemed to be qualified if the following three conditions are met: 
1. They are a licensed or certified medical professionals (physician, nurse, physical 
therapist, etc), 
2. They have prior experience completing the assessment being conducted, or have similar 
relevant experience, 
3. They have participated  and completed the 326 protocol specific training on the study 
assessment through either one of the following: 
a. Participation at the Investigator Meeting 
OR 
b. Completed the Pacira Pharmaceuticals ComplianceWire Training (the study 
specific Learning Management System) including review of the slide deck and 
training videos. 
The following criteria (Paauwe 2008) will be used to determine if a subject has achieved a level 
of clinically meaningful physical rehabilitation or “return to baseline”:  
1. Active flexion angle ≥80°. 
2. Active extension angle ≤10°. 
 
 
 
CONFIDENTIAL 
50 of 88 
 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
 
            402-C-326 (FNB TKA) 
EXPAREL® 
 
 
          Clinical Study Protocol Amendment 3 
 
If a subject demonstrates a motor function deficit at Baseline, the subject will be considered to 
have returned to baseline if, at 108 hours (or before), the following two criteria are met: 
1. The active flexion measurement is no more than 10° less than the Baseline measurement 
AND 
2. The active extension angle is no more than 10° greater than the Baseline measurement 
13.1.7. 
Clinical Laboratory Tests 
A urine drug screen and blood alcohol test will be conducted at Screening and a urine drug 
screen and an alcohol breath test will be conducted at baseline (on Day 0 prior to the nerve 
block).   
The scheduled clinical laboratory tests (hematology, chemistry, and urinalysis) will be conducted 
at Screening; baseline (on Day 0 prior to the nerve block); and on postsurgical Day 10 (see 
Appendix 8).  Clinical laboratory tests, as appropriate, may also be conducted if a subject 
experiences an AESI (ie, cardiac AE, neurological AE, or fall) or an SAE (see Section 13.1.12).  
13.1.8. 
Vital Signs 
The scheduled vital signs (heart rate and blood pressure) will be measured after the subject has 
rested in a supine position for at least 5 minutes at Screening; baseline (on Day 0 prior to the 
nerve block); every 5 minutes during the performance of the nerve block up to 30 minutes; and 
then every 15 minutes after completion of the block until arrival at the OR; upon arrival at the 
PACU; at 6, 9, 12, 24, 36, 48, 56, 60, 64, 68, 72, 76, 80, 84, 96, and 108 hours; and on 
postsurgical Days 6 and 10.  Vital signs will also be measured if a subject experiences an AESI 
(ie, cardiac AE, neurological AE, or fall) or an SAE (see Section 13.1.12).  The subject will 
remain in a supine position during the assessment.   
13.1.9. 
Physical Examination 
A full physical examination will be conducted at s Screening.  Superficial abnormalities that may 
interfere with participation in the study will be noted.  A targeted physical examination will be 
conducted on postsurgical Day 10 and will include examination of the lower extremity including 
the site of the femoral block and the knee itself.   
13.1.10. 
Electrocardiogram 
The scheduled 12-lead ECGs will be conducted after the subject has rested in a supine position 
for at least 5 minutes at Screening; baseline (on Day 0 prior to the nerve block); upon arrival at 
the PACU; at 6, 9, 12, 24, 36, 48, 56, 60, 64, 68, 72, 76, 80, 84, 96, and 108 hours; and on 
postsurgical Days 6 and 10.  The 12-lead ECG(s) will also be conducted if a subject experiences 
an AESI (ie, cardiac AE, neurological AE, or fall) or an SAE (see Section 13.1.12).  Note: ECGs 
must be read within 2 hours. 
13.1.11. 
Physical Therapy Assessments 
The physical therapy assessment (ie, timed walk, timed up and go, and stair climbing tests) will 
be conducted at Screening; once postsurgically on Day 0; each day at 8:00 am (±2h) and 8:00 pm 
(±2h) from Day 1 through hospital discharge; and once on Day 10. 
 
 
 
CONFIDENTIAL 
51 of 88 
 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
 
            402-C-326 (FNB TKA) 
EXPAREL® 
 
 
          Clinical Study Protocol Amendment 3 
 
Preemptive use of opioids or NSAIDs immediately prior to the physical therapy assessment is 
not permitted.  
The physical therapy assessments will be completed in the following order: timed walk test, 
followed by the timed up and go test, followed by the stair climbing test. 
At timepoints when multiple assessments coincide, the physical therapy assessments will be 
conducted last. 
Details regarding the information to be recorded for the physical therapy assessments are 
provided in Appendix 9. 
13.1.12. 
Adverse Events of Special Interest 
If a cardiac or neurological AESI, fall, or SAE occurs during the study, an unscheduled PK blood 
sample must be collected.  In addition, a 12-lead ECG, vital signs, and any appropriate clinical 
laboratory tests must be conducted.  If conducted, the ECG must be read within 2 hours. 
Cardiac AESIs include:  
• 
Chest pain (angina, myocardial infarction)  
• 
Abnormal/irregular heart rate (bradycardia, tachycardia, extrasystoles) 
• 
Shortness of breath requiring intervention  
Neurologic AESIs include:  
• 
Altered mental status/altered sensorium 
• 
Rigidity 
• 
Dysarthria 
• 
Seizure 
• 
Tremors 
• 
Metallic taste 
• 
Tinnitus 
• 
Perioral numbness 
• 
Visual disturbance 
• 
Severe or worsening dizziness 
• 
Dizziness beyond 72 hours postdose 
Additionally, the following events are of special interest if they persist or occur beyond 72-hours 
postdose:  
• 
Hyperesthesia 
• 
Muscular twitching 
• 
Tingling/paresthesia 
 
 
 
CONFIDENTIAL 
52 of 88 
 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
 
            402-C-326 (FNB TKA) 
EXPAREL® 
 
 
          Clinical Study Protocol Amendment 3 
 
13.2. 
Screening Procedures  
• 
Explain study purpose and procedures 
• 
Obtain signed ICF 
• 
Assess eligibility 
• 
Record relevant medical/surgical history, demographics, and baseline characteristics 
• 
Conduct urine pregnancy test for women of childbearing potential 
• 
Perform physical examination 
• 
Conduct urine drug screen and blood alcohol test 
• 
Conduct clinical laboratory tests (hematology, chemistry, and urinalysis; see 
Appendix 8) 
• 
Perform neurological assessment (see Appendix 4) 
• 
Measure vital signs (heart rate and blood pressure) after subject has rested in a supine 
position 
• 
Conduct 12-lead ECG after subject has rested in a supine position 
• 
Perform sensory function assessment (see Appendix 5) 
• 
Conduct motor function assessment (see Appendix 6) 
• 
Conduct physical therapy assessments (ie, timed walk, timed up and go, and stair 
climbing tests; see Appendix 9) 
• 
Record concomitant medications 
• 
Record AEs starting at signing of the ICF 
13.3. 
Baseline Procedures (Day 0 - Prior to Study Drug Administration) 
• 
Confirm eligibility 
• 
Update relevant medical and surgical history 
• 
Conduct urine pregnancy test for women of childbearing potential 
• 
Conduct urine drug screen and alcohol breath test 
• 
Record baseline VAS pain intensity score prior to any premedication (see 
Appendix 1) 
• 
Collect baseline blood sample for PK analysis 
• 
Perform neurological assessment (see Appendix 4) 
• 
Measure vital signs (heart rate and blood pressure) after subject has rested in a supine 
position 
• 
Conduct 12-lead ECG after subject has rested in a supine position.  ECG must be read 
within 2 hours 
 
 
 
CONFIDENTIAL 
53 of 88 
 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
 
            402-C-326 (FNB TKA) 
EXPAREL® 
 
 
          Clinical Study Protocol Amendment 3 
 
• 
Perform sensory function assessment (see Appendix 5) 
• 
Conduct motor function assessment (see Appendix 6) 
• 
Conduct clinical laboratory tests (hematology, chemistry, and urinalysis; see 
Appendix 8) 
• 
Randomize subject and prepare study drug 
• 
Record changes to concomitant medications since Screening 
• 
Record AEs and any treatment(s) for the events 
13.4. 
Baseline Procedures (Time 0) 
• 
Administer blinded study drug via femoral nerve block at least 1 hour prior to surgery 
• 
Measure vital signs (resting heart rate and blood pressure) every 5 minutes during the 
performance of the block  
• 
Record start and stop times of study drug administration 
• 
Take confirmatory photo of the ultrasound nerve block needle placement 
• 
Record concomitant medications 
• 
Record AEs and any treatment(s) for the events 
• 
Refer to Section 13.1.12 for additional procedures in the event a cardiac AE, 
neurological AE, fall, or SAE occurs 
13.5. 
Approximately 15, 30, and 45 Minutes After Study Drug 
Administration 
• 
Perform sensory function assessment (see Appendix 5) 
• 
Conduct motor function assessment (see Appendix 6) 
• 
Measure vital signs (resting heart rate and blood pressure) every 5 minutes upto 
30 minutes after the block and then every 15 minutes until entering the OR 
• 
Record concomitant medications 
• 
Record AEs and any treatment(s) for the events 
• 
Refer to Section 13.1.12 for additional procedures in the event a cardiac AE, 
neurological AE, fall, or SAE occurs 
13.6. 
Intraoperative Procedures  
• 
Prior to placement of the prosthesis, administer 8 mL of bupivacaine HCl (0.5%) 
(40 mg) diluted with 8 mL of normal saline as a periarticular infiltration to the 
posterior capsule 
• 
Record time of bupivacaine HCl administration 
• 
Record intraoperative opioids administered and doses 
 
 
 
CONFIDENTIAL 
54 of 88 
 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
 
            402-C-326 (FNB TKA) 
EXPAREL® 
 
 
          Clinical Study Protocol Amendment 3 
 
• 
Record start and stop times of tourniquet use and the maximum pressure (mm Hg) 
• 
Record time of insertion of drain(s), if used 
• 
Record start and stop times of surgery 
• 
Record concomitant medications 
• 
Record AEs and any treatment(s) for the events  
• 
Refer to Section 13.1.12 for additional procedures in the event a cardiac AE, 
neurological AE, fall, or SAE occurs 
13.7. 
Upon Arrival at the Post-Anesthesia Care Unit 
• 
Record VAS pain intensity score (see Appendix 1) upon arrival at the PACU and then 
every 15 minutes until PACU discharge 
• 
Collect scheduled PK blood sample; record date and time 
• 
Perform neurological assessment (see Appendix 4) 
• 
Measure vital signs (heart rate and blood pressure) after subject has rested in a supine 
position 
• 
Conduct 12-lead ECG after subject has rested in a supine position. ECG must be read 
within 2 hours 
• 
Administer rescue medication upon request, as needed (see Section 11.1) 
• 
Record times and doses of all opioid and non-opioid rescue medication administered. 
• 
Record other concomitant medications 
• 
Record AEs and any treatment(s) for the events 
• 
Refer to Section 13.1.12 for additional procedures in the event a cardiac AE, 
neurological AE, fall, or SAE occurs 
13.8. 
Prior to PACU Discharge 
• 
Record VAS pain intensity score (see Appendix 1) 
• 
Assess sensory function (see Appendix 5) 
• 
Assess degree of motor nerve block (see Appendix 6) 
• 
Record other concomitant medications 
• 
Record AEs and any treatment(s) for the events 
• 
Refer to Section 13.1.12 for additional procedures in the event a cardiac AE, 
neurological AE, fall, or SAE occurs 
 
 
 
CONFIDENTIAL 
55 of 88 
 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
 
            402-C-326 (FNB TKA) 
EXPAREL® 
 
 
          Clinical Study Protocol Amendment 3 
 
13.9. 
Postsurgical Assessments through Hour 108 
• 
Record VAS pain intensity scores at 6, 12, 24, 36, 48, 60, 72, 84, 96, and 108 hours; 
and immediately prior to each administration of rescue pain medication 
(see Appendix 1) 
• 
Collect scheduled blood samples for PK analysis per sequence schedule; record the 
date and time each sample is collected 
o PK Sequence Schedule 1: Blood collected at 24 (±1) hrs, 56 (±2) hrs, 68 (±2) hrs, 
80 (±2) hrs, and 108 (±6) hrs. 
o PK Sequence Schedule 2: Blood collected at 48 (±1) hrs, 60 (±2) hrs, 76 (±2) hrs, 
96 (±4) hrs, and Day 6 (±1 day) 
• 
Perform neurological assessment at 6, 9, 12, 24, 36, 48, 56, 60, 64, 68, 72, 76, 80, 84, 
96, and 108 hours (see Appendix 4) 
• 
Measure vital signs (heart rate and blood pressure) after subject has rested in a supine 
position at 6, 9, 12, 24, 36, 48, 56, 60, 64, 68, 72, 76, 80, 84, 96, and 108 hours 
• 
Conduct 12-lead ECG after the subject has rested in a supine position at 6, 9, 12, 24, 
36, 48, 56, 60, 64, 68, 72, 76, 80, 84, 96, and 108 hours.  ECG must be read within 2 
hours 
• 
Assess sensory function at 6, 9, 12, 18, 24, 36, 48, 60, 72, 84, 96, and 108 hours 
(see Appendix 5) 
• 
Assess degree of motor nerve block at 6, 9, 12, 18, 24, 36, 48, 60, 72, 84, 96, and 108 
hours (see Appendix 6) 
• 
Complete OBAS questionnaire at 24 and 72 hours (see Appendix 2) 
• 
Obtain overall rating of subject satisfaction with postsurgical pain control using the 
Likert scale at 24 and 72 hours (see Appendix 3) 
• 
Conduct physical therapy assessments (ie, timed walk, timed up and go, and stair 
climbing tests) once postsurgically on Day 0, and at 8:00 am (±2 hrs) and 8:00 pm 
(±2 hrs) from postsurgical Day 1 until hospital discharge (see Appendix 9) 
• 
Administer rescue medication upon request, as needed (see Section 11.1) 
• 
Record date, time, and amount of all opioid and non-opioid rescue medication 
administered 
• 
Record other concomitant medications 
• 
Record time of removal of drain(s), if used 
• 
Assess discharge readiness at 12, 24, 36, 48, 60, 72, 84, and 96 hours or until the 
subject is determined to be discharge ready, whichever occurs first (see Appendix 7) 
• 
Record date and time of discharge from hospital 
• 
Document any unscheduled phone calls or office visits related to pain after discharge 
• 
Record AEs and any treatment(s) for the events 
 
 
 
CONFIDENTIAL 
56 of 88 
 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
 
            402-C-326 (FNB TKA) 
EXPAREL® 
 
 
          Clinical Study Protocol Amendment 3 
 
• 
Refer to Section 13.1.12 for additional procedures in the event a cardiac AE, 
neurological AE, fall, or SAE occurs 
13.10. 
Postsurgical Day 6 Visit 
• 
Collect scheduled blood samples for PK analysis per sequence schedule; record date 
and time 
• 
Perform neurological assessment (see Appendix 4) 
• 
Measure vital signs (heart rate and blood pressure) after subject has rested in a supine 
position 
• 
Conduct 12-lead ECG after the subject has rested in a supine position. ECG must be 
read within 2 hours 
• 
If there was a sensory deficit at time of hospital discharge, reassess sensory function 
(see Appendix 5) 
• 
If there was a motor deficit at time of hospital discharge, reassess motor function 
(see Appendix 6) 
• 
Record date and time of discharge, if applicable 
• 
Document any unscheduled phone calls or office visits related to pain after discharge 
• 
Record concomitant medications including all analgesic medication administered 
• 
Record AEs and any treatment(s) for the events 
• 
Refer to Section 13.1.12 for additional procedures in the event a cardiac AE, 
neurological AE, fall, or SAE is reported 
13.11. 
Postsurgical Day 10 Visit 
• 
Measure vital signs (heart rate and blood pressure) after subject has rested in a supine 
position 
• 
Conduct 12-lead ECG after the subject has rested in a supine position. ECG must be 
read within 2 hours 
• 
Conduct targeted physical examination 
• 
Complete OBAS questionnaire (see Appendix 2) 
• 
Obtain overall rating of subject satisfaction with postsurgical pain control using the 
Likert scale (see Appendix 3) 
• 
Perform neurological assessment (see Appendix 4) 
• 
If there was a sensory deficit at Day 6, reassess sensory function (see Appendix 5).  If 
a sensory deficit persists, record this as an AE (see Section 13.1.5 for additional 
details) 
• 
If there was a motor function deficit at Day 6, reassess motor function 
(see Appendix 6). If a motor function deficit persists, record this as an AE (see 
Section 13.1.6 for additional details) 
 
 
 
CONFIDENTIAL 
57 of 88 
 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
 
            402-C-326 (FNB TKA) 
EXPAREL® 
 
 
          Clinical Study Protocol Amendment 3 
 
• 
Conduct clinical laboratory tests (hematology, chemistry, and urinalysis; 
see Appendix 8) 
• 
Conduct physical therapy assessments (ie, timed walk, timed up and go, and stair 
climbing tests; see Appendix 9) 
• 
Record date and time of discharge, if applicable 
• 
Document any unscheduled phone calls or office visits related to pain after discharge 
• 
Record concomitant medications including all analgesic medication administered 
• 
Record AEs and any treatment(s) for the events 
• 
Refer to Section 13.1.12 for additional procedures in the event a cardiac AE, 
neurological AE, fall, or SAE is reported 
13.12. 
Unscheduled Visit(s) 
• 
If a sensory (Appendix 5) or motor function (Appendix 6) deficit persists on 
postsurgical Day 10, this will be recorded as an AE and the physician will assess the 
subject for other etiologies that may explain the persistent deficit(s). The subject is to 
return for unscheduled visit(s) at the Investigator's discretion through postsurgical 
Day 29 or until the sensory or motor function has returned to baseline, whichever 
occurs first 
• 
Record concomitant medications including all analgesic medication administered 
• 
Record AEs and any treatment(s) for the events 
13.13. 
Postsurgical Day 29 Phone Call  
• 
Record concomitant medications including all analgesic medication administered 
• 
Record AEs and any treatment(s) for the events 
14. 
ADVERSE EVENT REPORTING  
Consistent with the current regulatory guidance provided by the US FDA CFR Part 312 and the 
ICH GCP, AEs and SAEs are defined in Section 14.1.1 and Section 14.2.1, respectively.   
The concepts of AEs and SAEs represent regulatory instruments used to evaluate and monitor 
the safety of clinical study subjects.  Therefore, these terms only apply in light of their regulatory 
definition.  The term serious, in a regulatory sense, does not necessarily mean severe.  The SAE 
concept is used primarily to identify, during the conduct of the study, those SAEs that may 
require expedited reporting to regulatory authorities. 
14.1. 
Adverse Events 
14.1.1. 
Definitions  
Definition of Adverse Event: Any untoward medical occurrence associated with the use of a 
drug in humans, whether or not considered drug related.  An AE (also referred to as an adverse 
 
 
 
CONFIDENTIAL 
58 of 88 
 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
 
            402-C-326 (FNB TKA) 
EXPAREL® 
 
 
          Clinical Study Protocol Amendment 3 
 
experience) can be any unfavorable and unintended sign (eg, abnormal laboratory finding), 
symptom, or disease temporally associated with the use of a drug, without any judgment about 
causality.  An AE can arise from any use of the drug (eg, off-label use in combination with 
another drug) and from any route of administration, formulation, or dose, including an overdose. 
An AE can be any unfavorable and unintended change in a body structure or body function.  
Adverse events include any clinically significant deterioration of a subject’s medical status.  
The AE may involve any organ or system and can be represented by the new onset or 
deterioration of a disease, a syndrome, a symptom, a physical sign, as well as by findings and 
results of instrumental examinations and laboratory tests.  Any medically relevant and untoward 
change after the subject signs the ICF, including frequency or pattern changes for a fluctuating 
condition (eg, migraine) is considered an AE.   
An AE that occurs after the ICF is signed and before the start of the study drug administration is 
identified as a pretreatment AE (PTAE).  An AE that occurs after the administration of the study 
treatment is considered a TEAE.   
Definition of Adverse Reaction: Any AE caused by a drug.  Adverse reactions are a subset of all 
suspected adverse reactions for which there is reason to conclude that the drug caused the event. 
Definition of Suspected Adverse Reaction: Any AE for which there is a reasonable possibility 
that the drug caused the AE.  A suspected adverse reaction implies a lesser degree of certainty 
about causality than adverse reaction, which means any AE caused by a drug.  Suspected adverse 
reactions are a subset of all AEs for which there is a reasonable possibility that the drug caused 
the event. 
14.1.2. 
Recording Adverse Events 
It is the responsibility of the Investigator to document all AEs (ie, PTAEs and TEAEs) with an 
onset after the subject signs the ICF.  For the purpose of this study, all AEs that occur through 
postsurgical Day 29 must be recorded regardless of whether or not they are considered related to 
study drug.  Whenever feasible, AE terms must be documented as medical diagnoses (highest 
possible level of integration); otherwise, the AEs must be reported separately as individual signs 
or symptoms.  Only one AE per line should be recorded in the AE CRF; for example, an AE of 
nausea and vomiting would be listed as two separate events: the event of nausea and the event of 
vomiting.  If a diagnosis is established after symptoms are recorded on the AE CRF, 
the diagnosis must be recorded and the symptoms collapsed (removed; ie, lined through and 
initialed).  Whenever possible, abnormal laboratory results must be reported as their clinical 
corollary (eg, low potassium should be recorded as hypokalemia). 
A continuous AE with varying grades of severity must be recorded as one AE.  The highest 
grade of severity experienced by that subject during the course of the continuous AE must be 
recorded. 
Any condition noted before the subject signs the ICF will be listed as Medical History and is 
considered a pre-existing condition.  If a pre-existing condition changes (ie, becomes more 
severe or more frequent) at any time after the ICF is signed, or after study drug administration, 
it is considered an AE.  Note: A change in treatment for a pre-existing condition (eg, new high 
blood pressure medication), does not necessarily indicate an AE. 
 
 
 
CONFIDENTIAL 
59 of 88 
 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
 
            402-C-326 (FNB TKA) 
EXPAREL® 
 
 
          Clinical Study Protocol Amendment 3 
 
Information recorded on the AE CRF will include the AE term, the date and time of onset, 
severity, seriousness, relationship to study drug, action taken with subject due to an AE, and the 
outcome of the AE, including the date and time of resolution, if applicable.   
14.1.3. 
Severity of Adverse Events 
The severity of an AE must be categorized using the following guidelines:  
Mild: 
An AE that is easily tolerated by the subject, causing minimal 
discomfort and not interfering with everyday activities. 
Moderate: 
An AE that is discomforting and interferes with normal everyday 
activities. 
Severe: 
An AE that prevents normal everyday activities. 
The term "severe" is often used to describe the intensity (severity) of a specific event (as in mild, 
moderate, or severe myocardial infarction); the event itself, however, may be of relatively minor 
medical significance (such as severe headache).  This is not the same as "serious," which is based 
on subject/event outcome or action criteria usually associated with events that pose a threat to a 
subject's life or functioning.  Seriousness (not severity) serves as a guide for defining regulatory 
reporting obligations. 
14.1.4. 
Relationship of Adverse Events to Study Drug 
The Investigator must assess the relationship of the AE to study drug after careful medical 
consideration on a case-by-case basis.  General guidelines for determining the AE’s causality to 
the study drug are provided below. 
Unrelated: 
A causal relationship between the study drug and the AE can be 
easily ruled out (eg, based on the temporal sequence, absence of a 
reasonable pathophysiological mechanism, or direct evidence of 
actual cause). 
Unlikely:  
A clinical event with a temporal relationship to study drug 
administration which makes a causal relationship improbable and in 
which other drugs, chemicals, or underlying disease provide a 
plausible explanation; 
Possible: 
A clinical event with a reasonable time sequence to administration 
of the study drug but which could also be explained by a concurrent 
disease or other drugs or chemicals; 
Probable: 
A clinical event with a reasonable time sequence to administration 
of the study drug unlikely to be attributed to a concurrent disease or 
other drugs or chemicals and which follows a clinically reasonable 
response on withdrawal (dechallenge); or 
Definite:  
The pharmacological properties of the study drug(s) or of the 
substance class, and the course of the AE after dechallenge and, if 
applicable, after rechallenge, and/or specific test indicate 
involvement of the study drug(s) in the occurrence/worsening of the 
AE, and no indication of other causes exists. 
 
 
 
CONFIDENTIAL 
60 of 88 
 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
 
            402-C-326 (FNB TKA) 
EXPAREL® 
 
 
          Clinical Study Protocol Amendment 3 
 
14.1.5. 
Outcome of Adverse Events 
The Investigator will assess the outcome of the AE after careful medical consideration, on a 
case-by-case basis.  General guidelines are provided below: 
Recovered/Resolved: 
The event resolved and the subject recovered from the AE. 
Recovered/Resolved 
with Sequelae: 
The initial event resolved, but has a continuing abnormal condition 
as a result of the AE. 
Not Recovered/ 
Not Resolved: 
At the time of last assessment, the event was ongoing, with an 
undetermined outcome.  Note: ongoing AEs are not to be considered 
resolved as a result of death. 
Recovering/Resolving: 
At the time of last assessment, the event was decreasing in 
frequency, severity, etc., and a resolution was expected. 
Fatal: 
The AE directly caused death. 
Unknown: 
There was an inability to access the subject or the subject’s records 
to determine the outcome (eg, subject withdrew consent or was 
lost to follow-up). 
14.1.6. 
Action Taken with Subject due to an Adverse Event 
The Investigator will provide any actions taken regarding the subject (eg, treatment, diagnostic 
tests, laboratory tests, or therapy) for each reported AE. 
• 
None. 
• 
Medication. 
• 
Non-pharmaceutical therapy.  (The specific therapy used must be recorded in the 
CRF.) 
• 
Discontinued from study. 
• 
Other.  (The specific action taken must be recorded.) 
14.2. 
Serious Adverse Events 
14.2.1. 
Definition of a Serious Adverse Event 
Definition of a Serious Adverse Event (SAE): An AE or suspected adverse reaction is considered 
“serious” if, in the view of either the Investigator or Sponsor, it results in any of the following 
outcomes: 
• 
Death1 
• 
A life-threatening adverse event2 
• 
Inpatient hospitalization or prolongation of existing hospitalization3 
 
 
 
CONFIDENTIAL 
61 of 88 
 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
 
            402-C-326 (FNB TKA) 
EXPAREL® 
 
 
          Clinical Study Protocol Amendment 3 
 
• 
A persistent or significant incapacity4 
• 
Congenital anomaly/birth defect 
• 
Medically significant5 
1Death: Any event resulting in a subject’s death must be reported as an SAE.  However, death, 
in and of itself, is not an AE; it is an outcome.  The cause of death is the AE.  Therefore, the 
Investigator must make every effort to obtain and document the cause of death for all subjects 
who die during the study.  If, despite all efforts, the cause of death remains unknown, the AE 
must be documented as an “unspecified fatal event.” 
2Life-threatening: An AE is considered life-threatening if, in the view of either the Investigator 
or Sponsor, its occurrence places the subject at immediate risk of death.  It does not include an 
AE that had it occurred in a more severe form might have caused death. 
3Hospitalization: It should be noted that hospitalization, in and of itself, does not represent an 
SAE.  It is the AE leading to the subject’s hospitalization that becomes “serious” when it 
requires inpatient care.  Consequently, an SAE must not be reported in case of preplanned 
hospitalizations for a pre-existing condition that did not worsen during the study.  However, 
any medical condition that delays a subject’s discharge from the hospital (ie, prolonged 
hospitalization) or requires the subject to be readmitted must be reported as an SAE. 
4Persistent or significant incapacity: A substantial disruption of a person’s ability to conduct 
normal life functions. 
5Medically Significant: Important medical events that may not result in death, be life-
threatening, or require hospitalization, may be considered serious when, based upon appropriate 
medical judgment, they may jeopardize the subject and may require medical or surgical 
intervention to prevent one of the outcomes listed in this definition.  Examples of such medically 
significant events include allergic bronchospasm requiring intensive treatment in an emergency 
room or at home, blood dyscrasias or convulsions that do not result in inpatient hospitalization, 
or the development of drug dependency or drug abuse. 
14.2.2. 
Reporting Serious Adverse Events 
Any SAE or death that occurs at any time after the subject signs the ICF through postsurgical 
Day 29, whether or not related to EXPAREL, must be reported by the Investigator or designee to 
Pacira Drug Safety within 24 hours of discovery by either email (drugsafety@pacira.com) or fax 
(973-201-0649).  In addition, the Investigator or designee is encouraged to contact the Medical 
Monitor to discuss the case, as needed.   
Investigators should not wait to receive additional information to fully document the event 
before notifying Pacira Drug Safety or designee of the SAE.  The fax or email report must be 
followed by a full written summary using the SAE Form detailing relevant aspects of the SAE in 
question.  Where applicable, information from relevant hospital records and autopsy reports must 
be obtained and all patient-identifying information redacted prior to forwarding to Pacira.  In the 
event of a fatal or life-threatening SAE, any required follow-up must be provided to Pacira Drug 
Safety or designee immediately.  The Investigator will follow all SAEs until resolved or the 
condition stabilizes and further follow-up is not warranted. 
 
 
 
CONFIDENTIAL 
62 of 88 
 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
 
            402-C-326 (FNB TKA) 
EXPAREL® 
 
 
          Clinical Study Protocol Amendment 3 
 
If the Investigator is made aware of any SAEs after postsurgical Day 29, these must also be 
reported to Pacira Drug Safety or designee provided the SAE is considered related to EXPAREL.  
The site would then provide a completed SAE form within 1 business day and the event would 
be followed until resolution, or until adequate stabilization is met.  
15. 
STATISTICAL METHODS 
A comprehensive statistical analysis plan (SAP) will be developed for this study.   
15.1. 
Study Hypothesis 
The primary null hypothesis is: 
 
H0: The means of the AUC of the VAS pain intensity scores through 72 hours are not different 
between the EXPAREL and placebo groups. 
The alternative hypothesis is: 
HA: The mean AUC of the VAS pain intensity scores through 72 hours for the EXPAREL group 
is less than that of the placebo group. 
15.2. 
Study Endpoints 
 
The endpoints to be assessed in this study are listed in Section 12.2 (Efficacy Endpoints), 
Section 12.4 (PK Endpoints), and Section 12.6 (Safety Endpoints). 
15.3. 
Determination of Sample Size  
The sample size was estimated based on the results of a Phase-3 study of  EXPAREL versus 
placebo in patients undergoing TKA where the means (standard deviation [SD]) AUC of the 
NRS-R pain intensity scores through 72 hours were 420 (169) and 514 (160) for the EXPAREL 
and placebo groups, respectively.  Assuming a 2.5% two-sided alpha, common SD of 170 and a 
3% drop-out rate, a sample size of 77 subjects per treatment group will have at least 80% power 
to detect a difference of 100 in at least one of the active treatment groups.. 
15.4. 
Analysis Populations 
The following analysis sets are planned: 
Safety: The safety analysis set will include all subjects who receive study drug and will be based 
on actual treatment received. 
Efficacy: The efficacy analysis set will include all subjects in the safety analysis set who undergo 
the planned surgery and will be based on randomized treatment, regardless of actual treatment 
received. 
15.5. 
Handling Subject Dropouts and Discontinuations 
For the calculation of the AUC of VAS pain intensity scores through any of the time periods, the 
following methods will be used for imputing missing data: 
 
 
 
CONFIDENTIAL 
63 of 88 
 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
 
            402-C-326 (FNB TKA) 
EXPAREL® 
 
 
          Clinical Study Protocol Amendment 3 
 
Missing scores before the first non-missing score will be replaced by the median score at the 
missing timepoint from other subjects in the same treatment group.  Missing scores after the last 
non-missing score will be replaced by the last non-missing score (last observation carried 
forward).  Missing scores between two non-missing scores will use linear interpolation to replace 
the missing score. 
Additional methods for dealing with missing data will be described in the SAP. 
15.6. 
Statistical Analyses 
15.6.1. 
Baseline Characteristics 
Demographic and baseline characteristics will be summarized by treatment group. 
15.6.2. 
Study Compliance 
The percentage of subjects in each analysis set and the percentage who fail to complete the study 
(as well as the reasons for discontinuation) will be displayed by treatment group. 
15.6.3. 
Efficacy Analyses 
All efficacy analyses will be based on randomized treatment, regardless of actual treatment 
received. 
15.6.3.1  Primary Efficacy Measures 
The primary efficacy measure in this study is the AUC of the VAS pain intensity scores through 
72 hours. 
For the AUC of the VAS pain intensity scores through 72 hours, each EXPAREL dose will be 
compared to placebo using analysis of variance (ANOVA) with treatment and site as main 
effects.  Each EXPAREL dose will be compared to placebo at the 0.025 level of significance to 
control the overall level of significance to not exceed 0.05.  Based on the model, the difference 
between the treatment groups will be estimated along with the 2-sided 97.5% confidence 
intervals (CIs). 
Handling of Subjects Requiring Rescue Medication 
For AUC of the VAS pain intensity scores, prior to analysis the windowed Worst-Observation-
Carried-Forward (wWOCF) imputation method will be applied.  For subjects who take rescue 
pain medication, their pain intensity scores recorded within the window of controlled type of 
rescue medication will be replaced by the ‘worst’ observation.  All pain scores within that 
window will be replaced by the ‘worst’ observation.  The worst observation will be the highest 
score in the time interval from the end of surgery up to the time prior to taking their first rescue 
pain medication.  Note that pain intensity scores in the window that are higher than the worst 
value prior to rescue pain medication will not be overwritten.  If no pain intensity score is 
available prior to the first rescue pain medication, the worst observation from all available 
measurements will be used instead. 
 
 
 
CONFIDENTIAL 
64 of 88 
 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
 
            402-C-326 (FNB TKA) 
EXPAREL® 
 
 
          Clinical Study Protocol Amendment 3 
 
15.6.3.2  Secondary Efficacy Measures 
See significance testing in Section 15.7 for an explanation of the statistical approach for 
secondary efficacy measures. 
Total postsurgical opioid consumption through 72 hours will be converted to morphine 
equivalents and analyzed using the same ANOVA model as the primary endpoint.  However, the 
alpha level for the secondary endpoint will be 0.05. 
Percentage of opioid-free subjects through 72 hours will be analyzed using a Cochran-Mantel-
Haenszel (CMH) test stratified by site. 
Time to first opioid rescue through 72 hours will be analyzed by the Kaplan-Meier method.   
15.6.3.3  Tertiary Efficacy Measures 
No statistical comparisons are planned for the tertiary efficacy measures. 
Continuous Measures of Efficacy 
For the AUC of the pain intensity scores, missing data will be imputed as described in 
Section 15.5 and fully described in the SAP. 
Summary statistics for each measure will be shown at each timepoint by treatment group.   
Categorical Measures of Efficacy 
For categorizing subjects as pain-free, the VAS pain intensity score must be ≤1.5 without prior 
rescue medication use at the assessed timepoint. 
The proportion of subjects in each category will be calculated and summarized at each timepoint 
by treatment group.   
Time to Event Measures 
The time from start of study drug administration to event will be summarized with Kaplan-Meier 
estimates.   
15.6.4. 
Pharmacokinetic Analyses 
Pharmacokinetic parameters will be estimated using a population PK approach. 
15.6.5. 
Safety Analyses 
All safety analyses will be based on actual treatment received.  
15.6.5.1. Adverse Events 
Adverse event verbatim terms will be mapped to preferred terms and related system organ class 
using the Medical Dictionary for Regulatory Activities (MedDRA).  Events that start prior to the 
start of study drug administration will be identified in listings only.  Incidence rates of TEAEs 
and the proportion of subject prematurely withdrawn from the study due to a TEAE will be 
shown for each treatment group.  Incidence rates will also be displayed for each treatment group 
for study drug-related TEAEs and by severity.  Incidence rates of SAEs will also be shown for 
each treatment group.  All incidence rates will be categorized and displayed by system organ 
class and preferred term. 
 
 
 
CONFIDENTIAL 
65 of 88 
 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
 
            402-C-326 (FNB TKA) 
EXPAREL® 
 
 
          Clinical Study Protocol Amendment 3 
 
15.6.5.2. Vital Signs 
Descriptive statistics for each vital sign for baseline, each timepoint, and change from baseline at 
each timepoint will be summarized for each treatment group. 
15.6.5.3. Clinical Laboratory Data 
Descriptive statistics for each laboratory test for baseline, each timepoint, and change from 
baseline at each timepoint will be summarized for each treatment group. 
15.6.5.4. Electrocardiograms 
Descriptive statistics for each ECG parameter for baseline, each timepoint, and change from 
baseline at each timepoint will be summarized for each treatment group. 
15.6.5.5. Neurological Assessment 
The proportion of subjects who are oriented at each timepoint will be summarized for each 
treatment group.  The proportion of subjects who have at least one of the neurological events will 
be summarized for each treatment group. 
15.7. 
Significance Testing 
Significance testing will be based on “Graphical approaches for multiple comparison procedures 
using weighted Bonferroni, Simes, or parametric tests” (Bretz 2011).  The initial alpha will be set 
to 0.025 for each of the primary efficacy analyses.  Subsequent testing will be conducted 
following the ideas of the paper.  The initial testing diagram and other details will be provided in 
the SAP.  
In addition to the primary endpoint (VAS AUC) there are three key secondary endpoints (total 
opioid consumption, percentage of opioid-free subjects, and time to first rescue medication), and 
for each of these four endpoints there are two primary pairwise comparisons. The procedure for 
multiplicity adjustment for these eight comparisons is described below, together with 
demonstration that it provides strong control of the type 1 error. 
Let HPrimLD, HSec1LD, HSec2LD, and HSec3LD represent the null hypotheses for the comparison of 
EXPAREL 133 mg versus Placebo. Likewise let HPrimHD, HSec1HD, HSec2HD, and HSec3HD represent 
the null hypotheses for the comparison of EXPAREL 266 mg versus Placebo.  Where HPrimLD, 
HSec1LD, HSec2LD, and HSec3LD are respectively VAS AUC, total opioid consumption, percentage of 
opioid-free subjects, and time to first rescue medication and similarly for HPrimHD, HSec1HD, 
HSec2HD, and HSec3HD. 
The first stage of the multiplicity adjustment will be carried out using a graphical approach to 
sequentially rejective multiple test procedures (Bretz et al, 2009).  This will be applied to the set 
of the four null hypotheses F = {HPrimLD, HPrimHD, HSec1LD, HSec1HD} corresponding to the primary 
endpoint and the first key secondary endpoint (total post-surgical opioid consumption through 48 
hours). Let FL = {HPrimLD, HSec1LD) and FH = {HPrimHD, HSec1HD) denote the families of null 
hypotheses corresponding to comparisons of EXPAREL 133 mg versus Placebo, and EXPAREL 
266 mg versus Placebo, respectively.  The particular graphical procedure used here initially 
assigns α = 0.0125 one-sided for testing of the first member of each family (corresponding to the 
primary endpoint) and then within each family the two endpoints are tested in a fixed sequence. 
 
 
 
CONFIDENTIAL 
66 of 88 
 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
 
            402-C-326 (FNB TKA) 
EXPAREL® 
 
 
          Clinical Study Protocol Amendment 3 
 
If for either family null hypotheses for both endpoints can be rejected, then the fixed sequence 
for the other dose level can be conducted using α = 0.025 one-sided.  This procedure can be 
viewed as a Bonferroni-Holm-type approach applied to the families FL and FH.  This procedure 
can be depicted graphically as follows: 
 
With F= {HPrimLD, HPrimHD, HSec1LD, HSec1HD} as above, then in the notation of Bretz et al (2009) 
we start with α = (0.0125, 0.0125, 0, 0).  A G matrix with elements gij is defined in that paper to 
denote the fraction of the local level αi that is allocated to null hypothesis j from set F in the case 
that null hypothesis i is rejected.  This 4x4 matrix G takes a simple form in the procedure 
considered here because g13 = g24 = g32 = g41 = 1, but all other elements are zero.  Bretz et al 
(2009) provides an updating procedure for the matrix G as successive null hypotheses are 
rejected, and prove that such procedures provide strong control of the type 1 error.  The 
particular procedure used in the current study implements the updating of α and G in accordance 
with Bretz et al’s (2009) “Algorithm 1.”  Further, the regularity conditions 0 ≤ gij ≤1,  gii = 0, and 
4
1
1
ik
k
g
=
≤
∑
 for all i, j = 1,...4, specified in equation (1) of that paper, are satisfied, and so strong 
control of type 1 error at α = 0.025 one-sided for testing of the four null hypotheses F = {HPrimLD, 
HPrimHD, HSec1LD, HSec1HD} follows from Bretz et al’s proof. 
The particular procedure used for the current trial is also given as an example to illustrate the  
graphical procedure within both Alosh et al (2014) and Bretz et al (2011). 
The second stage of the multiplicity adjustment procedure relates to S = {HSec2HD, HSec2LD, 
HSec3HD, HSec3LD}, ie, the four null hypotheses related to the second key efficacy parameter 
(percentage of opioid-free subjects through 48 hours) and the third key efficacy parameter (time 
to first opioid rescue through 48 hours).  These are only tested if all 4 null hypotheses from set F 
have already been rejected, and in that case HSec2HD, HSec2LD, HSec3HD, and HSec3LD are then tested 
sequentially in turn at α = 0.025 one-sided, where statistical significance is required for all 
preceding tests within set S as well as statistical significance for all tests from set F.  If the 
required preceding null hypotheses have not been rejected then p-values for later tests in this 
sequence will be viewed only as descriptive. 
Given that: (i) strong control of type 1 error at α = 0.025 one-sided has been demonstrated for 
testing of the four null hypotheses F; (ii) testing only proceeds to set S if all null hypotheses in 
 
 
 
CONFIDENTIAL 
67 of 88 
 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
 
            402-C-326 (FNB TKA) 
EXPAREL® 
 
 
          Clinical Study Protocol Amendment 3 
 
set F have been rejected; and (iii) the null hypotheses within set S are tested in a single step-
down procedure, the above procedure has strong control of type 1 error at α = 0.025 one-sided 
for testing of all eight null hypotheses. 
Note: While the above procedure is described in terms of one-sided p-values, results will be 
presented as two-sided p-values. 
15.8. 
Interim Pharmacokinetic Analysis 
A blinded interim PK analysis was completed after 30 subjects completed the assessments 
through postsurgical Day 10. All of the plasma samples from the subjects who received 
EXPAREL were analyzed and the plasma samples from the subjects randomized to placebo were 
analyzed through the 24-hour timepoint.  Enrollment continued while the interim PK data were 
analyzed.  The goal of this blinded analysis was to determine the appropriateness of the PK 
timepoints selected and make recommendations to keep, remove, or revise them in order to fully 
characterize the PK profile.   
The results of this analysis showed a median Tmax of 60 hours for the 133 mg EXPAREL group 
and a median Tmax of 78 hours for the 266 mg EXPAREL group. These data informed the 
changes to the PK collection schedule contained in this protocol amendment. 
In addition, the safety assessment timepoints, including the neurological exam, vital signs, and 
ECG were adjusted based on the interim PK data. 
 
 
 
CONFIDENTIAL 
68 of 88 
 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
 
            402-C-326 (FNB TKA) 
EXPAREL® 
 
 
          Clinical Study Protocol Amendment 3 
 
16. 
REFERENCES 
Alosh, M., Bretz, F., and Huque M. (2014), Advanced multiplicity adjustment methods in 
clinical trials, Statistics in Medicine, 33: 693-713. 
American Society of Anesthesiologists Task Force on Pain Management.  Practice guidelines 
for acute pain management in the postoperative setting: A report by the American Society 
for Anesthesiologist Task Force on Pain Management Acute Pain Section.  Anesthesiology. 
1995;82:1071–1081. 
Apfelbaum JL, Chen C, Mehta SS, et al.  Postoperative pain experience: Results from a national 
survey suggests postoperative pain continues to be undermanaged.  Anesth Analg.  
2003;97:535−540. 
Apseloff G, Onel E, Patou G.  Time to onset of analgesia following local infiltration of liposome 
bupivacaine in healthy volunteers: a randomized, single-blind, sequential cohort, crossover 
study.  Int J Clin Pharmacol Ther.  2013;51:367−373. 
Bigley GK. “Sensation,” Chapter 67 in Walker HK, Hall WD, Hurst JW (eds).  Clinical methods: 
The history, physical and laboratory examinations, 3rd edition, Butterworths 1990. 
Bretz F, Maurer W, Brannath W, and Posch M. A graphical approach to sequentially rejective 
multiple test procedures, Statistics in Medicine, 2009;28: 586-604. 
Bretz F, Posch M, Glimm E, et al.  Graphical approaches for multiple comparison procedures 
using weighted Bonferroni, Simes, or parametric tests.  Biom J.  2011;53(6): 894–913. 
Carlsson AM.  Assessment of Chronic Pain.  I.  Aspects of the Reliability and Validity of the 
Visual Analogue Scale.  Pain.  1983;16:87−101. 
Carroll NV, Miederhoff PA, Cox FM, et al.  Costs incurred by outpatient surgical centers in 
managing postoperative nausea and vomiting.  J Clin Anesth.  1994;6:364–369. 
Chernin T.  Painkillers and pill popping.  Drug Topics.  2001;15:31.  Accessed 04 January 2011.  
Available at: http://drugtopics.modernmedicine.com/drugtopics/PainManagement/ 
ArticleStandard/article/detail/118858. 
Chung F.  Discharge criteria – A new trend.  Can J Anesth. 1995;42:1056–1058. 
Chung F, Chan VW, Ong D.  A post-anesthetic discharge scoring system for home readiness 
after ambulatory surgery.  J Clin Anesth.  1995;7(6):500–506. 
EXPAREL Full Prescribing Information, December 2015. 
EXPAREL Investigator’s Brochure, Edition 17.1, 08 December 2015. 
Hu D, Onel E, Singla N, et al.  Pharmacokinetic profile of liposome bupivacaine injection 
following a single administration at the surgical site.  Clin Drug Investig.  2013;33:109–115. 
Joshi GP, Cushner FD, Barrington JW, et al.  Techniques for periarticular infiltration with 
liposomal bupivacaine for the management of pain after hip and knee arthroplasty: A consensus 
recommendation.  J Surg Orthop Adv.  2015;24(1):27–35. 
 
 
 
CONFIDENTIAL 
69 of 88 
 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
 
            402-C-326 (FNB TKA) 
EXPAREL® 
 
 
          Clinical Study Protocol Amendment 3 
 
Lehmann N, Joshi GP, Dirkmann D, et al.  Development and longitudinal validation of the 
overall benefit of analgesia score: a simple multi-dimensional quality assessment instrument.  
Br J Anasth.  2010;105(4):511–518.  Epub 2010 Aug 6. 
Mariano ER, Loland VJ, Sandhu NS, et al.  Ultrasound guidance versus electrical stimulation for 
femoral perineural catheter insertion.  J Ultrasound Med.  2009; 28:1453–60.  
McCormack HM, DJ Horne, Sheather S.  Clinical applications of visual analogue scales: 
A critical review.  Psychol Med.  1988;18(4):1007−1019. 
Nader A, Kendall MC, De Oliveira GS Jr, et al.  A dose-ranging study of 0.5% bupivacaine or 
ropivacaine on the success and duration of the ultrasound-guided, nerve-stimulator-assisted 
sciatic nerve block: a double-blind, randomized clinical trial.  Reg Anesth Pain Med.  2013; 
38(6):492–502.  
Oderda GM, Said Q, Evans RS, et al.  Opioid-related adverse drug events in surgical 
hospitalizations: Impact on cost and length of stay.  Ann Pharmacother.  2007;41(3):400–406. 
Paauwe JJ, Thomassen BJ, Wetering J, et al.  Femoral nerve block using ropivacaine 0.025%, 
0.05% and 0.1%: effects on the rehabilitation programme following total knee arthroplasty: 
A pilot study.  Anaesthesia.  2008;63(9):948–953. 
Sakura S, Sumi M, Yamada Y, Saito Y, and Kosaka Y.  Quantitative and selective assessment of 
sensory block during lumbar epidural anaesthesia with 1% or 2% lidocaine.  Br J Anaesth. 
1998;81(5):718-22. 
Scott J, Huskinsson EC.  Graphic representation of pain.  Pain.  1976;2(2):175−184. 
Viscusi ER.  New and emerging treatment options for acute postoperative pain in the inpatient 
setting: Barriers to effective pain management.  Medscape Pharmacists.  15 December 2009.  
Accessed 04 January 2011.  Available at: http://www.medscape.org/viewarticle/713472_2. 
 
 
 
CONFIDENTIAL 
70 of 88 
 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
 
            402-C-326 (FNB TKA) 
EXPAREL® 
 
 
          Clinical Study Protocol Amendment 3 
 
17. 
INVESTIGATOR AGREEMENT 
Printed Name of Investigator: 
 
Printed Title/Position: 
 
Printed Institution Address: 
 
 
 
 
 
 
 
I have reviewed this protocol (including Appendices) and agree: 
• 
To assume responsibility for the proper conduct of the study at this site; 
• 
To conduct the study in compliance with this protocol, with any future amendments, 
and with any other study conduct procedures provided by Pacira Pharmaceuticals, 
Inc. (Pacira) or designee.  I also agree to comply with Good Clinical Practice and all 
regulatory requirements; 
• 
Not to implement any changes to the protocol without agreement from Pacira or 
designee and prior review and written approval from the Independent Ethics 
Committee, except where it is necessary to eliminate an immediate hazard to the 
subjects or for administrative aspects of the study (where permitted by applicable 
regulatory requirements);  
• 
That I am thoroughly familiar with the appropriate use of the investigational 
product(s), as described in this protocol, and with other relevant information 
(eg, the Investigator’s Brochure); 
• 
To ensure that all persons assisting me with the conduct of this study are adequately 
informed about the investigational product(s) and about their study-related duties and 
functions as described in this protocol; 
• 
That I am aware that regulatory authorities may require Investigators to disclose all 
information about significant ownership interests and/or financial ties related to the 
Sponsor and/or the investigational product(s).  Consequently, I agree to disclose all 
such significant financial information to Pacira and to update this information 
promptly if any relevant changes occur during the course of the study through 1 year 
following completion of the study.  I also agree that any information regarding my 
significant financial interest related to Pacira and/or the investigational product(s) 
will be disclosed to the regulatory authorities by Pacira. 
 
Signature of Investigator 
Date 
 
 
 
CONFIDENTIAL 
71 of 88 
 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
 
            402-C-326 (FNB TKA) 
EXPAREL® 
 
 
          Clinical Study Protocol Amendment 3 
 
18. 
APPENDICES 
 
 
 
CONFIDENTIAL 
72 of 88 
 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
402-C-326 (FNB TKA) 
EXPAREL®  
                                            Clinical Study Protocol Amendment 3 
 
Appendix 1: Subject’s Reported Pain Intensity 
Subjects will be evaluated for pain using a 10-cm VAS at baseline (on Day 0 prior to the nerve 
block and prior to any premedication); upon arrival at the PACU, every 15 minutes while in the 
PACU, and prior to PACU discharge; at 6, 12, 24, 36, 48, 60, 72, 84, 96, and 108 hours; and 
immediately prior to each administration of rescue pain medication through 108 hours.   
Subjects will be asked, "How much pain are you experiencing right now?  Please place a vertical 
mark on the line below to indicate the level of pain you are experiencing right now." 
 
 
 
(For reference only; not for clinical use.) 
 
 
CONFIDENTIAL 
73 of 88 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
402-C-326 (FNB TKA) 
EXPAREL®  
                                            Clinical Study Protocol Amendment 3 
 
Appendix 2: 
Overall Benefit of Analgesia Score (OBAS) Questionnaire 
The OBAS questionnaire will be completed at 24 and 72 hours, and on postsurgical Day 10 
(Lehmann 2010). 
1.   Please rate your current pain at rest on a scale between  
0 = minimal pain and 4 = maximum imaginable pain 
2.   Please grade any distress and bother from vomiting in the past 24 h  
(0 = not at all to 4 = very much) 
3.   Please grade any distress and bother from itching in the past 24 h  
(0 = not at all to 4 = very much) 
4.   Please grade any distress and bother from sweating in the past 24 h  
(0 = not at all to 4 = very much) 
5.   Please grade any distress and bother from freezing in the past 24 h  
(0 = not at all to 4 = very much) 
6.   Please grade any distress and bother from dizziness in the past 24 h  
(0 = not at all to 4 = very much) 
7.   How satisfied are you with your pain treatment during the past 24 h  
(0 = not at all to 4 = very much) 
 
 
 
 
CONFIDENTIAL 
74 of 88 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
402-C-326 (FNB TKA) 
EXPAREL®  
                                            Clinical Study Protocol Amendment 3 
 
Appendix 3: 
Subject Satisfaction with Postsurgical Pain Control (Likert Scale)  
The subject’s satisfaction with postsurgical pain control will be assessed at 24 and 72 hours, 
and on postsurgical Day 10. 
 
Please circle the number below that best describes your overall satisfaction with the pain 
medication you received after surgery.  (Circle one number only.) 
 
1. Extremely dissatisfied 
2. Dissatisfied 
3. Neither satisfied nor dissatisfied 
4. Satisfied  
5. Extremely satisfied  
 
 
 
CONFIDENTIAL 
75 of 88 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
402-C-326 (FNB TKA) 
EXPAREL®  
                                            Clinical Study Protocol Amendment 3 
 
Appendix 4: 
Neurological Assessment 
The neurological assessment will be conducted at Screening; baseline (on Day 0 prior to the 
nerve block); upon arrival at the PACU; at 6, 9, 12, 24, 36, 48, 56, 60, 64, 68, 72, 76, 80, 84, 96, 
and 108 hours; and on postsurgical Days 6 and 10.  
 
The examination will include the subject's orientation.    
• Is the subject oriented? 
 
  Yes  
  No             Not Assessable 
 
If the subject is not oriented, the event should be recorded as an AE.  
 
 
 Additionally, the subject will be asked the following questions: 
 
• Since your last assessment have you had numbness of the lips, the tongue, or around the 
mouth?       
 
 
  Yes  
  No 
 
• Since your last assessment have you had a metallic taste in your mouth? 
 
 
  Yes  
  No 
 
• Since your last assessment, have you had problems with your hearing not related to the 
use of a hearing aid?  
  Yes  
  No 
 
• Since your last assessment, have you had problems with your vision not related to the use 
of eye glasses? 
  Yes  
  No 
 
• Since your last assessment, have your muscles been twitching? 
 
 
  Yes  
  No 
 
If the subject answers “yes” to any of these questions, the event should be recorded as an AE and 
additional safety procedures must be conducted (see Section 13.1.12).  
 
 
 
 
 
CONFIDENTIAL 
76 of 88 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
402-C-326 (FNB TKA) 
EXPAREL®  
                                            Clinical Study Protocol Amendment 3 
 
Appendix 5: 
Sensory Function Assessment (Cold, Pinprick, and Light Touch Tests) 
For the sensory function assessment, the subject’s sensitivity to cold, pinprick, and light touch in 
the proximal and distal part of innervated dermatomes that express the anterior femoral 
cutaneous nerve (L2/L3) and saphenous nerve (L4) will be assessed with their eyes closed at 
Screening; baseline (on Day 0 prior to the nerve block); at approximately 15, 30, and 45 minutes 
prior to the OR; prior to PACU discharge; at 6, 9, 12, 18, 24, 36, 48, 60, 72, 84, 96, and 108 
hours; and at hospital discharge. 
If there is a sensory deficit at time of hospital discharge, sensory function will again be assessed 
on Day 6. If there continues to be a sensory deficit on Day 6, sensory function will again be 
assessed on Day 10.  If there continues to be a sensory deficit on Day 10, the sensory deficit will 
be recorded as an AE and the physician will assess the subject for other etiologies that may 
explain the persistent deficit.  The subject will return for unscheduled visit(s) at the Investigator's 
discretion through postsurgical Day 29 or until the sensory function has returned to baseline, 
whichever occurs first. 
The cold, pinprick, and light touch tests will be conducted, starting with the cold test, followed 
randomly by the pinprick and light touch tests interspaced with blunt touch.  Subjects will be 
given four choices for reporting their perception of the stimulus: “sharp” (corresponding to 
pinprick), “blunt,”  “cold,” or “light touch.”  The test may be repeated in case of ambiguous or 
inconsistent responses until the examiner is satisfied with the accuracy of the assessment.  Only 
cold, pinprick, and light touch sensitivity will be assessed and recorded for study purposes.  
Blunt touch stimulation serves as a way to gauge the subject response and reduce the chance that 
the subject may guess the correct answer.  
Cold sensitivity will be tested by gently applying ice (Sakura 1998) to contact the skin spot in the 
proximal and distal part of dermatome for 3 seconds.  For the pinprick assessment, a disposable 
sharp-bevel needle will be used to prick the skin spot in the proximal and distal part of the 
dermatome.  Care is to be taken to prevent penetration of the dermis, and the sharp object used 
should be discarded after the test.  Blunt touch with a cotton swab (eg, Q-tip) will be conducted 
the same way.  Testing for light touch will be done using a wisp of cotton pulled from a cotton 
ball.   
The assessment will be conducted single-blinded (ie, the nature of the stimulus will be concealed 
from the subject) and the result will be defined as presence/absence of cold, pinprick, and light 
touch sensation. 
Instructions 
1. To prepare subjects for the cold, pinprick, and light touch tests, they should be placed in a 
comfortable position with their eyes closed.  
2. Before starting the assessments, all subjects should be well trained in all aspects of the 
testing.  It is critical that each subject knows precisely what to expect during the testing.   
3. For the proximal sensory cutaneous test, assess the dermatome located roughly 15-20cm 
on the medial to the midline of the anterior section of the thigh above the knee (patella) 
that corresponds to the anterior cutaneous nerve of the thigh. 
 
 
CONFIDENTIAL 
77 of 88 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
402-C-326 (FNB TKA) 
EXPAREL®  
                                            Clinical Study Protocol Amendment 3 
 
4. For the distal sensory cutaneous test, assess the dermatome located roughly 10 cm above 
the medial malleolus on the medial aspect of the leg below the knee that corresponds to 
the the saphenous nerve. 
5. Interactions between study subjects and Investigators should be limited to those 
necessary for collecting data.  Joking and small talk should be discouraged because they 
may compromise data consistency.   
6. Keep the instructions clear, simple, and consistent.  Emphasize that pain is subjective, 
and there are no right or wrong answers.  It is most important to be consistent.   
 
 
CONFIDENTIAL 
78 of 88 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
402-C-326 (FNB TKA) 
EXPAREL®  
                                            Clinical Study Protocol Amendment 3 
 
 
 
  
 
 
CONFIDENTIAL 
79 of 88 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
402-C-326 (FNB TKA) 
EXPAREL®  
                                            Clinical Study Protocol Amendment 3 
 
Appendix 6: 
Motor Function Assessment 
The degree of motor nerve block will be assessed at Screening; baseline (on Day 0 prior to the 
nerve block); at approximately 15, 30, and 45 minutes prior to the OR; prior to discharge from 
the PACU; at 6, 9, 12, 18, 24, 36, 48, 60, 72, 84, 96, and 108 hours; and at hospital discharge. 
If there is a motor function deficit at time of hospital discharge, motor function will again be 
assessed on Day 6. If there continues to be a motor function deficit on Day 6, motor function will 
again be assessed on Day 10.  If there continues to be a motor function deficit on Day 10, the 
motor function deficit will be recorded as an AE and the physician will assess the subject for 
other etiologies that may explain the persistent deficit.  The subject will return for unscheduled 
visit(s) at the Investigator's discretion through postsurgical Day 29 or until motor function has 
returned to baseline, whichever occurs first. 
The motor nerve block assessment should be conducted after the pain intensity assessment.  
The motor nerve block assessment will be conducted in accordance with the site’s standard of 
care.  Whenever possible, the same physical therapist is to conduct all motor nerve block 
assessments for a subject to reduce variability. 
The following assessments will be conducted at each timepoint: 
• 
Angle of flexion with active (against mild manual resistance, so as not to injure the 
knee) and passive (with gravitational resistance without assessor intervention);  
• 
Angle of extension with active (against mild manual resistance, so as not to injure the 
knee) and passive (with gravitational resistance without assessor intervention) 
(example shown below).  
 
 
 
 
 
 
The following criteria (Paauwe 2008), which were previously used in study SKY0402-C-208, 
will be used to determine if a subject has achieved a level of clinically meaningful physical 
rehabilitation or “return to Baseline”:  
1. Active flexion angle ≥80°. 
2. Active extension angle ≤10°. 
If a subject demonstrates a motor function deficit at Baseline, the subject will be considered to 
have returned to baseline if, at 108 hours (or before), the following two criteria are met: 
1. The active flexion measurement is no more than 10° less than the Baseline measurement 
AND 
2. The active extension angle is no more than 10° greater than the Baseline measurement 
 
 
CONFIDENTIAL 
80 of 88 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
402-C-326 (FNB TKA) 
EXPAREL®  
                                            Clinical Study Protocol Amendment 3 
 
Appendix 7: 
Discharge Readiness 
The subject’s discharge readiness will be assessed at 12, 24, 36, 48, 60, 72, 84, and 96 hours or 
until the subject is determined to be discharge ready, whichever occurs first, using the MPADSS 
below (Chung 1995a; Chung 1995b).  This discharge readiness assessment will be used for data 
collection only and is not intended to interfere with the surgical center’s policy for determining 
when the subject should be discharged from the site.  Only subjects who achieve a score of 9 or 
higher are considered ready for discharge.  Discontinue assessing discharge readiness once a 
score of 9 or higher is reached. 
 Modified Postanesthesia Discharge Scoring System (MPADSS) 
Parameter 
Score 
Vital Signs  
 
 
≤20% of preoperative value 
2 
 
20%-40% of preoperative value 
1 
 
>40% of preoperative value 
0 
Ambulation 
 
 
Steady gait/no dizziness 
2 
 
With assistance 
1 
 
None/dizziness 
0 
Nausea and Vomiting 
 
 
Minimal 
2 
 
Moderate 
1 
 
Severe 
0 
Pain 
 
 
Minimal 
2 
 
Moderate 
1 
 
Severe 
0 
Surgical Bleeding 
 
 
Minimal 
2 
 
Moderate 
1 
 
Severe 
0 
 
 
 
 
 
CONFIDENTIAL 
81 of 88 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
402-C-326 (FNB TKA) 
EXPAREL®  
                                            Clinical Study Protocol Amendment 3 
 
Appendix 8: 
Clinical Laboratory Tests 
The scheduled clinical laboratory tests (hematology, chemistry, and urinalysis) will be conducted 
at Screening; baseline (on Day 0 prior to the nerve block); and on postsurgical Day 10.  Clinical 
laboratory tests, as appropriate, may also be conducted if a subject experiences an AESI 
(ie, cardiac AE, neurological AE, or fall) or an SAE (see Section 13.1.12).  
General Chemistry Analysis 
General Hematology (CBC with Differential) 
Components 
Urinalysis 
Albumin 
White blood cells 
Color 
Alkaline phosphatase 
Red blood cells 
Appearance 
Alanine transaminase (ALT)  
Hemoglobin 
Specific gravity 
Amylase 
Hematocrit 
pH 
Aspartate transaminase (AST)  
Mean corpuscular volume 
Protein 
Bilirubin, direct 
Mean corpuscular hemoglobin 
Glucose 
Bilirubin, total 
Mean corpuscular hemoglobin concentration 
Ketones 
Blood urea nitrogen 
Red cell distribution width 
Bilirubin 
Calcium 
Platelets 
Blood 
Carbon dioxide (bicarbonate) 
Mean platelet volume 
Urobilinogen 
Chloride 
Absolute/percent neutrophil count 
Nitrite 
Cholesterol 
Absolute/percent lymphocyte count 
Leukocyte esterase 
Creatine kinase (CK), total  
Absolute/percent monocyte count 
(or creatine phosphokinase 
Absolute/percent eosinophil count 
[CPK]) 
Absolute/percent basophil count 
Creatinine, serum 
 
Gamma-glutamyl 
transpeptidase (GGT) 
 
Glucose 
Iron 
Iron binding capacity 
(UIBC/TIBC) 
Lactate dehydrogenase (LDH) 
Lipase 
Magnesium 
Phosphorus 
Potassium 
Sodium 
Total protein 
Transferrin 
Triglycerides 
Uric acid 
 
 
 
CONFIDENTIAL 
82 of 88 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
402-C-326 (FNB TKA) 
EXPAREL®  
                                            Clinical Study Protocol Amendment 3 
 
Appendix 9: 
Physical Therapy Assessments 
 
The physical therapy assessments will be conducted at Screening; once postsurgically on Day 0; 
each day at 8:00 am (±2h) and 8:00 pm (±2h) from Day 1 until hospital discharge; and once on 
Day 10. 
Physical Therapy Assessments List 
The following physical therapy assessments will be performed in this study: 
• Timed Walk Test  
• Timed Up and Go Test  
• Stair Climbing Test  
 
General Physical Therapy Assessment Guidelines 
• Preemptive use of opioids or NSAIDs immediately prior to the physical therapy 
assessment is not permitted 
• At timepoints when multiple assessments coincide, the physical therapy assessments 
will be conducted last 
• The physical assessments should be completed in the following order: 
1. Timed Walk Test 
2. Timed Up and Go Test 
3. Stair Climbing Test 
• For all 3 physical therapy tests, the following will be recorded by the physical 
therapist: 
o The date of the assessment 
o The time of the assessment 
o Whether the test was performed or not 
o The level of physical assistance required (record for timed walk and timed up and go 
tests only) 
1. Total assistance (subject contributes < 25% of the effort or is unable to do the 
task) 
2. Maximal assistance (subject provides less than half of the effort (25–49%)) 
3. Moderate assistance (subject still performs 50–75% of the task) 
4. Minimal assistance (requiring incidental hands-on help only (subject performs > 
75% of the task)) 
5. Supervision (requiring only standby assistance or verbal prompting or help with 
set-up) 
6. Modified independence (requiring the use of a device but no physical help) 
7. Complete independence (fully independent) 
o If a walking aid used 
 
 
 
CONFIDENTIAL 
83 of 88 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
402-C-326 (FNB TKA) 
EXPAREL®  
                                            Clinical Study Protocol Amendment 3 
 
TIMED WALK TEST 
 
EQUIPMENT REQUIRED 
• Timer/stop watch 
• Flat walking area (eg, hallway or open space), preferably greater than 20 meters in length.   
This can be a straight line, oval, or other shape. 
• Bright color tape or cones to mark course boundaries, if necessary 
• Tape or other marker to provide interval markings at regular intervals (eg, every 3 meters). 
This may not be necessary if floor is tiled and tile length is consistent and known (eg, 5 foot 
tiles). 
• Chair(s) for resting, if needed, spread out as necessary 
 
INSTRUCTIONS 
 
Therapist instructions 
1. Test should be conducted in a flat walking area with a known length  
2. Subject is instructed that on the word “GO” they should walk forward at a normal, 
comfortable pace until they reach the end of the walking area, turn around, and walk back to 
the starting point (modify instructions as needed based on shape of actual walking area). 
3. Physical therapist begins stopwatch and says “GO” 
4. Subject is allowed to rest as needed (time is not stopped for resting) 
5. The physical therapist walks alongside the subject, for safety purposes, and notes the amount 
of physical assistance required 
6. Physical therapist records how far the subject walks (ie, keeps track of full and partial 
walking area lengths) during the 6 minute test 
a. If test is not performed, the physical therapist will record the specific reason 
7. Physical therapist instructs the subject to stop walking after 6 minutes has passed 
a. If the subject cannot complete the 6 minutes, record distance walked at the time 
they stopped, but let the clock run out 6 minutes 
8. The same walking area should be used for all assessments of study participants 
 
Subject instructions 
1. Start with both feet on the start line. 
2. On “GO”, walk comfortably and safely up and down the hallway (modify instructions as 
necessary to suit walking area). 
3. Do the best you can by going at a normal, comfortable pace, but don’t push yourself to a 
point of overexertion or beyond what you think is safe for you. 
4. Keep walking for 6 minutes if possible, but don’t be concerned if you need to slow down or 
stop to rest. 
5. Get ready and GO. 
 
 
 
CONFIDENTIAL 
84 of 88 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
402-C-326 (FNB TKA) 
EXPAREL®  
                                            Clinical Study Protocol Amendment 3 
 
Scoring 
1. The test starts on the signal to start “GO” and terminates at 6 minutes. 
2. The distance walked over the 6 minutes is recorded in meters. 
3. A walking aid is allowed and should be recorded, if used. 
4. Record the physical assistance required. 
 
 
 
 
 
 
CONFIDENTIAL 
85 of 88 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
402-C-326 (FNB TKA) 
EXPAREL®  
                                            Clinical Study Protocol Amendment 3 
 
TIMED UP AND GO TEST 
 
EQUIPMENT REQUIRED 
• Timer/stop watch 
• Standard chair (seat height: approximately 17 inches) with two arm rests (arm rest height: 
approximately 26 inches) 
• Ruler to measure seat height and arm rest height 
• Measuring tape to measure 3 meters away from the chair (approximately 9 feet 10 inches) 
• Tape or other marker to mark the distance so that it is easily seen by the subject 
 
INSTRUCTIONS 
 
Therapist instructions 
1. Subject begins seated on a standard chair with arm rests.  Ensure the chair cannot slide 
backwards by placing it against a wall or otherwise bracing it (eg, physical therapist braces 
with foot). 
2. Subject is instructed to sit facing forward, with both feet on the floor, and their buttocks 
touching the back of the seat 
3. A line is placed on the floor 3 meters in front of the chair.  Use a measuring tape to measure 
this distance. Alternatively, place the chair 3 meters away from an existing marker (eg, floor 
tile). 
4. Subject is instructed that “On the word GO you will stand up, walk to the line on the floor, 
turn around and walk back to the chair and sit down. Walk at your regular pace.” 
5. The physical therapist then says “GO” and starts the stopwatch and records the time of 
assessment 
6. The physical therapist walks alongside the subject, for safety purposes, and notes the amount 
of physical assistance required. 
7. The goal of the test is to measure the subject’s ability to complete the activity without 
assistance. The therapist should endeavor to not provide assistance unless required for safety 
reasons. 
8. After the subject has completed the activity, the physical therapist stops the stopwatch and 
records the time lapsed in seconds 
a. If test is not performed, the physical therapist will record the specific reason 
b. Subject should be encouraged to complete the test. Time will continue to run until 
therapist determines it cannot be completed and the test is stopped. 
9. The same chair should be used for all assessments, while on study 
 
Subject instructions 
1. Start by sitting in the chair with your back resting on the backrest and your hands on the 
armrest. 
2. On “GO”, stand up, walk to the mark, turn around, return and sit back into the chair with 
your back resting on the back of the chair. 
 
 
CONFIDENTIAL 
86 of 88 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
402-C-326 (FNB TKA) 
EXPAREL®  
                                            Clinical Study Protocol Amendment 3 
 
3. Walk as quickly and safely as you can 
4. Get ready and GO 
 
Scoring 
1. The test starts on the signal to start (“GO”) and terminates once the participant sits back 
down fully with their back resting on the back of the chair. 
2. The duration of the test is recorded to nearest 10th of a second. 
3. A walking aid is allowed and should be recorded, if used. 
4. Record the physical assistance required. 
 
 
 
 
CONFIDENTIAL 
87 of 88 
07 November 2016 


Pacira Pharmaceuticals, Inc. 
402-C-326 (FNB TKA) 
EXPAREL®  
                                            Clinical Study Protocol Amendment 3 
 
STAIR CLIMBING TEST  
 
EQUIPMENT REQUIRED 
• Flight of stairs with handrail on one or both sides 
 
INSTRUCTIONS 
 
Therapist instructions 
1. Test should be conducted on a standard flight of stairs, each with a height of approximately 
18 cm and a depth of approximately 28 cm, with adequate lighting. 
2. Subject is instructed that on the word “GO” they should walk up the steps (facing in the 
direction they are walking) as quickly and safely as possible to the top, turn around on the 
landing, and then walk down the steps (facing in the direction they are walking) as quickly as 
they feel comfortable and return to the starting position 
3. Physical therapist should encourage subject to use only their legs if possible, though use of a 
walking aid or handrail(s) is allowed, as needed 
4. The physical therapist walks alongside the subject, for safety purposes 
a. If test is not performed, the physical therapist will record the specific reason 
b. Subject should be encouraged to complete the test 
5. The goal of test is to measure the subject’s ability to complete the activity without assistance. 
The therapist should endeavor to not provide assistance unless required for safety reasons. 
6. The same stairs should be used for all assessments of study participants 
 
Subject instructions 
1. Start with both feet on the bottom landing 
2. On “GO”, go to the top of the stairs, turn around, and come back to the bottom of the stairs  
3. Walk as quickly and safely as you can 
4. Stop with both feet back on the bottom landing 
5. Use the handrail, if needed 
6. Get ready and GO 
 
Scoring 
1. The test starts on the signal to start (“GO”) and terminates when the participant returns with 
both feet to the ground level. 
2. The participant can stop and rest if needed but the time keeps going. 
3. Walking aid is allowed 
 
 
 
 
 
 
 
CONFIDENTIAL 
88 of 88 
07 November 2016 

SAP_000.pdf: 
 
CONFIDENTIAL 
i of i 
 20Jun2017 
 
 
 
STATISTICAL ANALYSIS PLAN 
 
 
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, 
Safety, and Pharmacokinetics of Femoral Nerve Block with EXPAREL for Postsurgical 
Analgesia in Subjects Undergoing Total Knee Arthroplasty 
 
 
 
 
Protocol No.: 402-C-326 
IND No.: 69,198  
Study Phase: 3 
Study Drug: EXPAREL (bupivacaine liposome injectable 
suspension) 
Date/Version: 20 June 2017 / Version 1.0 
Prepared by: Richard Willey, M.S. 
Sponsor: Pacira Pharmaceuticals, Inc. 
5 Sylvan Way 
Parsippany, NJ 07054 
Tel: 973-254-3560 
 
 
 
 
 
 
 
Confidentiality Statement 
The information contained in this document is confidential and the property of Pacira Pharmaceuticals, 
Inc.  It should not be reproduced, revealed, or sent to third parties other than Institutional Review 
Boards/Independent Ethics Committees and the Investigator’s research support staff participating in the 
conduct of the study without the prior written authorization of Pacira Pharmaceuticals, Inc. 




Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL® 
Statistical Analysis Plan 
 
 
CONFIDENTIAL 
3 of 173 
20Jun2017 
 
2. 
TABLE OF CONTENTS 
1. 
SIGNATURE PAGE 
2 
2. 
TABLE OF CONTENTS 
3 
3. 
LIST OF ABBREVIATIONS 
5 
4. 
INTRODUCTION 
6 
5. 
STUDY OBJECTIVES 
7 
5.1. 
Primary Objective 
7 
5.2. 
Secondary Objectives 
7 
6. 
STUDY OVERVIEW 
8 
7. 
DEFINITIONS 
11 
8. 
ANALYSIS SETS 
15 
9. 
STATISTICAL METHODS OF ANALYSIS 
16 
9.1. 
General Principles 
16 
9.1.1. 
Handling Missing Values 
18 
9.1.1.1. 
Area under the VAS-Time Curve 
18 
9.1.1.2. 
Exposure, Surgery, and Rescue Medication Date or Time 
19 
9.1.1.3. 
Rescue Pain Medication 
19 
9.1.1.4. 
Adverse Event or Concomitant Medications Dates or Times 
19 
9.1.1.5. 
Adverse Event Severity or Relationship to Study Drug 
20 
9.1.1.6. 
Time to Event 
20 
9.1.2. 
Multiplicity Adjustments 
20 
9.1.3. 
By-Center Analyses 
20 
9.2. 
Subject Disposition 
20 
9.3. 
Description of Demographics and Baseline Characteristics 
21 
9.3.1. 
Demographics 
21 
9.3.2. 
Baseline Characteristics 
21 
9.4. 
Surgery Characteristics 
22 
9.5. 
Intraoperative, Prior and Concomitant Medications 
22 
9.6. 
Measurements of Treatment Compliance 
23 
9.7. 
Efficacy Analysis 
23 
9.7.1. 
Efficacy Endpoints 
23 
9.7.1.1. 
Primary Efficacy 
23 
9.7.1.2. 
Secondary Efficacy 
23 
9.7.1.3. 
Tertiary Efficacy 
24 
9.7.1.4. 
Area under the Curve 
24 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL® 
Statistical Analysis Plan 
 
 
CONFIDENTIAL 
4 of 173 
20Jun2017 
 
9.7.1.5. 
Opioid Consumption 
24 
9.7.1.6. 
Time to First Opioid Rescue Medication Use 
25 
9.7.1.7. 
Pain-free 
25 
9.7.1.8. 
Overall Benefit of Analgesia Score (OBAS) 
25 
9.7.2. 
Methods of Analysis 
26 
9.7.2.1. 
Primary Efficacy Analysis 
26 
9.7.2.2. 
Secondary Efficacy Analyses 
26 
9.7.2.3. 
Tertiary Efficacy Analyses 
27 
9.8. 
Safety Analyses 
31 
9.8.1. 
Vital Signs 
31 
9.8.2. 
Electrocardiograms 
31 
9.8.3. 
Neurological Assessments 
32 
9.8.4. 
Sensation Tests 
32 
9.8.5. 
Degree of motor nerve block Assessments 
33 
9.8.6. 
Adverse Events 
33 
9.8.7. 
Laboratory Parameters 
35 
9.9. 
Pharmacokinetic Analysis 
35 
9.10. 
Interim Analysis 
35 
9.10.1. 
Pharmacokinetic Review 
35 
9.11. 
Significance Testing 
36 
10. 
SAMPLE SIZE CALCULATIONS 
38 
11. 
REFERENCES 
39 
12. 
TIME AND EVENTS SCHEDULE OF STUDY PROCEDURES 
40 
13. 
MULTIPLE IMPUTATION EXAMPLE PROGRAM CODE 
41 
14. 
TABLE OF CONTENTS FOR TABLE MOCK-UPS 
43 
15. 
TABLE OF CONTENTS FOR LISTING MOCK-UPS 
131 
16. 
TABLE OF CONTENTS FOR FIGURE MOCK-UPS 
168 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL® 
Statistical Analysis Plan 
 
 
CONFIDENTIAL 
5 of 173 
20Jun2017 
 
3. 
LIST OF ABBREVIATIONS 
Abbreviation 
Description 
AE 
Adverse event 
ANOVA 
Analysis of variance 
ATC 
Anatomical therapeutic class 
AUC 
Area under the curve 
BLOQ 
Below the limit of quantification 
BMI 
Body mass index 
bpm 
Beats per minute 
CI 
Confidence interval 
CMH 
Cochran-Mantel-Haenszel 
CRF 
Case report form 
CSR 
Clinical study report 
d 
Day 
ECG 
Electrocardiogram 
EMA 
European Medicines Agency 
ER 
Emergency room 
FDA 
Food and Drug Administration 
FNB 
Femoral nerve block 
hr, h 
hour 
ICF 
Informed consent form 
ICH 
International Conference on Harmonization 
ICU 
Intensive care unit 
IV 
Intravenous 
LOCF 
Last observation carried forward 
LS 
Least square 
MedDRA 
Medical dictionary for regulatory affairs 
MMRM 
Mixed model repeated measures 
MPADSS 
Modified Postanesthesia Discharge Scoring System 
min 
minutes 
MED 
Morphine equivalent dose in mg 
n 
Number of subjects 
OBAS 
Overall benefit of analgesia 
OR 
Operating room 
PACU 
Postanesthesia care unit 
PCA 
Patient-controlled analgesia 
PK 
Pharmacokinetics 
PO 
Oral 
ROW 
Rest of world 
SAE 
Serious adverse event 
SAP 
Statistical analysis plan 
SD 
Standard deviation 
SE 
Standard error 
SPI 
Sum of pain intensity scores 
TEAE 
Treatment-emergent adverse event 
TKA 
Total knee arthroplasty 
TLF 
Table, listings and figures 
TUG 
Timed up-and-go 
TWT 
Timed walk test 
VAS 
Visual analog scale 
WHO 
World Health Organization 
WHO-DD 
World Health Organization – Drug Dictionary 
wWOCF 
Windowed worst observation carried forward 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL® 
Statistical Analysis Plan 
 
 
CONFIDENTIAL 
6 of 173 
20Jun2017 
 
4. 
INTRODUCTION 
This Statistical Analysis Plan (SAP) describes the planned statistical analysis and reporting of 
the clinical study 402-C-326 titled “A Multicenter, Randomized, Double-Blind, Placebo-
Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Femoral Nerve Block 
with EXPAREL for Postsurgical Analgesia in Subjects Undergoing Total Knee Arthroplasty”.  
This study is intended to evaluate the magnitude and duration of analgesic effect of a single 
femoral nerve block injection with EXPAREL in subjects undergoing primary unilateral total 
knee arthroplasty (TKA). 
The structure and content of this SAP provide sufficient detail to meet the requirements 
identified by the US Food and Drug Administration (FDA), European Medicines Agency 
(EMA), and International Conference on Harmonisation (ICH) of Technical Requirements for 
Registration of Pharmaceuticals for Human Use: Guidance on Statistical Principles in Clinical 
Trials1.  All work planned and reported for this SAP will follow internationally accepted 
guidelines, published by the American Statistical Association2 and the Royal Statistical Society3, 
for statistical practice.   
The purposes of this SAP are to: 
 
Outline the types of analyses and presentations of data that will form the basis for 
drawing conclusions to the study objectives and hypotheses outlined in the protocol. 
 
Explain in detail how the data will be handled and analyzed, adhering to commonly 
accepted standards and practices for Good Statistical Practice. 
The planned analyses identified in this SAP may be included in clinical study reports (CSRs), 
regulatory submissions, or manuscripts.  Post-hoc exploratory analyses not necessarily identified 
in this SAP may be performed to further examine study data.  Any post-hoc, unplanned, or 
exploratory analyses performed will be clearly identified as such in the final CSR. 
The following documents were reviewed in preparation of this SAP: 
 
Amendment 3 of Protocol 402-C-326 issued on 7Nov2016. 
 
Amendment 2 of Protocol 402-C-326 issued on 28Sep2016. 
 
Amendment 1 of Protocol 402-C-326 issued on 15Feb2016. 
 
Original Protocol 402-C-326 issued on 16Nov2015. 
 
CRF version 1.0 issued on 25Nov2015.  
 
ICH Guidance on Statistical Principles for Clinical Trials (E9). 
The reader of this SAP is encouraged to also read the clinical protocol and other identified 
documents for details on the planned conduct of this study.  Operational aspects related to 
collection and timing of planned clinical assessments are not repeated in this SAP unless relevant 
to the planned analyses. 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL® 
Statistical Analysis Plan 
 
 
CONFIDENTIAL 
7 of 173 
20Jun2017 
 
5. 
STUDY OBJECTIVES 
5.1. 
Primary Objective  
The primary objective of this study is to evaluate the magnitude and duration of the analgesic 
effect achieved following single-dose injection femoral nerve block with EXPAREL in subjects 
undergoing primary unilateral total knee arthroplasty (TKA).  
5.2. 
Secondary Objectives 
The secondary objectives of this study are to further assess the efficacy, safety, and 
pharmacokinetic (PK) profiles of EXPAREL as well as the onset and duration of sensory and 
motor function blockade following administration for analgesia in subjects undergoing primary 
unilateral TKA. 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL® 
Statistical Analysis Plan 
 
 
CONFIDENTIAL 
8 of 173 
20Jun2017 
 
6. 
STUDY OVERVIEW 
This is a Phase 3, double-blind, placebo-controlled, randomized study.  Subjects will be 
monitored for 5 days after surgery and followed for 30 days after surgery.  Subjects will be 
randomized (1:1:1) to receive a 20mL injection of EXPAREL 133mg (10mL of EXPAREL 
266mg/20mL expanded with 10mL of normal saline), EXPAREL 266mg or placebo (normal 
saline) via an ultrasound guided single-injection femoral nerve block approximately 1 hour 
before surgery.   
Subjects will be allowed rescue medication upon request to control their pain.  Rescue 
medication will be oral (PO) immediate release oxycodone.  If subject cannot tolerate PO 
medication, intravenous (IV) morphine or hydromorphone may be used as rescue medication. 
Pain will be assessed using a 10 cm visual analog scale (VAS).  Pain will be assessed at multiple 
timepoints during the study. 
Other postsurgical assessments include: 
 Postsurgical opioid consumption;  
 Overall benefit of analgesia score (OBAS);  
 Subject satisfaction with overall analgesia using a 5-point Likert scale;  
 Subject’s discharge ready as assessed by Modified Postanesthesia Discharge Scoring 
System (MPADSS);  
 Unscheduled phone calls or office visits related to pain;   
 Clinical laboratories;  
 Vital sign measurements; 
 ECGs; 
 Neurological assessment;  
 Sensory function assessment at 2 locations as measured by: 
o Cold, 
o Pinprick, 
o Light touch; 
 Degree of motor nerve block, both active and passive, assessment as measured by: 
o Angle of flexion, 
o Angle of extension,  
 Adverse events; 
 Concomitant medications; 
 Timed walk test (added with Amendment 2 of protocol); 
 Timed up-and-go test (added with Amendment 2 of protocol); 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL® 
Statistical Analysis Plan 
 
 
CONFIDENTIAL 
9 of 173 
20Jun2017 
 
 Stair climb test (added with Amendment 2 of protocol). 
Following are the major changes in Amendment 2 of the protocol impacting the statistical 
analyses (see Amendment 2 of the protocol for a complete record of changes): 
 Under Amendment 1 all subjects were to be in-hospital through 120 hours; under 
Amendment 2 subjects are to remain in-hospital through 108 hours. 
 Under Amendment 1 all subjects  had PK assessments at the same scheduled time; under 
Amendment 2 a population PK approach was adopted where subjects were randomized to 
one of two PK sampling schemes. 
 Time points of the motor and sensitivity assessments were changed from baseline (on 
Day 0 prior to the nerve block); at approximately 15, 30, and 45 minutes; at 6, 9, 12, 18, 
24, 36, 48, 60, 72, 84, 96, 108, and 120 hours to baseline (on Day 0 prior to the nerve 
block); at approximately 15, 30, and 45 minutes; at 6, 9, 12, 18, 24, 36, 48, 60, 72, 84, 96, 
and 108 hours; and at hospital discharge to align with the Tmax observed in the PK interim 
analysis. 
 Duration of in-house portion of the study was changed from 5 days to 4 days. 
 
Added physical therapy assessments of timed walk test, timed up-and-go test, and stair 
climb test scheduled for 8am and 8pm ± 2 hours. 
 
Assessment schedules were changed for: 
o Pain  
 
From ‘upon arrival at the PACU; at 6, 12, 24, 36, 48, 60, 72, 84, 96, 108, 
and 120 hours; and immediately prior to each administration of rescue 
pain medication through 120 hours’;  
 To ‘upon arrival at the PACU, every 15 minutes while in the PACU, and 
prior to PACU discharge; at 6, 12, 24, 36, 48, 60, 72, 84, 96, and 108 
hours; and immediately prior to each administration of rescue pain 
medication through 108 hours.’  
o Vital signs  
 From ‘baseline (on Day 0 prior to the nerve block); upon arrival at the 
PACU; at 6, 12, 24, 36, 48, 60, 66, 72, 78, 84, 96, 108, and 120 hours; 
and on postsurgical Days 7 and 10’;  
 To ‘baseline (on Day 0 prior to the nerve block); every 5 minutes during 
performance of the block and up to 30 minutes after the end of the 
injection and then every 15 minutes after the block until entering the 
operating room; upon arrival at the PACU; at 6, 9, 12, 24, 36, 48, 56, 60, 
64, 68, 72, 76, 80, 84, 96, and 108 hours; and on postsurgical Days 6 and 
10.’ 
o 12-lead ECG  
 From ‘baseline (on Day 0 prior to the nerve block); upon arrival at the 
PACU; at 6, 12, 24, 36, 48, 60, 66, 72, 78, 84, 96, 108, and 120 hours; 
and on postsurgical Days 7 and 10’;  


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL® 
Statistical Analysis Plan 
 
 
CONFIDENTIAL 
10 of 173 
20Jun2017 
 
 To ‘baseline (on Day 0 prior to the nerve block); upon arrival at the 
PACU; at 6, 9, 12, 24, 36, 48, 56, 60, 64, 68, 72, 76, 80, 84, 96, and 108 
hours; and on postsurgical Days 6 and 10.’ 
o Sensory and motor function  
 From ‘baseline (on Day 0 prior to the nerve block); at approximately 15, 
30, and 45 minutes; and at 6, 9, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, and 
120 hours’; 
 To ‘baseline (on Day 0 prior to the nerve block); at approximately 15, 30, 
and 45 minutes prior to the OR; prior to discharge from the PACU; at 6, 
9, 12, 18, 24, 36, 48, 60, 72, 84, 96, and 108 hours; and at hospital 
discharge.’  
o Neurological 
 From ‘baseline (on Day 0 prior to the nerve block); upon arrival at the 
PACU; at 6, 12, 24, 36, 48, 60, 66, 72, 78, 84, 96, 108, and 120 hours; 
and on postsurgical Days 7 and 10’; 
 To ‘baseline (on Day 0 prior to the nerve block); upon arrival at the 
PACU; at 6, 9, 12, 24, 36, 48, 56, 60, 64, 68, 72, 76, 80, 84, 96, and 108 
hours; and on postsurgical Days 6 and 10.’ 
 
Following are the major changes in Amendment 3 of the protocol impacting the statistical 
analyses are as follows (see Amendment 3 of the protocol for a complete record of changes): 
 Sample size calculation changed from 90% power to 80% power.  Resulting in a drop in 
sample size from 300 to 231 subjects. 
 Discharge readiness assessments schedule was changed 
o From ‘Discharge readiness at 12, 24, 36, 48, 60, 72, 84, and 96 hours or 
discharge ready, whichever occurs first’; 
o To ‘12, 24, 36, 48, 60, 72, 84, and 96 hours or until the subject is determined to 
be discharge ready, whichever occurs first.’ 
 Post-surgical medications were amended  
o From ‘Patient-controlled analgesia (PCA) is not permitted.  No other analgesic 
agents, including NSAIDs, are permitted through 108 hours (postsurgical Day 
4)’; 
o To ‘Patient-controlled analgesia (PCA) is not permitted.  Postsurgically, all 
subjects will receive the following scheduled medications until hospital 
discharge: Acetaminophen/paracetamol up to 1000 mg PO or IV every 8 hours 
(q8h) unless contraindicated.  The total daily dose of acetaminophen/paracetamol 
should not exceed 3000 mg and Cyclobenzaprine (eg, Flexeril®) 10 mg PO x1 
dose (PRN at the surgeon’s discretion).  No other analgesic agents, including 
NSAIDs, are permitted through 108 hours (postsurgical Day 4).’   


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL® 
Statistical Analysis Plan 
 
 
CONFIDENTIAL 
11 of 173 
20Jun2017 
 
7. 
DEFINITIONS 
Study Day 
Study Day is calculated as the date of event minus the date of surgery plus one (1), if the date of 
event is on or after the date of surgery.  Study Day is based on the calendar dates, thus days 
before the date of surgery have negative values while those on or after the date of surgery are 
positive.   
This Study Day definition differs from the protocol defined Study Day.  By this definition Day 1 
is the day of the operation while the protocol defines this as Day 0.  The definition assigning the 
operation to Day 1 aligns with the CDISC implementation guidance and FDA expectations. 
Treatment-emergent Adverse Events 
Treatment-emergent adverse events (TEAEs) are those with onset between the start date and 
time of study drug administration and end of study (Study Day 30±3 days). 
Time 0 (zero) 
Time 0 is defined as the date and time of the start of study drug administration. 
Time Periods 
All schedule times have a window associated with them (see Time and Events Schedule for 
individual timepoint windows).  Various time frames are used in the data analyses which are 
dependent on these windows.  The table below defines the actual elapsed times with allowance 
for the windows that can be included in the window. 
Defined time frame (hrs) 
Acceptable elapsed times (hrs) 
0-12 
[0 to 13] 
0-24 
[0 to 25] 
0-48 
[0 to 50] 
0-72 
[0 to 76] 
0-96 
[0 to 100] 
0-Day 6 
[0 to 168] 
0-Day 10 
[0 to 264] 
24-48 
[23 to 50] 
48-72 
[ 46 to 76] 
72-96 
[68 to 100] 
48-96 
[46 to 100] 
If there are two or more data points that fit the time window, the data point that occurs the latest 
in the window should be used.  For example when selecting the data point for the 48 hour 
timepoint, if a subject has data points collected at 47 and 49 hours then the 49 hour timepoint 
should be used.  In this example the 49 hour timepoint record will be used as the end and start of 
all time intervals, thus the 0-48 hour interval will end using the 49 hour record and the 48-72 
hour interval will start using the same 49 hour record.  In addition, if there are two measurements 
for a given assessment at the exact same time, the measurement with the highest value should be 
used.   


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL® 
Statistical Analysis Plan 
 
 
CONFIDENTIAL 
12 of 173 
20Jun2017 
 
Baseline 
Baseline is defined as the last available measurement or assessment prior to start of study 
treatment. 
Sensation Loss 
Sensation loss is when the subject reports absence of sensation for the sensory test (cold, 
pinprick or light touch) at each location [foot (anterior cutaneous nerve) and thigh (saphenous 
nerve)]. Subjects may experience loss of sensation multiple times and at different times in 
different locations.  A subject must have a return of sensation in the same sensory test in the 
same location before another loss of sensation can occur. 
Time to Sensation Loss 
Time to first loss of sensation is the first timepoint after baseline at which one of the three 
sensations (cold, pinprick and light touch) is absent at any location.  If sensation is not lost, time 
to sensation loss will be censored at the last available sensory assessment available for that 
subject.  Subjects who experience multiple losses of sensation will have multiple times to 
sensation loss but the time to first sensation loss will be used for analysis of time to first 
sensation loss.  
Return of Sensation 
Return of sensation is when a subject reports the presence of sensation after reporting a loss of 
sensation for the same sensory test (cold, pinprick or light touch) at the same location as the loss.  
Subjects may experience returns of sensation multiple times.  A subject must experience multiple 
losses of sensation before multiple returns can be experienced.  Subjects who experience 
multiple returns of sensation will have multiple times to sensation return. 
Time to Return of Sensation 
Time to return of sensation is when all three sensations (cold, pinprick and light touch) are 
present after a subject experienced a loss of sensation in at least one of the sensory tests.  If 
sensation doesn’t return, it will be censored at the time of the last sensory assessment available 
for that subject.  Only subjects who experience a loss of sensation can experience a return of 
sensation. 
Duration of Sensory Loss 
Duration of sensory loss is defined as the time from sensation loss to the time of sensation return.  
Subjects who never lose sensation will not be included in any analysis of Duration of Sensory 
Loss.  If sensation doesn’t return, then duration will be censored and is defined as the time 
between sensation loss and last sensory assessment.  
Duration will be calculated for each loss-return cycle for those subjects with multiple cycles.  If 
after the last sensation loss there is no return of sensation, the duration of the last cycle will be 
censored and defined as the time between sensation loss for that cycle and last sensory 
assessment. 
Total duration is the sum of all durations for a subject. 
Onset of Motor Function Loss 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL® 
Statistical Analysis Plan 
 
 
CONFIDENTIAL 
13 of 173 
20Jun2017 
 
Onset of motor function loss is the first timepoint after baseline where at least one of the motor 
function assessments (angle of flexion [active and passive] or angle of extension [active and 
passive]) meets the criteria below.  Passive assessments are assisted by medical staff while active 
assessments are done without medical assistance. 
Loss of motor function is defined as:  
L1. If the subject’s baseline active flexion angle is ≥ 80° then an active flexion angle < 80° 
indicates loss of motor function; otherwise a change (post-baseline) in active flexion 
angle ≤ -10° indicates loss of motor function OR 
L2. If the subject’s baseline active extension angle is ≤ 10° then an active extension angle > 
10° indicates loss of motor function; otherwise a change (post-baseline) in active 
extension angle > 10° indicates motor function loss.  
A subject satisfying at least one of the loss criteria L1 or L2 is considered as having loss of 
motor function.  These individual criteria are used to define loss of function within each specific 
motor function test. 
Return of Motor Function 
Return of motor function is defined when the following criteria R1 and R2 are met:  
R1. Active flexion angle is either ≥ 80° for those subjects whose baseline was ≥ 80° or 
change from baseline is > -10° for subjects whose baseline flexion was < 80° AND  
R2. Active extension angle is ≤ 10° for those subjects whose baseline extension was ≤ 10° or 
change from baseline is < 10° for those subjects whose baseline was > 10°.  
A subject who satisfies return criteria R1 and R2 is considered as having complete return of 
motor function. The individual criteria are used to define return of function within a specific 
motor function test.  
Time to Return of Motor Function 
Time to return of motor function is the time from first loss of motor function to last return of 
motor function for the motor assessment.  If a subjects doesn’t have return of motor function, the 
time to return of motor function will be censored on the date and time of last motor function 
assessment.  For those subjects who never lose motor function, time to return will be missing; 
these subjects will not be included in any analysis of time to return.   
Loss-Return Cycle 
A loss-return cycle is the event where a subject has loss and return of sensory or motor function.  
Subjects may experience multiple cycles.  Cycles are defined separately for each sensory and 
motor function tests. 
Ready for Discharge 
Ready for discharge is defined as a total score of 9 or more on the MPADSS.  The total score is 
the sum of all scores.  If there are missing data then the total score will not be calculated. 
Sum of Pain Intensity Score (SPIS) 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL® 
Statistical Analysis Plan 
 
 
CONFIDENTIAL 
14 of 173 
20Jun2017 
 
Sum of pain intensity scores (SPIS) are calculated by summing the imputed VAS scores for the 
time-frames of interest.  
Region 
Region is defined as US and ROW where ROW is any site outside of the US. 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL® 
Statistical Analysis Plan 
 
 
CONFIDENTIAL 
15 of 173 
20Jun2017 
 
8. 
ANALYSIS SETS 
The safety analysis set will include all subjects who receive study drug.  All analyses based on 
the safety set will be by actual treatment received. 
The efficacy analysis set will include all subjects in the safety analysis set who undergo the 
planned surgery.  All analyses based on the efficacy analysis set will be by randomized treatment 
regardless of treatment actually received. 
The per-protocol efficacy analysis set will include all subjects in the efficacy analysis set and do 
not have any important protocol deviations.  Important protocol deviations may include, but are 
not limited to, the following: 
1) Bilateral TKA or other concurrent surgical procedure 
2) 50% or more of the rescue medications are missing a VAS assessment (baseline through 72 hours +/- 
4 hours) within 30 minutes prior to rescue medication use and at least 4 rescue medication doses are 
missing the associated VAS assessments within 30 minutes prior to rescue medication use. 
3) Missing two or more scheduled VAS assessments between start study drug administration as the 
baseline VAS assessment and the 72 hour VAS assessment. 
4) Subject did not receive the study treatment to which he/she was randomized (determined after 
database lock and unblinding). 
All analyses for the per-protocol analysis set will be by randomized treatment.  
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL® 
Statistical Analysis Plan 
 
 
CONFIDENTIAL 
16 of 173 
20Jun2017 
 
9. 
STATISTICAL METHODS OF ANALYSIS 
9.1. 
General Principles 
The statistical analyses will be reported using summary tables, listings, and figures (TLFs).  All 
analyses and tabulations will be performed using SAS Version 9.1 or later.  Continuous 
variables will be summarized using descriptive statistics [sample size (n), mean, standard 
deviation (SD), minimum, median, and maximum].  Categorical variables will be tabulated with 
number and percentage of subjects.  Unless otherwise noted, percentages will be based on the 
number of subjects in the treatment group within the population. 
Individual subject data will be provided in listings.  All listings will be sorted by treatment, site, 
subject, and, if applicable, collection date and time. 
Unless otherwise stated summaries will present data across all sites (overall). 
Unless otherwise noted, tabulations of categorical data will present only those categories 
appearing in the data. 
On all figures, the comparator treatment will be represented in black with solid lines and filled 
squares; EXPAREL will be represented in red with solid lines and dots.   
For tables presenting summaries of VAS scores, if more than one VAS score is presented for a 
specific 
timeframe/timepoint 
of 
interest, 
the 
highest 
score 
within 
that 
specific 
timeframe/timepoint should be used.   
Plots of the VAS scores will show both observed and imputed scores.  A change in color and line 
type will differentiate the imputed VAS scores.  Imputed values will be represented by blue and 
green symbols and dashed lines for the comparator and EXPAREL respectively.  VAS scores 
obtained immediately prior to rescue will be indicated by a change in symbol.  For the 
comparator the symbol should be a triangle, for EXPAREL the symbol is a star.  The following 
table shows the SAS symbol statements: 
Treatment 
VAS Score 
SAS Statement 
Comparator 
Observed 
symbol font=marker interpol=j line=1 value=U color=black 
 
Imputed 
symbol font=marker interpol=j line=3 value=C color=brown 
EXPAREL 133 mg 
Observed 
symbol font=marker interpol=j line=1 value=W color=red 
 
Imputed 
symbol font=marker interpol=j line=3 value=V color=crimson 
EXPAREL 266 mg 
Observed 
symbol font=marker interpol=j line=1 value=W color=blue 
 
Imputed 
symbol font=marker interpol=j line=3 value=V color=cadetblue 
Note the symbol statement number will be dependent on the sort order of the treatment and VAS 
score group indicator variables. 
Sites with fewer than 5 subjects per treatment arm will be pooled with other sites for analysis.  
US sites will be pooled with other small US sites based on the US Census Bureau geographic 
regions (see Table 1) and European sites will be pooled with other small European sites based on 
country.  Sites meeting the criteria for pooling will be pooled with other similar sites within their 
census division.  If the resulting pooled site within a division still doesn’t have enough subjects 
per treatment group, it will be pooled with the site within the division with the smallest 
enrollment that doesn’t meet the pooling criteria.  If all sites within a division are pooled and the 
resulting pooled site still meets the pooling criteria, the site will be pooled with other small sites 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL® 
Statistical Analysis Plan 
 
 
CONFIDENTIAL 
17 of 173 
20Jun2017 
 
within the region.  If the pooled site with the region still meets the pooling criteria it will be 
pooled with the site with the smallest enrollment from the neighboring regions.   
Table 1: US Census Regions and Divisions 
Region 
Division 
State 
Midwest 
East North Central 
Illinois, Indiana, Michigan, Ohio, Wisconsin 
West North Central 
Iowa, Kansas, Minnesota, Missouri, Nebraska, North Dakota, South Dakota 
Northeast 
Middle Atlantic 
New Jersey, New York, Pennsylvania 
New England 
Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, Vermont 
South 
East South Central 
Alabama, Kentucky, Mississippi, Tennessee 
South Atlantic 
Delaware, District of Columbia, Florida, Georgia, Maryland, North Carolina, 
South Carolina, Virginia, West Virginia 
West South Central 
Arkansas, Louisiana, Oklahoma, Texas 
West 
Mountain 
Arizona, Colorado, Idaho, Montana, Nevada, New Mexico, Utah, Wyoming 
Pacific 
Alaska, California, Hawaii, Oregon, Washington 
 
Subjects who use opioid rescue medication will have the pain scores obtained after rescue 
replaced using pain scores obtained prior to rescue medication use.  Pain scores obtained during 
the opioid medication window will be replaced.  For this study the prescribed opioid rescue 
medication is oxycodone; however morphine or hydromorphone may be used.  The durations of 
effect for various opioids are listed in Table 2. 
Table 2: Opioid Windows 
Medication 
Route 
Window Used to Impute VAS 
Oxycodone, Oxycocet, Percocet, 
acetaminophen-oxycodone, 
Oxycontin 
PO, IM,IV,SC 
6 hours 
Morphine 
IV, PO, SC 
4 hours 
Hydromorphone (Dilaudid), 
Hydromorphone hydrochloride 
IV 
2 hours 
Hydromorphone (Dilaudid), 
Hydromorphone hydrochloride 
PO, IM, SC 
4 hours 
Hydrocodone 
PO 
6 hours 
Fentanyl 
IV, PO, IM 
6 hours 
Vicodin, Norco, Lorcet, Lortab, 
hydrocodone-acetaminophen 
PO 
6 hours 
Codeine (Tylenol 3, 
acetaminophen-coedine, 
Paracetamol Forte, Tylenol 4) 
PO 
6 hours 
Ultram, Tramadol, Tramacol 
hydrochloride 
PO 
6 hours 
PO = oral; IV = intravenous; VAS = visual analog scale. 
If other rescue medications are given then the window will be determined post-hoc.  If a combination 
opioid product is given then the window will be determined by the opioid part of the medication.  
Opioids given post surgically with an indication such as ‘anesthesia maintenance’ will not be included 
for imputation purposes. 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL® 
Statistical Analysis Plan 
 
 
CONFIDENTIAL 
18 of 173 
20Jun2017 
 
 
 
 
All non-efficacy tables will present EXPAREL 133 mg, EXPAREL 266 mg, All EXPAREL 
(combined doses), placebo, and all treatments as separate columns. 
Efficacy tables will present EXPAREL 133 mg, EXPAREL 266 mg, and placebo as separate 
columns.    
If there are multiple VAS records with the same actual date/time for a given subject, then the record 
with the highest VAS score will be used for that actual date/time for all endpoint derivations, 
summaries, and analyses. 
9.1.1. Handling Missing Values 
9.1.1.1. 
Area under the VAS-Time Curve 
9.1.1.1.1. 
Multiple Imputation Method 
Rubin’s (1987)4 multiple imputation procedure will be applied to replace each missing value 
with a set of plausible values that represent the uncertainty about the right value to impute.  This 
multiple imputation method is being implemented per the advice provided in “The prevention 
and treatment of missing data in clinical trials.”5 For calculation of area under the curve (AUC) 
of VAS pain intensity scores, the windowed worst observation carried forward (wWOCF) 
multiple imputation procedure will be used in the following order: 
a) Windowed worst observation carried forward (wWOCF) for rescue medications.   
For subjects who take a rescue medication, their VAS scores recorded within the window 
of controlled type of rescue medication (see Table 2) will be replaced by the ‘worst’ 
observation.  The non-rescue VAS score recorded right before taking a rescue medication 
(start of Rescue window) is considered as the ‘worst’ observation. This non-rescue worst 
VAS score shall be after the end of previous rescue window, where a rescue window ends 
once a subject is no longer considered under the effect of opioids (see Table 2 for 
individual rescue medication durations).  If there is no value available between the end of 
previous rescue window and the start of the current rescue window, then the first VAS 
score recorded on or right after the start of the current rescue window will be used for the 
imputation.   VAS scores recorded prior to the end of surgery will not be considered. 
b) After the wWOCF imputation, described in Step a, subject data still missing scheduled 
assessments with a non-monotone missing pattern (i.e., all pain scores between the last 
non-missing score and last timepoint) will have missing scores imputed using the 
Markov-Chain Monte-Carlo (MCMC) method (Schafer 1997)6 within each treatment, 
which will be applied in the multiple imputation procedure for arbitrary missing patterns.  
This MCMC method will simulate 10 datasets with only monotone missing data. In order 
to achieve the stationary distribution and to avoid dependency within samples generated 
by MCMC method, the number of iteration for the burn in period will be set to 2000 and 
the number of iterations between each sample will be set to 1000 (i.e.,  NBITER=2000 
and NITER=1000.) 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL® 
Statistical Analysis Plan 
 
 
CONFIDENTIAL 
19 of 173 
20Jun2017 
 
c) The AUC and SPIS at various time intervals will be derived from the VAS scores 
resulting from Step b.    
d) Rubin’s (1987) synthesizing procedure for the multiple imputed data will be applied to 
synthesize analysis results for each imputation.  SAS PROC MIANALYZE will be used 
for this procedure.  The mean parameter estimates, the asymptotic variance for this mean 
from the imputed data analysis in Step c will be created based on Rubin and Schenker 
method (1986)7. 
SAS pseudo-code for multiple imputations is provided in Section 13. 
9.1.1.2. 
Exposure, Surgery, and Rescue Medication Date or Time 
It is expected that all necessary information on study drug exposure, surgery, and postsurgical 
rescue medication dates and times will be complete.  Any such information that is missing and 
cannot be obtained through query resolution may be imputed, on a case-by-case basis, in a 
conservative manner that minimizes bias.  For example, if pain medication taken on Day 1 has 
no time of administration recorded, the imputed time will be the end of surgery. 
9.1.1.3. 
Rescue Pain Medication 
For calculation of the total rescue pain medication usage (IV Morphine Equivalent) through a 
time point, if a subject is discontinued early (e.g., dies, withdraws consent, is withdrawn from the 
study, or is lost to follow-up) before the end of the time interval (e.g., 24 hours after study drug 
administration), his or her total rescue pain medication usage through the time interval will be a 
projected amount.  For example, if a subject discontinues early at 6 hours after surgery, the 
projected amounts through 24 hours will be actual amount + average amount (actual amount/6 
hours) multiplied by the number of hours remaining in the time interval (18=24-6). 
9.1.1.4. 
Adverse Event or Concomitant Medications Dates or Times 
For AEs or concomitant medications with missing or partially missing start/stop date/time, the 
following imputation rules will be applied: 
For partial start date/time: 
 If the year is unknown, then the date will be assigned the date and time of first dose of 
study treatment. 
 If the month is unknown, then: 
i) 
If the year matches the year of the dose of study drug date, then the month and 
day of the dose of study drug date will be used to impute the missing month and 
corresponding day. 
ii) 
Otherwise, ‘January’ will be assigned. 
 If the day is unknown, then: 
i) 
If the month and year match the month and year of the dose of study drug date, 
then the day of the dose of study drug date will be imputed. 
ii) 
Otherwise, ‘01’ will be assigned. 
 If the time is unknown, then: 
i) 
If the date (day, month, and year) matches the date of the administration of study 
drug, then the time of the dose of study drug time will be imputed. 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL® 
Statistical Analysis Plan 
 
 
CONFIDENTIAL 
20 of 173 
20Jun2017 
 
ii) 
Otherwise, ’00:00’ will be assigned. 
For partial stop date/time: 
 If the year is unknown, then the date will be assigned the date subject discontinued from 
study, time will be set to the last time of the day (‘23:59’). 
 If the month is unknown, then month subject discontinued from study will be assigned. 
 If the day is unknown, then the last day of the month will be assigned. 
 If the time is unknown, then the last time of the day will be assigned (‘23:59’). 
9.1.1.5. 
Adverse Event Severity or Relationship to Study Drug 
If severity of an AE is not reported, then for tables of AEs by severity, the event will be 
classified as ‘Severe’.  If relationship to study drug is not reported for an AE, then for tables of 
study-drug related AEs, the event will be assigned the relationship of ‘definite’.  Tables 
presenting related AEs will include all AEs with relationships of ‘possible’, ‘probable’ or 
‘definite’ as assessed by the investigator. 
9.1.1.6. 
Time to Event  
For calculating time to an event when only the hour is reported, the minutes will be set to zero. 
9.1.2. Multiplicity Adjustments 
Significance testing will be based on "Graphical approaches for multiple comparison procedures 
using weighted Bonferroni, Simes, or parametric tests" (Bretz 2011)8. The initial alpha will be 
set to 0.025 for each of the primary efficacy analyses.  The diagram for sequential testing is in 
Section 9.11.  
Any analyses of tertiary efficacy endpoints are for sensitivity or exploratory purposes.  No 
multiplicity adjustments need be made for these endpoints. 
9.1.3. By-Center Analyses 
By-site summaries will present descriptive statistics only; no statistical analyses will be 
performed on individual sites.  By-site summaries will be presented for disposition, 
demographics, primary efficacy endpoint and secondary efficacy endpoints.  By-site summaries 
will present both pooled and individual sites.  The pooled site should be presented first 
immediately followed by the sites within that pool. 
9.2. 
Subject Disposition 
Subject disposition summaries will include the number of subjects that were: 
 Screened, 
o Screen failure 
o Enrolled 
 Randomized  
o Randomized not treated,  
o Randomized treated,  
 In the safety analysis set, 
 In the efficacy analysis set,  


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL® 
Statistical Analysis Plan 
 
 
CONFIDENTIAL 
21 of 173 
20Jun2017 
 
 In the per-protocol analysis set, 
 Protocol 
o Enrolled under Amendment 2 
o Enrolled under Amendment 1 
 Completed the study as planned, 
 Discontinued from the study, and 
 Reasons for discontinuation from the study. 
Percentages will be reported for the screen failures and enrolled using the number of subjects 
screened as the denominator; efficacy analysis set and per-protocol analysis set will use the 
number of subjects randomized, treated, and having surgery as denominator for percentages; all 
other percentages will use the number of subjects randomized and treated as denominator.   
The safety analysis set and enrollment data will be presented as treated.  All other data will be 
presented as randomized.  
The disposition summary will present the data for each treatment group (EXPAREL 133 mg, 
EXPAREL 266 mg, placebo), EXPAREL treatments combined (All EXPAREL), and across 
treatment groups (Total).  This summary table will present overall sites and for each site 
separately. 
9.3. 
Description of Demographics and Baseline Characteristics  
9.3.1. Demographics  
The summary of demographic data will present: 
 Age (years) – descriptive statistics 
 Sex – n (%) 
 Ethnicity – n (%) 
 Race – n (%) 
 Country – n (%) 
Age is calculated from the date the subject signed the informed consent form (ICF) and birth.  It 
is presented as the number of years between, rounding down to the nearest integer year.  For 
partial birthdates, impute the first of the month for missing day and January for missing month to 
calculate age.  It is presumed that birth year is known. 
The demographic summary will present the data for each treatment group (EXPAREL 133 mg, 
EXPAREL 266 mg, placebo), EXPAREL treatments combined (All EXPAREL), and across 
treatment groups (Total).  Summaries will be provided for all (safety, efficacy, and per-protocol) 
analysis sets.  This summary will present overall sites and for each site separately. 
9.3.2. Baseline Characteristics 
The summary of baseline characteristic data will present: 
 American Society of Anesthesiologists (ASA) Classification – n (%) 
 Baseline VAS scores 
 Baseline neurological assessments 
 Baseline ECG interpretation 
 Baseline degree of motor nerve block assessments (active and passive) 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL® 
Statistical Analysis Plan 
 
 
CONFIDENTIAL 
22 of 173 
20Jun2017 
 
o Flexion 
o Extension 
 Height (cm) 
 Weight (kg) 
 Body Mass Index (BMI) (kg/m2) 
 Baseline vital signs 
o Heart rate (bpm) 
o Systolic blood pressure (mmHg) 
o Diastolic blood pressure (mmHg) 
The formula for BMI is       , where w is weight in kilograms and h is height in meters.  
Weight in pounds will be converted to kilograms using the conversion factor of 2.2046 pounds to 
1 kilogram.  Height in inches will be converted to centimeters using the conversion factor of 2.54 
centimeters to 1 inch.  Height in centimeters will be converted to meters using the conversion 
factor of 100 centimeters to 1 meter. 
Baseline characteristics summaries will present the data for each treatment group (EXPAREL 
133 mg, EXPAREL 266 mg, All EXPAREL doses, placebo) and across treatment groups (Total).  
Summaries will be provided for all (safety, efficacy, and per-protocol) analysis sets.  This 
summary table will show summaries across all sites and for each site separately.  
Descriptive statistics (n, mean, SD, median, minimum and maximum) will be provided for VAS 
scores, degree of motor blockade, height, weight, BMI, and vital signs.  The number and percent 
of subjects will be tabulated for the various categories of sensory assessments, neurological 
assessments, and ECG interpretation. 
9.4. 
Surgery Characteristics 
Surgery characteristics include duration of surgery, tourniquet use (yes/no), duration of 
tourniquet inflation, maximum tourniquet inflation pressure and drain use (yes/no).  Duration of 
surgery is calculated as the difference between the end of surgery and start of surgery times and 
reported in hours.  Duration of tourniquet use is calculated as the difference between the end of 
tourniquet inflation and removal and reported in hours. Descriptive statistics will be provided for 
the duration of surgery, tourniquet inflation and duration of drain by treatment group and across 
all treatment groups. Use of tourniquet and drains (yes/no) will be tabulated by treatment group 
and across all treatment groups. 
9.5. 
Intraoperative, Prior and Concomitant Medications 
Intraoperative, prior and concomitant medications will be coded using the World Health 
Organization Drug Dictionary (WHO-DD) and will be classified according to the anatomical 
therapeutic chemical (ATC4) classification term and standard medication name. 
Intraoperative medications are defined as medications given as part of the surgical procedure. 
These may include anesthesia, opioids or other medications with start and stop dates on the day 
of surgery and start and stop times overlapping with the surgery start and stop times. 
Prior medications are defined as medications with a stop date and time prior to the start of study 
drug administration.   


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL® 
Statistical Analysis Plan 
 
 
CONFIDENTIAL 
23 of 173 
20Jun2017 
 
Concomitant medications are defined as medications taken after the start of study drug 
administration (i.e., started prior to the start of study drug administration and continued after or 
started after the start of study drug administration). 
Intraoperative, prior, and concomitant medications will be summarized separately using n (%) of 
subjects for each treatment group and across treatment groups by ATC class term and standard 
medication name for the safety analysis set.  Subjects may have more than one medication per 
ATC category and standard medication name.  At each level of subject summarization, a subject 
will be counted once if one or more medications are reported by the subject at that level.  
A listing mapping the ATC term and standard medication name to verbatim term will be 
presented. 
9.6. 
Measurements of Treatment Compliance 
Study treatment is administered by a party other than the subject, therefore compliance is 
assured.   
9.7. 
Efficacy Analysis 
For Primary and Secondary Efficacy Analyses, descriptive statistics that are appropriate for the 
efficacy variable will also be shown by site but no statistical analyses will be performed within a 
site.  The primary and secondary efficacy analyses will be performed on the efficacy and 
per-protocol analysis sets.  Tertiary efficacy analyses will be performed on the efficacy analysis 
set only. 
9.7.1. Efficacy Endpoints 
9.7.1.1. 
Primary Efficacy 
The primary endpoint is AUC of the VAS pain intensity scores through 72 hours [AUC(0-72)]. 
9.7.1.2. 
Secondary Efficacy 
The following secondary endpoints will be analyzed as described in Section 9.1.2: 
 Total postsurgical opioid consumption (mg) through 72 hours. 
 Percentage of opioid-free subjects through 72 hours. 
 Time to first rescue medication (opioid) dose through 72 hours. 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL® 
Statistical Analysis Plan 
 
 
CONFIDENTIAL 
24 of 173 
20Jun2017 
 
9.7.1.3. 
Tertiary Efficacy 
 
The AUC of the VAS pain intensity scores through 12, 24, 48 and 96 hours.  
 
The AUC of VAS pain intensity scores from 24-48, 48-72 and 72-96 hours.  
 
VAS pain intensity scores at each assessed timepoint. 
 
Proportion of subjects who are pain free (VAS score of ≤ 1.5) at each assessed timepoint. 
 
SPIS through 24, 48, 72, and 96 hours. 
 
SPIS from 24-48, 48-72, and 72-96 hours. 
 
Total opioid consumption in IV morphine equivalents through 24, 48 and 96 hours.  
 
Total opioid consumption in IV morphine equivalents from 24-48, 48-72 and 72-96 
hours. 
 
Percentage of subjects who are opioid-free through 24, 48 and 96 hours. 
 
Overall benefit of analgesia scale (OBAS) total score at 24 and 72 hours and Day 10. 
 
Subject satisfaction with overall analgesia at 24 and 72 hours and Day 10. 
 
Proportion of subjects ready for discharge at 12, 24, 36, 48, 60, 72, 84 and 96 hours 
 
Number of unscheduled phone calls or office visits related to pain after discharge through 
Day 29. 
 
Timed walk test at screening, postsurgically on day of surgery (Day 1) and q12h starting 
on Day 2 through hospital discharge. 
 
Timed up-and-go at screening, postsurgically on day of surgery (Day 1) and q12h starting 
on Day 2 through hospital discharge. 
 
Stair climb test at screening, postsurgically on day of surgery (Day 1) and q12h starting 
on Day 2 through hospital discharge. 
9.7.1.4. 
Area under the Curve 
Area under the pain-time curve is derived using the trapezoidal rule (see formula below) on the 
pain scores adjusted for rescue medication use using the imputed values (see Section 9.1.1.1).  
AUC will start with the first pain assessment obtained after surgery and use all following pain 
assessments including those collected prior to rescue medication and unscheduled.  Actual 
assessment times will be used in deriving AUC. 
     ∑ 
 
   
                         
Where pi is the VAS pain score at time i and ti is the time, in hours, from end of surgery.  Note that i starts at 3 since 
t1 is not used in AUC calculation (prior to surgery) and t2 is arrival at PACU.  
9.7.1.5. 
Opioid Consumption 
Opioids will be converted to IV morphine equivalent dose (MED mg) using the appropriate 
conversion factor from Table 3 for all summaries.  Total opioid dose is the IV morphine 
equivalent sum of all opioids taken after surgery up to the timepoint of interest.  Subjects with no 
opioid use during the period in question will be assigned a dose of 0 for summaries and changed 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL® 
Statistical Analysis Plan 
 
 
CONFIDENTIAL 
25 of 173 
20Jun2017 
 
to the lesser of 0.1 or half of the smallest total amount observed in the study, whichever is 
smaller, prior to being transformed with the natural logarithm for analysis. 
 
Table 3: IV Morphine Equivalents 
Medication 
Unit 
Route 
Conversion (Multiplication) 
Factor 
Oxycodone, Oxycocet, Percocet, acetaminophen-
oxycodone, Oxycontin 
mg 
PO,IV,IM,SC 
2 
Morphine 
mg 
IV,IM,SC 
1 
Morphine 
mg 
PO 
0.33 
Hydromorphone (Dilaudid), Hydromorphone 
hydrochloride 
mg 
IV,IM 
7.7 
Hydromorphone (Dilaudid), Hydromorphone 
hydrochloride 
mg 
PO 
1.3 
Hydromorphone (Dilaudid), Hydromorphone 
hydrochloride 
mg 
SC 
4 
Fentanyl 
mg 
IV,PO,IM 
100 
Vicodin, Norco, Lorcet, Lortab, hydrocodone-
acetaminophen 
mg 
PO 
2 
Codeine (Tylenol 3, acetaminophen-coedine, 
Paracetamol Forte, Tylenol 4) 
mg 
PO 
0.05 
Ultram, Tramadol, Tramacol hydrochloride 
mg 
PO, IM 
0.08 
PO = oral; IV = intravenous; VAS = visual analog scale. 
If other rescue medications are given then the conversion to IV Morphine Equivalent will 
be determined post-hoc.  If a combination opioid product is given then the IV Morphine 
Equivalent will be determined by the opioid part of the medication.  Opioids given post 
surgically with an indication such as ‘anesthesia maintenance’ will not be included. 
 
9.7.1.6. 
Time to First Opioid Rescue Medication Use 
Time to first opioid rescue medication use will be calculated as the time from end of surgery to 
time of event in hours. 
9.7.1.7. 
Pain-free 
Pain-free is defined as an observed VAS score less than or equal to 1.5 with no prior rescue 
medication and all prior VAS scores less than or equal to 1.5. 
9.7.1.8. 
Overall Benefit of Analgesia Score (OBAS) 
The OBAS is derived as follows: 
1. Add all of the scores of questions 1 to 6. 
2. To this number, add four. 
3. Subtract the score of question 7 from this number.  
If a response is missing to any question in the OBAS, the total score will not be calculated. 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL® 
Statistical Analysis Plan 
 
 
CONFIDENTIAL 
26 of 173 
20Jun2017 
 
9.7.2. Methods of Analysis 
For Primary and Secondary Efficacy Analyses, descriptive statistics that are appropriate for the 
efficacy variable will also be shown by site but no statistical analyses will be performed within a 
site.   
9.7.2.1. 
Primary Efficacy Analysis 
The primary efficacy variable is the AUC of VAS scores through 72 hours [AUC(0-72)] using 
the multiple imputation method described in Section 9.1.1.1. 
Tests for the treatment effect of EXPAREL versus placebo will be based on the following null 
hypothesis (Ho) and two-sided alternative hypothesis (Ha): 
Ho: μs = μp versus Ha: μs ≠ μp 
where μs and μp are the mean of AUC(0-72) for EXPAREL and the mean of AUC(0-72) for 
placebo, respectively. A two-sided test will be performed at 2.5% level of significance 
comparing each EXPAREL dose to placebo. The treatment effect of EXPAREL will be 
considered significantly better than that of placebo if the null hypothesis of no difference is 
rejected and a difference in mean of AUC(0-72) in favor of EXPAREL (mean for EXPAREL 
less than the mean for placebo) is observed. 
For the primary efficacy variable of AUC(0-72), each EXPAREL dose will be compared to 
placebo using analysis of variance (ANOVA) with age, weight, and height as covariates. Based 
on the model, the LS mean, and the SE of the LS mean, will be reported for each treatment. The 
LS treatment difference for the active minus placebo, 95% CI for the active minus placebo 
treatment difference, and p-value will be reported as well as for each active treatment. 
Descriptive statistics of the primary efficacy variable will also be shown by site but no statistical 
analyses will be performed within a site. 
9.7.2.2. 
Secondary Efficacy Analyses 
 
9.7.2.2.1. 
Postsurgical Opioid Consumption 
Postsurgical narcotic consumption (MED mg) will be summarized (n, Geometric Mean,  
coefficient of variation, minimum, and maximum) by treatment group for the total dose 
consumed over the 72 hours after the end of surgery.  The number and percentages of the types 
of opioids used will be presented by treatment group, subjects will be counted only once for each 
opioid used.  This summary table will show summaries across all sites and for each site 
separately. 
Prior to analysis, the natural logarithm transformation will be applied to the total opioid 
consumption amount. When total amount of opioids (IV Morphine Equivalent) used is 0, then 
the result will be changed to 0.1 or half of the smallest total amount observed in the study, 
whichever is smaller, prior to being transformed with the natural logarithm. To test for 
significant differences between EXPAREL and placebo, an ANOVA with age, weight, and 
height as covariates will be used. The LS means, LS mean difference between the two treatment 
groups, 95% CI for the LS mean difference between EXPAREL and placebo, and p-value will be 
reported.  The LS means, LS mean differences and 95% CI will be back transformed for 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL® 
Statistical Analysis Plan 
 
 
CONFIDENTIAL 
27 of 173 
20Jun2017 
 
presentation (note the LS mean difference becomes the ratio when back-transformed) along with 
the descriptive statistics (untransformed) by treatment. 
9.7.2.2.2. 
Opioid-free 
Percentage of opioid-free subjects through 72 hours will be analyzed using a Cochran-Mantel-
Haenszel (CMH) test.  The p-value from the CMH analysis and mean treatment difference and 
95% CI about the mean difference derived using the Newcombe9 method (SAS pseudo-code 
below) will be presented. The tabulation of opioid-free subjects will be presented across all sites 
and for each site separately.  No inferential statistics will be calculated for individual sites. 
The number and percentage of subjects opioid-free will also be tabulated by timepoint.  
Pseudo-code for Newcombe method: 
PROC FREQ; 
TABLE SITE*TREATMENT*RESPONSE / RISKDIFF(CL=NEWCOMBE COMMON); 
RUN; 
9.7.2.2.3. 
Time to First Opioid Rescue Medication 
Time to first opioid rescue medication will be computed in hours as the date and time of the first 
opioid rescue medication minus the date and time of the end of surgery. If a subject is not 
administered an opioid rescue medication, the time to first administration will be censored at 72 
hours after surgery or at the time of last follow-up, whichever is earliest. Time of last follow-up 
will be defined as the latter of (1) the last pain assessment, (2) the start time of the last 
concomitant medication, or (3) the start time of the last AE.  
Time to first opioid rescue will be analyzed by the Kaplan-Meier method. The n (%) of subjects 
administered an opioid as well as the n (%) of censored observations will be presented for each 
treatment group. In addition, Kaplan-Meier estimates in terms of the median and its 95% CI, and 
the 25th and 75th percentiles will be presented for each treatment. Log-rank tests will be used to 
compare each EXPAREL dose to placebo. 
9.7.2.3. 
Tertiary Efficacy Analyses 
P-values computed for the tertiary endpoints are for descriptive purposes only and are not 
adjusted for multiple comparisons.   
9.7.2.3.1. 
Visual analog scale (VAS) AUC 
Summary statistics will be presented by treatment for VAS AUC(0-12), VAS AUC(0-24), VAS 
AUC(0-48), VAS AUC(0-96), VAS AUC(24-48), VAS AUC(48-72) and VAS AUC(72-96).  
For each of these variables, each EXPAREL dose will be compared to placebo using analysis of 
variance (ANOVA) with age, weight, and height as covariates. Based on the model, the LS mean 
and SE of the LS mean will be reported for each treatment. The LS treatment difference for the 
active minus placebo, 95% CI for the active minus placebo treatment difference, and p-value will 
be reported as well as for each active treatment.     
9.7.2.3.2. 
Visual analog scale (VAS) 
Summary statistics will be presented by treatment for VAS at each assessment timepoint.  This 
summary will be based on the observed VAS values. 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL® 
Statistical Analysis Plan 
 
 
CONFIDENTIAL 
28 of 173 
20Jun2017 
 
9.7.2.3.3. 
Proportion of Pain-Free Subjects 
The proportion of pain-free subjects will be tabulated by treatment.  The number and proportion 
of subjects who are pain-free and not pain-free (or VAS score is missing) will be presented at 
assessment timepoint.  For the proportion of pain-free subjects, each EXPAREL dose will be 
compared to placebo using a Cochran-Mantel-Haenszel (CMH) test.  The p-value from the CMH 
analysis and mean treatment difference and 95% CI about the mean difference derived using the 
Newcombe10 method.   
9.7.2.3.4. 
Sum of Pain Intensity Scores (SPIS) 
Summary statistics will be presented by treatment for SPIS(0-12), SPIS(0-24), SPIS(0-48), 
SPIS(0-72), SPIS(0-96), SPIS(24-48), SPIS(48-72) and SPIS(72-96).  For each of these 
variables, each EXPAREL dose will be compared to placebo using analysis of variance 
(ANOVA) with age, weight, and height as covariates. Based on the model, the LS mean and SE 
of the LS mean will be reported for each treatment. The LS treatment difference for the active 
minus placebo, 95% CI for the active minus placebo treatment difference, and p-value will be 
reported as well as for each active treatment.    
9.7.2.3.5. 
Total Opioid Consumption through 24, 48 and 96 hours 
Total opioid consumption through 24, 48, and 96 hours will each be summarized by treatment 
group.  The summaries and analyses will be calculated similar as the postsurgical opioid 
consumption through the 72 hour secondary endpoint (see Section 9.7.2.2.1).   
9.7.2.3.6. 
Total Opioid Consumption During Specific Time Intervals 
Total opioid consumption from 24-48, 48-72 and 72-96 hours will be summarized by treatment 
group.  The summaries and analyses will be calculated similar as the postsurgical opioid 
consumption through the 72 hour secondary endpoint (see Section 9.7.2.2.1).  
9.7.2.3.7. 
Percentage of Opioid-free Subjects through 24, 48 and 96 hours  
The percentage of opioid-free subjects at 24, 48, and 96 hours will be tabulated by treatment.  
The summaries and analyses of the percentage of opioid-free subjects at 24, 48, and 96 hours 
will be calculated similar as the percentage of opioid-free subjects at 72 hours secondary 
endpoint (see Section 9.7.2.2.2). 
9.7.2.3.8. 
Overall Benefit of Analgesia (OBAS) 
The OBAS total score will be summarized by treatment and individual question responses 
tabulated at each assessment timepoint.  For the OBAS total score, each EXPAREL dose will be 
compared separately to placebo using a Kruskal-Wallis test.   
9.7.2.3.9. 
Subject Satisfaction with Overall Analgesia 
Subject satisfaction with overall analgesia (obtained using a 5-point Likert scale) will be 
summarized and individual responses tabulated by treatment for each assessment timepoint.  The 
numeric value of the response will be presented using descriptive statistics.  For each value of 
the scale the number and percentage of subjects selecting that value will also be presented.  For 
the subject satisfaction with overall analgesia, each EXPAREL dose will be compared to placebo 
using a Kruskal-Wallis test. 
9.7.2.3.10. 
Discharge Readiness 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL® 
Statistical Analysis Plan 
 
 
CONFIDENTIAL 
29 of 173 
20Jun2017 
 
Time to discharge ready will be computed in hours as the date and time of subjects first meeting 
the discharge readiness criterion and time of the end of surgery.  Time to discharge ready will be 
when the MPADSS criteria is met (total score of 9 or more) for discharge readiness or the time 
of discharge, whichever occurs first.  If a subject has not met the discharge ready criteria prior to 
or at a given timepoint (12, 24, 36, 48, 60, 72, 84, 96 and 120 hours), then the time to discharge 
ready will be censored at the time of their last MPADSS assessment in the study or the specific 
assessment timepoint (12, 24, 36, 48, 60, 72, 84, 96 and 120 hours), whichever occurs sooner. 
Time to discharge ready will be analyzed by the Kaplan-Meier method for each of the following 
assessment timepoints: 12, 24, 36, 48, 60, 72, 84, 96 and 120 hours. The n (%) of subjects 
administered an opioid as well as the n (%) of censored observations will be presented for each 
treatment group. In addition, Kaplan-Meier estimates in terms of the median and its 95% CI, and 
the 25th and 75th percentiles will be presented for each treatment at 12, 24, 36, 48, 60, 72, 84, 96 
and 120 hours. Log-rank tests will be used to compare each EXPAREL dose to placebo at 12, 24, 
36, 48, 60, 72, 84, 96 and 120 hours. 
The number and percent of subjects meeting the discharge readiness criteria at 12, 24, 36, 48, 60, 
72, 84, 96 and 120 hours will be summarized.   
If a subject is discharge ready at an early timepoint, the subject will be considered discharge 
ready at all subsequent (future) timepoints.  If a subject has a discharge readiness total score of 
less than 9 or if the total score is missing, the subject will be considered not discharge ready, 
unless they were previously considered discharge ready. 
9.7.2.3.11. 
Number of Pain-Related Visits/Phone Calls after Discharge 
The number of pain-related unscheduled phone calls or office visits will be summarized (n, 
mean, SD, median, minimum, and maximum) by treatment group.  The number and percentage 
of subjects reporting for each number of pain-related unscheduled phone calls or visits (0, 1, 2, 
… maximum number observed) will be presented by treatment group.  For the number of pain-
related unscheduled phone calls or office visits, each EXPAREL dose will be compared to 
placebo using a Kruskal-Wallis test.  
9.7.2.3.12. 
Timed Walk Test 
Subjects who did not perform the timed walk test will have a zero (0) imputed for distance 
walked in the analysis.  The distance, in meters, covered during the timed walk test will be 
analyzed using a mixed model repeated measures (MMRM) analysis with fixed effects for 
treatment, site and time and a treatment-by-time interaction with subject within treatment as the 
random effect.  The LS mean and SE of the LS mean will be reported for each treatment. The LS 
treatment difference for the active minus placebo, 95% CI for the active minus placebo treatment 
difference, and p-value will be reported as well as for each active treatment.  Analyses will be 
performed on the efficacy and per-protocol analysis sets. 
The MMRM will be fit with covariance matrices of UN (unstructured), CS (compound 
symmetry) and AR(1) (auto-regressive 1).  The analysis with the lowest AIC criteria will be 
reported on the table.  Other covariance matrix structures may be used if none of these converge. 
The timed walk test summary will include tabulations of whether the test was performed and if 
not performed, reasons why not and the use of a walking aid (yes/no), level of physical 
assistance required, and descriptive statistics for the distance covered. Statistics overall sites, 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL® 
Statistical Analysis Plan 
 
 
CONFIDENTIAL 
30 of 173 
20Jun2017 
 
pooled site(s) and site within pooled site will be presented.  This summary will be provided for 
both the efficacy and per-protocol analysis set. 
9.7.2.3.13. 
Timed Up-and-go Test (TUG) 
Subjects who did not perform the timed walk test will have a zero (0) imputed for time in the 
analysis.  The time, in seconds, to complete the TUG test will be analyzed using a mixed model 
repeated measures analysis with fixed effects for treatment, site and time and a treatment-by-time 
interaction with subject within treatment as the random effect.  The LS mean, SE of the LS 
mean, LS treatment difference, 95% CI for the active minus placebo treatment difference and p-
value will be reported as well as the treatment.  Analyses will be performed on the efficacy and 
per-protocol analysis sets.  
The MMRM will be fit with covariance matrices of UN, CS, and AR(1).  The analysis with the 
lowest Akaike’s information criterion (AIC) criteria will be reported on the table.  Other 
covariance matrix structures may be used if none of these converge. 
The TUG test summary will include tabulations of whether the test was performed and if not 
performed, reasons why not and the use of a walking aid (yes/no), level of physical assistance 
required, and descriptive statistics for the time to complete. Statistics for overall sites, pooled 
site(s) and site within pooled site will be presented.  This summary will be provided for both the 
efficacy and per-protocol analysis set. 
9.7.2.3.14. 
Stair Climb Test 
The stair climb test will be analyzed using a general mixed effect model with the logit link 
function and fixed effects for treatment, site and time with treatment-by-time interaction and 
subject within treatment as the repeated effect (PROC GENMOD; class …; model … / d=bin 
link=logit; LSMEANS … /DIFF=CONTROL(…) CL alpha=0.05  ILINK  EXP; repeated …/ 
type=…; run;).  The odds ratio (each EXPAREL dose / Placebo) and its 95% CI and p-value will 
be reported as well as the odds ratio and its 95% CI at each testing timepoint as derived from the 
model. Analyses will be performed on the efficacy and per-protocol analysis sets.  The number 
of subjects not completing and completing the test will be reported at each testing timepoint. 
This analysis will be provided for both the efficacy and per-protocol analysis set. 
9.7.2.3.15. 
Region Analysis 
Summaries and tabulations looking at region will be performed for the following: 
 
Disposition 
 
Demographics 
 
Baseline Characteristics 
 
Intraoperative medicines 
 
VAS AUC(0-72)  
 
Total opioid consumption through 72 hours 
 
Percentage opioid-free through 72 hours  
 
Sensation Loss and Return 
 
Motor Function Loss and Return 
 
Overall summary of adverse events 
 
Incidence of TEAEs 
 
Incidence of Serious TEAEs 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL® 
Statistical Analysis Plan 
 
 
CONFIDENTIAL 
31 of 173 
20Jun2017 
 
The populations for each the summary and tabulation as planned for the non-region tables will be 
repeated for the region tables.   
For analyses considering region, the age, weight, and height covariates will be replaced with 
region, this will be performed for the following: 
 
VAS AUC(0-72)  
 
Total opioid consumption through 72 hours 
 
Percentage opioid-free through 72 hours  
 
Sensation Loss and Return 
 
Motor Function Loss and Return 
Region summaries, tabulations, and analyses will be the final block within the 14.1, 14.2 and 
14.3 series of tables.  
9.8. 
Safety Analyses 
Safety assessments in this study consist of vital signs, 12-lead ECGs, neurological assessments, 
sensory and motor nerve block assessments, motor function assessments, and AEs.  Vital signs, 
ECGs, neurological, nerve block assessments (sensory and motor), and motor function 
assessments will be serially collected (see Time and Events Schedule of Study Procedures). 
Adverse events will be collected from the time of informed consent through Day 30. 
P-values computed for the safety endpoints are for descriptive purposes only and are not adjusted 
for multiple comparisons. 
9.8.1. Vital Signs 
Vitals signs are resting heart rate (bpm), systolic blood pressure (mmHg), and diastolic blood 
pressure (mmHg).  Vital signs will be summarized by treatment group and the All EXPAREL 
group at each assessment timepoint.  Summaries will present both actual and change-from-
baseline results.  Baseline statistics will be presented at each assessment timepoint for those 
subjects reporting data at that timepoint. 
Vital signs will also be assessed for potentially clinically significant abnormal values (see Table 
4).  The number and percentage of subjects satisfying the potentially clinically significant 
abnormal criteria (critical value, critical change separately and then value and change 
concurrently) at any time during the study and at each assessment timepoint will be tabulated by 
treatment and overall treatments.   
Table 4: Criteria for Potentially Clinically Significant Abnormal Vital Signs 
Vital Sign 
Unit 
Critical Value 
Critical Change1 
Resting Heart Rate 
beats/minute (bpm) 
High: ≥ 120 
Low: ≤ 50 
Increase of at least 15 
Decrease of at least 15 
Systolic Blood Pressure 
mmHg 
High: ≥ 180 
Low: ≤ 90 
Increase of at least 20 
Decrease of at least 20 
Diastolic Blood Pressure 
mmHg 
High: ≥ 105 
Low: ≤ 50 
Increase of at least 15 
Decrease of at least 15 
1Change criteria not applicable at baseline or screening. 
9.8.2. Electrocardiograms 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL® 
Statistical Analysis Plan 
 
 
CONFIDENTIAL 
32 of 173 
20Jun2017 
 
Investigators will classify ECG tracings as ‘normal, ‘abnormal not clinically significant’ or 
‘abnormal clinically significant’.  The investigator classifications will be tabulated by treatment 
and overall treatments at any time during the study and each assessment timepoint. 
A shift table comparing the investigator classification of the ECG results at baseline to each 
timepoint will also be provided. 
9.8.3. Neurological Assessments 
Neurological assessments include orientation (orientated, disoriented, not assessable), numbness 
(of lips, tongue, or around mouth), metallic taste, hearing problems, vision problems, and muscle 
twitching.  The number and percentage of subjects will be tabulated for each neurological 
assessment by treatment group at any time after baseline and at each assessment timepoint.   
9.8.4. Sensation Tests 
Sensations tests are assessed on the thigh (anterior cutaneous nerve) and foot (saphenous nerve).  
The number and percentage of subjects will be tabulated for each response (present/absent) 
within each nerve and sensory test (cold, pinprick and light touch) by treatment group at each 
assessment timepoint. 
The number and percentage of subjects will be tabulated for loss and return of sensation (see 
Section 7) across all locations and within each location (thigh and foot) and each sensory test 
(cold, pinprick and light touch) and combinations of sensory tests (ANY, CPL, CP, CL, and PL) 
by treatment group at each assessment timepoint.  Where the combinations of ANY, CPL, CP, 
CL and PL are defined as follows: 
 ANY = at least one sensation 
 CPL = all sensations (cold, pinprick and light touch) 
 CP = cold and pinprick 
 CL = cold and light touch 
 PL = pinprick and light touch 
A subject will be considered as having a loss of sensation if either of the locations has a loss of 
sensation; a return of sensation is when both locations have sensation for the subject. 
The times to first loss of, last loss of, first return of sensation, and last return of sensation (see 
Section 7 subsection loss of sensation and return of sensation) will be summarized by the 
Kaplan-Meier method. The n (%) of subjects administered an opioid as well as the n (%) of 
censored observations will be presented for each treatment group. In addition, Kaplan-Meier 
estimates in terms of the median and its 95% CI (using log-log method), and the 25th and 75th 
percentiles will be presented for each treatment. Log-rank tests will be used to compare each 
EXPAREL dose to placebo.  This analysis will be performed across locations and within each 
location. 
Duration of sensation loss will be summarized across locations and within each location.  Total 
duration is defined as the sum of durations of each lost-return cycle for a subject.  If more than 
10% of the subjects in at least one treatment group experience multiple lost-return cycles, then 
duration will be summarized for total duration and within each cycle. 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL® 
Statistical Analysis Plan 
 
 
CONFIDENTIAL 
33 of 173 
20Jun2017 
 
An additional table summarizing the number of cycles and tabulating the distribution number of 
cycles by treatment group will be presented within each location by treatment group. 
9.8.5. Degree of motor nerve block Assessments 
Degree of motor nerve block assessments includes active and passive flexion and extension.  The 
actual and change from baseline values for each of these parameters will be summarized by 
treatment at each assessment timepoint.  At each assessment timepoint the baseline values will 
be summarized for those subjects who have data at that timepoint. 
At each assessment timepoint, the number and percent of subjects with loss and return of motor 
function (see Section 7) will be summarized by treatment. 
For each active assessment the time to return to motor function will be analyzed by treatment in 
the same manner as time to first rescue medication (see Section 9.7.1.6).   
9.8.6. Adverse Events 
Adverse events will be coded using the Medical Dictionary for Regulatory Activities 
(MedDRA).   
An AE will be considered TEAE if the onset date and time is between the start date and time of 
study treatment and Day 30.   
If an AE has a partial onset date and time the imputed start and stop dates and times will be used 
to determine treatment-emergence (e.g., stop date and time is before start date and time of study 
treatment). All AE summaries will present TEAEs only; AEs that are not treatment-emergent 
will be included in listings but not summarized. 
The incidence of subjects reporting TEAEs will be tabulated by the number and percentage of 
subjects reporting the TEAE.  Incidence is defined as a subject reporting at least one TEAE 
within the summary level.  Summary levels are ‘at least one TEAE’, system organ class and 
preferred term.  Subjects will be counted only once within each reporting level on the table.  For 
example if a subject reports a TEAE of headache on two separate occasions, the subject will be 
counted only once in the headache row of the table.  Similarly if a subject reports two separate 
TEAEs within the same system organ class the subject will only be counted once in the summary 
row for that system organ class.  A summary of subjects reporting at least one TEAE during the 
study will also be presented. 
The first row on every TEAE table will be the number and percentage of subjects reporting at 
least one TEAE.  Subsequent rows will be presented in descending order of subject counts for 
the overall treatment group with the most common system organ class first, followed within each 
system organ class by the preferred terms in descending subject count order.  For tables 
presenting the severity or relation to study treatment of AE, the sort order will be determined by 
the number and percentage of subjects reporting the preferred term, thus the sort order of rows 
will remain the same for the relation or severity tables as the tables by preferred term. . 
The following summaries will be presented for the AEs reported by the subjects: 
An overview of all TEAEs, serious TEAEs and TEAEs of Special Interest will present the 
number and percentage of subjects in the following categories: 
 Any TEAE 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL® 
Statistical Analysis Plan 
 
 
CONFIDENTIAL 
34 of 173 
20Jun2017 
 
o Maximum severity: Mild 
o Maximum severity: Moderate 
o Maximum severity: Severe 
 At least one related TEAE 
 At least one serious TEAE 
 Subjects discontinued due to a TEAE 
 Died on study 
Subjects will be counted once in each of the above categories except for maximum severity.  
Subjects will be counted only once at the highest severity reported.  For example, if a subject has 
a mild and severe headache and a moderate rash, the subject will be counted under maximum 
severity of severe only. 
Adverse event tables will present the data by treatment group and across all treatment groups.  
Incidence tables will be created for the following groups of TEAEs: 
 All TEAEs 
 Study treatment related TEAEs 
 TEAEs leading to study withdrawal 
 Study treatment related TEAEs leading to study withdrawal 
 All TEAEs by severity  
 All TEAEs by relationship to study treatment 
 All serious TEAEs 
 Study treatment related serious TEAEs 
 Serious TEAEs leading to study withdrawal 
 Study treatment related serious TEAEs leading to study withdrawal 
 Serious TEAEs resulting in death 
 Study treatment related serious TEAEs resulting in death 
 All TEAEs of special interest 
 Study treatment related TEAEs of special interest 
 TEAEs of special interest leading to study withdrawal 
 Study treatment related TEAEs of special interest leading to study withdrawal 
 TEAEs of special interest resulting in death  
 Study treatment related TEAEs of special interest resulting in death 
 
If there are no AEs to report on any of the above tables, the table should be created with the line 
‘no adverse events were reported’ in the body of the table. 
Adverse events will be considered related if the investigator assessment of relationship to study 
treatment is either ‘possible’, ‘probable’ or ‘definite’.  
All AE summaries based on related AEs will be produced based on the investigator assessment 
of relatedness.  Below are the MedDRA terms for the adverse events of special interest: 
 
 
MedDRA 18.1 Dictionary Terms 
Group 
Protocol term 
Term Level 
Term 
Cardiac 
Angina 
Preferred term 
Angina Pectoris 
Myocardial infarction 
Preferred term 
Myocardial Infarction 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL® 
Statistical Analysis Plan 
 
 
CONFIDENTIAL 
35 of 173 
20Jun2017 
 
A listing of the mapping of the system organ class and preferred terms to verbatim terms will be 
presented.  
9.8.7. Laboratory Parameters 
Clinical laboratory assessments are collected at screening, baseline and Day 10. Laboratory 
results will be summarized by treatment group and the All EXPAREL group at each assessment 
timepoint.  Summaries will present both actual and change-from-baseline results.  Baseline 
statistics will be presented at each assessment timepoint for those subjects reporting data at that 
timepoint. 
Tabulations of the number and percentage of subjects with value below normal, normal or above 
normal will be provided by treatment group, All EXPAREL group and across all treatment 
groups at each timepoint. 
Shifts in laboratory results categorized as low (below the lower limit of the normal range), 
normal (within the normal range, limits inclusive) and above (above the upper limit of the 
normal range) will be presented in shift tables with baseline categories across the columns and 
Day 10 down the rows for EXPAREL 133 mg, EXPAREL 266 mg, All EXPAREL and placebo 
separately.  Each cell will present the number and percentage of subjects in that cell. Due to the 
width of these tables, only 2 treatments can be presented on a page.  For ease of comparing 
active treatments to placebo, placebo data will be presented on each page.  Thus the shift table 
will present all laboratory data for EXPAREL 133 mg and placebo then for EXPAREL 266 mg 
and placebo and finally for All EXPAREL and placebo. 
9.9. 
Pharmacokinetic Analysis 
The analysis of the PK endpoints will be described in a separate document.   
9.10. 
Interim Analysis 
9.10.1. Pharmacokinetic Review 
Bradycardia 
Preferred term 
Bradycardia 
Tachycardia 
Preferred term 
Tachycardia 
Extrasystoles 
Preferred term 
Extrasystoles 
Shortness of breath requiring intervention 
Preferred term 
Dyspnoea 
Neurologic 
Altered mental status 
Preferred term 
Mental Status Changes 
Altered sensorium 
Preferred term 
Depressed level of consciousness 
Rigidity 
Preferred term 
Muscle Rigidity 
Dysarthria 
Preferred term 
Dysarthria 
Seizure 
Preferred term 
Seizure 
Tremors 
Preferred term 
Tremor 
Metallic taste 
Preferred term 
Dysgeusia 
Tinnitus 
Preferred term 
Tinnitus 
Perioral numbness 
Preferred term 
Hypoaesthesia Oral 
Visual disturbance 
Preferred term 
Visual Impairment 
Dizziness 
Preferred term 
Dizziness 
Hyperesthesia 
Preferred term 
Hyperaesthesia 
Muscular twitching* 
Preferred term 
Muscle Twitching 
Tingling* 
Preferred term 
Paraesthesia 
Paresthesia* 
Preferred term 
Paraesthesia 
Other 
Fall 
Preferred term 
Fall 
* if event persists beyond or occurs after 72 hours after start of study treatment dose. 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL® 
Statistical Analysis Plan 
 
 
CONFIDENTIAL 
36 of 173 
20Jun2017 
 
An interim PK analysis was completed by QuantPharm LLC after 30 subjects completed the 
assessments through post-surgical Day 10.  All of the plasma samples from the subjects who 
received EXPAREL were analyzed and the plasma samples from the subjects randomized to 
placebo were analyzed through the 24-hour timepoint. Enrollment continued while the interim 
PK data were analyzed.  The goal of this blinded analysis was to determine the appropriateness 
of the PK timepoints selected and make recommendations to keep, remove, or revise them in 
order to fully characterize the PK profile.   
QuantPharm LLC indicated that the results of this analysis showed a median Tmax of 60 hours for 
the 133 mg EXPAREL group and a median Tmax of 78 hours for the 266 mg EXPAREL group. 
This information informed the changes to the PK collection schedule contained protocol 
amendment 2. 
In addition, the safety assessment timepoints, including the neurological exam, vital signs, and 
ECG were adjusted based on the initial interim PK data.  
9.11. 
Significance Testing 
Significance testing will be based on “Graphical approaches for multiple comparison procedures 
using weighted Bonferroni, Simes, or parametric tests” (Bretz 2011).  The initial alpha will be set 
to a two-sided 0.025 for each of the primary efficacy analyses.  Subsequent testing will be 
conducted following the ideas of the paper.   
In addition to the primary endpoint (VAS AUC) there are three key secondary endpoints (total 
opioid consumption, percentage of opioid-free subjects, and time to first rescue medication), and 
for each of these four endpoints there are two primary pairwise comparisons. The procedure for 
multiplicity adjustment for these eight comparisons is described below, together with 
demonstration that it provides strong control of the type 1 error. 
Let HPrimLD, HSec1LD, HSec2LD, and HSec3LD represent the null hypotheses for the comparison of 
EXPAREL 133 mg versus Placebo. Likewise let HPrimHD, HSec1HD, HSec2HD, and HSec3HD represent 
the null hypotheses for the comparison of EXPAREL 266 mg versus Placebo.  Where HPrimLD, 
HSec1LD, HSec2LD, and HSec3LD are respectively VAS AUC, total opioid consumption, percentage of 
opioid-free subjects, and time to first rescue medication and similarly for HPrimHD, HSec1HD, 
HSec2HD, and HSec3HD. 
The first stage of the multiplicity adjustment will be carried out using a graphical approach to 
sequentially rejective multiple test procedures (Bretz et al, 2009).  This will be applied to the set 
of the four null hypotheses F = {HPrimLD, HPrimHD, HSec1LD, HSec1HD} corresponding to the primary 
endpoint and the first key secondary endpoint (total post-surgical opioid consumption through 48 
hours). Let FL = {HPrimLD, HSec1LD) and FH = {HPrimHD, HSec1HD) denote the families of null 
hypotheses corresponding to comparisons of EXPAREL 133 mg versus Placebo, and EXPAREL 
266 mg versus Placebo, respectively.  The particular graphical procedure used here initially 
assigns α = 0.0250 two-sided for testing of the first member of each family (corresponding to the 
primary endpoint) and then within each family the two endpoints are tested in a fixed sequence. 
If for either family null hypotheses for both endpoints can be rejected, then the fixed sequence 
for the other dose level can be conducted using α = 0.05 two-sided.  This procedure can be 
viewed as a Bonferroni-Holm-type approach applied to the families FL and FH.  This procedure 
can be depicted graphically for F = {HPrimLD, HPrimHD, HSec1LD, HSec1HD} as follows: 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL® 
Statistical Analysis Plan 
 
 
CONFIDENTIAL 
37 of 173 
20Jun2017 
 
 
With F= {HPrimLD, HPrimHD, HSec1LD, HSec1HD} as above, in the notation of Bretz et al (2009), we 
start with α = (0.0250, 0.0250, 0, 0).  A G matrix with elements gij is defined in that paper to 
denote the fraction of the local level αi that is allocated to null hypothesis j from set F in the case 
that null hypothesis i is rejected.  This 4x4 matrix G takes a simple form in the procedure 
considered here because g13 = g24 = g32 = g41 = 1, but all other elements are zero.  Bretz et al 
(2009) provides an updating procedure for the matrix G as successive null hypotheses are 
rejected, and prove that such procedures provide strong control of the type 1 error.  The 
particular procedure used in the current study implements the updating of α and G in accordance 
with Bretz et al’s (2009) “Algorithm 1.”  Further, the regularity conditions 0 ≤ gij ≤1,  gii = 0, and 
4
1
1
ik
k
g



 for all i, j = 1,...4, specified in equation (1) of that paper, are satisfied, and so strong 
control of type 1 error at α = 0.05 two-sided for testing of the four null hypotheses F = {HPrimLD, 
HPrimHD, HSec1LD, HSec1HD} follows from Bretz et al’s proof. 
The particular procedure used for the current trial is also given as an example to illustrate the 
graphical procedure within both Alosh et al (2014) and Bretz et al (2011). 
The second stage of the multiplicity adjustment procedure relates to S = {HSec2HD, HSec2LD, 
HSec3HD, HSec3LD}, ie, the four null hypotheses related to the second key efficacy parameter 
(percentage of opioid-free subjects through 48 hours) and the third key efficacy parameter (time 
to first opioid rescue through 48 hours).  These are only tested if all 4 null hypotheses from set F 
have already been rejected, and in that case HSec2HD, HSec2LD, HSec3HD, and HSec3LD are then tested 
sequentially in turn at α = 0.05 two-sided, where statistical significance is required for all 
preceding tests within set S as well as statistical significance for all tests from set F.  If the 
required preceding null hypotheses have not been rejected then p-values for later tests in this 
sequence will be viewed only as descriptive and not as hypothesis testing. 
Given that: (i) strong control of type 1 error at α = 0.05 two-sided has been demonstrated for 
testing of the four null hypotheses F; (ii) testing only proceeds to set S if all null hypotheses in 
set F have been rejected; and (iii) the null hypotheses within set S are tested in a single step-
down procedure, the above procedure has strong control of type 1 error at α = 0.05 two-sided for 
testing of all eight null hypotheses. 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL® 
Statistical Analysis Plan 
 
 
CONFIDENTIAL 
38 of 173 
20Jun2017 
 
10. 
SAMPLE SIZE CALCULATIONS 
Under Amendments 1 and 2 a study population of approximately 300 subjects was planned with 
approximately 100 subjects in each treatment group (EXPAREL 133 mg, EXPAREL 266 mg and 
placebo).  The sample size was estimated based on the results of a Phase 3 TKA study of  EXPAREL 
versus placebo where the mean (SD) AUC of the NRS-R pain intensity scores through 72 hours was 
420 (169) and 514 (160) for the EXPAREL and placebo groups, respectively.  Assuming a 2.5% two-
sided alpha, common SD of 170 and a 5% drop-out rate, a sample size of 85 subjects per arm will 
have at least 90% power to detect a difference of 100 in at least one of the active treatment arms.  
Under Amendment 3 the sample size was estimate was revised by changing the power from 90% to 
80% and the drop-out rate was reduced from 5% to 3%; no other assumptions were changed in the 
derivation of the sample size.  Thus the sample size, under Amendment 3, was estimated based on 
the results of a Phase-3 study of  EXPAREL versus placebo in patients undergoing TKA where the 
means (standard deviation [SD]) AUC of the NRS-R pain intensity scores through 72 hours were 420 
(169) and 514 (160) for the EXPAREL and placebo groups, respectively.  Assuming a 2.5% two-
sided alpha, common SD of 170 and a 3% drop-out rate, a sample size of 77 subjects per treatment 
group will have at least 80% power to detect a difference of 100 in at least one of the active treatment 
groups.  Approximately 231 subjects (77 subjects per treatment group) are planned for enrollment in 
this study in order to have at least 225 evaluable subjects. 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL® 
Statistical Analysis Plan 
 
 
CONFIDENTIAL 
39 of 173 
20Jun2017 
 
11. 
REFERENCES 
 
                                                     
1 American Statistical Association.  Ethical Guidelines for Statistical Practice.  Prepared by the Committee on 
Professional Ethics, 07 August 1999.  http://www.amstat.org/profession/ethicalstatistics.html 
2 US Federal Register.  International Conference on Harmonisation; Guidance on Statistical Principles for Clinical 
Trials.  Department of Health and Human Services: Food and Drug Administration [Docket No. 97D-0174].  Federal 
Register Volume 63, Number 179, pages 49583-49598.  16 September 1998. 
3 Royal Statistical Society.  The Royal Statistical Society: Code of Conduct, August 1993. 
http://www.rss.org.uk/about/conduct.html. 
4 Rubin, D. B. (1987). Multiple Imputation for Nonresponse in Surveys. New York: John Wiley & Sons. 
 
5 The National Academies Press. The Prevention and Treatment of Missing Data in Clinical Trials, prepared by the 
Panel on Handling Missing Data in Clinical Trials and Committee on National Statistics, 2010. 
 
6 Schafer, J. L. (1997). Analysis of Incomplete Multivariate Data. New York: Chapman & Hall. 
 
7 Rubin DB, Schenker N.  Multiple imputation for interval estimation from simple random samples with ignorable 
nonresponse.  J Am Stat Assoc 1986;81:366-374. 
 
8 Bretz F, Posch M, Glimm E, et al. Graphical approaches for multiple comparison procedures using weighted 
Bonferroni, Simes, or parametric tests. Biom J. 2011;53(6): 894–913. 
 
9 Newcombe RG, Interval Estimation for the Difference between Independent Proportions: Comparison of Eleven 
Methods.  Statist. Med. 17, 873-890 (1998). 
 
10Bretz, F., Maurer, W., Brannath, W. and Posch, M. (2009). A graphical approach to sequentially rejective 
multiple test procedures. Statistics in Medicine 28, 586–604. 
 
11Alosh, M., Bretz, F., and Huque, M. (2014) Advanced multiplicity adjustment methods in clinical trials. Statistics 
in Medicine 33(4), 693-713. 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL® 
Statistical Analysis Plan 
 
CONFIDENTIAL 
Page 40 of 173 
20Jun2017 
12. 
TIME AND EVENTS SCHEDULE OF STUDY PROCEDURES  
Please see the Protocol for the full “Time and Events Schedule of Study Procedures”.  Note that the study days defined in the table and footnotes 
start with surgery as Day 0 for the Protocol “Time and Events Schedule of Study Procedures”; however, the SAP definitions start with surgery as 
Day 1.  The SAP follows the CDISC convention to define study day.  Thus in the SAP preop Day 0 is Day 1, Day 7 is Day 8, Day 10 is Day 11 
and Day 29 is Day 30.   


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
41 of 173 
20Jun2017 
 
13. 
MULTIPLE IMPUTATION EXAMPLE PROGRAM CODE 
 
** Note: INPUT_DATA is the dataset that contains the VAS data with the wWOCF imputation performed 
**; 
 
** Step 1 use Markov-Chain Monte-Carlo (MCMC) method **; 
** Note the value for the random seed is fixed to be 123 so that the results are reproducible 
**; 
proc mi data= INPUT_DATA seed=123 nimpute=10 out= OUTPUT_STEP1 minimum=0 maximum=10; 
        by TRT01P; 
        mcmc impute=monotone nbiter=2000 niter=1000; 
        var aval atptn; 
run; quit; 
 
*** Step 2 derive endpoint using appropriate techniques from INPUT_DATA to create INPUT_DATA2**; 
 
*** Step 3 analyze imputations   
 
 
 
 
 
 
 
**;  
DATA &a;  
 
set INPUT_DATA2; 
 
if param = &select and efffl = 'Y' and trt01pn ne 2; 
run; quit; 
proc sort data=&a; by _IMPUTATION_; run; quit; 
 
PROC MIXED DATA= &a METHOD=TYPE3; 
 
by _IMPUTATION_; 
 
class TRT01P; 
 
model AVAL = TRT01P AGE WEIGHT HEIGHT; 
 
lsmeans TRT01P/ diff= CONTROL('Placebo')  CL ; 
 
ods output LSMeans  = &b; 
 
ods output diffs    = &c; 
run; quit;  
 
proc sort data= &b; by TRT01P; run; 
PROC MIANALYZE DATA=&b ALPHA=0.05 THETA0=0;  
 
by TRT01P; 
 
modeleffects ESTIMATE;  
 
stderr STDERR; 
 
ods output PARAMETERESTIMATES=&d; 
run; quit; 
 
** Step 4 build report    
 
 
 
 
 
 
 
**; 
 
 
LAYOUT OF TABLES, LISTINGS AND FIGURES 
The following are planned summary tables.  Tables will be numbered according to the 
nomenclature used to support the CSR.  The final table numbering may be different from the 
SAP.  No amendment will be made for changes in table numbering.  All headers, titles, 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
42 of 173 
20Jun2017 
 
footnotes, and footers specified in the table mock-ups will be displayed in the produced output 
unless otherwise specified.  Notes to programmers will not be included in the tables.   
Tables and listings will have 10 point font size.  Listings font size may be reduced to 9 point if 
needed.  The TLFs will have either Times New Roman, Courier New or SAS Monospace type 
face.  All final TLFs will be provided in both PDF and Word (or RTF) file formats. 
Percentages should not appear if the count is zero.  
Italicized text in the TLF mock-ups indicate notes to programmers and is not to appear on any 
TLF. 
Note headers and footers on mock-ups are reflective of the SAP document and are not intended 
to appear on the TLFs. 
Titles on the TLFs in the mock-ups are presented left-justified as a single line of text.  However, 
the presentation for final TFLs should be center-justified with the TLF number on one line and 
the remaining titles on multiple lines of text where the line breaks are delimited by hyphens (-) in 
the TLF mock-ups titles.  For example, for Table 14.2-1.1.1 the title in the mock-up appears as: 
Table 14.2-1.1.1: Analysis of AUC of VAS Pain Intensity Scores through 72 
hours – Efficacy Analysis Set – Multiple Imputation Results 
but should appear as follows on the final TLF: 
Table 14.2-1.1.1 
Analysis of AUC of VAS Pain Intensity Scores through 72 hours 
Efficacy Analysis Set 
Multiple Imputation Results 
The title format in the mock-ups is due to limitations of MSWord.  The mock-up format enables 
MSWord to generate a table of contents for the mock-ups. 
On all listings the treatments, in order of appearance, are: EXPAREL 133 mg, EXPAREL 266 
mg, PLACEBO and, if applicable, NOT RANDOMIZED.  Always insert a page break between 
treatments. 
On all listings sort within treatment by site, subject, with further sorts dependent on listing. 
Table and listing shells follow.  
For categorical variables, if subjects are missing data for a certain category (example Race), a 
missing subcategory should be added under the respective category. 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
43 of 173 
20Jun2017 
 
14. 
TABLE OF CONTENTS FOR TABLE MOCK-UPS 
TABLE 14.1-1: SUMMARY OF SUBJECT DISPOSITION – ALL SCREENED SUBJECTS 
49 
TABLE 14.1-2.1.1: SUMMARY OF SUBJECT DEMOGRAPHICS - SAFETY ANALYSIS SET 
51 
TABLE 14.1-2.1.2: SUBJECT DEMOGRAPHICS – EFFICACY ANALYSIS SET 
52 
TABLE 14.1-2.1.3: SUBJECT DEMOGRAPHICS – PER-PROTOCOL ANALYSIS SET 
52 
TABLE 14.1-2.2.1: SUMMARY OF SUBJECT BASELINE CHARACTERISTICS - SAFETY 
ANALYSIS SET 
53 
TABLE 14.1-2.2.2: SUBJECT BASELINE CHARACTERISTICS – EFFICACY ANALYSIS SET 
57 
TABLE 14.1-2.2.3: SUBJECT BASELINE CHARACTERISTICS – PER-PROTOCOL ANALYSIS SET57 
TABLE 14.1-3.1: SUMMARY OF SURGERY CHARACTERISTICS - SAFETY ANALYSIS SET 
58 
TABLE 14.1-3.2: SUMMARY OF SURGERY CHARACTERISTICS – EFFICACY ANALYSIS SET 59 
TABLE 14.1-3.3: SUMMARY OF SURGERY CHARACTERISTICS – PER-PROTOCOL ANALYSIS 
SET 
59 
TABLE 14.1-4.1: INCIDENCE OF INTRAOPERATIVE MEDICATIONS - SAFETY ANALYSIS SET 60 
TABLE 14.1-4.2: INCIDENCE OF INTRAOPERATIVE MEDICATIONS - EFFICACY ANALYSIS 
SET 
60 
TABLE 14.1-4.3: INCIDENCE OF INTRAOPERATIVE MEDICATIONS – PER-PROTOCOL 
ANALYSIS SET 
60 
TABLE 14.1-5.1: SUMMARY OF SUBJECT DISPOSITION – BY REGION – ALL SCREENED 
SUBJECTS 
61 
TABLE 14.1-5.2.1.1: SUMMARY OF SUBJECT DEMOGRAPHICS – BY REGION - SAFETY 
ANALYSIS SET 
61 
TABLE 14.1-5.2.1.3: SUBJECT DEMOGRAPHICS – BY REGION – PER-PROTOCOL ANALYSIS 
SET 
61 
TABLE 14.1-5.2.2.1: SUMMARY OF SUBJECT BASELINE CHARACTERISTICS – BY REGION - 
SAFETY ANALYSIS SET 
61 
TABLE 14.1-5.2.2.2: SUBJECT BASELINE CHARACTERISTICS – BY REGION – EFFICACY 
ANALYSIS SET 
61 
TABLE 14.1-5.2.2.3: SUBJECT BASELINE CHARACTERISTICS – BY REGION – PER-PROTOCOL 
ANALYSIS SET 
61 
TABLE 14.1-5.3.1: SUMMARY OF SURGERY CHARACTERISTICS – BY REGION - SAFETY 
ANALYSIS SET 
61 
TABLE 14.1-5.3.2: SUMMARY OF SURGERY CHARACTERISTICS – BY REGION – EFFICACY 
ANALYSIS SET 
61 
TABLE 14.1-5.3.3: SUMMARY OF SURGERY CHARACTERISTICS – BY REGION – 
PER-PROTOCOL ANALYSIS SET 
61 
TABLE 14.2-1.1.1: ANALYSIS OF AUC OF VAS PAIN INTENSITY SCORES THROUGH 72 HOURS 
– EFFICACY ANALYSIS SET - MULTIPLE IMPUTATION RESULTS 
62 
TABLE 14.2-1.1.2: SUMMARY OF AUC OF VAS PAIN INTENSITY SCORES THROUGH 72 
HOURS BY SITE – EFFICACY ANALYSIS SET - MULTIPLE IMPUTATION 
RESULTS 
63 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
44 of 173 
20Jun2017 
 
TABLE 14.2-1.2.1: ANALYSIS OF AUC OF VAS PAIN INTENSITY SCORES THROUGH 72 HOURS 
– PER-PROTOCOL ANALYSIS SET - MULTIPLE IMPUTATION RESULTS 
65 
TABLE 14.2-1.2.2: SUMMARY OF AUC OF VAS PAIN INTENSITY SCORES THROUGH 72 
HOURS BY SITE – PER-PROTOCOL ANALYSIS SET - MULTIPLE IMPUTATION 
RESULTS 
65 
TABLE 14.2-2.1.1: ANALYSIS OF POSTSURGICAL TOTAL OPIOID CONSUMPTION (MED MG) 
THROUGH 72 HOURS – EFFICACY ANALYSIS SET 
66 
TABLE 14.2-2.1.2: SUMMARY OF TOTAL OPIOID CONSUMPTION (MED MG) THROUGH 72 
HOURS BY SITE - EFFICACY ANALYSIS SET 
67 
TABLE 14.2-2.1.3: ANALYSIS OF TOTAL OPIOID CONSUMPTION (MED MG) BY TIME PERIOD 
- EFFICACY ANALYSIS SET 
68 
TABLE 14.2-2.1.4: SUMMARY OF THE NUMBER OF TIMES OPIOID (RESCUE) MEDICATION 
WAS USED BY SUBJECT - EFFICACY ANALYSIS SET 
70 
TABLE 14.2-2.2.1: ANALYSIS OF POSTSURGICAL TOTAL OPIOID CONSUMPTION (MED MG) 
THROUGH 72 HOURS – PER-PROTOCOL ANALYSIS SET 
71 
TABLE 14.2-2.2.2: SUMMARY OF TOTAL OPIOID CONSUMPTION (MED MG) THROUGH 72 
HOURS BY SITE - PER-PROTOCOL ANALYSIS SET 
71 
TABLE 14.2-2.2.3: ANALYSIS OF TOTAL OPIOID CONSUMPTION (MED MG) BY TIME PERIOD 
- PER-PROTOCOL ANALYSIS SET 
71 
TABLE 14.2-2.2.4: SUMMARY OF THE NUMBER OF TIMES OPIOID (RESCUE) MEDICATION 
WAS USED BY SUBJECT - PER-PROTOCOL ANALYSIS SET 
71 
TABLE 14.2-3.1.1: ANALYSIS OF OPIOID-FREE SUBJECTS THROUGH 72 HOURS - EFFICACY 
ANALYSIS SET 
72 
TABLE 14.2-3.1.2: SUMMARY OF OPIOID-FREE SUBJECTS THROUGH 72 HOURS BY SITE - 
EFFICACY ANALYSIS SET 
73 
TABLE 14.2-3.2.1: ANALYSIS OF OPIOID-FREE SUBJECTS THROUGH 72 HOURS - 
PER-PROTOCOL ANALYSIS SET 
74 
TABLE 14.2-3.2.2: SUMMARY OF OPIOID-FREE SUBJECTS THROUGH 72 HOURS BY SITE - 
PER-PROTOCOL ANALYSIS SET 
74 
TABLE 14.2-4.1: ANALYSIS OF TIME TO FIRST RESCUE MEDICATION USE (HOURS) - 
EFFICACY ANALYSIS SET 
75 
TABLE 14.2-5.1: SUMMARY OF VAS AUC AT VARIOUS TIME INTERVALS - EFFICACY 
ANALYSIS SET 
76 
TABLE 14.2-5.2: SUMMARY OF VAS AT ASSESSMENT TIMEPOINTS - EFFICACY ANALYSIS 
SET 
78 
TABLE 14.2-5.3: SUMMARY OF VAS SPIS AT VARIOUS TIME INTERVALS - EFFICACY 
ANALYSIS SET 
79 
TABLE 14.2-6: ANALYSIS OF PAIN-FREE SUBJECTS AT ASSESSMENT TIMEPOINTS - 
EFFICACY ANALYSIS SET 
80 
TABLE 14.2-7: ANALYSIS OF OPIOID-FREE SUBJECTS THROUGH 24, 48, AND 96 HOURS - 
EFFICACY ANALYSIS SET 
81 
TABLE 14.2-8: SUMMARY OF OVERALL BENEFIT OF ANALGESIA SCALE BY TIMEPOINT 
AND QUESTION - EFFICACY ANALYSIS SET 
82 
TABLE 14.2-9: SUMMARY OF SATISFACTION WITH POSTSURGICAL PAIN CONTROL 
QUESTIONNAIRE SCORE BY TIMEPOINT - EFFICACY ANALYSIS SET 
84 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
45 of 173 
20Jun2017 
 
TABLE 14.2-10.1: SUMMARY OF TIME TO DISCHARGE READY - EFFICACY ANALYSIS SET 85 
TABLE 14.2-10.2: SUMMARY OF DISCHARGE READY BY ASSESSMENT - EFFICACY 
ANALYSIS SET 
86 
TABLE 14.2-11: SUMMARY OF NUMBER OF UNSCHEDULED PHONE CALLS OR OFFICE 
VISITS RELATED TO PAIN - EFFICACY ANALYSIS SET 
87 
TABLE 14.2-12.1: ANALYSIS OF DISTANCE WALKED (METERS) DURING TIMED WALK TEST 
– EFFICACY ANALYSIS SET 
88 
TABLE 14.2-12.2: SUMMARY OF TIMED WALK TEST BY TIMEPOINT – EFFICACY ANALYSIS 
SET 
90 
TABLE 14.2-13: ANALYSIS OF TIMED UP-AND-GO TEST (SECONDS) – EFFICACY ANALYSIS 
SET 
91 
TABLE 14.2-14: ANALYSIS OF STAIR CLIMB TEST – EFFICACY ANALYSIS SET 
92 
TABLE 14.2-15.1.1.1: REGION ANALYSIS OF AUC OF VAS PAIN INTENSITY SCORES 
THROUGH 72 HOURS – EFFICACY ANALYSIS SET - MULTIPLE IMPUTATION 
RESULTS 
93 
TABLE 14.2-15.1.2.1: REGION ANALYSIS OF AUC OF VAS PAIN INTENSITY SCORES 
THROUGH 72 HOURS – PER-PROTOCOL ANALYSIS SET - MULTIPLE 
IMPUTATION RESULTS 
93 
TABLE 14.2-15.2.1.1: REGION ANALYSIS OF POSTSURGICAL TOTAL OPIOID CONSUMPTION 
(MED MG) THROUGH 72 HOURS – EFFICACY ANALYSIS SET 
93 
TABLE 14.2-15.2.1.2: REGION SUMMARY OF TOTAL OPIOID CONSUMPTION (MED MG) 
THROUGH 72 HOURS BY REGION - EFFICACY ANALYSIS SET 
93 
TABLE 14.2-15.2.1.3: REGION SUMMARY OF TOTAL OPIOID CONSUMPTION (MED MG) BY 
TIME PERIOD - EFFICACY ANALYSIS SET 
93 
TABLE 14.2-15.2.1.4: REGION SUMMARY OF THE NUMBER OF TIMES OPIOID (RESCUE) 
MEDICATION WAS USED BY SUBJECT - EFFICACY ANALYSIS SET 
93 
TABLE 14.2-15.2.2.1: REGION ANALYSIS OF POSTSURGICAL TOTAL OPIOID CONSUMPTION 
(MED MG) THROUGH 72 HOURS – PER-PROTOCOL ANALYSIS SET 
93 
TABLE 14.2-15.2.2.2: REGION SUMMARY OF TOTAL OPIOID CONSUMPTION (MED MG) 
THROUGH 72 HOURS BY SITE - PER-PROTOCOL ANALYSIS SET 
94 
TABLE 14.2-15.2.2.3: REGION SUMMARY OF TOTAL OPIOID CONSUMPTION (MED MG) BY 
TIME PERIOD - PER-PROTOCOL ANALYSIS SET 
94 
TABLE 14.2-15.2.2.4: REGION SUMMARY OF THE NUMBER OF TIMES OPIOID (RESCUE) 
MEDICATION WAS USED BY SUBJECT - PER-PROTOCOL ANALYSIS SET 
94 
TABLE 14.2-15.3.1.1: REGION ANALYSIS OF OPIOID-FREE SUBJECTS THROUGH 72 HOURS - 
EFFICACY ANALYSIS SET 
94 
TABLE 14.2-15.3.1.2: REGION SUMMARY OF OPIOID-FREE SUBJECTS THROUGH 72 HOURS 
BY SITE - EFFICACY ANALYSIS SET 
94 
TABLE 14.2-15.3.2.1: REGION ANALYSIS OF OPIOID-FREE SUBJECTS THROUGH 72 HOURS - 
PER-PROTOCOL ANALYSIS SET 
94 
TABLE 14.2-15.3.2.2: REGION SUMMARY OF OPIOID-FREE SUBJECTS THROUGH 72 HOURS 
BY SITE - PER-PROTOCOL ANALYSIS SET 
94 
TABLE 14.3-1.1.1: SUMMARY OF CLINICAL LABORATORY DATA BY TIMEPOINT – 
HEMATOLOGY - SAFETY ANALYSIS SET 
95 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
46 of 173 
20Jun2017 
 
TABLE 14.3-1.1.2: SUMMARY OF CLINICAL LABORATORY DATA BY TIMEPOINT – 
CHEMISTRY - SAFETY ANALYSIS SET 
96 
TABLE 14.3-1.1.3.1: SUMMARY OF CLINICAL LABORATORY DATA BY TIMEPOINT – 
URINALYSIS - SAFETY ANALYSIS SET 
96 
TABLE 14.3-1.1.3.2: TABULATION OF CLINICAL LABORATORY DATA BY TIMEPOINT – 
URINALYSIS - SAFETY ANALYSIS SET 
97 
TABLE 14.3-1.2.1: TABULATION OF CLINICAL LABORATORY RANGE BY TIMEPOINT – 
HEMATOLOGY - SAFETY ANALYSIS SET 
98 
TABLE 14.3-1.2.2: TABULATION OF CLINICAL LABORATORY RANGE BY TIMEPOINT – 
CHEMISTRY - SAFETY ANALYSIS SET 
98 
TABLE 14.3-1.2.3: TABULATION OF CLINICAL LABORATORY RANGE BY TIMEPOINT – 
URINALYSIS - SAFETY ANALYSIS SET 
98 
TABLE 14.3-1.3.1: SHIFT TABLE FOR CLINICAL LABORATORY DATA BY TIMEPOINT – 
HEMATOLOGY - SAFETY ANALYSIS SET 
99 
TABLE 14.3-1.3.2: SHIFT TABLE FOR CLINICAL LABORATORY DATA BY TIMEPOINT – 
CHEMISTRY - SAFETY ANALYSIS SET 
99 
TABLE 14.3-1.3.3: SHIFT TABLE FOR CLINICAL LABORATORY DATA BY TIMEPOINT – 
URINALYSIS - SAFETY ANALYSIS SET 
99 
TABLE 14.3-2.1: SUMMARY OF VITAL SIGNS BY TIMEPOINT – SAFETY ANALYSIS SET 
100 
TABLE 14.3-2.2: SUMMARY OF POTENTIALLY CLINICALLY SIGNIFICANT ABNORMAL 
VITAL SIGNS – SAFETY ANALYSIS SET 
102 
TABLE 14.3-3.1: SUMMARY OF ELECTROCARDIOGRAM INTERPRETATION – INVESTIGATOR 
READ - SAFETY ANALYSIS SET 
105 
TABLE 14.3-3.2: SHIFT TABLE FOR ELECTROCARDIOGRAM INTERPRETATION – 
INVESTIGATOR READ - SAFETY ANALYSIS SET 
106 
TABLE 14.3-4: SUMMARY OF NEUROLOGICAL ASSESSMENTS BY TIMEPOINT- SAFETY 
ANALYSIS SET 
107 
TABLE 14.3-5.1: TABULATION OF SENSATION TESTS – SAFETY ANALYSIS SET 
108 
TABLE 14.3-5.2: SUMMARY OF SENSATION LOSS AND RETURN BY TIMEPOINT – SAFETY 
ANALYSIS SET 
109 
TABLE 14.3-5.3.1: ANALYSIS OF TIME TO FIRST SENSATION LOSS – SAFETY ANALYSIS SET110 
TABLE 14.3-5.4.1: ANALYSIS OF TIME TO FIRST SENSATION RETURN – SAFETY ANALYSIS 
SET 
112 
TABLE 14.3-5.5: SUMMARY OF DURATION (HRS) OF SENSATION LOSS – SAFETY ANALYSIS 
SET 
114 
TABLE 14.3-5.6: SUMMARY OF THE NUMBER OF SENSATION LOSS-RETURN CYCLES - 
SAFETY ANALYSIS SET 
115 
TABLE 14.3-6.1: SUMMARY OF ACTIVE MOTOR FUNCTION LOSS AND RETURN BY 
TIMEPOINT – SAFETY ANALYSIS SET 
116 
TABLE 14.3-6.2: ANALYSIS OF TIME TO ONSET OF MOTOR FUNCTION LOSS - EFFICACY 
ANALYSIS SET 
117 
TABLE 14.3-6.3: ANALYSIS OF TIME TO RETURN OF MOTOR FUNCTION - EFFICACY 
ANALYSIS SET 
118 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
47 of 173 
20Jun2017 
 
TABLE 14.3-6.4: SUMMARY OF MOTOR FUNCTION ASSESSMENTS BY TIMEPOINT – SAFETY 
ANALYSIS SET 
119 
TABLE 14.3-7.1: OVERVIEW OF TREATMENT-EMERGENT ADVERSE EVENTS (TEAES) - 
SAFETY ANALYSIS SET 
121 
TABLE 14.3-7.1.2: SUMMARY OF INCIDENCE OF TREATMENT-EMERGENT ADVERSE 
EVENTS (TEAES) - SAFETY ANALYSIS SET 
122 
TABLE 14.3-7.1.3: SUMMARY OF INCIDENCE OF STUDY DRUG-RELATED TREATMENT-
EMERGENT ADVERSE EVENTS (TEAES) - SAFETY ANALYSIS SET 
122 
TABLE 14.3-7.1.4: SUMMARY OF INCIDENCE OF TREATMENT-EMERGENT ADVERSE 
EVENTS (TEAES) LEADING TO STUDY WITHDRAWAL - SAFETY ANALYSIS SET122 
TABLE 14.3-7.1.5: SUMMARY OF INCIDENCE OF STUDY DRUG-RELATED TREATMENT-
EMERGENT ADVERSE EVENTS (TEAES) LEADING TO STUDY WITHDRAWAL - 
SAFETY ANALYSIS SET 
122 
TABLE 14.3-7.1.6: SUMMARY OF INCIDENCE OF TREATMENT-EMERGENT ADVERSE 
EVENTS (TEAES) BY SEVERITY - SAFETY ANALYSIS SET 
123 
TABLE 14.3-7.1.7: SUMMARY OF INCIDENCE OF TREATMENT-EMERGENT ADVERSE 
EVENTS (TEAES) BY RELATIONSHIP TO STUDY DRUG - SAFETY ANALYSIS SET124 
TABLE 14.3-7.2.1: OVERVIEW OF SERIOUS TREATMENT-EMERGENT ADVERSE EVENTS 
(TEAES) - SAFETY ANALYSIS SET 
125 
TABLE 14.3-7.2.2: SUMMARY OF INCIDENCE OF SERIOUS TREATMENT-EMERGENT 
ADVERSE EVENTS (TEAES) - SAFETY ANALYSIS SET 
125 
TABLE 14.3-7.2.3: SUMMARY OF INCIDENCE OF STUDY DRUG-RELATED SERIOUS 
TREATMENT-EMERGENT ADVERSE EVENTS (TEAES) - SAFETY ANALYSIS SET125 
TABLE 14.3-7.2.4: SUMMARY OF INCIDENCE OF SERIOUS TREATMENT-EMERGENT 
ADVERSE EVENTS (TEAES) LEADING TO STUDY WITHDRAWAL - SAFETY 
ANALYSIS SET 
125 
TABLE 14.3-7.2.5: SUMMARY OF INCIDENCE OF STUDY DRUG-RELATED SERIOUS 
TREATMENT-EMERGENT ADVERSE EVENTS (TEAES) LEADING TO STUDY 
WITHDRAWAL - SAFETY ANALYSIS SET 
125 
TABLE 14.3-7.2.6: SUMMARY OF INCIDENCE OF SERIOUS TREATMENT-EMERGENT 
ADVERSE EVENTS (TEAES) RESULTING IN DEATH - SAFETY ANALYSIS SET 125 
TABLE 14.3-7.2.7: SUMMARY OF INCIDENCE OF STUDY DRUG-RELATED SERIOUS 
TREATMENT-EMERGENT ADVERSE EVENTS (TEAES) RESULTING IN DEATH - 
SAFETY ANALYSIS SET 
125 
TABLE 14.3-7.3.1: OVERVIEW OF TREATMENT-EMERGENT ADVERSE EVENTS (TEAES) OF 
SPECIAL INTEREST - SAFETY ANALYSIS SET 
125 
TABLE 14.3-7.3.2: SUMMARY OF INCIDENCE OF TREATMENT-EMERGENT ADVERSE 
EVENTS (TEAES) OF SPECIAL INTEREST - SAFETY ANALYSIS SET 
125 
TABLE 14.3-7.3.3: SUMMARY OF INCIDENCE OF STUDY DRUG-RELATED TREATMENT-
EMERGENT ADVERSE EVENTS (TEAES) OF SPECIAL INTEREST - SAFETY 
ANALYSIS SET 
125 
TABLE 14.3-7.3.4: SUMMARY OF INCIDENCE OF TREATMENT-EMERGENT ADVERSE 
EVENTS (TEAES) OF SPECIAL INTEREST LEADING TO STUDY WITHDRAWAL - 
SAFETY ANALYSIS SET 
125 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
48 of 173 
20Jun2017 
 
TABLE 14.3-7.3.5: SUMMARY OF INCIDENCE OF STUDY DRUG-RELATED TREATMENT-
EMERGENT ADVERSE EVENTS (TEAES) OF SPECIAL INTEREST LEADING TO 
STUDY WITHDRAWAL - SAFETY ANALYSIS SET 
126 
TABLE 14.3-7.3.6: SUMMARY OF INCIDENCE OF TREATMENT-EMERGENT ADVERSE 
EVENTS (TEAES) OF SPECIAL INTEREST RESULTING IN DEATH - SAFETY 
ANALYSIS SET 
126 
TABLE 14.3-7.3.7: SUMMARY OF INCIDENCE OF STUDY DRUG-RELATED TREATMENT-
EMERGENT ADVERSE EVENTS (TEAES) OF SPECIAL INTEREST RESULTING IN 
DEATH - SAFETY ANALYSIS SET 
126 
TABLE 14.3-8.1: INCIDENCE OF PRIOR MEDICATIONS – SAFETY ANALYSIS SET 
127 
TABLE 14.3-8.2: INCIDENCE OF CONCOMITANT MEDICATIONS – SAFETY ANALYSIS SET 127 
TABLE 14.3-9.1.1: REGION TABULATION OF SENSATION TESTS – SAFETY ANALYSIS SET 128 
TABLE 14.3-9.1.2: REGION SUMMARY OF SENSATION LOSS AND RETURN BY TIMEPOINT – 
SAFETY ANALYSIS SET 
128 
TABLE 14.3-9.1.3: REGION ANALYSIS OF TIME TO SENSATION LOSS – SAFETY ANALYSIS 
SET 
128 
TABLE 14.3-9.1.4: REGION ANALYSIS OF TIME TO SENSATION RETURN – SAFETY 
ANALYSIS SET 
128 
TABLE 14.3-9.1.5: REGION SUMMARY OF DURATION (HRS) OF SENSATION LOSS – SAFETY 
ANALYSIS SET 
128 
TABLE 14.3-9.2.1: REGION SUMMARY OF ACTIVE MOTOR FUNCTION LOSS AND RETURN 
BY TIMEPOINT – SAFETY ANALYSIS SET 
128 
TABLE 14.3-9.2.2: REGION ANALYSIS OF TIME TO ONSET OF MOTOR FUNCTION LOSS - 
EFFICACY ANALYSIS SET 
128 
TABLE 14.3-9.2.3: REGION ANALYSIS OF TIME TO RETURN OF MOTOR FUNCTION - 
EFFICACY ANALYSIS SET 
128 
TABLE 14.3-9.2.4: REGION SUMMARY OF MOTOR FUNCTION ASSESSMENTS BY TIMEPOINT 
– SAFETY ANALYSIS SET 
128 
TABLE 14.3-9.3.1: REGION OVERVIEW OF TREATMENT-EMERGENT ADVERSE EVENTS 
(TEAES) - SAFETY ANALYSIS SET 
129 
TABLE 14.3-9.3.2: REGION SUMMARY OF INCIDENCE OF TREATMENT-EMERGENT 
ADVERSE EVENTS (TEAES) - SAFETY ANALYSIS SET 
130 
TABLE 14.3-9.3.3: REGION SUMMARY OF INCIDENCE OF SERIOUS TREATMENT-EMERGENT 
ADVERSE EVENTS (TEAES) - SAFETY ANALYSIS SET 
130 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
49 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Table 14.1-1: Summary of Subject Disposition – All Screened Subjects 
 
Site: Overall 
EXPAREL 
 
 
 
133 mg 
n (%) 
266 mg 
n (%) 
All EXPAREL 
n (%) 
Placebo 
n (%) 
Total 
n (%) 
Screened [1] 
 
 
 
 
xx 
   Screen Failure [1] 
 
 
 
 
xx (xx.x) 
   Enrolled [1] 
 
 
 
 
xx (xx.x) 
 
 
 
 
 
 
Randomized 
xx 
xx 
xx 
xx 
xx 
  Not Treated 
xx 
xx 
xx 
xx 
xx 
  Treated 
xx 
xx 
xx 
xx 
xx 
 
 
 
 
 
 
Safety Analysis Set [2]# 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
 
Efficacy Analysis Set [3]@ 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
 
Per-Protocol Analysis Set [4]@ 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
 
Protocol 
 
 
 
 
 
  Enrolled under Amendment 2 [2]# 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  Enrolled under Amendment 1 [2]# 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
 
Completed Study@ 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
Discontinued from Study@ 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  Reasons for Discontinuation@ 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
    Death@ 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
    Adverse Event@ 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
    Lack of Efficacy@ 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
    Lost to Follow-up@ 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
    Withdrawal by Subject@ 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
    Other@ 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
 
# = as treated; 
@ = as randomized; 
[1] Signed the informed consent form; 
[2] Received study drug; 
[3] Received study drug and surgery; 
 
[4] All subjects in the efficacy analysis set who do not have any important protocol deviations;    
Percentages for screen failure and enrolled based on number screened; others on number randomized. 
Subjects randomized to EXPAREL but treated with placebo: list subjects; 
Subjects randomized to placebo but treated with EXPAREL: list subjects; 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
50 of 173 
20Jun2017 
 
SAS X.Y 
 
program_name 
Note to programmer: First page will present overall sites; subsequent pages will present each site – one 
site per page. For reasons for discontinuation only those reasons that appear in the data will appear on 
the table.  For individual sites the label should be the site number.  For the footnotes “Subjects treated 
with...” if no subjects were mistreated, then omit footnote. 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
51 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Table 14.1-2.1.1: Summary of Subject Demographics - Safety Analysis Set 
 
Site: Overall 
 
EXPAREL 
 
 
 
Statistic 
133 mg 
[N=XX] 
266 mg 
[N=XX] 
All EXPAREL 
[N=XX] 
Placebo 
[N=XX] 
Total 
[N=XX] 
Age (yrs) 
n 
xx 
xx 
xx 
xx 
xx 
 
Mean 
xx.x 
xx.x 
xx.x 
xx.x 
xx.x 
 
SD 
x.xx 
x.xx 
x.xx 
x.xx 
x.xx 
 
Minimum 
xx 
xx 
xx 
xx 
xx 
 
Median 
xx.x 
xx.x 
xx.x 
xx.x 
xx.x 
 
Maximum 
xx 
xx 
xx 
xx 
xx 
 
 
 
 
 
 
 
Sex 
 
 
 
 
 
 
  Female 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  Male 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
 
 
Ethnicity 
 
 
 
 
 
 
  Hispanic or Latino 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  Not Hispanic or Latino 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
 
 
Race 
 
 
 
 
 
 
  American Indian/Alaska Native 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  Black/African American 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  Asian 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  White  
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  Native Hawaiian/Pacific Islander 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
 
 
Country 
 
 
 
 
 
 
  Belgium 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  Denmark 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  USA 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
52 of 173 
20Jun2017 
 
Note to programmer: First page will present overall sites; subsequent pages will present each site – one 
site per page. Only categories available in the data will appear on the table.  For individual sites the 
label should be the site number. If subjects are missing data for a category (example Race), a missing 
subcategory should be added under the respective category. Use this mock-up also for table: 
 
Table 14.1-2.1.2: Subject Demographics – Efficacy Analysis Set  
Table 14.1-2.1.3: Subject Demographics – Per-protocol Analysis Set  
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
53 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page 1 of 4) 
Protocol: 402-C-326 
Table 14.1-2.2.1: Summary of Subject Baseline Characteristics - Safety Analysis Set 
 
Site: Overall 
 
EXPAREL 
 
 
 
Statistic 
133 mg  
[N=XX] 
266 mg 
[N=XX] 
All EXPAREL 
[N=XX] 
Placebo 
[N=XX] 
Total 
[N=XX] 
 
 
 
 
 
 
 
Neurological Assessments 
 
 
 
 
 
 
   Subject oriented 
 
 
 
 
 
 
    Yes 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) xxx (xx.x%) 
    No 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) xxx (xx.x%) 
  Numb lips, tongue, mouth 
 
 
 
 
 
 
    Yes 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) xxx (xx.x%) 
    No 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) xxx (xx.x%) 
  Metallic taste 
 
 
 
 
 
 
    Yes 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) xxx (xx.x%) 
    No 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) xxx (xx.x%) 
  Problems hearing 
 
 
 
 
 
 
    Yes 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) xxx (xx.x%) 
    No 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) xxx (xx.x%) 
  Problems with vision 
 
 
 
 
 
 
    Yes 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) xxx (xx.x%) 
    No 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) xxx (xx.x%) 
  Muscle twitch 
 
 
 
 
 
 
    Yes 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) xxx (xx.x%) 
    No 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) xxx (xx.x%) 
ECG 
 
 
 
 
 
 
  Normal 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) xxx (xx.x%) 
  Abnormal, NCS 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) xxx (xx.x%) 
  Abnormal, CS 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) xxx (xx.x%) 
 
 
 
 
 
 
 
NCS = Not clinically significant 
CS = Clinically significant 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
Note to programmer: If subjects are missing data for a category (example Race), a missing subcategory should be added under the respective 
category. 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
54 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page 2 of 4) 
Protocol: 402-C-326 
Table 14.1-2.2.1: Summary of Subject Baseline Characteristics - Safety Analysis Set 
 
Site: Overall 
 
EXPAREL 
 
 
 
Statistic 
133 mg  
[N=XX] 
266 mg 
[N=XX] 
All EXPAREL 
[N=XX] 
Placebo 
[N=XX] 
Total 
[N=XX] 
 
 
 
 
 
 
 
Motor Assessments 
 
 
 
 
 
 
  Active Flexion (degrees) 
n 
xx 
xx 
xx 
xx 
xx 
 
Mean 
xx.x 
xx.x 
xx.x 
xx.x 
xx.x 
 
SD 
x.xx 
x.xx 
x.xx 
x.xx 
x.xx 
 
Minimum 
xx 
xx 
xx 
xx 
xx 
 
Median 
xx.x 
xx.x 
xx.x 
xx.x 
xx.x 
 
Maximum 
xx 
xx 
xx 
xx 
xx 
 
 
 
 
 
 
 
  Active Extension (degrees) 
n 
xx 
xx 
xx 
xx 
xx 
 
Mean 
xx.x 
xx.x 
xx.x 
xx.x 
xx.x 
 
SD 
x.xx 
x.xx 
x.xx 
x.xx 
x.xx 
 
Minimum 
xx 
xx 
xx 
xx 
xx 
 
Median 
xx.x 
xx.x 
xx.x 
xx.x 
xx.x 
 
Maximum 
xx 
xx 
xx 
xx 
xx 
 
 
 
 
 
 
 
  Passive Flexion (degrees) 
n 
xx 
xx 
xx 
xx 
xx 
 
Mean 
xx.x 
xx.x 
xx.x 
xx.x 
xx.x 
 
SD 
x.xx 
x.xx 
x.xx 
x.xx 
x.xx 
 
Minimum 
xx 
xx 
xx 
xx 
xx 
 
Median 
xx.x 
xx.x 
xx.x 
xx.x 
xx.x 
 
Maximum 
xx 
xx 
xx 
xx 
xx 
 
 
 
 
 
 
 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
55 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page 2 of 4) 
Protocol: 402-C-326 
Table 14.1-2.2.1: Summary of Subject Baseline Characteristics - Safety Analysis Set 
 
Site: Overall 
 
EXPAREL 
 
 
 
Statistic 
133 mg  
[N=XX] 
266 mg 
[N=XX] 
All EXPAREL 
[N=XX] 
Placebo 
[N=XX] 
Total 
[N=XX] 
 
 
 
 
 
 
 
Motor Assessments 
 
 
 
 
 
 
  Passive Extension (degrees) n 
xx 
xx 
xx 
xx 
xx 
 
Mean 
xx.x 
xx.x 
xx.x 
xx.x 
xx.x 
 
SD 
x.xx 
x.xx 
x.xx 
x.xx 
x.xx 
 
Minimum 
xx 
xx 
xx 
xx 
xx 
 
Median 
xx.x 
xx.x 
xx.x 
xx.x 
xx.x 
 
Maximum 
xx 
xx 
xx 
xx 
xx 
 
 
 
 
 
 
 
VAS Score (cm) 
n 
xx 
xx 
xx 
xx 
xx 
 
Mean 
xx.x 
xx.x 
xx.x 
xx.x 
xx.x 
 
SD 
x.xx 
x.xx 
x.xx 
x.xx 
x.xx 
 
Minimum 
xx 
xx 
xx 
xx 
xx 
 
Median 
xx.x 
xx.x 
xx.x 
xx.x 
xx.x 
 
Maximum 
xx 
xx 
xx 
xx 
xx 
 
 
 
 
 
 
 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
56 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page 3 of 4) 
Protocol: 402-C-326 
Table 14.1-2.2.1: Summary of Subject Baseline Characteristics - Safety Analysis Set 
 
Site: Overall 
 
EXPAREL 
 
 
 
Statistic 
133 mg  
[N=XX] 
266 mg 
[N=XX] 
All EXPAREL 
[N=XX] 
Placebo 
[N=XX] 
Total 
[N=XX] 
 
 
 
 
 
 
 
ASA Classification 
 
 
 
 
 
 
  1 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  2 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  3 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  ≥ 4 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
 
 
Height(cm) 
n 
xx 
xx 
xx 
xx 
xx 
 
Mean 
xx.x 
xx.x 
xx.x 
xx.x 
xx.x 
 
SD 
x.xx 
x.xx 
x.xx 
x.xx 
x.xx 
 
Minimum 
xx 
xx 
xx 
xx 
xx 
 
Median 
xx.x 
xx.x 
xx.x 
xx.x 
xx.x 
 
Maximum 
xx 
xx 
xx 
xx 
xx 
 
 
 
 
 
 
 
Weight (kg) 
n 
xx 
xx 
xx 
xx 
xx 
 
Mean 
xx.x 
xx.x 
xx.x 
xx.x 
xx.x 
 
SD 
x.xx 
x.xx 
x.xx 
x.xx 
x.xx 
 
Minimum 
xx 
xx 
xx 
xx 
xx 
 
Median 
xx.x 
xx.x 
xx.x 
xx.x 
xx.x 
 
Maximum 
xx 
xx 
xx 
xx 
xx 
 
Maximum 
xx 
xx 
xx 
xx 
xx 
Body Mass Index (kg/m2) 
 
 
 
 
 
 
 
n 
xx 
xx 
xx 
xx 
xx 
 
Mean 
xx.x 
xx.x 
xx.x 
xx.x 
xx.x 
 
SD 
x.xx 
x.xx 
x.xx 
x.xx 
x.xx 
 
Minimum 
xx 
xx 
xx 
xx 
xx 
 
Median 
xx.x 
xx.x 
xx.x 
xx.x 
xx.x 
 
Maximum 
xx 
xx 
xx 
xx 
xx 
 
Maximum 
xx 
xx 
xx 
xx 
xx 
 
 
 
 
 
 
 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name  
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
57 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page 4 of 4) 
Protocol: 402-C-326 
Table 14.1-2.2.1: Summary of Subject Baseline Characteristics - Safety Analysis Set 
 
Site: Overall 
 
EXPAREL 
 
 
 
Statistic 
133 mg  
[N=XX] 
266 mg 
[N=XX] 
All EXPAREL 
[N=XX] 
Placebo 
[N=XX] 
Total 
[N=XX] 
 
 
 
 
 
 
 
Heart Rate (bpm) 
n 
xx 
xx 
xx 
xx 
xx 
 
Mean 
xx.x 
xx.x 
xx.x 
xx.x 
xx.x 
 
SD 
x.xx 
x.xx 
x.xx 
x.xx 
x.xx 
 
Minimum 
xx 
xx 
xx 
xx 
xx 
 
Median 
xx.x 
xx.x 
xx.x 
xx.x 
xx.x 
 
Maximum 
xx 
xx 
xx 
xx 
xx 
 
 
 
 
 
 
 
Systolic Blood Pressure (mmHg) 
n 
xx 
xx 
xx 
xx 
xx 
 
Mean 
xx.x 
xx.x 
xx.x 
xx.x 
xx.x 
 
SD 
x.xx 
x.xx 
x.xx 
x.xx 
x.xx 
 
Minimum 
xx 
xx 
xx 
xx 
xx 
 
Median 
xx.x 
xx.x 
xx.x 
xx.x 
xx.x 
 
Maximum 
xx 
xx 
xx 
xx 
xx 
 
 
 
 
 
 
 
Diastolic Blood Pressure (mmHg) n 
xx 
xx 
xx 
xx 
xx 
 
Mean 
xx.x 
xx.x 
xx.x 
xx.x 
xx.x 
 
SD 
x.xx 
x.xx 
x.xx 
x.xx 
x.xx 
 
Minimum 
xx 
xx 
xx 
xx 
xx 
 
Median 
xx.x 
xx.x 
xx.x 
xx.x 
xx.x 
 
Maximum 
xx 
xx 
xx 
xx 
xx 
 
Maximum 
xx 
xx 
xx 
xx 
xx 
 
 
 
 
 
 
 
 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
Note to programmer: First page will present overall sites; subsequent pages will present each site – one 
site per page. For individual sites the label should be the site number. Use this mock-up also for table: 
 
Table 14.1-2.2.2: Subject Baseline Characteristics – Efficacy Analysis Set  
Table 14.1-2.2.3: Subject Baseline Characteristics – Per-protocol Analysis Set  
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
58 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Table 14.1-3.1: Summary of Surgery Characteristics - Safety Analysis Set 
 
Site: Overall 
EXPAREL 
 
 
Characteristic 
Statistic 
133 mg  
[N=XX] 
266 mg 
[N=XX] 
All EXPAREL 
[N=XX] 
Placebo  
[N=XX] 
Total 
[N=XX] 
 
 
 
 
 
 
 
Duration of Surgery (hours) 
n 
xx 
xx 
xx 
xx 
xx 
 
Mean 
xx.x 
xx.x 
xx.x 
xx.x 
xx.x 
 
SD 
x.xx 
x.xx 
x.xx 
x.xx 
x.xx 
 
Median 
xx 
xx 
xx 
xx 
xx 
 
Minimum 
xx.x 
xx.x 
xx.x 
xx.x 
xx.x 
 
Maximum 
xx 
xx 
xx 
xx 
xx 
 
 
 
 
 
 
 
Tourniquet 
 
 
 
 
 
 
   Used 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
   Not Used 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
 
 
   Duration (hours) 
n 
xx 
xx 
xx 
xx 
xx 
 
Mean 
xx.x 
xx.x 
xx.x 
xx.x 
xx.x 
 
SD 
x.xx 
x.xx 
x.xx 
x.xx 
x.xx 
 
Median 
xx 
xx 
xx 
xx 
xx 
 
Minimum 
xx.x 
xx.x 
xx.x 
xx.x 
xx.x 
 
Maximum 
xx 
xx 
xx 
xx 
xx 
 
 
 
 
 
 
 
Drain 
 
 
 
 
 
 
   Used 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
   Not Used 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
 
 
   Duration (hours) 
n 
xx 
xx 
xx 
xx 
xx 
 
Mean 
xx.x 
xx.x 
xx.x 
xx.x 
xx.x 
 
SD 
x.xx 
x.xx 
x.xx 
x.xx 
x.xx 
 
Median 
xx 
xx 
xx 
xx 
xx 
 
Minimum 
xx.x 
xx.x 
xx.x 
xx.x 
xx.x 
 
Maximum 
xx 
xx 
xx 
xx 
xx 
 
 
 
 
 
 
 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
Note to programmer: First page will present overall sites; subsequent pages will present each site – one 
site per page. For individual sites the label should be the site number.  


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
59 of 173 
20Jun2017 
 
 
Use this mock-up also for tables: 
 
Table 14.1-3.2: Summary of Surgery Characteristics – Efficacy Analysis Set  
Table 14.1-3.3: Summary of Surgery Characteristics – Per-protocol Analysis Set  
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
60 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Table 14.1-4.1: Incidence of Intraoperative Medications - Safety Analysis Set 
 
EXPAREL 
 
 
Anatomical Therapeutic Class (ATC) 
  Preferred Name 
133 mg 
[N=XX] 
n (%) 
266 mg 
[N=XX] 
n (%) 
All EXPAREL 
[N=XX] 
n (%) 
Placebo  
[N=XX]  
n (%) 
Total  
[N=XX] 
n (%) 
 
 
 
 
 
 
Subjects taking at least one medication 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
 
ATC1 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  PN1.1 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  PN1.2 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
 
ATC2 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  PN2.1 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  PN2.2 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
ETC. 
 
 
 
 
 
 
 
 
 
 
 
Medications are coded using World Health Organization Drug Dictionary (WHO-DD) March 2015. 
Sorted by descending total incidence by ATC for Total column.  Subjects using the same intraoperative 
medication (PT) more than once or multiple medications within an ATC class are counted only once at each 
ATC summary level. 
Intraoperatives medications are those indicated as such by the investigator. 
Subjects using the same prior medication more than once are counted only once at each summary level. 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
Note to programmer:  Use mock-up 14.1-4.1 for tables: 
 
Table 14.1-4.2: Incidence of Intraoperative Medications - Efficacy Analysis Set 
Table 14.1-4.3: Incidence of Intraoperative Medications – Per-protocol Analysis Set 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
61 of 173 
20Jun2017 
 
Note to programmer:  For the following region summaries, ‘Site:’ will be replaced with ‘Region:’.  Regions, 
in order of appearance, are US and ROW.  There will be no overall region summary presented on these tables. 
  
Use mock-up 14.1-1 for table: 
 
Table 14.1-5.1: Summary of Subject Disposition – By Region – All Screened Subjects 
 
Use mock-up 14.1-2.1.1 for tables: 
 
Table 14.1-5.2.1.1: Summary of Subject Demographics – By Region - Safety Analysis Set 
Table 14.1-5.2.1.2: Subject Demographics – By Region – Efficacy Analysis Set  
Table 14.1-5.2.1.3: Subject Demographics – By Region – Per-protocol Analysis Set  
 
Use mock-up 14.1-2.2.1 for tables: 
 
Table 14.1-5.2.2.1: Summary of Subject Baseline Characteristics – By Region - Safety Analysis Set 
Table 14.1-5.2.2.2: Subject Baseline Characteristics – By Region – Efficacy Analysis Set  
Table 14.1-5.2.2.3: Subject Baseline Characteristics – By Region – Per-protocol Analysis Set  
 
Use mock-up 14.1-3.1 for tables: 
 
Table 14.1-5.3.1: Summary of Surgery Characteristics – By Region - Safety Analysis Set 
Table 14.1-5.3.2: Summary of Surgery Characteristics – By Region – Efficacy Analysis Set  
Table 14.1-5.3.3: Summary of Surgery Characteristics – By Region – Per-protocol Analysis Set  
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
62 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Table 14.2-1.1.1: Analysis of AUC of VAS Pain Intensity Scores through 72 hours – Efficacy Analysis Set - 
Multiple Imputation Results 
 
 
EXPAREL 
 
Statistic 
133 mg  
[N=XX] 
266 mg 
[N=XX] 
Placebo  
[N=XX] 
 
 
 
 
N 
 
xx 
 
xx 
 
xx 
Mean 
 
xxx.x 
 
xxx.x 
 
xxx.x 
SD 
 
xxx.xx 
 
xxx.xx 
 
xxx.xx 
Median 
 
xxx.x 
 
xxx.x 
 
xxx.x 
Minimum 
 
xx 
 
xx 
 
xx 
Maximum 
 
xxx 
 
xxx 
 
xxx 
 
 
 
 
LS Mean [1]  
 
xxx.x 
 
xxx.x 
 
xxx.x 
Standard Error of LS Mean [1] 
 
xxx.xx 
 
xxx.xx 
 
xxx.xx 
LS Treatment Difference [1][2] 
 
xx.x 
 
xx.x 
 
Treatment Difference 95% Confidence Interval [1][2] 
(xx.x, xx.x) 
(xx.x, xx.x) 
 
Treatment Difference p-value [1][2] 
 
0.xxx 
 
0.xxx 
 
 
 
 
 
 
AUC = area under the curve calculated using the trapezoidal method; 
LS = least squares; 
VAS = 10 cm visual analog scale for pain, where 0 = no pain and 10 = worst possible pain; 
[1] From an ANOVA with age, weight, and height as covariates.   
[2] Treatment difference is EXPAREL – placebo. 
 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
Note to programmer: The raw SAS outputs from the procedures used to produce ALL 14.2-1.1.* & 14.2-1.2 
series tables should be saved as a possible appendix to the clinical study report (CSR).   
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
63 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Table 14.2-1.1.2: Summary of AUC of VAS Pain Intensity Scores through 72 hours by Site – Efficacy Analysis 
Set - Multiple Imputation Results 
 
 
 
EXPAREL 
 
Site 
Statistic 
133 mg  
[N=XX] 
266 mg 
[N=XX] 
Placebo  
[N=XX] 
 
 
 
 
 
XXX 
N 
 
xx 
 
xx 
 
xx 
 
Mean 
 
xxx.x 
 
xxx.x 
 
xxx.x 
 
SD 
 
xxx.xx 
 
xxx.xx 
 
xxx.xx 
 
Median 
 
xxx.x 
 
xxx.x 
 
xxx.x 
 
Minimum 
 
xx 
 
xx 
 
xx 
 
Maximum 
 
xxx 
 
xxx 
 
xxx 
 
 
 
 
 
YYY 
N 
 
xx 
 
xx 
 
xx 
 
Mean 
 
xxx.x 
 
xxx.x 
 
xxx.x 
 
SD 
 
xxx.xx 
 
xxx.xx 
 
xxx.xx 
 
Median 
 
xxx.x 
 
xxx.x 
 
xxx.x 
 
Minimum 
 
xx 
 
xx 
 
xx 
 
Maximum 
 
xxx 
 
xxx 
 
xxx 
 
 
 
 
 
ZZZ 
N 
 
xx 
 
xx 
 
xx 
 
Mean 
 
xxx.x 
 
xxx.x 
 
xxx.x 
 
SD 
 
xxx.xx 
 
xxx.xx 
 
xxx.xx 
 
Median 
 
xxx.x 
 
xxx.x 
 
xxx.x 
 
Minimum 
 
xx 
 
xx 
 
xx 
 
Maximum 
 
xxx 
 
xxx 
 
xxx 
 
 
 
 
 
AUC = area under the curve calculated using the trapezoidal method; 
LS = least squares; 
VAS = 10 cm visual analog scale for pain, where 0 = no pain and 10 = worst possible pain; 
 
 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
64 of 173 
20Jun2017 
 
 
 
Note to programmer: The raw SAS outputs from the procedures used to produce ALL 14.2-1.1.* series tables 
should be saved as a possible appendix to the clinical study report (CSR).  
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
65 of 173 
20Jun2017 
 
Mock-up 14.2-1.1.1:  
Table 14.2-1.2.1: Analysis of AUC of VAS Pain Intensity Scores through 72 hours – Per-protocol Analysis Set 
- Multiple Imputation Results  
 
Mock-up 14.2-1.1.2:  
Table 14.2-1.2.2: Summary of AUC of VAS Pain Intensity Scores through 72 hours by Site – Per-protocol 
Analysis Set - Multiple Imputation Results 
 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
66 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Table 14.2-2.1.1: Analysis of Postsurgical Total Opioid Consumption (MED mg) through 72 hours – Efficacy 
Analysis Set  
Statistic 
EXPAREL 133 mg  
[N=XX] 
EXPAREL 266 mg 
[N=XX] 
Placebo  
[N=XX] 
 
 
 
 
N 
 
xx 
 
xx 
 
xx 
Geometric Mean 
 
xxx.x 
 
xxx.x 
 
xxx.x 
%CV 
 
xxx.xx 
 
xxx.xx 
 
xxx.xx 
Minimum 
 
xx 
 
xx 
 
xx 
Maximum 
 
xxx 
 
xxx 
 
xxx 
 
 
 
 
LS Mean [1]  
 
xxx.x 
 
xxx.x 
 
xxx.x 
 Standard Error of LS Mean [1] 
 
xxx.xx 
 
xxx.xx 
 
xxx.xx 
LS Treatment Ratio [1][2] 
 
xx.x 
 
xx.x 
 
Treatment Ratio 95% Confidence Interval [1][2] 
(xx.x, xx.x) 
(xx.x, xx.x) 
 
Treatment Ratio p-value [1][2] 
 
0.xxx 
 
0.xxx 
 
 
 
 
 
 
[1] From an ANOVA with  age, weight, and height as covariates on log-transformed total opioid consumption.   
    Subjects without any opioid use are set to 0.1 or half of the smallest total amount observed in the 
study, whichever is smaller, prior to being transformed with the natural logarithm. Results are back-
transformed.   
[2] Treatment ratio is EXPAREL / placebo. 
 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
67 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Table 14.2-2.1.2: Summary of Total Opioid Consumption (MED mg) through 72 hours by Site - Efficacy Analysis 
Set 
 
 
Site  
Statistic 
EXPAREL 133 mg 
[N=XX] 
EXPAREL 266 mg 
[N=XX] 
Placebo  
[N=XX] 
 
 
 
 
 
XXX 
n 
xx 
xx 
xx 
 
Geometric Mean 
xx.x 
xx.x 
xx.x 
 
%CV 
x.xx 
x.xx 
x.xx 
 
Minimum 
xx 
xx 
xx 
 
Maximum 
xx 
xx 
xx 
 
 
 
 
 
YYY 
n 
xx 
xx 
xx 
 
Geometric Mean 
xx.x 
xx.x 
xx.x 
 
%CV 
x.xx 
x.xx 
x.xx 
 
Minimum 
xx 
xx 
xx 
 
Maximum 
xx 
xx 
xx 
 
 
 
 
 
ZZZ 
n 
xx 
xx 
xx 
 
Geometric Mean 
xx.x 
xx.x 
xx.x 
 
%CV 
x.xx 
x.xx 
x.xx 
 
Minimum 
xx 
xx 
xx 
 
Maximum 
xx 
xx 
xx 
 
 
 
 
 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
Note to programmer: Present for each site.  For pooled sites, present the pooled site first and then each 
site contributing to the pool immediately after.  Do not split a site’s statistics across pages. 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
68 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Table 14.2-2.1.3: Analysis of Total Opioid Consumption (MED mg) by Time Period - Efficacy Analysis Set 
 
 
Statistic 
EXPAREL 133 mg 
[N=XX] 
EXPAREL 266 mg 
[N=XX] 
Placebo 
[N=XX] 
 
 
 
 
 
0-24 hrs 
N 
xx 
xx 
xx 
 
Geometric Mean 
xxx.x 
xxx.x 
xxx.x 
 
%CV 
xxx.xx 
xxx.xx 
xxx.xx 
 
Minimum 
xx 
xx 
xx 
 
Maximum 
xxx 
xxx 
xxx 
 
 
 
 
 
 
LS Mean [1]  
xxx.x 
xxx.x 
xxx.x 
 
 Standard Error of LS Mean [1] 
xxx.xx 
xxx.xx 
xxx.xx 
 
LS Treatment Ratio [1][2] 
xx.x 
xx.x 
 
 
Treatment Ratio 95% Confidence 
Interval [1][2] 
(xx.x, xx.x) 
(xx.x, xx.x) 
 
 
Treatment Ratio p-value [1][2] 
0.xxx 
0.xxx 
 
 
     
 
 
 
 
0-48 hrs 
N 
xx 
xx 
xx 
 
Geometric Mean 
xxx.x 
xxx.x 
xxx.x 
 
%CV 
xxx.xx 
xxx.xx 
xxx.xx 
 
Minimum 
xx 
xx 
xx 
 
Maximum 
xxx 
xxx 
xxx 
 
 
 
 
 
 
LS Mean [1]  
xxx.x 
xxx.x 
xxx.x 
     
 Standard Error of LS Mean [1] 
xxx.xx 
xxx.xx 
xxx.xx 
 
LS Treatment Ratio [1][2] 
xx.x 
xx.x 
 
 
Treatment Ratio 95% Confidence 
Interval [1][2] 
(xx.x, xx.x) 
(xx.x, xx.x) 
 
 
Treatment Ratio p-value [1][2] 
xxx.x 
xxx.x 
xxx.x 
[1] From an ANOVA with  age, weight, and height as covariates on log-transformed total opioid consumption.   
    Subjects without any opioid use are set to 0.1 or half of the smallest total amount observed in the 
study, whichever is smaller, prior to being transformed with the natural logarithm. Results are back-
transformed.   
[2] Treatment ratio is EXPAREL / placebo. 
 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
69 of 173 
20Jun2017 
 
Note to programmer: Time periods to appear on this table, in order, are 0-24, 0-48, 0-96, 24-48, 48-72 and 
72-96.  Do not split a time period statistics across pages. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
70 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Table 14.2-2.1.4: Summary of the Number of Times Opioid (Rescue) Medication was used by Subject - Efficacy 
Analysis Set 
 
 
Statistic 
EXPAREL 133 mg 
[N=XX] 
EXPAREL 266 mg 
[N=XX] 
Placebo  
[N=XX] 
 
 
 
 
 
Count Summary 
n 
xx 
xx 
xx 
 
Mean 
xx.x 
xx.x 
xx.x 
 
SD 
x.xx 
x.xx 
x.xx 
 
Minimum 
xx.x 
xx.x 
xx.x 
 
Median 
xx 
xx 
xx 
 
Maximum 
xx 
xx 
xx 
 
 
 
 
 
Count Distribution 
 
 
 
 
  0  
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  1 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  2 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  3 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  4 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  5 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  … 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  U 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
Note to programmer: Present overall sites and for each site. Distribution should present all counts up to 
the highest number of visits in the data (U) on each page. 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
71 of 173 
20Jun2017 
 
Note to programmer:  Use the mock-ups indicated to for following tables: 
Mock-up 14.2.1.1: 
Table 14.2-2.2.1: Analysis of Postsurgical Total Opioid Consumption (MED mg) through 72 hours – 
Per-protocol Analysis Set  
Mock-up 14.2.1.2: 
Table 14.2-2.2.2: Summary of Total Opioid Consumption (MED mg) through 72 hours by Site - Per-protocol 
Analysis Set  
Mock-up 14.2.1.3: 
Table 14.2-2.2.3: Analysis of Total Opioid Consumption (MED mg) by Time Period - Per-protocol Analysis Set 
Set  
Mock-up 14.2.1.4: 
Table 14.2-2.2.4: Summary of the Number of Times Opioid (Rescue) Medication was used by Subject - 
Per-protocol Analysis Set 
 
 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
72 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Table 14.2-3.1.1: Analysis of Opioid-Free Subjects through 72 hours - Efficacy Analysis Set 
 
 
 
EXPAREL 
 
Statistic 
133 mg  
[N=XX] 
266 mg 
[N=XX] 
Placebo  
[N=XX] 
 
 
 
 
 
No Opioid Use 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
Opioid Used 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
 
Treatment Difference [1] 
xx.x 
xx.x 
 
 
95% CI for Difference [1] 
(xx.x, xx.x) 
(xx.x, xx.x) 
 
 
p-value [2] 
0.xxxx 
0.xxxx 
 
 
 
 
 
 
[1] Treatment difference (EXPAREL – placebo) and confidence intervals (CI) are based on the normal 
approximation to the binomial distribution using SAS PROC FREQ with RISKDIFFC option. 
[2] From Cochran-Mantel-Haenszel (CMH) test. 
 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
73 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Table 14.2-3.1.2: Summary of Opioid-Free Subjects through 72 hours by Site - Efficacy Analysis Set 
 
Site 
  Opioid Use 
 
EXPAREL 
 
Statistic 
133 mg  
[N=XX] 
266 mg 
[N=XX] 
Placebo  
[N=XX] 
 
 
 
 
 
XXX 
 
 
 
 
  No Opioid Use 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  Opioid Used 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
YYY 
 
 
 
 
  No Opioid Use 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  Opioid Used 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
Etc. 
 
 
 
 
  No Opioid Use 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  Opioid Used 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
Note to programmer: Present for each site.  For pooled sites, present the pooled site first and then each 
site contributing to the pool immediately after.  Do not split a site’s statistics across pages. 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
74 of 173 
20Jun2017 
 
Note to programmer:  Use the mock-ups indicated to for following tables: 
Mock-up 14.2-3.1.1: 
Table 14.2-3.2.1: Analysis of Opioid-Free Subjects through 72 hours - Per-protocol Analysis Set  
Mock-up 14.2-3.1.2: 
Table 14.2-3.2.2: Summary of Opioid-Free Subjects through 72 hours by Site - Per-protocol Analysis Set 
 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
75 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Table 14.2-4.1: Analysis of Time to First Rescue Medication Use (hours) - Efficacy Analysis Set 
 
 
Statistic 
EXPAREL 133 mg 
[N=XX] 
EXPAREL 266 mg 
[N=XX] 
Placebo 
[N=XX] 
 
 
 
 
 
Number of Subjects on 
 
 
 
 
  Rescue Medication (Opioid) 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  No Rescue Medication (censored) 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
Time to Rescue 
 
 
 
 
  Quartiles [1] 
 
 
 
 
    First (25% rescued) 
Estimate  
xx.xx 
xx.xx 
xx.xx 
 
(95% CI) 
(xx.xx,xx.xx) 
(xx.xx,xx.xx) 
(xx.xx,xx.xx) 
 
 
 
 
 
    Median (50% rescued) 
Estimate 
xx.xx 
xx.xx 
xx.xx 
 
(95% CI) 
(xx.xx,xx.xx) 
(xx.xx,xx.xx) 
(xx.xx,xx.xx) 
 
 
 
 
 
    Third (75% rescued) 
Estimate 
xx.xx 
xx.xx 
xx.xx 
 
(95% CI) 
(xx.xx,xx.xx) 
(xx.xx,xx.xx) 
(xx.xx,xx.xx) 
 
 
 
 
 
  Minimum 
Observed 
xx.xx 
xx.xx 
xx.xx 
  Maximum 
Observed 
xx.xx* 
xx.xx* 
xx.xx 
 
 
 
 
 
  p-value [2] 
 
0.xxxx 
0.xxxx 
 
 
 
 
 
 
* indicates censored observation 
 
CI = confidence interval 
[1] Estimates from Kaplan-Meier analysis.  
[2] p-value from Log-rank test comparing EXPAREL to placebo. 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
Note to programmer:  Use this mock-ups indicated to for following table: 
Table 14.2-4.2: Analysis of Time to First Rescue Medication Use (hours) – Per-protocol Analysis Set 
 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
76 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Table 14.2-5.1: Summary of VAS AUC at Various Time Intervals - Efficacy Analysis Set 
 
Parameter Statistic 
EXPAREL 133 
mg 
[N=XX] 
EXPAREL 266 
mg 
[N=XX] 
Placebo  
[N=XX] 
 
 
 
 
 
AUC(0-24) n 
xx 
xx 
xx 
 
Mean 
xx.x 
xx.x 
xx.x 
 
SD 
x.xx 
x.xx 
x.xx 
 
Minimum 
xx 
xx 
xx 
 
Median 
xx.x 
xx.x 
xx.x 
 
Maximum 
xx 
xx 
xx 
 
 
 
 
 
 
LS Mean [1]  
xxx.x 
xxx.x 
xxx.x 
 
Standard Error of LS Mean [1] 
xxx.xx 
xxx.xx 
xxx.xx 
 
LS Treatment Difference [1][2] 
xx.x 
xx.x 
 
 
Treatment Difference 95% Confidence Interval [1][2] 
(xx.x, xx.x) 
(xx.x, xx.x) 
 
 
Treatment Difference p-value [1][2] 
0.xxx 
0.xxx 
 
 
 
 
 
 
 
Etc. 
n 
xx 
xx 
xx 
 
Mean 
xx.x 
xx.x 
xx.x 
 
SD 
x.xx 
x.xx 
x.xx 
 
Minimum 
xx 
xx 
xx 
 
Median 
xx.x 
xx.x 
xx.x 
 
Maximum 
xx 
xx 
xx 
 
 
 
 
 
 
LS Mean [1]  
xxx.x 
xxx.x 
xxx.x 
 
Standard Error of LS Mean [1] 
xxx.xx 
xxx.xx 
xxx.xx 
 
LS Treatment Difference [1][2] 
xx.x 
xx.x 
 
 
Treatment Difference 95% Confidence Interval [1][2] 
(xx.x, xx.x) 
(xx.x, xx.x) 
 
 
Treatment Difference p-value [1][2] 
0.xxx 
0.xxx 
 
 
 
 
 
 
 
AUC = area under the curve calculated using the trapezoidal method; 
LS = least squares; 
VAS = 10 cm visual analog scale for pain, where 0 = no pain and 10 = worst possible pain; 
[1] From an ANOVA with  age, weight, and height as covariates.   
[2] Treatment difference is EXPAREL – placebo. 
 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
77 of 173 
20Jun2017 
 
Note to programmer: VAS AUCs to be presented on this table are, in order, AUC(0-12), AUC(0-24), AUC(0-48), 
AUC(0-96), AUC(24-48), AUC(48-72) and AUC(72-96). Do not break an AUC’s statistics across pages.  
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
78 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Table 14.2-5.2: Summary of VAS at Assessment Timepoints - Efficacy Analysis Set 
 
 
Timepoint 
Statistic 
EXPAREL 133 mg 
[N=XX] 
EXPAREL 266 mg 
[N=XX] 
Placebo  
[N=XX] 
 
 
 
 
 
Baseline 
n 
xx 
xx 
xx 
 
Mean 
xx.x 
xx.x 
xx.x 
 
SD 
x.xx 
x.xx 
x.xx 
 
Minimum 
xx 
xx 
xx 
 
Median 
xx.x 
xx.x 
xx.x 
 
Maximum 
xx 
xx 
xx 
 
 
 
 
 
PACU 
n 
xx 
xx 
xx 
 
Mean 
xx.x 
xx.x 
xx.x 
 
SD 
x.xx 
x.xx 
x.xx 
 
Minimum 
xx 
xx 
xx 
 
Median 
xx.x 
xx.x 
xx.x 
 
Maximum 
xx 
xx 
xx 
 
 
 
 
 
Etc. 
n 
xx 
xx 
xx 
     
Mean 
xx.x 
xx.x 
xx.x 
 
SD 
x.xx 
x.xx 
x.xx 
 
Minimum 
xx 
xx 
xx 
 
Median 
xx.x 
xx.x 
xx.x 
 
Maximum 
xx 
xx 
xx 
 
 
 
 
 
PACU is Post Anesthesia Care Unit 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
Note to programmer: Timepoints to appear on this table are, in order, Baseline, PACU and 6, 12, 24, 36, 48, 
60, 72, 84, 96, 108 and 120 hours.   
 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
79 of 173 
20Jun2017 
 
Note to programmer: Use the indicated mock-up for the following tables:  
 
Use mock-up 14.2-5.1: 
 
Table 14.2-5.3: Summary of VAS SPIS at Various Time Intervals - Efficacy Analysis Set  
 
Note to programmer: Remove “AUC = area under the curve calculated using the trapezoidal method;” footnote.  
VAS SPIS to be presented on Table 14.2-5.3 are, in order, SPIS(0-12), SPIS(0-24), SPIS(0-48), SPIS(0-96), 
SPIS(24-48), SPIS(48-72) and SPIS(72-96). Do not break an SPIS’s statistics across pages.  
 
  
 
 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
80 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Table 14.2-6: Analysis of Pain-Free Subjects at Assessment Timepoints - Efficacy Analysis Set 
 
Timepoint 
  Opioid Use 
 
EXPAREL 
 
Statistic 
133 mg  
[N=XX] 
266 mg 
[N=XX] 
Placebo  
[N=XX] 
Baseline 
 
 
 
 
  Pain-Free 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  Pained 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
 
Treatment Difference [1] 
xx.x 
xx.x 
 
 
95% CI for Difference [1] 
(xx.x, xx.x) 
(xx.x, xx.x) 
 
 
p-value [2] 
0.xxxx 
0.xxxx 
 
 
 
 
 
 
Etc. 
 
 
 
 
  Pain-Free 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  Pained 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
 
Treatment Difference [1] 
xx.x 
xx.x 
 
 
95% CI for Difference [1] 
(xx.x, xx.x) 
(xx.x, xx.x) 
 
 
p-value [2] 
0.xxxx 
0.xxxx 
 
 
 
 
 
 
[1] Pain-Free Treatment difference (EXPAREL – placebo) and confidence intervals (CI) are based on the 
normal approximation to the binomial distribution using SAS PROC FREQ with RISKDIFFC option. 
[2] From Cochran-Mantel-Haenszel (CMH) test. 
Pain-free = VAS score ≤ 1.5 and no prior rescue medication use and all prior VAS scores ≤ 1.5. 
 
 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
Note to programmer: Timepoints to appear on this table are, in order, Baseline, PACU and 6, 12, 24, 36, 48, 
60, 72, 84, 96, 108, and 120 hours.  Do not split a timepoint across pages.   
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
81 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Table 14.2-7: Analysis of Opioid-Free Subjects through 24, 48, and 96 hours - Efficacy Analysis Set 
 
Timepoint 
  Opioid Use 
 
EXPAREL 
 
Statistic 
133 mg  
[N=XX] 
266 mg 
[N=XX] 
Placebo  
[N=XX] 
0-24 
 
 
 
 
  Yes 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  No 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
 
Treatment Difference [1] 
xx.x 
xx.x 
 
 
95% CI for Difference [1] 
(xx.x, xx.x) 
(xx.x, xx.x) 
 
 
p-value [2] 
0.xxxx 
0.xxxx 
 
 
 
 
 
 
0-48 
 
 
 
 
  Yes 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  No 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
 
Treatment Difference [1] 
xx.x 
xx.x 
 
 
95% CI for Difference [1] 
(xx.x, xx.x) 
(xx.x, xx.x) 
 
 
p-value [2] 
0.xxxx 
0.xxxx 
 
 
 
 
 
 
[1] Opioid-Free Treatment difference (EXPAREL – placebo) and confidence intervals (CI) are based on the 
normal approximation to the binomial distribution using SAS PROC FREQ with RISKDIFFC option. 
[2] From Cochran-Mantel-Haenszel (CMH) test. 
 
 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
Note to programmer: Timepoints to appear on this table are, in order, 0-24, 0-48, 0-96 hours.  Do not split 
a timepoint across pages.   


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
82 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Table 14.2-8: Summary of Overall Benefit of Analgesia Scale by Timepoint and Question - Efficacy Analysis 
Set  
 
Timepoint 
  Question 
 
Statistic 
EXPAREL 133 mg 
[N=XX] 
EXPAREL 266 mg 
[N=XX] 
Placebo 
[N=XX] 
 
 
 
 
 
 
24 hours 
 
 
 
 
 
  Total Score 
Summary  
n 
xx 
xx 
xx 
 
 
Mean 
xx.x 
xx.x 
xx.x 
 
 
SD 
x.xx 
x.xx 
x.xx 
 
 
Minimum 
xx 
xx 
xx 
 
 
Median 
xx.x 
xx.x 
xx.x 
 
 
Maximum 
xx 
xx 
xx 
 
 
p-value[1] 
0.xxx 
0.xxx 
 
 
Score 
 
 
 
 
 
0 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
1 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
2 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
… 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
… 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
 
  1. Current Pain 
Summary  
n 
xx 
xx 
xx 
 
 
Mean 
xx.x 
xx.x 
xx.x 
 
 
SD 
x.xx 
x.xx 
x.xx 
 
 
Minimum 
xx 
xx 
xx 
 
 
Median 
xx.x 
xx.x 
xx.x 
 
 
Maximum 
xx 
xx 
xx 
 
Score 
 
 
 
 
 
0 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
1 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
2 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
3 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
4 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
 
Total score = sum of scores from questions 1 to 6 plus 4 minus question 7 score. 
[1] p-value from Kruskal-Wallis test. 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
Note to programmer: Timepoints to appear on this table, in order, are 24 and 72 hours and Day 10.  
Questions to appear on this table, in order, are ‘Total Score’, ‘1. Current Pain’, ‘2. Vomiting’, ‘3. 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
83 of 173 
20Jun2017 
 
Itching’, ‘4. Sweating’, ‘5. Freezing’, ‘6. Dizziness’, and ‘7. Satisfaction’.  Do not split a question’s 
statistics across pages. P-Values should only be generated for ‘Total score’. 
Note to programmer: Use the indicated mock-up for the following tables: 
 
  
 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
84 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Table 14.2-9: Summary of Satisfaction with Postsurgical Pain Control Questionnaire Score by Timepoint - 
Efficacy Analysis Set  
 
Timepoint Score 
Statistic 
EXPAREL 133 
mg 
[N=XX] 
EXPAREL 266 
mg 
[N=XX] 
Placebo 
[N=XX] 
 
 
 
 
 
 
24 hours 
Summary  
n 
xx 
xx 
xx 
 
 
Mean 
xx.x 
xx.x 
xx.x 
 
 
SD 
x.xx 
x.xx 
x.xx 
 
 
Minimum 
xx 
xx 
xx 
 
 
Median 
xx.x 
xx.x 
xx.x 
 
 
Maximum 
xx 
xx 
xx 
 
 
p-value[1] 
0.xxx 
0.xxx 
 
 
Score 
 
 
 
 
 
1: Extremely dissatisfied 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
2: Dissatisfied 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
3: Neither satisfied nor dissatisfied n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
4: Satisfied 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
5: Extremely Satisfied 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
 
 [1] p-value from Kruskal-Wallis test. 
 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
Note to programmer: Timepoints to appear on this table are 24 and 72 hours and Day 10.  Do not split 
timepoint across pages.  
 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
85 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Table 14.2-10.1: Summary of Time to Discharge Ready - Efficacy Analysis Set 
 
Assessment Time 
  Discharge Ready 
Statistic 
EXPAREL 133 mg 
[N=XX] 
EXPAREL 266 mg 
[N=XX] 
Placebo 
[N=XX] 
 
 
 
 
 
12 hours 
 
 
 
 
  No 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
  Yes 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
Time to Discharge Ready 
 
 
 
 
  Quartiles [1] 
 
 
 
 
    First (25% Discharge Ready) 
Estimate  
xx.xx 
xx.xx 
xx.xx 
 
(95% CI) 
(xx.xx,xx.xx) 
(xx.xx,xx.xx) 
(xx.xx,xx.xx) 
 
 
 
 
 
    Median (50% Discharge Ready) 
Estimate 
xx.xx 
xx.xx 
xx.xx 
 
(95% CI) 
(xx.xx,xx.xx) 
(xx.xx,xx.xx) 
(xx.xx,xx.xx) 
 
 
 
 
 
    Third (75% Discharge Ready) 
Estimate 
xx.xx 
xx.xx 
xx.xx 
 
(95% CI) 
(xx.xx,xx.xx) 
(xx.xx,xx.xx) 
(xx.xx,xx.xx) 
 
 
 
 
 
  Minimum 
Observed 
xx.xx 
xx.xx 
xx.xx 
  Maximum 
Observed 
xx.xx* 
xx.xx* 
xx.xx 
 
 
 
 
 
  p-value [2] 
 
0.xxxx 
0.xxxx 
 
 
 
 
 
 
* indicates censored observation 
 
CI = confidence interval 
[1] Estimates from Kaplan-Meier analysis.  
[2] p-value from Log-rank test comparing EXPAREL to placebo. 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
Note to programmer:  Assessments Time to be presented are 12, 24, 36, 48, 60, and 72 hours.  
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
86 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Table 14.2-10.2: Summary of Discharge Ready by Assessment - Efficacy Analysis Set 
 
Assessment Time 
  Discharge Ready 
 
EXPAREL 
 
Statistic 
133 mg  
[N=XX] 
266 mg 
[N=XX] 
Placebo  
[N=XX] 
 
 
 
 
 
12 hours 
 
 
 
 
    No  
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
    Yes 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
24 hours 
 
 
 
 
    No  
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
    Yes 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
36 hours 
 
 
 
 
    No  
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
    Yes 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
48 hours 
 
 
 
 
    No  
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
    Yes 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
60 hours 
 
 
 
 
    No  
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
    Yes 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
72 hours 
 
 
 
 
    No  
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
    Yes 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
96 hours 
 
 
 
 
    No  
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
    Yes 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
Note to programmer: Do not split timepoint across pages.  
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
87 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Table 14.2-11: Summary of Number of Unscheduled Phone Calls or Office Visits Related to Pain - Efficacy 
Analysis Set 
 
 
Statistic 
EXPAREL 133 mg 
[N=XX] 
EXPAREL 266 mg 
[N=XX] 
Placebo  
[N=XX] 
 
 
 
 
 
Count Summary 
n 
xx 
xx 
xx 
 
Mean 
xx.x 
xx.x 
xx.x 
 
SD 
x.xx 
x.xx 
x.xx 
 
Minimum 
xx.x 
xx.x 
xx.x 
 
Median 
xx 
xx 
xx 
 
Maximum 
xx 
xx 
xx 
 
p-value[1] 
0.xxx 
0.xxx 
 
 
 
 
 
 
Count Distribution 
 
 
 
 
  0  
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  1 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  2 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  3 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  4 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  5 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  … 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  U 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
[1] p-value from Kruskal-Wallis test. 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
Note to programmer: Distribution should present all counts up to the highest number of visits in the data 
(U).  
 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
88 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-331 
Table 14.2-12.1: Analysis of Distance Walked (meters) During Timed Walk Test – Efficacy Analysis Set 
 
Timepoint 
Statistic 
EXPAREL 133 mg 
[N=XX] 
EXPAREL 266 mg 
[N=XX] 
Placebo  
[N=XX] 
 
 
 
 
 
Overall 
LS Mean 
 
xxx.x 
 
xxx.x 
 
xxx.x 
 
Standard Error of LS Mean 
 
xxx.xx 
 
xxx.xx 
 
xxx.xx 
 
LS Treatment Difference  
 
xx.x 
 
xx.x 
 
 
Treatment Difference 95% Confidence 
Interval 
(xx.x, xx.x) 
(xx.x, xx.x) 
 
 
Treatment Difference p-value 
 
0.xxx 
 
0.xxx 
 
 
 
 
 
 
At Day 1-PM 
LS Mean 
 
xxx.x 
 
xxx.x 
 
xxx.x 
 
Standard Error of LS Mean 
 
xxx.xx 
 
xxx.xx 
 
xxx.xx 
 
LS Treatment Difference  
 
xx.x 
 
xx.x 
 
 
Treatment Difference 95% Confidence 
Interval 
(xx.x, xx.x) 
(xx.x, xx.x) 
 
 
Treatment Difference p-value 
 
0.xxx 
 
0.xxx 
 
 
 
 
 
 
At Day 2-AM 
LS Mean 
 
xxx.x 
 
xxx.x 
 
xxx.x 
 
Standard Error of LS Mean 
 
xxx.xx 
 
xxx.xx 
 
xxx.xx 
 
LS Treatment Difference  
 
xx.x 
 
xx.x 
 
 
Treatment Difference 95% Confidence 
Interval 
(xx.x, xx.x) 
(xx.x, xx.x) 
 
 
Treatment Difference p-value 
 
0.xxx 
 
0.xxx 
 
 
 
 
 
 
At Day 2-PM 
LS Mean 
 
xxx.x 
 
xxx.x 
 
xxx.x 
 
Standard Error of LS Mean 
 
xxx.xx 
 
xxx.xx 
 
xxx.xx 
 
LS Treatment Difference  
 
xx.x 
 
xx.x 
 
 
Treatment Difference 95% Confidence 
Interval 
(xx.x, xx.x) 
(xx.x, xx.x) 
 
 
Treatment Difference p-value 
 
0.xxx 
 
0.xxx 
 
 
 
 
 
 
 [1] MMRM with fixed effect of treatment and a random effect of subject within treatment with XXXX 
covariance structure.   
 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
89 of 173 
20Jun2017 
 
Note to programmer:  Timepoints for this table are Day 1-PM, Day 2-AM, Day 2-PM, Day 3-AM, Day 3-PM, Day 4-
AM, Day 4 – PM, and Day 10.  
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
90 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-331 
Table 14.2-12.2: Summary of Timed Walk Test by Timepoint – Efficacy Analysis Set 
 
Timepoint Parameter 
Statistic 
EXPAREL 133 mg 
[N=XX] 
EXPAREL 266 
mg 
[N=XX] 
Placebo  
[N=XX] 
 
 
 
 
 
 
Day 1-PM 
Not performed 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
Reasons not performed 
 
 
 
 
 
  Pain 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
  Weakness 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
  Nausea/Vomiting 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
  Other 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
 
 
Walking Aid 
 
 
 
 
 
  No 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
  Yes 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
 
 
Physical Assistance 
 
 
 
 
 
  Total Assistance 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
  Maximal Assistance 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
  Minimal Assistance 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
  Supervision 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
  Modified Independence 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
  Complete Independence 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
 
 
Distance (meters) 
N 
 
xx 
 
xx 
 
xx 
 
 
Mean 
 
xxx.x 
 
xxx.x 
 
xxx.x 
 
 
SD 
 
xxx.xx 
 
xxx.xx  
xxx.xx 
 
 
Median 
 
xxx.x 
 
xxx.x 
 
xxx.x 
 
 
Minimum 
 
xx 
 
xx 
 
xx 
 
 
Maximum 
 
xxx 
 
xxx 
 
xxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
91 of 173 
20Jun2017 
 
SAS X.Y 
 
program_name 
 
Note to programmer: Break out by site.  Timepoints for this table are Day 1-PM, Day 2-AM, Day 2-PM, Day 3-
AM, Day 3-PM, Day 4-AM, Day 4 – PM, and Day 10 with one timepoint per page. If a subject did not have an 
evaluation at a given timepoint then they should be counted under "Not performed".  
Note to programmer: Timepoints for this table are Day 1-PM, Day 2-AM, Day 2-PM, Day 3-AM, Day 3-PM, Day 4-
AM, and Day 14.  If a subject did not have an evaluation at a given timepoint then they should be counted 
under "Not performed". Use mock-up 14.2-12.1 for the following tables: 
 
Table 14.2-13: Analysis of Timed Up-and-Go Test (Seconds) – Efficacy Analysis Set 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
92 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-331 
Table 14.2-14: Analysis of Stair Climb Test – Efficacy Analysis Set 
 
Timepoint Completed Test? Statistic 
EXPAREL 266 mg 
[N=XX] 
EXPAREL 266 mg 
[N=XX] 
No EXPAREL 
[N=XX] 
 
 
 
 
 
 
Day 1-PM 
No 
n (%) 
XXX (XXX.X) 
XXX (XXX.X) 
XXX (XXX.X) 
 
Yes 
n (%) 
XXX (XXX.X) 
XXX (XXX.X) 
XXX (XXX.X) 
 
 
Odds Ratio EXAPAREL/Placebo   
XXX.X 
XXX.X 
 
 
 
Odds Ratio 95% Confidence Interval 
(XX.X, XX.X) 
(XX.X, XX.X) 
 
 
 
 
 
 
 
Day 2-AM 
No 
n (%) 
XXX (XXX.X) 
XXX (XXX.X) 
XXX (XXX.X) 
   
Yes 
n (%) 
XXX (XXX.X) 
XXX (XXX.X) 
XXX (XXX.X) 
 
 
Odds Ratio EXAPAREL/Placebo   
XXX.X 
XXX.X 
 
 
 
Odds Ratio 95% Confidence Interval 
(XX.X, XX.X) 
(XX.X, XX.X) 
 
 
 
 
 
 
 
Day 2-PM 
No 
n (%) 
XXX (XXX.X) 
XXX (XXX.X) 
XXX (XXX.X) 
 
Yes 
n (%) 
XXX (XXX.X) 
XXX (XXX.X) 
XXX (XXX.X) 
 
 
Odds Ratio EXAPAREL/Placebo   
XXX.X 
XXX.X 
 
 
 
Odds Ratio 95% Confidence Interval 
(XX.X, XX.X) 
(XX.X, XX.X) 
 
 
 
 
 
 
 
Day 3-AM 
No 
n (%) 
XXX (XXX.X) 
XXX (XXX.X) 
XXX (XXX.X) 
 
Yes 
n (%) 
XXX (XXX.X) 
XXX (XXX.X) 
XXX (XXX.X) 
 
 
Odds Ratio EXAPAREL/Placebo   
XXX.X 
XXX.X 
 
 
 
Odds Ratio 95% Confidence Interval 
(XX.X, XX.X) 
(XX.X, XX.X) 
 
 
 
 
 
 
 
Day 3-PM 
No 
n (%) 
XXX (XXX.X) 
XXX (XXX.X) 
XXX (XXX.X) 
 
Yes 
n (%) 
XXX (XXX.X) 
XXX (XXX.X) 
XXX (XXX.X) 
 
 
Odds Ratio EXAPAREL/Placebo   
XXX.X 
XXX.X 
 
 
 
Odds Ratio 95% Confidence Interval 
(XX.X, XX.X) 
(XX.X, XX.X) 
 
Etc. 
 
 
 
 
 
 
 
 
 
 
 
Odds ratio from GEE with effect of treatment and subject within treatment as the repeated effect and logit 
linking function.  
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
Note to programmer: Break out by site.  Timepoints for this table are Day 1-PM, Day 2-AM, Day 2-PM, Day 3-
AM, Day 3-PM, Day 4-AM, Day 4 – PM, and Day 10.  If a subject did not have an evaluation at a given 
timepoint then they should be counted under "No".   
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
93 of 173 
20Jun2017 
 
Note to programmer:  For the following region summaries, ‘Site:’ will be replaced with ‘Region:’ in the 
statistical models, row labels, footnotes and by lines of summaries as appropriate.  When summarizing by 
region, the regions are, in order of appearance, US and ROW.  There will be no overall region summary 
presented on these tables. 
 
Use mock-up 14.2-1.1.1 for tables: 
 
Table 14.2-15.1.1.1: Region Analysis of AUC of VAS Pain Intensity Scores through 72 hours – Efficacy 
Analysis Set - Multiple Imputation Results 
 
Table 14.2-15.1.2.1: Region Analysis of AUC of VAS Pain Intensity Scores through 72 hours – Per-protocol 
Analysis Set - Multiple Imputation Results 
 
Use mock-up 14.2-2.1.1 for table: 
 
Table 14.2-15.2.1.1: Region Analysis of Postsurgical Total Opioid Consumption (MED mg) through 72 hours – 
Efficacy Analysis Set 
 
Use mock-up 14.2-2.1.2 for table: 
 
Table 14.2-15.2.1.2: Region Summary of Total Opioid Consumption (MED mg) through 72 hours by Region - 
Efficacy Analysis Set 
 
Use mock-up 14.2-2.1.3 for table: 
 
Table 14.2-15.2.1.3: Region Summary of Total Opioid Consumption (MED mg) by Time Period - Efficacy Analysis 
Set 
 
Use mock-up 14.2-2.1.4 for table: 
 
Table 14.2-15.2.1.4: Region Summary of the Number of Times Opioid (Rescue) Medication was used by Subject - 
Efficacy Analysis Set 
 
Use mock-up 14.2-2.1.1 for table: 
 
Table 14.2-15.2.2.1: Region Analysis of Postsurgical Total Opioid Consumption (MED mg) through 72 hours – 
Per-protocol Analysis Set 
 
Use mock-up 14.2-2.1.2 for table: 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
94 of 173 
20Jun2017 
 
Table 14.2-15.2.2.2: Region Summary of Total Opioid Consumption (MED mg) through 72 hours by Site - Per-
protocol Analysis Set 
 
Use mock-up 14.2-2.1.3 for table: 
 
Table 14.2-15.2.2.3: Region Summary of Total Opioid Consumption (MED mg) by Time Period - Per-protocol 
Analysis Set 
 
Use mock-up 14.2-2.1.4 for table: 
 
Table 14.2-15.2.2.4: Region Summary of the Number of Times Opioid (Rescue) Medication was used by Subject - 
Per-protocol Analysis Set 
 
Use mock-up 14.2-3.1.1 for table: 
 
Table 14.2-15.3.1.1: Region Analysis of Opioid-Free Subjects through 72 hours - Efficacy Analysis Set 
 
Use mock-up 14.2-3.1.2 for table: 
 
Table 14.2-15.3.1.2: Region Summary of Opioid-Free Subjects through 72 hours by Site - Efficacy Analysis 
Set 
 
Use mock-up 14.2-3.1.1 for table: 
 
Table 14.2-15.3.2.1: Region Analysis of Opioid-Free Subjects through 72 hours - Per-protocol Analysis Set 
 
Use mock-up 14.2-3.1.2 for table: 
 
Table 14.2-15.3.2.2: Region Summary of Opioid-Free Subjects through 72 hours by Site - Per-protocol 
Analysis Set 
 
 
 
 
 
 
 
 
 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
95 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Table 14.3-1.1.1: Summary of Clinical Laboratory Data by Timepoint – Hematology - Safety Analysis Set 
Laboratory parameter (units) 
EXPAREL 
 
 
Timepoint 
Value 
Statistic 
133 mg 
[N=XXX] 
266 mg 
[N=XXX] 
All 
EXPAREL 
[N=XXX] 
Placebo 
[N=XXX] 
Total 
[N=XXX] 
 
 
 
 
 
 
 
 
Baseline 
Actual 
n 
xx 
xx 
xx 
xx 
xx 
 
 
Mean 
xx.x 
xx.x 
xx.x 
xx.x 
xx.x 
 
 
SD 
x.xx 
x.xx 
x.xx 
x.xx 
x.xx 
 
 
Minimum 
xx 
xx 
xx 
xx 
xx 
 
 
Median 
xx.x 
xx.x 
xx.x 
xx.x 
xx.x 
 
 
Maximum 
xx 
xx 
xx 
xx 
xx 
 
 
 
 
 
 
 
 
Day 10 
Baseline [1] 
n 
xx 
xx 
xx 
xx 
xx 
 
 
Mean 
xx.x 
xx.x 
xx.x 
xx.x 
xx.x 
 
 
SD 
x.xx 
x.xx 
x.xx 
x.xx 
x.xx 
 
 
Minimum 
xx 
xx 
xx 
xx 
xx 
 
 
Median 
xx.x 
xx.x 
xx.x 
xx.x 
xx.x 
 
 
Maximum 
xx 
xx 
xx 
xx 
xx 
 
 
 
 
 
 
 
 
 
Actual 
n 
xx 
xx 
xx 
xx 
xx 
 
 
Mean 
xx.x 
xx.x 
xx.x 
xx.x 
xx.x 
 
 
SD 
x.xx 
x.xx 
x.xx 
x.xx 
x.xx 
 
 
Minimum 
xx 
xx 
xx 
xx 
xx 
 
 
Median 
xx.x 
xx.x 
xx.x 
xx.x 
xx.x 
 
 
Maximum 
xx 
xx 
xx 
xx 
xx 
 
 
 
 
 
 
 
 
 
Change  
n 
xx 
xx 
xx 
xx 
xx 
 
 
Mean 
xx.x 
xx.x 
xx.x 
xx.x 
xx.x 
 
 
SD 
x.xx 
x.xx 
x.xx 
x.xx 
x.xx 
 
 
Minimum 
xx 
xx 
xx 
xx 
xx 
 
 
Median 
xx.x 
xx.x 
xx.x 
xx.x 
xx.x 
 
 
Maximum 
xx 
xx 
xx 
xx 
xx 
 
 
 
 
 
 
 
 
[1] Baseline (prior to surgery) for subjects with data at the timepoint. 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
Note to programmer: Only present overall sites. Timepoints to appear on this table are, in order of 
appearance, Baseline (prior to surgery) and Day 10.  Do not split timepoint statistics across pages.  See 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
96 of 173 
20Jun2017 
 
protocol for list of lab analytes.  Analytes should be sorted in alphabetical order.  Use this mock-up for 
the following tables: 
 
Table 14.3-1.1.2: Summary of Clinical Laboratory Data by Timepoint – Chemistry - Safety Analysis Set 
Table 14.3-1.1.3.1: Summary of Clinical Laboratory Data by Timepoint – Urinalysis - Safety Analysis Set 
 
For urinalysis results only numeric results will appear on this table. 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
97 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Table 14.3-1.1.3.2: Tabulation of Clinical Laboratory Data by Timepoint – Urinalysis - Safety Analysis Set 
 
 
 
 
EXPAREL 
 
 
Analyte 
  Timepoint Category Statistic 
133 mg 
[N=XXX] 
266 mg 
[N=XXX] 
All EXPAREL 
[N=XXX] 
Placebo 
[N=XXX] 
Total 
[N=XXX] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Analyte 1 Baseline 
Cat 1 
n (%) 
xxx (xx.x%) xxx (xx.x%) xxx (xx.x%) 
xxx (xx.x%) xxx (xx.x%) 
 
 
Cat 2 
n (%) 
xxx (xx.x%) xxx (xx.x%) xxx (xx.x%) 
xxx (xx.x%) xxx (xx.x%) 
 
 
Etc. 
n (%) 
xxx (xx.x%) xxx (xx.x%) xxx (xx.x%) 
xxx (xx.x%) xxx (xx.x%) 
 
 
 
 
 
 
 
 
 
 
Day 10 
Cat 1 
n (%) 
xxx (xx.x%) xxx (xx.x%) xxx (xx.x%) 
xxx (xx.x%) xxx (xx.x%) 
 
 
Cat 2 
n (%) 
xxx (xx.x%) xxx (xx.x%) xxx (xx.x%) 
xxx (xx.x%) xxx (xx.x%) 
 
 
Etc. 
n (%) 
xxx (xx.x%) xxx (xx.x%) xxx (xx.x%) 
xxx (xx.x%) xxx (xx.x%) 
 
 
 
 
 
 
 
 
 
Analyte 2 Baseline 
Cat 1 
n (%) 
xxx (xx.x%) xxx (xx.x%) xxx (xx.x%) 
xxx (xx.x%) xxx (xx.x%) 
 
 
Cat 2 
n (%) 
xxx (xx.x%) xxx (xx.x%) xxx (xx.x%) 
xxx (xx.x%) xxx (xx.x%) 
 
 
Etc. 
n (%) 
xxx (xx.x%) xxx (xx.x%) xxx (xx.x%) 
xxx (xx.x%) xxx (xx.x%) 
 
 
 
 
 
 
 
 
 
 
Day 10 
Cat 1 
n (%) 
xxx (xx.x%) xxx (xx.x%) xxx (xx.x%) 
xxx (xx.x%) xxx (xx.x%) 
 
 
Cat 2 
n (%) 
xxx (xx.x%) xxx (xx.x%) xxx (xx.x%) 
xxx (xx.x%) xxx (xx.x%) 
 
 
Etc. 
n (%) 
xxx (xx.x%) xxx (xx.x%) xxx (xx.x%) 
xxx (xx.x%) xxx (xx.x%) 
Etc. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[1] Baseline (prior to surgery) for subjects with data at the timepoint. 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
Note to programmer: Only present overall sites. Timepoints to appear on this table are, in order of 
appearance, Baseline (prior to surgery) and Day 10.  Do not split timepoint statistics across pages, if 
possible.  Present all avaliable lab analytes. Categories are the superset of those reported in the data 
for both timepoints combined.  All categories should appear for both timepoints with zeros (0) as counts 
where needed. 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
98 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Table 14.3-1.2.1: Tabulation of Clinical Laboratory Range by Timepoint – Hematology - Safety Analysis Set 
Laboratory parameter (units) 
EXPAREL 
 
 
Timepoint 
Normal 
Range 
Statistic 
133 mg 
[N=XXX] 
266 mg 
[N=XXX] 
All EXPAREL 
[N=XXX] 
Placebo 
[N=XXX] 
Total 
[N=XXX] 
 
 
 
 
 
 
 
 
Baseline 
Below 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
Normal 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
Above 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
 
 
 
Day 10 
Below 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
Normal 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
Above 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
 
 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
Note to programmer: Only present overall sites. Timepoints to appear on this table are, in order of 
appearance, Baseline (prior to surgery)and Day 10.  Do not split timepoint statistics across pages.  
Present all avaliable analytes.  Analytes should be sorted in alphabetical order.  Use this mock-up for the 
following tables: 
 
Table 14.3-1.2.2: Tabulation of Clinical Laboratory Range by Timepoint – Chemistry - Safety Analysis Set 
Table 14.3-1.2.3: Tabulation of Clinical Laboratory Range by Timepoint – Urinalysis - Safety Analysis Set 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
99 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Table 14.3-1.3.1: Shift Table for Clinical Laboratory Data by Timepoint – Hematology - Safety Analysis Set 
 
 
Baseline 
 
Normal Range 
EXPAREL XXXXXXX [N=XXX] 
Placebo [N=XXX] 
Analyte 
Day 10 
Below 
Normal 
Above 
Below 
Normal 
Above 
 
 
 
 
 
 
 
 
Analyte 1 
Below 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
 
Normal 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
 
Above 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
 
 
 
 
 
 
 
 
Analyte 2 
Below 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
 
Normal 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
 
Above 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
 
 
 
 
 
 
 
 
Analyte 3 
Below 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
 
Normal 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
 
Above 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
 
 
 
 
 
 
 
 
ETC. 
Below 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
 
Normal 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
 
Above 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
 
 
 
 
 
 
 
 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
Note to programmer: Only present overall sites.  Do not split an analyte across pages.  EXPAREL 133 mg and 
EXPAREL 266 mg will appear on separate pages.  All analytes for an EXPAREL group (combined, 133 mg, 266 mg) 
should appear on consecutive pages before starting the next EXPAREL group. Analytes should be sorted in 
alphabetical order.  Use this mock-up for the following tables: 
 
Table 14.3-1.3.2: Shift Table for Clinical Laboratory Data by Timepoint – Chemistry - Safety Analysis Set 
Table 14.3-1.3.3: Shift Table for Clinical Laboratory Data by Timepoint – Urinalysis - Safety Analysis Set 
 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
100 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Table 14.3-2.1: Summary of Vital Signs by Timepoint – Safety Analysis Set 
Heart Rate (bpm) 
EXPAREL 
 
 
Timepoint 
Value 
Statistic 
133 mg 
[N=XXX] 
266 mg 
[N=XXX] 
All 
EXPAREL 
[N=XXX] 
Placebo 
[N=XXX] 
Total 
[N=XXX] 
 
 
 
 
 
 
 
 
Baseline 
Actual 
n 
xx 
xx 
xx 
xx 
xx 
 
 
Mean 
xx.x 
xx.x 
xx.x 
xx.x 
xx.x 
 
 
SD 
x.xx 
x.xx 
x.xx 
x.xx 
x.xx 
 
 
Minimum 
xx 
xx 
xx 
xx 
xx 
 
 
Median 
xx.x 
xx.x 
xx.x 
xx.x 
xx.x 
 
 
Maximum 
xx 
xx 
xx 
xx 
xx 
 
 
 
 
 
 
 
 
PACU 
Baseline [1] 
n 
xx 
xx 
xx 
xx 
xx 
 
 
Mean 
xx.x 
xx.x 
xx.x 
xx.x 
xx.x 
 
 
SD 
x.xx 
x.xx 
x.xx 
x.xx 
x.xx 
 
 
Minimum 
xx 
xx 
xx 
xx 
xx 
 
 
Median 
xx.x 
xx.x 
xx.x 
xx.x 
xx.x 
 
 
Maximum 
xx 
xx 
xx 
xx 
xx 
 
 
 
 
 
 
 
 
 
Actual 
n 
xx 
xx 
xx 
xx 
xx 
 
 
Mean 
xx.x 
xx.x 
xx.x 
xx.x 
xx.x 
 
 
SD 
x.xx 
x.xx 
x.xx 
x.xx 
x.xx 
 
 
Minimum 
xx 
xx 
xx 
xx 
xx 
 
 
Median 
xx.x 
xx.x 
xx.x 
xx.x 
xx.x 
 
 
Maximum 
xx 
xx 
xx 
xx 
xx 
 
 
 
 
 
 
 
 
 
Change  
n 
xx 
xx 
xx 
xx 
xx 
 
 
Mean 
xx.x 
xx.x 
xx.x 
xx.x 
xx.x 
 
 
SD 
x.xx 
x.xx 
x.xx 
x.xx 
x.xx 
 
 
Minimum 
xx 
xx 
xx 
xx 
xx 
 
 
Median 
xx.x 
xx.x 
xx.x 
xx.x 
xx.x 
 
 
Maximum 
xx 
xx 
xx 
xx 
xx 
 
 
 
 
 
 
 
 
[1] Baseline (prior to surgery) for subjects with data at the timepoint. 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
Note to programmer: Only present overall sites. Vital signs are ‘Resting Heart Rate (bpm)’, ‘Systolic Blood 
Pressure (mmHg)’ and ‘Diastolic Blood Pressure (mmHg)’. Timepoints to appear on this table are, in order of 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
101 of 173 
20Jun2017 
 
appearance, Baseline (prior to surgery), PACU and, 6, 12, 24, 36, 48, 60, 72, 84, 96, 108 and 120 hours and 
Days 7 and 10.  Do not split timepoint statistics across pages. 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
102 of 173 
20Jun2017 
 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Table 14.3-2.2: Summary of Potentially Clinically Significant Abnormal Vital Signs – Safety Analysis Set 
Heart Rate (bpm) 
EXPAREL 
 
 
Timepoint 
Criteria 
133 mg 
[N=XX] 
n (%) 
266 mg 
[N=XX] 
n (%) 
All EXPAREL 
[N=XX] 
n (%) 
Placebo 
[N=XX]  
n (%) 
Total 
[N=XXX]  
n (%) 
Baseline 
<= 50 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
 
Decrease >= 15 
NA 
NA 
NA 
NA 
NA 
 
<= 50 & Decrease >= 15 
NA 
NA 
NA 
NA 
NA 
 
 
 
 
 
 
 
 
>= 120 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
 
Increase >= 15 
NA 
NA 
NA 
NA 
NA 
 
>= 120 & Increase >= 15 
NA 
NA 
NA 
NA 
NA 
 
 
 
 
 
 
 
Any Time 
<= 50 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
After 
Decrease >= 15 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
Baseline 
<= 50 & Decrease >= 15 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
 
 
 
 
 
 
 
 
>= 120 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
 
Increase >= 15 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
 
>= 120 & Increase >= 15 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
 
 
 
 
 
 
 
Etc. 
<= 50 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
 
Decrease >= 15 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
 
<= 50 & Decrease >= 15 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
 
 
 
 
 
 
 
 
>= 120 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
 
Increase >= 15 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
 
>= 120 & Increase >= 15 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
 
 
 
 
 
 
 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
103 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Table 14.3-2.2: Summary of Potentially Clinically Significant Abnormal Vital Signs – Safety Analysis Set 
Systolic Blood Pressure (mmHg) 
EXPAREL 
 
 
Timepoint 
Criteria 
133 mg 
[N=XX] 
n (%) 
266 mg 
[N=XX] 
n (%) 
All EXPAREL 
[N=XX] 
n (%) 
Placebo 
[N=XX]  
n (%) 
Total 
[N=XXX]  
n (%) 
Baseline 
<= 90 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
 
Decrease >= 20 
NA 
NA 
NA 
NA 
NA 
 
<= 90 & Decrease >= 20 
NA 
NA 
NA 
NA 
NA 
 
 
 
 
 
 
 
 
>= 180 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
 
Increase >= 20 
NA 
NA 
NA 
NA 
NA 
 
>= 180 & Increase >= 20 
NA 
NA 
NA 
NA 
NA 
 
 
 
 
 
 
 
Any Time 
<= 90 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
After 
Decrease >= 20 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
Baseline 
<= 90 & Decrease >= 20 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
 
 
 
 
 
 
 
 
>= 180 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
 
Increase >= 20 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
 
>= 180 & Increase >= 20 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
 
 
 
 
 
 
 
Etc. 
<= 90 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
 
Decrease >= 20 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
 
<= 90 & Decrease >= 20 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
 
 
 
 
 
 
 
 
>= 180 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
 
Increase >= 20 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
 
>= 180 & Increase >= 20 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
 
 
 
 
 
 
 
 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
104 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Table 14.3-2.2: Summary of Potentially Clinically Significant Abnormal Vital Signs – Safety Analysis Set 
Diastolic Blood Pressure (mmHg) 
EXPAREL 
 
 
Timepoint 
Criteria 
133 mg 
[N=XX] 
n (%) 
266 mg 
[N=XX] 
n (%) 
All EXPAREL 
[N=XX] 
n (%) 
Placebo 
[N=XX]  
n (%) 
Total 
[N=XXX]  
n (%) 
Baseline 
<= 50 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
 
Decrease >= 15 
NA 
NA 
NA 
NA 
NA 
 
<= 50 & Decrease >= 15 
NA 
NA 
NA 
NA 
NA 
 
 
 
 
 
 
 
 
>= 105 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
 
Increase >= 15 
NA 
NA 
NA 
NA 
NA 
 
>= 105 & Increase >= 15 
NA 
NA 
NA 
NA 
NA 
 
 
 
 
 
 
 
Any Time 
<= 50 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
After 
Decrease >= 15 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
Baseline 
<= 50 & Decrease >= 15 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
 
 
 
 
 
 
 
 
>= 105 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
 
Increase >= 15 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
 
>= 105 & Increase >= 15 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
 
 
 
 
 
 
 
Etc. 
<= 50 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
 
Decrease >= 15 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
 
<= 50 & Decrease >= 15 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
 
 
 
 
 
 
 
 
>= 105 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
 
Increase >= 15 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
 
>= 105 & Increase >= 15 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
 
 
 
 
 
 
 
 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
Note to programmer: Only present overall sites. Timepoints to appear on this table are, in order of 
appearance, Baseline (prior to surgery), Any Time After Baseline, PACU and, 6, 12, 24, 36, 48, 60, 72, 84, 
96, 108 and 120 hours and Days 7 and 10.  Do not split timepoint statistics across pages. 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
105 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Table 14.3-3.1: Summary of Electrocardiogram Interpretation – Investigator Read - Safety Analysis Set 
 
 
EXPAREL 
 
 
 
Time Point 
Interpretation 
133 mg 
[N=XX] 
n (%) 
266 mg 
[N=XX] 
n (%) 
All 
EXPAREL 
[N=XX] 
n (%) 
Placebo 
[N=XX]  
n (%) 
Total 
[N=XXX]  
n (%) 
 
 
 
 
 
 
Baseline (Prior to Surgery) 
Normal 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
 
Abnormal, NCS 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
 
Abnormal, CS 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
 
 
 
 
 
 
 
Any Time After Baseline 
Normal 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
 
Abnormal, NCS 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
 
Abnormal, CS 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
 
 
 
 
 
 
 
At Tmax* 
Normal 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
N/A 
N/A 
 
Abnormal, NCS 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
N/A 
N/A 
 
Abnormal, CS 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
N/A 
N/A 
 
 
 
 
 
 
 
Etc. 
Normal 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
 
Abnormal, NCS 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
 
Abnormal, CS 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
 
 
 
 
 
 
 
*QuantPharm LLC indicated that the results of the interim PK analysis showed a median Tmax of 60 hours for 
the 133 mg EXPAREL group and a median Tmax of 78 hours for the 266 mg EXPAREL group. The ‘at Tmax’ 
timepoint is the time nearest in absolute value to the population PK estimated median Tmax. 
NCS = not clinically significant 
 
CS = clinically significant 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
Note to programmer: Only present overall sites.  Timepoints to appear on this table are, in order of 
appearance, Baseline (prior to surgery), At any time after baseline, At Tmax, PACU and, 6, 12, 24, 36, 48, 
60, 72, 84, 96, 108 and 120 hours and Days 7 and 10.  Do not split a timepoint across pages.  For the 
timepoint ‘any time after baseline’ report the worst interpretation reported at any timepoint but baseline.  
The ‘at Tmax’ timepoint is the time nearest in absolute value to the population PK estimated median Tmax. 
 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
106 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Table 14.3-3.2: Shift Table for Electrocardiogram Interpretation – Investigator Read - Safety Analysis Set 
 
 
Baseline 
 
 
All EXPAREL [N=XXX] 
Placebo [N=XXX] 
 
 
 
Abnormal 
 
Abnormal 
Time Point 
Interpretation 
Normal 
NCS 
CS 
Normal 
NCS 
CS 
 
 
 
 
 
 
 
 
Any Time  
Normal 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
After 
NCS 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
Baseline 
CS 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
 
 
 
 
 
 
 
 
 
Normal 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
 
NCS 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
 
CS 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
 
 
 
 
 
 
 
 
At Tmax* 
Normal 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
N/A 
N/A 
N/A 
 
NCS 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
N/A 
N/A 
N/A 
 
CS 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
N/A 
N/A 
N/A 
 
 
 
 
 
 
 
 
Etc. 
Normal 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
 
NCS 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
 
CS 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
 
 
 
 
 
 
 
 
*QuantPharm LLC indicated that the results of the interim PK analysis showed a median Tmax of 60 hours for 
the 133 mg EXPAREL group and a median Tmax of 78 hours for the 266 mg EXPAREL group. The ‘at Tmax’ 
timepoint is the time nearest in absolute value to the population PK estimated median Tmax. 
NCS = not clinically significant 
 
CS = clinically significant 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
Note to programmer: Only present overall sites.  Timepoints to appear on this table are, in order of 
appearance, Baseline (prior to surgery), At any time after baseline, At Tmax, PACU and, 6, 12, 24, 36, 48, 
60, 72, 84, 96, 108 and 120 hours and Days 7 and 10.  Do not split a timepoint across pages.  For the 
timepoint ‘any time after baseline’ report the worst interpretation reported at any timepoint but baseline.  
The ‘at Tmax’ timepoint is the time nearest in absolute value to the population PK estimated median Tmax.  
EXPAREL 133 mg and EXPAREL 266 mg will appear on separate pages.  All timepoints for an EXPAREL group (All 
EXPAREL, 133 mg, 266 mg) should appear on consecutive pages before starting the next EXPAREL group. 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
107 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Table 14.3-4: Summary of Neurological Assessments by Timepoint- Safety Analysis Set  
 
 
 
EXPAREL 
 
 
Timepoint Assessment 
 
133 mg 
[N=XX] 
n (%) 
266 mg 
[N=XX] 
n (%) 
All EXPAREL 
[N=XX] 
n (%) 
Placebo 
[N=XX]  
n (%) 
Total 
[N=XXX]  
n (%) 
Baseline (Prior to Surgery) 
 
 
 
 
 
 
 
Subject Oriented 
No 
XX (XX.X) 
XX (XX.X) 
XX (XX.X) 
XX (XX.X) 
XX (XX.X) 
 
 
Yes 
XX (XX.X) 
XX (XX.X) 
XX (XX.X) 
XX (XX.X) 
XX (XX.X) 
 
 
 
 
 
 
 
 
 
Numb lips, tongue or mouth 
No 
XX (XX.X) 
XX (XX.X) 
XX (XX.X) 
XX (XX.X) 
XX (XX.X) 
 
 
Yes 
XX (XX.X) 
XX (XX.X) 
XX (XX.X) 
XX (XX.X) 
XX (XX.X) 
 
 
 
 
 
 
 
 
 
Metallic taste 
No 
XX (XX.X) 
XX (XX.X) 
XX (XX.X) 
XX (XX.X) 
XX (XX.X) 
 
 
Yes 
XX (XX.X) 
XX (XX.X) 
XX (XX.X) 
XX (XX.X) 
XX (XX.X) 
 
 
 
 
 
 
 
 
 
Hearing problems 
No 
XX (XX.X) 
XX (XX.X) 
XX (XX.X) 
XX (XX.X) 
XX (XX.X) 
 
 
Yes 
XX (XX.X) 
XX (XX.X) 
XX (XX.X) 
XX (XX.X) 
XX (XX.X) 
 
 
 
 
 
 
 
 
 
Vision problems 
No 
XX (XX.X) 
XX (XX.X) 
XX (XX.X) 
XX (XX.X) 
XX (XX.X) 
 
 
Yes 
XX (XX.X) 
XX (XX.X) 
XX (XX.X) 
XX (XX.X) 
XX (XX.X) 
 
 
 
 
 
 
 
 
 
Muscle twitching 
No 
XX (XX.X) 
XX (XX.X) 
XX (XX.X) 
XX (XX.X) 
XX (XX.X) 
 
 
Yes 
XX (XX.X) 
XX (XX.X) 
XX (XX.X) 
XX (XX.X) 
XX (XX.X) 
 
 
 
 
 
 
 
 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
Note to programmer: Only present overall sites.  Timepoints to appear on this table are, in order of 
appearance, Baseline (prior to surgery), At any time after baseline, PACU and, 6, 12, 24, 36, 48, 60, 72, 
84, 96, 108 and 120 hours and Days 7 and 10. Put one timepoint per page.  For the timepoint ‘any time after 
baseline’ if there is at least one ‘yes’ at any timepoint other than baseline, the subject will be a ‘yes’. 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
108 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Table 14.3-5.1: Tabulation of Sensation Tests – Safety Analysis Set 
 
Location: location-name (nerve name) 
EXPAREL 
 
 
Timepoint 
Sensation 
 
133 mg 
[N=XXX] 
n (%) 
266 mg 
[N=XXX]  
n (%) 
All EXPAREL 
[N=XXX]  
n (%) 
Placebo 
[N=XXX]  
n (%) 
Total 
[N=XXX]  
n (%) 
 
 
 
 
 
 
 
 
Baseline 
Cold  
Absent 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
Present xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
 
 
 
 
Pinprick 
Absent 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
Present xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
 
 
 
 
Light Touch 
Absent 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
Present xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
 
 
 
Etc. 
Cold 
Absent 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
Present xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
 
 
 
 
Pinprick 
Absent 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
Present xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
 
 
 
 
Light Touch 
Absent 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
Present xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
 
 
 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
Note to programmer: Locations to appear on this table, in order, are ‘Thigh (Anterior Cutaneous)’ and ‘Foot 
(Saphenous)’. Timepoints to appear on this table are, in order, are: Baseline, 15, 30 and 45 minutes and 6, 
9, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108 and 120 hours.  Do not split a timepoint across pages. 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
109 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Table 14.3-5.2: Summary of Sensation Loss and Return by Timepoint – Safety Analysis Set 
 
Location: location-name (nerve name) 
EXPAREL 
 
 
Timepoint 
Sensation 
 
133 mg 
[N=XXX] 
n (%) 
266 mg 
[N=XXX]  
n (%) 
All EXPAREL 
[N=XXX]  
n (%) 
Placebo 
[N=XXX]  
n (%) 
Total 
[N=XXX]  
n (%) 
 
 
 
 
 
 
 
 
At Any Time 
Any 
Loss 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
Return 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
CPL 
Loss 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
Return 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
CP 
Loss 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
Return 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
CL 
Loss 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
Return 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
PL 
Loss 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
Return 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
Cold (C) 
Loss 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
Return 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
Pinprick (P) 
Loss 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
Return 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
Light Touch (L) 
Loss 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
Return 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
 
 
Loss is the absence of sensation 
Return is the presence of sensation after a loss of sensation 
Sensation: CPL = All; CP = cold & pinprick; CL = cold & light touch; PL = pinprick & light touch 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
Note to programmer: Nerves to appear on this table, in order, are ‘All’  ‘Thigh (Anterior Cutaneous)’ and 
‘Foot (Saphenous)’. Timepoints to appear on this table are, in order, are: At Any Time, 15, 30 and 45 
minutes and 6, 9, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108 and 120 hours.  For ‘at any time’ timepoint 
subjects’ experiencing a loss/return at any time during the study will be counted only once. For ‘any’ 
sensation, subjects’ experiencing a loss/return for at least one of the sensation at that timepoint will be 
counted only once.  Do not split a timepoint across pages. 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
110 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Table 14.3-5.3.1: Analysis of Time to First Sensation Loss – Safety Analysis Set 
 
Location: location-name (nerve name) 
EXPAREL 
 
Sensation 
Statistic 
133 mg 
[N=XXX] 
n (%) 
266 mg 
[N=XXX]  
n (%) 
All EXPAREL 
[N=XXX]  
n (%) 
Placebo 
[N=XXX]  
n (%) 
 
 
 
 
 
 
Loss 
 
 
 
 
 
  Ever 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
  Never* 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
 
Time to First Loss (hrs) 
 
 
 
 
 
  Quartiles [1] 
 
 
 
 
 
    First (25%) 
Estimate  
xx.xx 
xx.xx 
xx.xx 
xx.xx 
 
(95% CI) 
(xx.xx,xx.xx) 
(xx.xx,xx.xx) 
(xx.xx,xx.xx) 
(xx.xx,xx.xx) 
    Median (50%) 
Estimate 
xx.xx 
xx.xx 
xx.xx 
xx.xx 
 
(95% CI) 
(xx.xx,xx.xx) 
(xx.xx,xx.xx) 
(xx.xx,xx.xx) 
(xx.xx,xx.xx) 
    Third (75%) 
Estimate 
xx.xx 
xx.xx 
xx.xx 
xx.xx 
 
(95% CI) 
(xx.xx,xx.xx) 
(xx.xx,xx.xx) 
(xx.xx,xx.xx) 
(xx.xx,xx.xx) 
  Minimum 
Observed 
xx.xx 
xx.xx 
xx.xx 
xx.xx 
  Maximum 
Observed 
xx.xx* 
xx.xx* 
xx.xx 
xx.xx 
  p-value [2] 
 
0.xxxx 
0.xxxx 
0.xxxx 
 
 
 
 
 
 
 
Loss: absence of at least one of cold, pinprick or light touch sensation. 
* = censored 
Time to sensation loss is the time from end of surgery to first loss of sensation. 
[1] Estimates from Kaplan-Meier analysis.  
[2] p-value from log-rank test with a term for treatment comparing EXPAREL to placebo. 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
Note to programmer: Nerves to appear on this table, in order, are ‘All’  ‘Thigh (Anterior Cutaneous)’ and 
‘Foot (Saphenous)’.  
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
111 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Table 14.3-5.3.2: Analysis of Time to Last Sensation Loss – Safety Analysis Set 
 
Location: location-name (nerve name) 
EXPAREL 
 
Sensation 
Statistic 
133 mg 
[N=XXX] 
n (%) 
266 mg 
[N=XXX]  
n (%) 
All EXPAREL 
[N=XXX]  
n (%) 
Placebo 
[N=XXX]  
n (%) 
 
 
 
 
 
 
Time to Last Loss (hrs) 
 
 
 
 
 
  Quartiles [1] 
 
 
 
 
 
    First (25%) 
Estimate  
xx.xx 
xx.xx 
xx.xx 
xx.xx 
 
(95% CI) 
(xx.xx,xx.xx) 
(xx.xx,xx.xx) 
(xx.xx,xx.xx) 
(xx.xx,xx.xx) 
    Median (50%) 
Estimate 
xx.xx 
xx.xx 
xx.xx 
xx.xx 
 
(95% CI) 
(xx.xx,xx.xx) 
(xx.xx,xx.xx) 
(xx.xx,xx.xx) 
(xx.xx,xx.xx) 
    Third (75%) 
Estimate 
xx.xx 
xx.xx 
xx.xx 
xx.xx 
 
(95% CI) 
(xx.xx,xx.xx) 
(xx.xx,xx.xx) 
(xx.xx,xx.xx) 
(xx.xx,xx.xx) 
  Minimum 
Observed 
xx.xx 
xx.xx 
xx.xx 
xx.xx 
  Maximum 
Observed 
xx.xx* 
xx.xx* 
xx.xx 
xx.xx 
  p-value [2] 
 
0.xxxx 
0.xxxx 
0.xxxx 
 
 
 
 
 
 
 
Loss: absence of at least one of cold, pinprick or light touch sensation. 
* = censored 
Return: all 3 (cold, pinprick and light touch) sensations are present after loss of sensation 
Time to sensation return is the time from first sensation loss to first sensation return. 
[1] Estimates from Kaplan-Meier analysis.  
[2] p-value from log-rank test with a term for treatment comparing EXPAREL to placebo. 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
Note to programmer: Nerves to appear on this table, in order, are ‘All’  ‘Thigh (Anterior Cutaneous)’ and 
‘Foot (Saphenous)’. If a subject meets the loss criteria at any timepoint, the subject will be counted in 
‘loss ever’ category; otherwise the subject will be counted in ‘loss never’ category.  Note time to last 
loss will only be provided if more than 10% of the subjects in a treatment arm have more than 1 sensation 
loss-return cycle.    


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
112 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Table 14.3-5.4.1: Analysis of Time to First Sensation Return – Safety Analysis Set 
 
Location: location-name (nerve name) 
EXPAREL 
 
Sensation 
Statistic 
133 mg 
[N=XXX] 
n (%) 
266 mg 
[N=XXX]  
n (%) 
All EXPAREL 
[N=XXX]  
n (%) 
Placebo 
[N=XXX]  
n (%) 
 
 
 
 
 
 
Loss Ever 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
Return 
 
 
 
 
 
  Ever 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
  Never* 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
 
Time to First Return (hrs) 
 
 
 
 
 
  Quartiles [1] 
 
 
 
 
 
    First (25%) 
Estimate  
xx.xx 
xx.xx 
xx.xx 
xx.xx 
 
(95% CI) 
(xx.xx,xx.xx) 
(xx.xx,xx.xx) 
(xx.xx,xx.xx) 
(xx.xx,xx.xx) 
    Median (50%) 
Estimate 
xx.xx 
xx.xx 
xx.xx 
xx.xx 
 
(95% CI) 
(xx.xx,xx.xx) 
(xx.xx,xx.xx) 
(xx.xx,xx.xx) 
(xx.xx,xx.xx) 
    Third (75%) 
Estimate 
xx.xx 
xx.xx 
xx.xx 
xx.xx 
 
(95% CI) 
(xx.xx,xx.xx) 
(xx.xx,xx.xx) 
(xx.xx,xx.xx) 
(xx.xx,xx.xx) 
  Minimum 
Observed 
xx.xx 
xx.xx 
xx.xx 
xx.xx 
  Maximum 
Observed 
xx.xx* 
xx.xx* 
xx.xx 
xx.xx 
  p-value [2] 
 
0.xxxx 
0.xxxx 
0.xxxx 
 
 
 
 
 
 
 
Loss: absence of at least one of cold, pinprick or light touch sensation. 
* = censored 
Return: all 3 (cold, pinprick and light touch) sensations are present after loss of sensation 
Time to sensation return is the time from first sensation loss to first sensation return. 
[1] Estimates from Kaplan-Meier analysis.  
[2] p-value from log-rank test with a term for treatment comparing EXPAREL to placebo. 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
Note to programmer: Nerves to appear on this table, in order, are ‘All’  ‘Thigh (Anterior Cutaneous)’ and 
‘Foot (Saphenous)’.  This table based on only those subjects who lost sensation (ie, the loss ever row is 
the population appearing in analyses).  
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
113 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Table 14.3-5.4.2: Analysis of Time to Last Sensation Return – Safety Analysis Set 
 
Location: location-name 
(nerve name) 
 
EXPAREL 
 
Sensation 
Statistic 
133 mg 
[N=XXX] 
n (%) 
266 mg 
[N=XXX]  
n (%) 
All EXPAREL 
[N=XXX]  
n (%) 
Placebo 
[N=XXX]  
n (%) 
 
 
 
 
 
 
Time to Last Return (hrs) 
 
 
 
 
 
  Quartiles [1] 
 
 
 
 
 
    First (25%) 
Estimate  
xx.xx 
xx.xx 
xx.xx 
xx.xx 
 
(95% CI) 
(xx.xx,xx.xx) 
(xx.xx,xx.xx) 
(xx.xx,xx.xx) 
(xx.xx,xx.xx) 
    Median (50%) 
Estimate 
xx.xx 
xx.xx 
xx.xx 
xx.xx 
 
(95% CI) 
(xx.xx,xx.xx) 
(xx.xx,xx.xx) 
(xx.xx,xx.xx) 
(xx.xx,xx.xx) 
    Third (75%) 
Estimate 
xx.xx 
xx.xx 
xx.xx 
xx.xx 
 
(95% CI) 
(xx.xx,xx.xx) 
(xx.xx,xx.xx) 
(xx.xx,xx.xx) 
(xx.xx,xx.xx) 
  Minimum 
Observed 
xx.xx 
xx.xx 
xx.xx 
xx.xx 
  Maximum 
Observed 
xx.xx* 
xx.xx* 
xx.xx 
xx.xx 
  p-value [2] 
 
0.xxxx 
0.xxxx 
0.xxxx 
 
 
 
 
 
 
 
Loss: absence of at least one of cold, pinprick or light touch sensation. 
* = censored 
Return: all 3 (cold, pinprick and light touch) sensations are present after loss of sensation 
Time to sensation return is the time from first sensation loss to first sensation return. 
[1] Estimates from Kaplan-Meier analysis.  
[2] p-value from log-rank test with a term for treatment comparing EXPAREL to placebo. 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
Note to programmer: Nerves to appear on this table, in order, are ‘All’  ‘Thigh (Anterior Cutaneous)’ and 
‘Foot (Saphenous)’. ‘Loss Ever’ counts on this table should agree with ‘loss ever’ counts on Table 14.3-
5.1.1. If a subject meets the return criteria at any time, the subject will be counted in ‘return ever’ 
category; otherwise the subject will be counted in the ‘return never’ category.  The sum of ‘return ever’ 
and ‘return never’ should add up to ‘loss ever’; subjects who did not experience a loss of sensation cannot 
have a return of sensation.  Only subjects experiencing a ‘loss ever’ will contribute to the body of this 
table.  Note time to last return will only be provided if more than 10% of the subjects in a treatment arm 
have more than 1 sensation loss-return cycle. 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
114 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Table 14.3-5.5: Summary of Duration (hrs) of Sensation Loss – Safety Analysis Set 
 
Location: location-name 
(nerve name) 
 
EXPAREL 
 
 
Statistic 
133 mg 
[N=XXX] 
n (%) 
266 mg 
[N=XXX]  
n (%) 
All EXPAREL 
[N=XXX]  
n (%) 
Placebo 
[N=XXX]  
n (%) 
 
 
 
 
 
 
Total Duration  
n 
xx 
xx 
xx 
xx 
 
Mean 
xx.x 
xx.x 
xx.x 
xx.x 
 
SD 
x.xx 
x.xx 
x.xx 
x.xx 
 
Minimum 
xx 
xx 
xx 
xx 
 
Median 
xx.x 
xx.x 
xx.x 
xx.x 
 
Maximum 
xx 
xx 
xx 
xx 
 
 
 
 
 
 
Cycle 1 
n 
xx 
xx 
xx 
xx 
 
Mean 
xx.x 
xx.x 
xx.x 
xx.x 
 
SD 
x.xx 
x.xx 
x.xx 
x.xx 
 
Minimum 
xx 
xx 
xx 
xx 
 
Median 
xx.x 
xx.x 
xx.x 
xx.x 
 
Maximum 
xx 
xx 
xx 
xx 
 
 
 
 
 
 
Etc. 
n 
xx 
xx 
xx 
xx 
 
Mean 
xx.x 
xx.x 
xx.x 
xx.x 
 
SD 
x.xx 
x.xx 
x.xx 
x.xx 
 
Minimum 
xx 
xx 
xx 
xx 
 
Median 
xx.x 
xx.x 
xx.x 
xx.x 
 
Maximum 
xx 
xx 
xx 
xx 
 
 
 
 
 
 
Duration is the time between loss and return of sensation. 
Total duration is the sum, within a subject, of all sensation loss-return cycles. 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
Note to programmer: Nerves to appear on this table, in order, are ‘All’  ‘Thigh (Anterior Cutaneous)’ and 
‘Foot (Saphenous)’. Only subjects experiencing a sensation loss will contribute to the body of this table.  
Note summaries of cycles will only be provided if more than 10% of the subjects in a treatment arm have 
more than 1 sensation loss-return cycle. 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
115 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Table 14.3-5.6: Summary of the Number of Sensation Loss-Return Cycles - Safety Analysis Set 
 
Location: location-name (nerve name) 
EXPAREL 
 
 
Statistic 
133 mg 
[N=XX] 
266 mg 
[N=XX] 
All EXPAREL 
[N=XX] 
Placebo  
[N=XX] 
 
 
 
 
 
 
Count Summary 
n 
xx 
xx 
xx 
xx 
 
Mean 
xx.x 
xx.x 
xx.x 
xx.x 
 
SD 
x.xx 
x.xx 
x.xx 
x.xx 
 
Minimum 
xx.x 
xx.x 
xx.x 
xx.x 
 
Median 
xx 
xx 
xx 
xx 
 
Maximum 
xx 
xx 
xx 
xx 
 
 
 
 
 
 
Count Distribution 
 
 
 
 
 
  0  
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  1 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  2 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  3 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  4 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  5 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  … 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  U 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
Note to programmer: Locations to appear on this table, in order, are ‘Thigh (Anterior Cutaneous)’ and ‘Foot 
(Saphenous)’. Distribution should present all counts up to the highest number of loss-return cycles in the 
data (U). Only subjects experiencing a sensation loss will contribute to the body of this table.  This 
table will only be provided if at least 1 subject has more than 1 sensation loss-return cycle. 
 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
116 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Table 14.3-6.1: Summary of Active Motor Function Loss and Return by Timepoint – Safety Analysis Set 
 
 
 
EXPAREL 
 
 
Timepoint 
 
133 mg 
[N=XXX] 
n (%) 
266 mg 
[N=XXX]  
n (%) 
All EXPAREL 
[N=XXX]  
n (%) 
Placebo 
[N=XXX]  
n (%) 
Total 
[N=XXX]  
n (%) 
 
 
 
 
 
 
 
At Any Time 
Loss 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
  Flexion 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
  Extension 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
  FE 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
Return 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
 
 
15 min 
Loss 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
  Flexion 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
  Extension 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
  FE 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
Return 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
 
 
FE = flexion and extension loss;  
 
 
Loss (at least one of active flexion or active extension motor functions is lost): 
 
Flexion = angle < 80° if baseline ≥ 80°, otherwise post-baseline change > -10°  
 
Extension = angle > 10° if baseline ≤ 10°, otherwise post-baseline change ≥ 10° 
Return (Flexion and Extension must return): 
 
Flexion = angle ≥ 80° if baseline ≥ 80°, otherwise post-baseline change ≤ -10° 
 
Extension = angle ≤ 10° if baseline ≤ 10°, otherwise post-baseline change ≤ 10° 
 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
Note to programmer: Timepoints to appear on this table are, in order, are: At Any Time, 15, 30 and 45 
minutes and 6, 9, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108 and 120 hours.  For at any time, the criteria 
must be met at the same time point to be counted.  For example loss in extension need only be met any 
timepoint during the study, but flexion and extension loss (FE) must be met at the same timepoint to be 
counted under at any time. 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
117 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Table 14.3-6.2: Analysis of Time to Onset of Motor Function Loss - Efficacy Analysis Set 
 
 
Statistic 
EXPAREL 133 mg 
[N=XX] 
EXPAREL 266 mg 
[N=XX] 
Placebo 
[N=XX] 
 
 
 
 
 
Number of Subjects with 
 
 
 
 
  Motor Function Loss 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  No Motor Function Loss 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
Time to Loss 
 
 
 
 
  Quartiles [1] 
 
 
 
 
    First (25%) 
Estimate  
xx.xx 
xx.xx 
xx.xx 
 
(95% CI) 
(xx.xx,xx.xx) 
(xx.xx,xx.xx) 
(xx.xx,xx.xx) 
 
 
 
 
 
    Median (50%) 
Estimate 
xx.xx 
xx.xx 
xx.xx 
 
(95% CI) 
(xx.xx,xx.xx) 
(xx.xx,xx.xx) 
(xx.xx,xx.xx) 
 
 
 
 
 
    Third (75%) 
Estimate 
xx.xx 
xx.xx 
xx.xx 
 
(95% CI) 
(xx.xx,xx.xx) 
(xx.xx,xx.xx) 
(xx.xx,xx.xx) 
 
 
 
 
 
  Minimum 
Observed 
xx.xx 
xx.xx 
xx.xx 
  Maximum 
Observed 
xx.xx* 
xx.xx* 
xx.xx 
 
 
 
 
 
  p-value [2] 
 
0.xxxx 
0.xxxx 
 
 
 
 
 
 
Loss (at least one of active flexion or active extension motor functions is lost): 
 
Flexion = angle < 80° if baseline ≥ 80°, otherwise post-baseline change > -10°  
 
Extension = angle > 10° if baseline ≤ 10°, otherwise post-baseline change ≥ 10° 
* indicates censored observation 
 
CI = confidence interval 
[1] Estimates from Kaplan-Meier analysis.  
[2] p-value from log-rank test with a term for treatment comparing EXPAREL to placebo. 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
118 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Table 14.3-6.3: Analysis of Time to Return of Motor Function - Efficacy Analysis Set 
 
 
Statistic 
EXPAREL 133 mg 
[N=XX] 
EXPAREL 266 mg 
[N=XX] 
Placebo 
[N=XX] 
 
 
 
 
 
Number of Subjects with 
 
 
 
 
  Motor Function Return 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  No Motor Function Return 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
Time to Return 
 
 
 
 
  Quartiles [1] 
 
 
 
 
    First (25%) 
Estimate  
xx.xx 
xx.xx 
xx.xx 
 
(95% CI) 
(xx.xx,xx.xx) 
(xx.xx,xx.xx) 
(xx.xx,xx.xx) 
 
 
 
 
 
    Median (50%) 
Estimate 
xx.xx 
xx.xx 
xx.xx 
 
(95% CI) 
(xx.xx,xx.xx) 
(xx.xx,xx.xx) 
(xx.xx,xx.xx) 
 
 
 
 
 
    Third (75%) 
Estimate 
xx.xx 
xx.xx 
xx.xx 
 
(95% CI) 
(xx.xx,xx.xx) 
(xx.xx,xx.xx) 
(xx.xx,xx.xx) 
 
 
 
 
 
  Minimum 
Observed 
xx.xx 
xx.xx 
xx.xx 
  Maximum 
Observed 
xx.xx* 
xx.xx* 
xx.xx 
 
 
 
 
 
  p-value [2] 
 
0.xxxx 
0.xxxx 
 
 
 
 
 
 
Return (Flexion and Extension must return): 
 
Flexion = angle ≥ 80° if baseline ≥ 80°, otherwise post-baseline change ≤ -10° 
 
Extension = angle ≤ 10° if baseline ≤ 10°, otherwise post-baseline change ≤ 10° 
* indicates censored observation 
 
CI = confidence interval 
[1] Estimates from Kaplan-Meier analysis.  
[2] p-value from log-rank test with a term for treatment comparing EXPAREL to placebo. 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
119 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Table 14.3-6.4: Summary of Motor Function Assessments by Timepoint – Safety Analysis Set 
 
Active Flexion (degrees) 
EXPAREL 
 
 
Timepoint 
Value 
Statistic 
133 mg 
[N=XXX] 
266 mg 
[N=XXX] 
All EXPAREL 
[N=XXX] 
Placebo 
[N=XXX] 
Total 
[N=XXX] 
 
 
 
 
 
 
 
 
Baseline 
Actual 
n 
xx 
xx 
xx 
xx 
xx 
 
 
Mean 
xx.x 
xx.x 
xx.x 
xx.x 
xx.x 
 
 
SD 
x.xx 
x.xx 
x.xx 
x.xx 
x.xx 
 
 
Minimum 
xx 
xx 
xx 
xx 
xx 
 
 
Median 
xx.x 
xx.x 
xx.x 
xx.x 
xx.x 
 
 
Maximum 
xx 
xx 
xx 
xx 
xx 
 
 
 
 
 
 
 
 
15 min 
Baseline [1] 
n 
xx 
xx 
xx 
xx 
xx 
 
 
Mean 
xx.x 
xx.x 
xx.x 
xx.x 
xx.x 
 
 
SD 
x.xx 
x.xx 
x.xx 
x.xx 
x.xx 
 
 
Minimum 
xx 
xx 
xx 
xx 
xx 
 
 
Median 
xx.x 
xx.x 
xx.x 
xx.x 
xx.x 
 
 
Maximum 
xx 
xx 
xx 
xx 
xx 
 
 
 
 
 
 
 
 
 
Actual 
n 
xx 
xx 
xx 
xx 
xx 
 
 
Mean 
xx.x 
xx.x 
xx.x 
xx.x 
xx.x 
 
 
SD 
x.xx 
x.xx 
x.xx 
x.xx 
x.xx 
 
 
Minimum 
xx 
xx 
xx 
xx 
xx 
 
 
Median 
xx.x 
xx.x 
xx.x 
xx.x 
xx.x 
 
 
Maximum 
xx 
xx 
xx 
xx 
xx 
 
 
 
 
 
 
 
 
 
Change  
n 
xx 
xx 
xx 
xx 
xx 
 
 
Mean 
xx.x 
xx.x 
xx.x 
xx.x 
xx.x 
 
 
SD 
x.xx 
x.xx 
x.xx 
x.xx 
x.xx 
 
 
Minimum 
xx 
xx 
xx 
xx 
xx 
 
 
Median 
xx.x 
xx.x 
xx.x 
xx.x 
xx.x 
 
 
Maximum 
xx 
xx 
xx 
xx 
xx 
 
 
 
 
 
 
 
 
[1] Baseline (prior to surgery) for subjects with data at the timepoint. 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
120 of 173 
20Jun2017 
 
Note to programmer: Motor assessments to appear on this table, in order, are: ‘Active Flexion (degrees)’, 
‘Active Extension (degrees)’, ‘Passive Flexion (degrees)’ and ‘Passive Extension (degrees)’.  Timepoints to 
appear on this table are, in order, are: Baseline, 15, 30 and 45 minutes and 6, 9, 12, 18, 24, 36, 48, 60, 
72, 84, 96, 108 and 120 hours. 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
121 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Table 14.3-7.1: Overview of Treatment-Emergent Adverse Events (TEAEs) - Safety Analysis Set 
 
EXPAREL 
 
 
Number of 
133 mg 
[N=XX] 
n (%) 
266 mg 
[N=XX] 
n (%) 
All EXPAREL 
[N=XX] 
n (%) 
Placebo  
[N=XX]  
n (%) 
Total  
[N=XX] 
n (%) 
 
 
 
 
 
 
Subjects with Any TEAE 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  Maximum Severity of Mild 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  Maximum Severity of Moderate 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  Maximum Severity of Severe 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
 
  At least one Related 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
 
  At least one Serious 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
 
Subjects Discontinued due to TEAE 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
 
Died on Study 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
 
Related TEAEs are those AEs indicated as ‘possible’, ‘probable’ or ‘definite’ related by the investigator 
on the AE CRF. 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
Note to programmer: Only present overall sites. All categories on this table should appear, even if not 
present in the data. 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
122 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Table 14.3-7.1.2: Summary of Incidence of Treatment-Emergent Adverse Events (TEAEs) - Safety Analysis Set 
 
EXPAREL 
 
 
System Organ Class 
  Preferred Term 
133 mg 
[N=XX] 
n (%) 
266 mg 
[N=XX] 
n (%) 
All EXPAREL 
[N=XX] 
n (%) 
Placebo  
[N=XX]  
n (%) 
Total  
[N=XX] 
n (%) 
 
 
 
 
 
 
Subjects with at least one TEAE 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
 
SOC1 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  PT1.1 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  PT1.2 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
 
SOC2 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  PT2.1 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  PT2.2 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
ETC. 
 
 
 
 
 
 
 
 
 
 
 
Adverse events coded using the Medical Dictionary for Regulatory Activities (MedDRA TBD). 
Sorted by descending total incidence by system organ class and preferred term within system organ class. 
Subjects experiencing the same TEAE more than once are counted only once at each summary level. 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
Note to programmer: Only present overall sites.  Use mock-up Table 14.3-2.1.2 for the following tables: 
 
Table 14.3-7.1.3: Summary of Incidence of Study Drug-Related Treatment-Emergent Adverse Events (TEAEs) - 
Safety Analysis Set  
Table 14.3-7.1.4: Summary of Incidence of Treatment-Emergent Adverse Events (TEAEs) Leading to Study 
Withdrawal - Safety Analysis Set 
Table 14.3-7.1.5: Summary of Incidence of Study Drug-Related Treatment-Emergent Adverse Events (TEAEs) 
Leading to Study Withdrawal - Safety Analysis Set 
 
For related tables add the following footnote to the table: 
Related TEAEs are those AEs indicated as ‘possible’, ‘probable’ or ‘definite’ related by the investigator 
on the AE CRF. 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
123 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Table 14.3-7.1.6: Summary of Incidence of Treatment-Emergent Adverse Events (TEAEs) by Severity - Safety 
Analysis Set 
 
 
EXPAREL 
 
 
System Organ Class 
  Preferred Term 
Severity 
133 mg 
[N=XX] 
n (%) 
266 mg 
[N=XX] 
n (%) 
All 
EXPAREL 
[N=XX] 
n (%) 
Placebo  
[N=XX]  
n (%) 
Total  
[N=XX] 
n (%) 
 
 
 
 
 
 
 
Subjects with at least one TEAE 
Mild 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
Moderate 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
Severe 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
 
 
SOC1 
Mild 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
Moderate 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
Severe 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
 
 
  PT1.1 
Mild 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
Moderate 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
Severe 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
 
 
Adverse events coded using the Medical Dictionary for Regulatory Activities (MedDRA TBD). 
Sorted by descending total incidence by system organ class and preferred term within system organ class. 
Subjects experiencing the same TEAE more than once are counted only once at each summary level. 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
124 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Table 14.3-7.1.7: Summary of Incidence of Treatment-Emergent Adverse Events (TEAEs) by Relationship to 
Study Drug - Safety Analysis Set 
 
 
EXPAREL 
 
 
System Organ Class 
  Preferred Term 
Relation 
133 mg 
[N=XX] 
n (%) 
266 mg 
[N=XX] 
n (%) 
All 
EXPAREL 
[N=XX] 
n (%) 
Placebo  
[N=XX]  
n (%) 
Total  
[N=XX] 
n (%) 
 
 
 
 
 
 
 
Subjects with at least one TEAE 
Unrelated 
xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) 
 
Unlikely 
xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) 
 
Possible 
xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) 
 
Probable 
xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) 
 
Definite 
xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) 
 
 
 
 
 
 
 
SOC1 
Unrelated 
xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) 
 
Unlikely 
xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) 
 
Possible 
xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) 
 
Probable 
xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) 
 
Definite 
xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) 
 
 
 
 
 
 
 
  PT1.1 
Unrelated 
xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) 
 
Unlikely 
xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) 
 
Possible 
xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) 
 
Probable 
xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) 
 
Definite 
xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) 
 
 
 
 
 
 
 
Adverse events coded using the Medical Dictionary for Regulatory Activities (MedDRA TBD). 
Sorted by descending total incidence by system organ class and preferred term within system organ class. 
Subjects experiencing the same TEAE more than once are counted only once at each summary level. 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
125 of 173 
20Jun2017 
 
 
Note to programmer: Only present overall sites. For related tables add the following footnote to the table, 
“Related TEAEs are those AEs indicated as ‘possible’, ‘probable’ or ‘definite’ related by the investigator 
on the AE CRF.”  Use indicated mock-up for the following tables:  
 
Use mock-up 14.7-1.1 
Table 14.3-7.2.1: Overview of Serious Treatment-Emergent Adverse Events (TEAEs) - Safety Analysis Set  
Use mock-up 14.7-1.2 
Table 14.3-7.2.2: Summary of Incidence of Serious Treatment-Emergent Adverse Events (TEAEs) - Safety 
Analysis Set  
Use mock-up 14.7-1.3 
Table 14.3-7.2.3: Summary of Incidence of Study Drug-Related Serious Treatment-Emergent Adverse Events 
(TEAEs) - Safety Analysis Set  
Use mock-up 14.7-1.4 
Table 14.3-7.2.4: Summary of Incidence of Serious Treatment-Emergent Adverse Events (TEAEs) Leading to 
Study Withdrawal - Safety Analysis Set  
Use mock-up 14.7-1.5 
Table 14.3-7.2.5: Summary of Incidence of Study Drug-Related Serious Treatment-Emergent Adverse Events 
(TEAEs) Leading to Study Withdrawal - Safety Analysis Set  
Use mock-up 14.7-1.6 
Table 14.3-7.2.6: Summary of Incidence of Serious Treatment-Emergent Adverse Events (TEAEs) Resulting in 
Death - Safety Analysis Set  
Use mock-up 14.7-1.7 
Table 14.3-7.2.7: Summary of Incidence of Study Drug-Related Serious Treatment-Emergent Adverse Events 
(TEAEs) Resulting in Death - Safety Analysis Set 
 
  
Use mock-up 14.7-1.1 
Table 14.3-7.3.1: Overview of Treatment-Emergent Adverse Events (TEAEs) of Special Interest - Safety 
Analysis Set  
Use mock-up 14.7-1.2 
Table 14.3-7.3.2: Summary of Incidence of Treatment-Emergent Adverse Events (TEAEs) of Special Interest - 
Safety Analysis Set  
Use mock-up 14.7-1.3 
Table 14.3-7.3.3: Summary of Incidence of Study Drug-Related Treatment-Emergent Adverse Events (TEAEs) of 
Special Interest - Safety Analysis Set  
Use mock-up 14.7-1.4 
Table 14.3-7.3.4: Summary of Incidence of Treatment-Emergent Adverse Events (TEAEs) of Special Interest 
Leading to Study Withdrawal - Safety Analysis Set  
Use mock-up 14.7-1.5 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
126 of 173 
20Jun2017 
 
Table 14.3-7.3.5: Summary of Incidence of Study Drug-Related Treatment-Emergent Adverse Events (TEAEs) of 
Special Interest Leading to Study Withdrawal - Safety Analysis Set  
Use mock-up 14.7-1.6 
Table 14.3-7.3.6: Summary of Incidence of Treatment-Emergent Adverse Events (TEAEs) of Special Interest 
Resulting in Death - Safety Analysis Set  
Use mock-up 14.7-1.7 
Table 14.3-7.3.7: Summary of Incidence of Study Drug-Related Treatment-Emergent Adverse Events (TEAEs) of 
Special Interest Resulting in Death - Safety Analysis Set 
 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
127 of 173 
20Jun2017 
 
 
 
Note to programmer: Use mock-up 14.1-4.1 for tables: 
 
Table 14.3-8.1: Incidence of Prior Medications – Safety Analysis Set.  
 
On this table change the footnote ‘Intraoperatives medications are those indicated as such by the 
investigator’ to read ‘Prior medications are those stopped before start of study drug administration.’ 
 
Table 14.3-8.2: Incidence of Concomitant Medications – Safety Analysis Set.  
 
On this table change the footnote ‘Intraoperatives medications are those indicated as such by the 
investigator’ to read ‘Concomitant medications are those taken between the start of study drug 
administration and discharge from study and are not designated intraoperative medications.’ 
 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
128 of 173 
20Jun2017 
 
Note to programmer: For the following tables, only present US and ROW regions; there is no overall regions 
group.  All of the following mock-ups will put the region as a by-line title in the table.  
 
Use mock-up 14.3-5.1 for table: 
 
Table 14.3-9.1.1: Region Tabulation of Sensation Tests – Safety Analysis Set  
 
Use mock-up 14.3-5.2 for table: 
 
Table 14.3-9.1.2: Region Summary of Sensation Loss and Return by Timepoint – Safety Analysis Set 
 
Use mock-up 14.3-5.3 for table: 
 
Table 14.3-9.1.3: Region Analysis of Time to Sensation Loss – Safety Analysis Set 
 
Use mock-up 14.3-5.4 for table: 
 
Table 14.3-9.1.4: Region Analysis of Time to Sensation Return – Safety Analysis Set 
 
Use mock-up 14.3-5.5 for table: 
 
Table 14.3-9.1.5: Region Summary of Duration (hrs) of Sensation Loss – Safety Analysis Set 
 
Use mock-up 14.3-6.1 for table: 
 
Table 14.3-9.2.1: Region Summary of Active Motor Function Loss and Return by Timepoint – Safety Analysis 
Set 
 
Use mock-up 14.3-6.2 for table: 
 
Table 14.3-9.2.2: Region Analysis of Time to Onset of Motor Function Loss - Efficacy Analysis Set 
 
Use mock-up 14.3-6.3 for table: 
Table 14.3-9.2.3: Region Analysis of Time to Return of Motor Function - Efficacy Analysis Set 
 
Use mock-up 14.3-6.4 for table: 
 
Table 14.3-9.2.4: Region Summary of Motor Function Assessments by Timepoint – Safety Analysis Set 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
129 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Table 14.3-9.3.1: Region Overview of Treatment-Emergent Adverse Events (TEAEs) - Safety Analysis Set 
Region: US 
EXPAREL 
 
 
Number of 
133 mg 
[N=XX] 
n (%) 
266 mg 
[N=XX] 
n (%) 
All EXPAREL 
[N=XX] 
n (%) 
Placebo  
[N=XX]  
n (%) 
Total  
[N=XX] 
n (%) 
 
 
 
 
 
 
Subjects with Any TEAE 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  Maximum Severity of Mild 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  Maximum Severity of Moderate 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  Maximum Severity of Severe 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
 
  At least one Related 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
 
  At least one Serious 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
 
Subjects Discontinued due to TEAE 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
 
Died on Study 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
Note to programmer: Only present US and ROW regions; there is no overall regions group. All categories on 
this table should appear, even if not present in the data. 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
130 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Table 14.3-9.3.2: Region Summary of Incidence of Treatment-Emergent Adverse Events (TEAEs) - Safety 
Analysis Set 
Region:  
EXPAREL 
 
 
System Organ Class 
  Preferred Term 
133 mg 
[N=XX] 
n (%) 
266 mg 
[N=XX] 
n (%) 
All EXPAREL 
[N=XX] 
n (%) 
Placebo  
[N=XX]  
n (%) 
Total  
[N=XX] 
n (%) 
 
 
 
 
 
 
Subjects with at least one TEAE 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
 
SOC1 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  PT1.1 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  PT1.2 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
 
SOC2 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  PT2.1 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  PT2.2 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
ETC. 
 
 
 
 
 
 
 
 
 
 
 
Adverse events coded using the Medical Dictionary for Regulatory Activities (MedDRA TBD). 
Sorted by descending total incidence by system organ class and preferred term within system organ class. 
Subjects experiencing the same TEAE more than once are counted only once at each summary level. 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
Note to programmer: Only present US and ROW regions; there is no overall regions group. Use this mock-up 
for table: 
 
Table 14.3-9.3.3: Region Summary of Incidence of Serious Treatment-Emergent Adverse Events (TEAEs) - Safety 
Analysis Set 
  


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
131 of 173 
20Jun2017 
15. 
TABLE OF CONTENTS FOR LISTING MOCK-UPS 
LISTING 16.2-1: SUBJECT DISPOSITION – ALL SUBJECTS 
133 
LISTING 16.2-2: RANDOMIZATION AND ANALYSIS SETS – RANDOMIZED SUBJECTS 
134 
LISTING 16.2-3: DEMOGRAPHICS – ALL SUBJECTS 
135 
LISTING 16.2-4: HEIGHT AND WEIGHT – ALL SUBJECTS 
136 
LISTING 16.2-5: SURGERY – RANDOMIZED SUBJECTS 
137 
LISTING 16.2-6: VISUAL ANALOG SCALE (VAS) – RANDOMIZED SUBJECTS 
138 
LISTING 16.2-7.1: RESCUE MEDICATION TOTAL DOSE (MED MG) AND OPIOID-FREE STATUS 
- RANDOMIZED SUBJECTS 
139 
LISTING 16.2-7.2: RESCUE MEDICATION – RANDOMIZED SUBJECTS 
140 
LISTING 16.2-8: OVERALL BENEFIT OF ANALGESIA – RANDOMIZED SUBJECTS 
141 
LISTING 16.2-9: SUBJECT SATISFACTION WITH POST-SURGICAL PAIN CONTROL – 
RANDOMIZED SUBJECTS 
142 
LISTING 16.2-10: MODIFIED POST-ANESTHESIA DISCHARGE SCORING SYSTEM (MPADSS)– 
RANDOMIZED SUBJECTS 
143 
LISTING 16.2-11: DAY 29 PHONE CALL – RANDOMIZED SUBJECTS 
144 
LISTING 16.2-12: HEMATOLOGY – RANDOMIZED SUBJECTS 
145 
LISTING 16.2-13: CHEMISTRY – RANDOMIZED SUBJECTS 
145 
LISTING 16.2-14.1: URINALYSIS – NUMERIC RESULTS – RANDOMIZED SUBJECTS 
145 
LISTING 16.2-14.2: URINALYSIS – CHARACTER RESULTS – RANDOMIZED SUBJECTS 
146 
LISTING 16.2-15: VITAL SIGNS ASSESSMENT – ALL SUBJECTS 
147 
LISTING 16.2-16: ELECTROCARDIOGRAM FINDINGS – INVESTIGATOR ASSESSMENT – ALL 
SUBJECTS 
148 
LISTING 16.2-17: NEUROLOGICAL ASSESSMENT – ALL SUBJECTS 
149 
LISTING 16.2-18.1: SENSORY FUNCTION ASSESSMENT – ALL SUBJECTS 
150 
LISTING 16.2-18.2: TIME TO LOSS AND RETURN OF SENSORY FUNCTION – RANDOMIZED 
SUBJECTS 
151 
LISTING 16.2-19.1.1: ACTIVE MOTOR FUNCTION ASSESSMENT – ALL SUBJECTS 
152 
LISTING 16.2-19.1.2: PASSIVE MOTOR FUNCTION ASSESSMENT – ALL SUBJECTS 
153 
LISTING 16.2-19.2: TIME TO LOSS AND RETURN OF MOTOR FUNCTION – RANDOMIZED 
SUBJECTS 
154 
LISTING 16.2-20: TIMED WALK TEST – RANDOMIZED SUBJECTS 
155 
LISTING 16.2-21: TIMED UP-AND-GO TEST – RANDOMIZED SUBJECTS 
156 
LISTING 16.2-22: STAIR CLIMBING TEST – RANDOMIZED SUBJECTS 
157 
LISTING 16.2-23.1: ALL ADVERSE EVENTS – ALL SUBJECTS 
158 
LISTING 16.2-23.2.1: TREATMENT-EMERGENT ADVERSE EVENTS – RANDOMIZED SUBJECTS158 
LISTING 16.2-23.2.2: TREATMENT-EMERGENT STUDY DRUG RELATED ADVERSE EVENTS – 
RANDOMIZED SUBJECTS 
158 
LISTING 16.2-23.3: ALL SERIOUS ADVERSE EVENTS – ALL SUBJECTS 
158 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
132 of 173 
20Jun2017 
LISTING 16.2-23.4.1: TREATMENT-EMERGENT SERIOUS ADVERSE EVENTS – RANDOMIZED 
SUBJECTS 
158 
LISTING 16.2-23.4.2: TREATMENT-EMERGENT STUDY DRUG RELATED SERIOUS ADVERSE 
EVENTS – RANDOMIZED SUBJECTS 
158 
LISTING 16.2-23.5.1: TREATMENT-EMERGENT ADVERSE EVENTS OF SPECIAL INTEREST – 
RANDOMIZED SUBJECTS 
158 
LISTING 16.2-23.5.2: TREATMENT-EMERGENT STUDY DRUG RELATED ADVERSE EVENTS 
OF SPECIAL INTEREST – RANDOMIZED SUBJECTS 
158 
LISTING 16.2-24.1: ALL PRIOR AND CONCOMITANT MEDICATIONS – ALL SUBJECTS 
159 
LISTING 16.2-24.2: PRIOR MEDICATIONS – RANDOMIZED SUBJECTS 
159 
LISTING 16.2-24.3: CONCOMITANT MEDICATIONS – RANDOMIZED SUBJECTS 
159 
LISTING 16.2-25: MEDICAL HISTORY – ALL SUBJECTS 
160 
LISTING 16.2-26: INTRAOPERATIVE OPIOIDS – RANDOMIZED SUBJECTS 
161 
LISTING 16.2-27: STUDY DRUG ADMINISTRATION – RANDOMIZED SUBJECTS 
162 
LISTING 16.2-28: URINE DRUG SCREEN, ALCOHOL BLOOD TEST AND PREGNANCY TEST – 
ALL SUBJECTS 
163 
LISTING 16.2-29: ADMISSION AND DISCHARGE – RANDOMIZED SUBJECTS 
164 
LISTING 16.2-30: UNIQUE ADVERSE EVENTS TERMS AND ASSOCIATED CODED TERMS 
165 
LISTING 16.2-31: UNIQUE MEDICATION TERMS AND ASSOCIATED CODED TERMS 
166 
LISTING 16.2-32: PROTOCOL DEVIATIONS 
167 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
133 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Listing 16.2-1: Subject Disposition – All Subjects 
TREATMENT: treatment-name 
Site Subject 
Date of 
Last Visit 
End of Study Status 
Specify 
 
 
 
 
 
XXX 
XXX-YYYY 
DDMONYYYY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
Note to programmer: End of study status for subject who early terminated from the study is the primary 
reason for termination. If subject discontinued due to an AE then the reason should read ‘ADVERSE EVENT, AE 
# X’. If subject discontinued due to death the reason should read ‘DEATH ON DDMONYYYY’. For those reasons 
that also collected a specify text, that text belongs in the specify column. 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
134 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Listing 16.2-2: Randomization and Analysis Sets – Randomized Subjects 
TREATMENT: treatment-name 
 
 
Randomization 
 
Analysis Set 
Site 
Subject 
Date and Time 
Number 
 
Safety 
Efficacy 
Per-protocol 
PK 
 
 
 
 
 
 
 
XXX 
XXX-YYYY 
DDMONYYYYTHH:MM 
XXXXX 
 
X 
X 
X 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
Note to programmer: Analysis set will by ‘Y’ if subject in set, blank otherwise.  
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
135 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Listing 16.2-3: Demographics – All Subjects 
TREATMENT: treatment-name 
Site 
Subject 
ID 
Subject 
Initials Birth Date 
Age  
(yrs) Sex 
Race 
Ethnicity 
ASA 
Class Region Country 
 
 
 
 
 
 
 
XXX 
XXX-YYYY 
AMZ 
DDMONYYYY 
XX 
XXXXXX XXXXXXXXXXXXXXXXXXX 
XXXXXXXXX 
X 
XXX 
XXXXXXX 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
Note to programmer: If race is ‘other’ then race should be ‘Other: other-specify-text’.  
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
136 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Listing 16.2-4: Height and Weight – All Subjects 
TREATMENT: treatment-name 
 
 
 
 
 
 
Body Mass 
Site 
Subject 
 
Height and Weight 
Collection Date 
Height (cm) 
Weight (kg) 
Index 
(kg/m2) 
 
 
 
 
 
 
XXX 
XXX-YYYY 
 
DDMONYYYYTHH:MM 
XXX.X 
XXX.X 
XX.X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
137 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Listing 16.2-5: Surgery – Randomized Subjects 
TREATMENT: treatment-name 
Site Subject 
Date 
Start 
Time 
Stop 
Time 
Duration 
(hrs) 
Location 
Incision 
Length 
(cm) 
Bupivacaine HCl 
Administration 
Time 
Anesthesia Type 
 
 
 
 
 
 
 
 
 
XXX 
XXX-YYYY DDMONYYYY HH:MM HH:MM 
X.X 
XXXXX 
XX.X 
HH:MM 
XXXXXXXXXXXXXXXXXXXX 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
Note to programmer: If anesthesia type is ‘other’ then text should read ‘other: specify-text’. 
 
 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
138 of 173 
20Jun2017 
 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Listing 16.2-6: Visual Analog Scale (VAS) – Randomized Subjects 
TREATMENT: treatment-name 
 
 
 
Time From Dose 
 
 
  
Site 
Subject 
Date Time 
Scheduled 
(hr) 
Actual 
(hr) 
Deviation 
(hrs) 
VAS 
(cm) 
Pain-Free 
(VAS ≤ 1.5cm) 
  
 
 
 
 
 
 
 
XXX 
XXX-YYYY 
DDMONYYYYTHH:MM 
XX.XX 
XX.XX 
XXXX 
XX.X 
Y 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
VAS: 0=No pain to 10=Worst Pain Imaginable 
 
ND=Not Done  NA=Not Applicable 
* = out of window 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
Note to programmer: Sort by VAS collection date and time. If VAS was taken due to rescue medication dosing, 
put RESCUE in scheduled column and hours from dose in actual column – leave deviation column blank. Do not 
split a subject’s data across pages if it can be avoided.  Pain-free will have Y if VAS ≤ 1.5 otherwise 
blank.  An asterisk (*) will be placed next to the deviation if an assessment is out of window.  See Table 
of Time and Events for windows.


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
139 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Listing 16.2-7.1: Rescue Medication Total Dose (MED mg) and Opioid-free Status - Randomized Subjects 
TREATMENT: treatment-name 
Site 
Subject 
72 hrs 
24 hrs 
48 hrs 
96 hrs 
24-48hrs 
48-72hrs 
72-96 hrs 
Opioid-Free 
 
 
 
 
 
 
 
 
 
 
XXX 
XXX-YYYY 
XXXX.X 
XXXX.X 
XXXX.X 
XXXX.X 
XXXX.X 
XXXX.X 
XXXX.X 
NO 
XXX 
XXX-YYYY 
- 
- 
- 
- 
- 
- 
- 
YES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total dose is dose from end of surgery through timepoint. 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
Note to programmer: If medication is ‘Other’, text should read ‘Other: specify-text’.  Sort by date and 
time within subject. 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
140 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Listing 16.2-7.2: Rescue Medication – Randomized Subjects 
TREATMENT: treatment-name 
Site 
Subject 
Date and Time 
Time to  
Rescue (hr) 
Medication 
Dose 
(units) 
Conversion 
Factor 
Dose 
(MED 
mg) 
Route 
 
 
 
 
 
 
 
 
 
XXX 
XXX-YYYY 
DDMONYYYYTHH:MM 
XXX.X 
XXXXXXXXXXXX XX(XXXX) 
X.XX 
XXX.X 
XXXXXXX  
 
 
DDMONYYYYTHH:MM 
XXX.X 
XXXXXXXXXXXX XX(XXXX) 
X.XX 
XXX.X 
XXXXXXX  
 
 
DDMONYYYYTHH:MM 
XXX.X 
XXXXXXXXXXXX XX(XXXX) 
X.XX 
XXX.X 
XXXXXXX  
 
 
DDMONYYYYTHH:MM 
XXX.X 
XXXXXXXXXXXX XX(XXXX) 
X.XX 
XXX.X 
XXXXXXX  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Time to rescue is time from end of surgery to rescue medication dose. 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
Note to programmer: If medication is ‘Other’, text should read ‘Other: specify-text’.  Sort by date and 
time within subject. 
 
 
 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
141 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Listing 16.2-8: Overall Benefit of Analgesia – Randomized Subjects 
TREATMENT: treatment-name 
 
 
 
Assessment 
Question 
 
Site 
Subject 
Date and Time 
Schedule 
(hrs) 
Actual 
(hrs) 
Deviation 
(hrs) 
1 
2 
3 
4 
5 
6 
7 
Total 
Score 
 
 
 
 
 
 
 
 
XXX 
XXX-YYYY 
DDMONYYYYTHH:MM 
24 
XX.X 
XX.X 
X 
X 
X 
X 
X 
X 
X 
XX 
 
 
DDMONYYYYTHH:MM 
72 
XX.X 
XX.X 
X 
X 
X 
X 
X 
X 
X 
XX 
 
 
DDMONYYYYTHH:MM 
240 (D10) 
XXX.X 
XX.X 
X 
X 
X 
X 
X 
X 
X 
XX 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total score = sum of questions 1 to 6 scores minus question 7 score plus 4. 
1) Please rate your current pain at rest on a scale between 0=minimal pain and 4=maximum imaginable pain 
2) Please grade any distress and bother from vomiting in the past 24 h (0=not at all to 4=very much) 
3) Please grade any distress and bother from itching in the past 24 h (0=not at all to 4=very much)  
4) Please grade any distress and bother from sweating in the past 24 h (0=not at all to 4=very much) 
5) Please grade any distress and bother from freezing in the past 24 h (0=not at all to 4=very much) 
6) Please grade any distress and bother from dizziness in the past 24 h (0=not at all to 4=very much) 
7) How satisfied are you with your pain treatment during in the past 24 h (0=not at all to 4=very much) 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
Note to programmer: Sort by date and time within subject.  
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
142 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Listing 16.2-9: Subject Satisfaction with Post-Surgical Pain Control – Randomized Subjects 
TREATMENT: treatment-name 
Site 
Subject 
Assessment 
Date and Time 
Rating 
Score 
    
 
 
 
 
 
XXX 
XXX-YYYY 
24 hr 
DDMONYYYYTHH:MM 
EXTREMELY DISSATISFIED 
1 
    
 
 
72 hr 
DDMONYYYYTHH:MM 
DISSATISFIED 
2 
    
 
 
Day 10 
DDMONYYYYTHH:MM 
NEITHER SATISFIED NOR DISSATISFIED 
3 
    
 
 
 
 
 
 
    
XXX 
XXX-YYYY 
24 hr 
DDMONYYYYTHH:MM 
SATISFIED 
4 
    
 
 
72 hr 
DDMONYYYYTHH:MM 
EXTREMELY SATISIFIED 
5 
    
 
 
Day 10 
DDMONYYYYTHH:MM 
EXTREMELY SATISIFIED 
5 
    
 
 
 
 
 
 
    
Etc. 
 
 
 
 
 
    
 
 
 
 
 
 
    
 
 
 
 
 
 
    
 
 
 
 
 
 
    
 
 
 
 
 
 
    
Time to rescue is time from end of surgery to rescue medication dose. 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
Note to programmer: Sort by date and time within subject. 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
143 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Listing 16.2-10: Modified Post-Anesthesia Discharge Scoring System (MPADSS)– Randomized Subjects 
TREATMENT: treatment-name 
 
 
 
Assessment 
Question 
 
Site 
Subject 
Date and Time 
Schedule 
(hrs) 
Actual 
(hrs) 
Deviation 
(hrs) 
1 
2 
3 
4 
5 
Total 
Score 
 
 
 
 
 
 
 
 
XXX 
XXX-YYYY 
DDMONYYYYTHH:MM 
24 
XX.X 
XX.X 
X 
X 
X 
X 
X 
XX 
 
 
DDMONYYYYTHH:MM 
72 
XX.X 
XX.X 
X 
X 
X 
X 
X 
XX 
 
 
DDMONYYYYTHH:MM 
240 (D10) 
XXX.X 
XX.X 
X 
X 
X 
X 
X 
XX 
 
 
 
 
 
 
 
 
 
 
 
 
*=out of window 
Total score = sum of scores. 
1) Vital signs: 2 = ≤ 20%; 1 = 20-40%; 0 = >40% of preoperative value. 
2) Ambulation: 2 = steady gait/no dizziness; 1 = with assistance; 0 = none/dizziness 
3) Nausea and Vomiting: 2 = minimal; 1 = moderate; 0 = severe 
4) Pain: 2 = minimal; 1 = moderate; 0 = severe 
5) Surgical bleeding: 2 = minimal; 1 = moderate; 0 = severe  
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
Note to programmer: Sort by date and time within subject.  
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
144 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Listing 16.2-11: Day 29 Phone Call – Randomized Subjects 
TREATMENT: treatment-name 
 
 
 
 
 
 
 
Number of pain-related 
 
Site 
Subject 
Date  
Schedule 
(days) 
Actual 
(days) 
Deviation 
(days) 
Phone 
Calls 
Visits 
Total 
 
 
 
 
 
 
 
 
XXX 
XXX-YYYY 
DDMONYYYY 
29 
XX.X 
XX.X 
XX 
XX 
XXXX 
XXX 
XXX-YYYY 
DDMONYYYY 
29 
XX.X 
XX.X 
XX 
XX 
XXXX 
XXX 
XXX-YYYY 
DDMONYYYY 
29 
XX.X 
XX.X 
XX 
XX 
XXXX 
 
 
 
 
 
 
 
 
 
Total = sum of calls and visits. 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
Note to programmer: Sort by date and time within subject.  
 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
145 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Listing 16.2-12: Hematology – Randomized Subjects 
TREATMENT: treatment-name 
 
 
 
 
 
 
 
Normal Range 
 
 
 
Site Subject 
Visit 
Date and Time 
Analyte (units) 
Low 
High 
Result Change Flag 
 
 
 
 
 
XXX 
XXX-YYYY Screening DDMONYYYYTHH:MM XXXXXXXXXXXXXXXX (units) 
xxx.xx xxx.xx xxx.xx 
- 
H 
 
 
 
 
XXXXXXXXXXXXXXXX (units) 
xxx.xx xxx.xx xxx.xx 
- 
 
 
 
 
 
XXXXXXXXXXXXXXXX (units) 
xxx.xx xxx.xx xxx.xx 
- 
L 
 
 
 
 
XXXXXXXXXXXXXXXX (units) 
xxx.xx xxx.xx xxx.xx 
- 
 
 
 
 
 
… 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Baseline 
DDMONYYYYTHH:MM XXXXXXXXXXXXXXXX (units) 
xxx.xx xxx.xx xxx.xx 
- 
 
 
 
 
 
XXXXXXXXXXXXXXXX (units) 
xxx.xx xxx.xx xxx.xx 
- 
 
 
 
 
 
XXXXXXXXXXXXXXXX (units) 
xxx.xx xxx.xx xxx.xx 
- 
L 
 
 
 
 
XXXXXXXXXXXXXXXX (units) 
xxx.xx xxx.xx xxx.xx 
- 
 
 
 
 
 
… 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Day 10 
DDMONYYYYTHH:MM XXXXXXXXXXXXXXXX (units) 
xxx.xx xxx.xx xxx.xx 
XX.X 
 
 
 
 
 
XXXXXXXXXXXXXXXX (units) 
xxx.xx xxx.xx xxx.xx 
XX.X 
 
 
 
 
 
XXXXXXXXXXXXXXXX (units) 
xxx.xx xxx.xx xxx.xx 
XX.X 
L 
 
 
 
 
XXXXXXXXXXXXXXXX (units) 
xxx.xx xxx.xx xxx.xx 
XX.X 
 
 
 
 
 
 
 
 
 
 
 
Flag: L=below normal range; H=above normal range. 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
Note to programmer: Sort by date and time within subject and analyte alphabetically within date.  Change is 
only calculated for Day 10 visit. Use this mock-up for the following listings: 
 
Listing 16.2-13: Chemistry – Randomized Subjects 
Listing 16.2-14.1: Urinalysis – Numeric Results – Randomized Subjects 
 
 
 
 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
146 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Listing 16.2-14.2: Urinalysis – Character Results – Randomized Subjects 
TREATMENT: treatment-name 
 
Site 
Subject 
Visit 
Date and Time 
Analyte  
Normal Criteria 
Result 
Flag 
 
 
 
 
 
 
 
XXX 
XXX-YYYY 
Screening 
DDMONYYYYTHH:MM 
XXXXXXXXXXXXXXXX  
XXXXXXXX 
XXXXXXXX 
A 
 
 
 
 
XXXXXXXXXXXXXXXX  
XXXXXXXX 
XXXXXXXX 
 
 
 
 
 
XXXXXXXXXXXXXXXX  
XXXXXXXX 
XXXXXXXX 
 
 
 
 
 
XXXXXXXXXXXXXXXX  
XXXXXXXX 
XXXXXXXX 
 
 
 
 
 
… 
 
 
 
 
 
 
 
 
 
 
 
 
 
Baseline 
DDMONYYYYTHH:MM 
XXXXXXXXXXXXXXXX  
XXXXXXXX 
XXXXXXXX 
A 
 
 
 
 
XXXXXXXXXXXXXXXX  
XXXXXXXX 
XXXXXXXX 
 
 
 
 
 
XXXXXXXXXXXXXXXX  
XXXXXXXX 
XXXXXXXX 
 
 
 
 
 
XXXXXXXXXXXXXXXX  
XXXXXXXX 
XXXXXXXX 
 
 
 
 
 
… 
 
 
 
 
 
 
 
 
 
 
 
 
 
Day 10 
DDMONYYYYTHH:MM 
XXXXXXXXXXXXXXXX  
XXXXXXXX 
XXXXXXXX 
 
 
 
 
 
XXXXXXXXXXXXXXXX  
XXXXXXXX 
XXXXXXXX 
 
 
 
 
 
XXXXXXXXXXXXXXXX  
XXXXXXXX 
XXXXXXXX 
 
 
 
 
 
XXXXXXXXXXXXXXXX  
XXXXXXXX 
XXXXXXXX 
 
 
 
 
 
 
 
 
 
Flag: A = abnormal. 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
Note to programmer: Sort by date and time within subject and analyte alphabetically within date. 
 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
147 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Listing 16.2-15: Vital Signs Assessment – All Subjects 
TREATMENT: treatment-name 
 
 
 
 
 
 
 
Heart Rate 
Blood Pressure (mmHg) 
 
 
Assessment 
 (bpm) 
Systolic 
Diastolic 
Site Subject 
Date and Time 
Schedule 
(hrs) 
Actual 
(hrs) 
Dev. 
(hrs) 
Actual Change Actual Change Actual Change 
 
 
 
 
 
 
XXX 
XXX-YYYY 
DDMONYYYYTHH:MM 
Screening 
- 
- 
XX 
- 
XXX 
- 
XX 
- 
 
 
DDMONYYYYTHH:MM 
Baseline 
- 
- 
XX 
- 
XXX 
- 
XX 
- 
 
 
DDMONYYYYTHH:MM 
PACU 
- 
- 
XX 
XX 
XXX 
-X 
XX 
X 
 
 
DDMONYYYYTHH:MM 
6 
XXX.XX 
XXX 
XX 
-XX 
XXX 
X 
XX 
-X 
 
 
DDMONYYYYTHH:MM 
12 
XXX.XX 
XXX 
XX 
XX 
XXX 
X 
XX 
X 
 
 
DDMONYYYYTHH:MM 
24 
XXX.XX 
XXX 
XX 
XX 
XXX 
-X 
XX 
X 
 
 
DDMONYYYYTHH:MM 
36 
XXX.XX 
XXX 
XX 
XX 
XXX 
X 
XX 
X 
 
 
DDMONYYYYTHH:MM 
48 
XXX.XX 
XXX 
XX@ 
-XX 
XXX 
X 
XX 
-X 
 
 
DDMONYYYYTHH:MM 
60 
XXX.XX 
XXX 
XX 
XX 
XXX 
-X 
XX 
X 
 
 
DDMONYYYYTHH:MM 
66 
XXX.XX 
XXX 
XX 
XX 
XXX 
-X 
XX 
-X 
 
 
DDMONYYYYTHH:MM 
72 
XXX.XX 
XXX 
XX 
-XX 
XXX 
X 
XX 
X 
 
 
DDMONYYYYTHH:MM 
78 
XXX.XX 
XXX* 
XX 
XX 
XXX 
-X 
XX 
-X 
 
 
DDMONYYYYTHH:MM 
84 
XXX.XX 
XXX 
XX 
-XX 
XXX 
X 
XX 
X 
 
 
DDMONYYYYTHH:MM 
96 
XXX.XX 
XXX 
XX 
XX 
XXX 
X 
XX 
X 
 
 
DDMONYYYYTHH:MM 
108 
XXX.XX 
XXX 
XX 
-XX 
XXX 
-X 
XX 
X 
 
 
DDMONYYYYTHH:MM 
120 
XXX.XX 
XXX 
XX 
XX 
XXX 
X 
XX 
-X 
 
 
DDMONYYYYTHH:MM 
168 (D7) 
XXX.XX 
XXX 
XX 
XX 
XXX 
X 
XX 
X 
 
 
DDMONYYYYTHH:MM 
240 (D10 
XXX.XX 
XXX 
XX 
-XX 
XXX 
-X 
XX 
X 
 
 
 
 
 
 
 
 
 
 
 
 
*=out of window 
 
@=potentially clinically significant value 
Change is change from baseline (Preop). 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
Note to programmer: Sort by date and time within subject. An asterisk (*) will be placed next to the 
deviation if an assessment is out of window.  See Table of Time and Events for windows. 
  
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
148 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Listing 16.2-16: Electrocardiogram Findings – Investigator Assessment – All Subjects 
TREATMENT: treatment-name 
 
 
Assessment 
 
Site Subject 
Date and Time 
Schedule 
(hrs) 
Actual 
(hrs) 
Deviation 
(hrs) 
Finding 
 
 
 
 
 
 
XXX 
XXX-YYYY 
DDMONYYYYTHH:MM 
Screening 
- 
- 
Normal 
 
 
DDMONYYYYTHH:MM 
Preop 
- 
- 
Abnormal, clinically significant 
 
 
DDMONYYYYTHH:MM 
PACU 
- 
- 
Abnormal, not clinically significant 
 
 
DDMONYYYYTHH:MM 
6 
XXX.XX 
XXX 
Normal 
 
 
DDMONYYYYTHH:MM 
12 
XXX.XX 
XXX 
Normal 
 
 
DDMONYYYYTHH:MM 
24 
XXX.XX 
XXX 
Normal 
 
 
DDMONYYYYTHH:MM 
36 
XXX.XX 
XXX 
Normal 
 
 
DDMONYYYYTHH:MM 
48 
XXX.XX 
XXX 
Normal 
 
 
DDMONYYYYTHH:MM 
60 
XXX.XX 
XXX 
Normal 
 
 
DDMONYYYYTHH:MM 
66 
XXX.XX 
XXX 
Normal 
 
 
DDMONYYYYTHH:MM 
72 
XXX.XX 
XXX 
Normal 
 
 
DDMONYYYYTHH:MM 
78 
XXX.XX 
XXX* 
Normal 
 
 
DDMONYYYYTHH:MM 
84 
XXX.XX 
XXX 
Normal 
 
 
DDMONYYYYTHH:MM 
96 
XXX.XX 
XXX 
Normal 
 
 
DDMONYYYYTHH:MM 
108 
XXX.XX 
XXX 
Normal 
 
 
DDMONYYYYTHH:MM 
120 
XXX.XX 
XXX 
Normal 
 
 
DDMONYYYYTHH:MM 
168 (D7) 
XXX.XX 
XXX 
Normal 
 
 
DDMONYYYYTHH:MM 
240 (D10 
XXX.XX 
XXX 
Normal 
 
 
 
 
 
 
 
*=out of window 
 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
Note to programmer: Sort by date and time within subject. An asterisk (*) will be placed next to the 
deviation if an assessment is out of window.  See Table of Time and Events for windows. 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
149 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Listing 16.2-17: Neurological Assessment – All Subjects 
TREATMENT: treatment-name 
 
 
Assessment 
Question 
Site 
Subject 
Date and Time 
Schedule 
(hrs) 
Actual 
(hrs) 
Deviation 
(hrs) 
1 
2 
3 
4 
5 
6 
 
 
 
 
 
 
XXX 
XXX-YYYY 
DDMONYYYYTHH:MM 
Screening 
- 
- 
X 
X 
X 
X 
X 
X 
 
 
DDMONYYYYTHH:MM 
Preop 
- 
- 
X 
X 
X 
X 
X 
X 
 
 
DDMONYYYYTHH:MM 
PACU 
- 
- 
X 
X 
X 
X 
X 
X 
 
 
DDMONYYYYTHH:MM 
6 
XXX.XX 
XXX 
X 
X 
X 
X 
X 
X 
 
 
DDMONYYYYTHH:MM 
12 
XXX.XX 
XXX 
X 
X 
X 
X 
X 
X 
 
 
DDMONYYYYTHH:MM 
24 
XXX.XX 
XXX 
X 
X 
X 
X 
X 
X 
 
 
DDMONYYYYTHH:MM 
36 
XXX.XX 
XXX 
X 
X 
X 
X 
X 
X 
 
 
DDMONYYYYTHH:MM 
48 
XXX.XX 
XXX 
X 
X 
X 
X 
X 
X 
 
 
DDMONYYYYTHH:MM 
60 
XXX.XX 
XXX 
X 
X 
X 
X 
X 
X 
 
 
DDMONYYYYTHH:MM 
66 
XXX.XX 
XXX 
X 
X 
X 
X 
X 
X 
 
 
DDMONYYYYTHH:MM 
72 
XXX.XX 
XXX 
X 
X 
X 
X 
X 
X 
 
 
DDMONYYYYTHH:MM 
78 
XXX.XX 
XXX* 
X 
X 
X 
X 
X 
X 
 
 
DDMONYYYYTHH:MM 
84 
XXX.XX 
XXX 
X 
X 
X 
X 
X 
X 
 
 
DDMONYYYYTHH:MM 
96 
XXX.XX 
XXX 
X 
X 
X 
X 
X 
X 
 
 
DDMONYYYYTHH:MM 
108 
XXX.XX 
XXX 
X 
X 
X 
X 
X 
X 
 
 
DDMONYYYYTHH:MM 
120 
XXX.XX 
XXX 
X 
X 
X 
X 
X 
X 
 
 
DDMONYYYYTHH:MM 
168 (D7) 
XXX.XX 
XXX 
X 
X 
X 
X 
X 
X 
 
 
DDMONYYYYTHH:MM 
240 (D10 
XXX.XX 
XXX 
X 
X 
X 
X 
X 
X 
 
 
 
 
 
 
 
 
 
 
 
 
*=out of window 
1) Is subject oriented? 
2) Do you have numbness of the lips, the tongue or around the mouth? 
3) Do you have a metallic taste in your mouth? 
4) Are you having problems with your hearing not related to the use of a hearing aid? 
5) Are you having problems with your vision not related to the use of eye glasses? 
6) Are your muscles twitching? 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
Note to programmer: Sort by date and time within subject. An asterisk (*) will be placed next to the 
deviation if an assessment is out of window.  See Table of Time and Events for windows. 
  
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
150 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Listing 16.2-18.1: Sensory Function Assessment – All Subjects 
TREATMENT: treatment-name 
 
 
 
Assessment 
Anterior Cutaneous Nerve 
Saphenous Nerve 
Site Subject 
Date and Time 
Schedule 
(hrs) 
Actual 
(hrs) 
Dev. 
(hrs) 
Cold 
Pin- 
prick 
Light 
Touch 
Cold 
Pin- 
prick 
Light 
Touch 
 
 
 
 
 
 
 
XXX 
XXX-YYYY 
DDMONYYYYTHH:MM Screening 
- 
- 
+ 
+ 
+ 
+ 
+ 
+ 
 
 
DDMONYYYYTHH:MM 
Baseline 
- 
- 
+ 
+ 
+ 
+ 
+ 
+ 
 
 
DDMONYYYYTHH:MM 
PACU 
- 
- 
+ 
+ 
+ 
+ 
+ 
+ 
 
 
DDMONYYYYTHH:MM 
6 
XXX.XX 
XXX 
+ 
+ 
+ 
+ 
+ 
+ 
 
 
DDMONYYYYTHH:MM 
9 
XXX.XX 
XXX 
-L 
+ 
+ 
+ 
+ 
+ 
 
 
DDMONYYYYTHH:MM 
12 
XXX.XX 
XXX 
- 
+ 
+ 
+ 
+ 
+ 
 
 
DDMONYYYYTHH:MM 
18 
XXX.XX 
XXX 
- 
+ 
+ 
+ 
+ 
+ 
 
 
DDMONYYYYTHH:MM 
24 
XXX.XX 
XXX 
- 
+ 
+ 
+ 
+ 
+ 
 
 
DDMONYYYYTHH:MM 
36 
XXX.XX 
XXX 
- 
-L 
+ 
+ 
+ 
+ 
 
 
DDMONYYYYTHH:MM 
48 
XXX.XX 
XXX 
+R 
+R 
+ 
+ 
+ 
+ 
 
 
DDMONYYYYTHH:MM 
60 
XXX.XX 
XXX 
+ 
+ 
+ 
+ 
+ 
+ 
 
 
DDMONYYYYTHH:MM 
72 
XXX.XX 
XXX 
+ 
+ 
+ 
+ 
+ 
+ 
 
 
DDMONYYYYTHH:MM 
84 
XXX.XX 
XXX 
+ 
+ 
+ 
+ 
+ 
+ 
 
 
DDMONYYYYTHH:MM 
96 
XXX.XX 
XXX 
+ 
+ 
+ 
+ 
+ 
+ 
 
 
DDMONYYYYTHH:MM 
108 
XXX.XX 
XXX 
+ 
+ 
+ 
+ 
+ 
+ 
 
 
DDMONYYYYTHH:MM 
120 
XXX.XX 
XXX 
+ 
+ 
+ 
-L 
+ 
+ 
 
 
DDMONYYYYTHH:MM 
Unsched. 
- 
- 
+ 
+ 
+ 
- 
+ 
+ 
 
 
 
 
 
 
 
 
 
 
 
 
*=out of window 
‘-/+‘=Absent/Present; L/R=Loss/Return of sensation 
Unsched=Unscheduled 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
Note to programmer: Sort by date and time within subject. An asterisk (*) will be placed next to the 
deviation if an assessment is out of window.  See Table of Time and Events for windows.  
 
 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
151 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Listing 16.2-18.2: Time to Loss and Return of Sensory Function – Randomized Subjects 
TREATMENT: treatment-name 
 
 
Loss-Return 
Date and Time of 
Time to (hrs) 
Site 
Subject 
Cycle 
Number 
Location 
Dose 
Loss 
Return 
Loss 
[1] 
Return 
[2] 
 
 
 
 
 
 
 
 
XXX 
XXX-
YYYY 
1 
Anterior 
DDMONYYYYTHH:MM 
DDMONYYYYTHH:MM 
DDMONYYYYTHH:MM 
XXX.X 
XXX.X 
 
 
2 
Saphenous 
- 
DDMONYYYYTHH:MM 
DDMONYYYYTHH:MM 
XXX.X 
XXX.X 
 
 
… 
Saphenous 
- 
DDMONYYYYTHH:MM 
DDMONYYYYTHH:MM 
XXX.X 
XXX.X 
 
 
n 
Anterior 
- 
DDMONYYYYTHH:MM 
DDMONYYYYTHH:MM* 
XXX.X 
XXX.X* 
 
 
Total 
 
- 
- 
- 
- 
D.D 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[1] Time to loss is the time from start of study drug administration to loss of sensation 
[2] Time to return is time the time from most recent loss of sensation to return of sensation 
*=Censored return (time of last sensory assessment) 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
 
Note to programmer: Sort by date and time within subject. In total row, D.D is sum of durations from all 
cycles.  Some subjects may have more losses of sensation than returns. 
 
 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
152 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Listing 16.2-19.1.1: Active Motor Function Assessment – All Subjects 
TREATMENT: treatment-name 
 
 
Assessment 
Flexion 
(degrees) 
Extension 
(degrees) 
Site 
Subject 
Date and Time 
Schedule 
(hrs) 
Actual 
(hrs) 
Dev. 
(hrs) 
Act 
Chg 
Act 
Chg 
 
 
 
 
 
 
 
XXX 
XXX-YYYY 
DDMONYYYYTHH:MM 
Screening 
- 
- 
XXX 
- 
XXX 
- 
 
 
DDMONYYYYTHH:MM 
Baseline 
- 
- 
XXX 
- 
XXX 
- 
 
 
DDMONYYYYTHH:MM 
PACU 
- 
- 
XXX 
XXX 
XXX 
XXX 
 
 
DDMONYYYYTHH:MM 
6 
XXX.XX 
XXX 
XXX 
XXX 
XXX 
XXX 
 
 
DDMONYYYYTHH:MM 
9 
XXX.XX 
XXX 
XXX 
XXX 
XXX 
XXX 
 
 
DDMONYYYYTHH:MM 
12 
XXX.XX 
XXX 
XXX 
XXX 
XXX 
XXX 
 
 
DDMONYYYYTHH:MM 
18 
XXX.XX 
XXX 
XXX 
XXX 
XXX 
XXX 
 
 
DDMONYYYYTHH:MM 
24 
XXX.XX 
XXX 
XXX 
XXX 
XXX 
XXX 
 
 
DDMONYYYYTHH:MM 
36 
XXX.XX 
XXX 
XXX 
XXX 
XXX 
XXX 
 
 
DDMONYYYYTHH:MM 
48 
XXX.XX 
XXX 
XXXL 
XXX 
XXX 
XXX 
 
 
DDMONYYYYTHH:MM 
60 
XXX.XX 
XXX 
XXX 
XXX 
XXX 
XXX 
 
 
DDMONYYYYTHH:MM 
72 
XXX.XX 
XXX 
XXX 
XXX 
XXX 
XXX 
 
 
DDMONYYYYTHH:MM 
84 
XXX.XX 
XXX 
XXXR 
XXX 
XXX 
XXX 
 
 
DDMONYYYYTHH:MM 
96 
XXX.XX 
XXX 
XXX 
XXX 
XXX 
XXX 
 
 
DDMONYYYYTHH:MM 
108 
XXX.XX 
XXX 
XXX 
XXX 
XXX 
XXX 
 
 
DDMONYYYYTHH:MM 
120 
XXX.XX 
XXX 
XXX 
XXX 
XXX 
XXX 
 
 
DDMONYYYYTHH:MM 
Unsched. 
- 
- 
XXX 
XXX 
XXX 
XXX 
 
 
 
 
 
 
 
 
 
 
*=out of window 
L=Loss of function/R=Return of function 
Unsched=Unscheduled 
Act = Actual; Chg = Change from Baseline (Preop) 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
Note to programmer: Sort by date and time within subject. An asterisk (*) will be placed next to the 
deviation if an assessment is out of window.  See Table of Time and Events for windows.  


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
153 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Listing 16.2-19.1.2: Passive Motor Function Assessment – All Subjects 
TREATMENT: treatment-name 
 
 
Assessment 
Flexion 
(degrees) 
Extension 
(degrees) 
Site 
Subject 
Date and Time 
Schedule 
(hrs) 
Actual 
(hrs) 
Dev. 
(hrs) 
Act 
Chg 
Act 
Chg 
 
 
 
 
 
 
 
XXX 
XXX-YYYY 
DDMONYYYYTHH:MM 
Screening 
- 
- 
XXX 
- 
XXX 
- 
 
 
DDMONYYYYTHH:MM 
Baseline 
- 
- 
XXX 
- 
XXX 
- 
 
 
DDMONYYYYTHH:MM 
PACU 
- 
- 
XXX 
XXX 
XXX 
XXX 
 
 
DDMONYYYYTHH:MM 
6 
XXX.XX 
XXX 
XXX 
XXX 
XXX 
XXX 
 
 
DDMONYYYYTHH:MM 
9 
XXX.XX 
XXX 
XXX 
XXX 
XXX 
XXX 
 
 
DDMONYYYYTHH:MM 
12 
XXX.XX 
XXX 
XXX 
XXX 
XXX 
XXX 
 
 
DDMONYYYYTHH:MM 
18 
XXX.XX 
XXX 
XXX 
XXX 
XXX 
XXX 
 
 
DDMONYYYYTHH:MM 
24 
XXX.XX 
XXX 
XXX 
XXX 
XXX 
XXX 
 
 
DDMONYYYYTHH:MM 
36 
XXX.XX 
XXX 
XXX 
XXX 
XXX 
XXX 
 
 
DDMONYYYYTHH:MM 
48 
XXX.XX 
XXX 
XXX 
XXX 
XXX 
XXX 
 
 
DDMONYYYYTHH:MM 
60 
XXX.XX 
XXX 
XXX 
XXX 
XXX 
XXX 
 
 
DDMONYYYYTHH:MM 
72 
XXX.XX 
XXX 
XXX 
XXX 
XXX 
XXX 
 
 
DDMONYYYYTHH:MM 
84 
XXX.XX 
XXX 
XXX 
XXX 
XXX 
XXX 
 
 
DDMONYYYYTHH:MM 
96 
XXX.XX 
XXX 
XXX 
XXX 
XXX 
XXX 
 
 
DDMONYYYYTHH:MM 
108 
XXX.XX 
XXX 
XXX 
XXX 
XXX 
XXX 
 
 
DDMONYYYYTHH:MM 
120 
XXX.XX 
XXX 
XXX 
XXX 
XXX 
XXX 
 
 
DDMONYYYYTHH:MM 
Unsched. 
- 
- 
XXX 
XXX 
XXX 
XXX 
 
 
 
 
 
 
 
 
 
 
*=out of window 
L=Loss of function/R=Return of function 
Unsched=Unscheduled 
Act = Actual; Chg = Change from Baseline (Preop) 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
Note to programmer: Sort by date and time within subject. An asterisk (*) will be placed next to the 
deviation if an assessment is out of window.  See Table of Time and Events for windows. 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
154 of 173 
20Jun2017 
 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Listing 16.2-19.2: Time to Loss and Return of Motor Function – Randomized Subjects 
TREATMENT: treatment-name 
 
 
Loss-Return 
Date and Time of 
Time to (hrs) 
Site 
Subject 
Cycle Number 
Active 
Assessment 
Dose 
Loss 
Return 
Loss 
[1] 
Return 
[2] 
 
 
 
 
 
 
 
 
XXX 
XXX-YYYY 
1 
Flexion 
DDMONYYYYTHH:MM DDMONYYYYTHH:MM 
DDMONYYYYTHH:MM 
XXX.X 
XXX.X 
 
 
2 
Extension 
- 
DDMONYYYYTHH:MM 
DDMONYYYYTHH:MM 
XXX.X 
XXX.X 
 
 
… 
Flexion 
- 
DDMONYYYYTHH:MM 
DDMONYYYYTHH:MM 
XXX.X 
XXX.X 
 
 
n 
Flexion 
- 
DDMONYYYYTHH:MM DDMONYYYYTHH:MM* XXX.X XXX.X* 
 
 
Total 
 
- 
- 
- 
- 
D.D 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[1] Time to loss is the time from start of study drug administration to loss of motor function 
[2] Time to return is time the time from most recent loss of to return of motor function 
Total Return is the time from first loss to last return of motor function. 
*=Censored return (time of last sensory assessment) 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
 
Note to programmer: Sort by date and time within subject. In total row, D.D is the time from first loss of 
motor function to last return of motor function.  Some subjects may have more losses of motor function than 
returns.  
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
155 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Listing 16.2-20: Timed Walk Test – Randomized Subjects 
TREATMENT: treatment-name 
Site 
Subject 
 
Timepoint 
Date and Time 
Done? Reason not done 
Distance 
(m) 
Walking 
Aid? 
Physical 
Assistance 
 
 
 
 
 
 
 
 
XXX 
XXX-YYYY Day 1-PM 
DDMONYYYYTHH:MM 
Y 
 
XX 
XXX 
X 
 
 
Day 2-AM 
DDMONYYYYTHH:MM 
N 
XXXXXXXXXXXXXXX 
 
 
 
 
 
Day 2-PM 
DDMONYYYYTHH:MM 
Y 
 
XX 
XX 
X 
 
 
Day 3-AM 
DDMONYYYYTHH:MM 
Y 
 
XX 
XX 
X 
 
 
Day 3-PM 
DDMONYYYYTHH:MM 
Y 
 
XX 
XX 
X 
 
 
Day 4-AM 
DDMONYYYYTHH:MM 
Y 
 
XX 
XX 
X 
 
 
Day 4-PM 
DDMONYYYYTHH:MM 
Y 
 
XX 
XX 
X 
 
 
Day 15 
DDMONYYYYTHH:MM 
Y 
 
XX 
XX 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Physical Assistance: 
1=Total Assistance 
2=Maximal Assistance 
3=Moderate Assistance 
4=Minimal Assistance 
5=Supervision 
6=Modified Independence 
7=Complete Independence  
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
156 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-331 
Listing 16.2-21: Timed Up-and-go Test – Randomized Subjects 
 
TREATMENT: treatment-name 
Site Subject 
 
Timepoint 
Date and Time 
Change 
from 
Baseline 
Done? 
Reason not 
done 
Duration 
of Test 
(seconds) 
Aid 
Used? 
Physical 
Assistance 
 
 
 
 
 
 
 
 
 
 
XXX 
XXX-YYYY 
Baseline 
DDMONYYYYTHH:MM 
N/A 
Y 
 
 
 
 
 
 
Day 1-PM 
DDMONYYYYTHH:MM 
XX.X 
Y 
 
 
 
 
 
 
Day 2-AM 
DDMONYYYYTHH:MM 
XX.X 
N 
XXXXXXXXXX 
XXX 
XXX 
 
 
 
Day 2-PM 
DDMONYYYYTHH:MM 
XX.X 
Y 
 
 
 
 
 
 
Day 3-AM 
DDMONYYYYTHH:MM 
XX.X 
Y 
 
 
 
 
 
 
Day 3-PM 
DDMONYYYYTHH:MM 
XX.X 
Y 
 
 
 
 
 
 
Day 4-AM 
DDMONYYYYTHH:MM 
XX.X 
Y 
 
 
 
 
 
 
Day 4-PM 
DDMONYYYYTHH:MM 
XX.X 
Y 
 
 
 
 
 
 
Day 15 
DDMONYYYYTHH:MM 
XX.X 
Y 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Physical Assistance: 
1=Total Assistance 
2=Maximal Assistance 
3=Moderate Assistance 
4=Minimal Assistance 
5=Supervision 
6=Modified Independence 
7=Complete Independence  
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
Note to Programmer: All of the Not Done visits should be included in this listing.  In addition, in ADQS, variable CHG, (Change from Baseline), 
is present, include this in the listing. 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
157 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-331 
Listing 16.2-22: Stair Climbing Test – Randomized Subjects 
TREATMENT: treatment-name 
Site Subject 
 
Timepoint 
Date and Time 
Done? Reason not done 
Successfully 
Completed 
 
 
 
 
 
 
 
 
 
XXX 
XXX-
YYYY 
Day 1-PM 
DDMONYYYYTHH:MM 
Y 
 
 
 
 
 
 
Day 2-AM 
DDMONYYYYTHH:MM 
N 
XXXXXXXXXXXXXXX 
XXX 
 
 
 
 
Day 2-PM 
DDMONYYYYTHH:MM 
Y 
 
 
 
 
 
 
Day 3-AM 
DDMONYYYYTHH:MM 
Y 
 
 
 
 
 
 
Day 3-PM 
DDMONYYYYTHH:MM 
Y 
 
 
 
 
 
 
Day 4-AM 
DDMONYYYYTHH:MM 
Y 
 
 
 
 
 
 
Day 4-PM 
DDMONYYYYTHH:MM 
Y 
 
 
 
 
 
 
Day 15 
DDMONYYYYTHH:MM 
Y 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Physical Assistance: 
1=Total Assistance 
2=Maximal Assistance 
3=Moderate Assistance 
4=Minimal Assistance 
5=Supervision 
6=Modified Independence 
7=Complete Independence  
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
158 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Listing 16.2-23.1: All Adverse Events – All Subjects 
Treatment: treatment-name 
Site Subject 
TEAE Data Type 
Data 
XXX 
XXX-YYYY 
N 
Start 
DDMONYYYYTHH:MM 
 
 
 
Stop 
DDMONYYYYTHH:MM 
 
 
 
AE Number 
X 
 
 
 
System Organ Class 
XXXXXXXXXXXXXXXXXX 
 
 
 
  Preferred 
  XXXXXXXXXXXXXXXXXXXX 
 
 
 
    Verbatim 
    XXXXXXXXXXXXXXXXXXXXXX 
 
 
 
Severity 
XXXXXXXX 
 
 
 
Relationship to Study Drug XXXXXXXX 
 
 
 
Action Taken 
XXXXXXXXXXXXXXXXXXXXX 
 
 
 
Outcome 
XXXXXXXXXXXXXX 
 
 
 
Serious 
XXX 
 
 
 
  Serious Cause(s) 
  XXXXXXXXXXXXX 
 
 
 
 
  XXXXXXXXXXXXXXXXXXXXXX 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TEAE: Treatment-emergent AE (Y=TEAE/N=Not TEAE) 
Source: list SAS datasets used to create listing 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
Note to programmer: If AE is ongoing, put ONGOING in stop row.  Do not split an AE across pages.  Insert a 
page break between subjects.  Use this mock-up for the following listings: 
 
Listing 16.2-23.2.1: Treatment-emergent Adverse Events – Randomized Subjects  
Listing 16.2-23.2.2: Treatment-emergent Study Drug Related Adverse Events – Randomized Subjects  
Listing 16.2-23.3: All Serious Adverse Events – All Subjects  
Listing 16.2-23.4.1: Treatment-emergent Serious Adverse Events – Randomized Subjects  
Listing 16.2-23.4.2: Treatment-emergent Study Drug Related Serious Adverse Events – Randomized Subjects  
Listing 16.2-23.5.1: Treatment-emergent Adverse Events of Special Interest – Randomized Subjects  
Listing 16.2-23.5.2: Treatment-emergent Study Drug Related Adverse Events of Special Interest – Randomized 
Subjects 
 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
159 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Listing 16.2-24.1: All Prior and Concomitant Medications – All Subjects 
Treatment: treatment-name 
Site Subject 
Category 
Data Type 
Data 
XXX 
XXX-YYYY 
 
Start 
DDMONYYYYTHH:MM 
 
 
 
Stop 
DDMONYYYYTHH:MM 
 
 
 
Medication Number 
X 
 
 
 
ATC Level 1 
XXXXXXXXXXXXXXXXXX 
 
 
 
  ATC Level 2 
  XXXXXXXXXXXXXXXXXXXX 
 
 
 
    ATC Level 3 
    XXXXXXXXXXXXXXXXXXXXXX 
 
 
 
      ATC Level 4 
      XXXXXXXXXXXXXXXXXXXX 
 
 
 
  Preferred Name 
XXXXXXXXXXXXXXXXXXXXX 
 
 
 
    Verbatim 
  XXXXXXXXXXXXXXXXXXXX 
 
 
 
Route 
XXXXXXXX 
 
 
 
Frequency 
XXXXXXXX 
 
 
 
Given for AE or MH? 
XXXXXXXXXXXXXXXXXXXXX AE # XX (or MH # XX) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ATC=Anatomical therapeutic class 
Source: list SAS datasets used to create listing 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
Note to programmer: If medication is ongoing, put ONGOING in stop row.  Do not split a medication across 
pages.  Insert a page break between subjects.  Values for category column are: CONCOMITANT; 
SURGICAL/ANESTHESIA; NON-MEDICATION; PRIOR.  Use this mock-up for the following listings: 
 
Listing 16.2-24.2: Prior Medications – Randomized Subjects  
Listing 16.2-24.3: Concomitant Medications – Randomized Subjects 
 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
160 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Listing 16.2-25: Medical History – All Subjects 
Treatment: treatment-name 
Site Subject 
Data Type 
Data 
XXX 
XXX-YYYY Start 
DDMONYYYY 
 
 
Stop 
DDMONYYYY 
 
 
System Organ Class 
XXXXXXXXXXXXXXXXXX 
 
 
  Preferred 
  XXXXXXXXXXXXXXXXXXXX 
 
 
    History Verbatim 
    XXXXXXXXXXXXXXXXXXXXXX 
 
 
 
 
 
 
Start 
DDMONYYYY 
 
 
Stop 
DDMONYYYY 
 
 
System Organ Class 
XXXXXXXXXXXXXXXXXX 
 
 
  Preferred 
  XXXXXXXXXXXXXXXXXXXX 
 
 
    History Verbatim 
    XXXXXXXXXXXXXXXXXXXXXX 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: list SAS datasets used to create listing 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
161 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Listing 16.2-26: Intraoperative Opioids – Randomized Subjects 
TREATMENT: treatment-name 
Site 
Subject 
Administered 
Name 
Dose 
Unit 
Route 
   
 
 
 
 
 
 
 
 
XXX 
XXX-YYYY 
YES 
OPIOID-NAME 
XXX.XX 
(UNITS) 
XXXX 
   
XXX 
XXX-YYYY 
NO 
 
 
 
 
   
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
   
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
162 of 173 
20Jun2017 
 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Listing 16.2-27: Study Drug Administration – Randomized Subjects 
TREATMENT: treatment-name 
Site 
Subject 
Date 
Start 
Time 
Stop 
Time 
Total Volume 
(mL) 
    
 
 
 
 
 
 
XXX 
XXX-YYYY 
DDMONYYYY 
HH:MM 
HH:MM 
XXX 
    
 
 
 
 
 
 
    
 
 
 
 
 
 
    
 
 
 
 
 
 
    
 
 
 
 
 
 
    
 
 
 
 
 
 
    
 
 
 
 
 
 
    
 
 
 
 
 
 
    
 
 
 
 
 
 
    
 
 
 
 
 
 
    
 
 
 
 
 
 
    
 
 
 
 
 
 
    
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
163 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Listing 16.2-28: Urine Drug Screen, Alcohol Blood Test and Pregnancy Test – All Subjects 
TREATMENT: treatment-name 
Site 
Subject 
Visit 
Urine Drug 
Blood 
Alcohol 
Pregnancy 
 
 
 
 
 
 
 
 
XXX 
XXX-YYYY 
Screening 
XXXXXXXX 
XXXXXXXX 
XXXXXXXX 
 
 
 
Day 0 (Preop) 
XXXXXXXX 
XXXXXXXX 
XXXXXXXX 
 
 
 
 
 
 
 
 
XXX 
XXX-YYYY 
Screening 
XXXXXXXX 
XXXXXXXX 
XXXXXXXX 
 
 
 
Day 0 (Preop) 
XXXXXXXX 
XXXXXXXX 
XXXXXXXX 
 
 
 
 
 
 
 
 
XXX 
XXX-YYYY 
Screening 
XXXXXXXX 
XXXXXXXX 
XXXXXXXX 
 
 
 
Day 0 (Preop) 
XXXXXXXX 
XXXXXXXX 
XXXXXXXX 
 
 
 
 
 
 
 
 
XXX 
XXX-YYYY 
Screening 
XXXXXXXX 
XXXXXXXX 
XXXXXXXX 
 
 
 
Day 0 (Preop) 
XXXXXXXX 
XXXXXXXX 
XXXXXXXX 
 
 
 
 
 
 
 
 
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
 
 
 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
164 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-326 
Listing 16.2-29: Admission and Discharge – Randomized Subjects 
TREATMENT: treatment-name 
 
 
Date and Time 
 
Site 
Subject 
Admission 
Discharge 
 
 
 
 
 
 
XXX 
XXX-YYYY 
DDMONYYYYTHH:MM 
DDMONYYYYTHH:MM 
 
XXX 
XXX-YYYY 
DDMONYYYYTHH:MM 
DDMONYYYYTHH:MM 
 
XXX 
XXX-YYYY 
DDMONYYYYTHH:MM 
DDMONYYYYTHH:MM 
 
 
 
 
 
 
*=out of window 
Total score = sum of scores. 
1) Vital signs: 2 = ≤ 20%; 1 = 20-40%; 0 = >40% of preoperative value. 
2) Ambulation: 2 = steady gait/no dizziness; 1 = with assistance; 0 = none/dizziness 
3) Nausea and Vomiting: 2 = minimal; 1 = moderate; 0 = severe 
4) Pain: 2 = minimal; 1 = moderate; 0 = severe 
5) Surgical bleeding: 2 = minimal; 1 = moderate; 0 = severe  
Source: list SAS datasets used to create table 
 
DDMONYYYYTHH:MM 
SAS X.Y 
 
program_name 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
165 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-327 
Listing 16.2-30: Unique Adverse Events Terms and Associated Coded Terms 
MedDRA Terms 
SOC 
  Preferred Term 
Verbatim(s) 
SOC1 
XXXXXXXXXXXXXXXXXXXXXXXXXXX 
  PT1.1 
XXXXXXXXXXXXXXXXXXXXXXXXXXX 
 
XXXXXXXXXXXXXXXXXXXXXXXXXXX 
 
XXXXXXXXXXXXXXXXXXXXXXXXXXX 
 
 
  PT1.2 
XXXXXXXXXXXXXXXXXXXXXXXXXXX 
   
XXXXXXXXXXXXXXXXXXXXXXXXXXX 
 
 
SOC2 
 
  PT2.1 
XXXXXXXXXXXXXXXXXXXXXXXXXXX 
 
XXXXXXXXXXXXXXXXXXXXXXXXXXX 
 
 
Coded using MedDRA 
Source: list SAS datasets used to create listing 
 
DDMONYYYYTHH:MM  
SAS X.Y 
 
program_name 
 
Note to programmer: Sort by SOC and preferred term in alphabetical order 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
166 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-327 
Listing 16.2-31: Unique Medication Terms and Associated Coded Terms 
Who Drug Dictionary Terms 
ACT1 
  ACT2 
    ACT3 
      ACT4 
        Preferred name 
Verbatim(s) 
ATC1 
 
  ATC1.2 
 
        PN1.2.1 
XXXXXXXXXXXXXXXXXXXXXXXXXX 
 
XXXXXXXXXXXXXXXXXXXXXXXXXX 
 
 
        PN1.2.2 
XXXXXXXXXXXXXXXXXXXXXXXXXX 
 
 
ATC2 
 
  ATC2.2 
 
    ATC2.3 
 
      ATC2.4 
 
        PN2.2.3.4.1 
XXXXXXXXXXXXXXXXXXXXXXXXXX 
 
XXXXXXXXXXXXXXXXXXXXXXXXXX 
Coded using Who Drug Dictionary 
Source: list SAS datasets used to create listing 
 
DDMONYYYYTHH:MM  
SAS X.Y 
 
program_name 
 
Note to programmer: Sort by ATC1, ATC2, ATC3, ATC4 and preferred name in alphabetical order 
 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
167 of 173 
20Jun2017 
 
Pacira Pharmaceuticals 
(Page X of Y) 
Protocol: 402-C-327 
Listing 16.2-32: Protocol Deviations 
TREATMENT: treatment-name 
  Surgery: surgery-type 
    Nerve Block: nerve-block type 
Site Subject Category Important 
Date 
Description 
 
 
 
 
 
 
XXX XXX-YYYY 
XXXXXX 
XXX 
DDMONYYYYTHH:MM XXXXXXXXXXXXXXXXXX 
 
 
 
 
DDMONYYYYTHH:MM XXXXXXXXXXXXXXXXXX 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Categories: Important, might significantly impact; not-important, none to minimal impact on study outcomes. 
Important:   
Source: list SAS datasets used to create listing 
 
DDMONYYYYTHH:MM  
SAS X.Y 
 
program_name 
 
Note to programmer: Subjects may have multiple deviations.  Sort deviations by treatment, surgery type, 
nerve block type, site, subject, then category ‘Important’ followed by ‘Not-Important’ and finally 
important (‘YES’ then ‘NO’).  Date may or may not include time. 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
168 of 173 
20Jun2017 
 
16. 
TABLE OF CONTENTS FOR FIGURE MOCK-UPS 
FIGURE 1.1: PLOT OF MEAN PAIN INTENSITY SCORE (VAS) VS TIME THROUGH 72 HOURS – 
EFFICACY ANALYSIS SET 
173 
FIGURE 1.2: PLOT OF MEAN PAIN INTENSITY SCORE (VAS) VS TIME THROUGH 72 HOURS – 
PER-PROTOCOL ANALYSIS SET 
173 
FIGURE 2.1: PLOT OF MEAN PAIN INTENSITY SCORE (VAS) VS TIME THROUGH 96 HOURS – 
EFFICACY ANALYSIS SET 
173 
FIGURE 2.2: PLOT OF MEAN PAIN INTENSITY SCORE (VAS) VS TIME THROUGH 96 HOURS – 
PER-PROTOCOL ANALYSIS SET 
173 
FIGURE 3: PLOT OF INDIVIDUAL SUBJECT PAIN INTENSITY SCORE (VAS) VS TIME 
THROUGH 72 HOURS – EFFICACY ANALYSIS SET 
173 
FIGURE 4: PLOT OF INDIVIDUAL SUBJECT PAIN INTENSITY SCORE (VAS) VS TIME 
THROUGH 96 HOURS – EFFICACY ANALYSIS SET 
173 
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
169 of 173 
20Jun2017 
 
Figure Mock-up 1 
  


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
170 of 173 
20Jun2017 
 
Figure Mock-up 2
 


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
171 of 173 
20Jun2017 
 
Figure Mock-up 3
 
Pain Intensity Score (VAS)
0
1
2
3
4
5
6
7
8
9
10
Time (hours)
-5
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
Subject=XXX-XXX-XXXX Treatment=EXPAREL XXX mg
Gray bars indicate rescue medication windows
VAS - Actual
VAS - Imputed


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
172 of 173 
20Jun2017 
 
Figure Mock-up 4 
Pain Intensity Score (VAS)
0
1
2
3
4
5
6
7
8
9
10
Time (hours)
-5
5
15
25
35
45
55
65
75
85
95
105
115
125
Subject=XXX-XXX-XXXX Treatment=EXPAREL XXX mg
Gray bars indicate rescue medication windows
VAS - Actual
VAS - Imputed


Pacira Pharmaceuticals, Inc. 
402-C-326 (TKA FNB) 
EXPAREL 
Statistical Analysis Plan 
 
CONFIDENTIAL 
173 of 173 
20Jun2017 
 
Note to programmers:  The colors and symbols used in the figure mock-ups are not correct per the SAP 
description; all figures created should use the SAP defined colors and symbols. In figure mock-ups 3 and 4: 
the gray bars highlight the rescue medication windows for that subject; the time axes are set to ensure the 
entire period is captured and doesn’t end at the limits of the figure.  Use the indicated figure mock-up 
for the following figures. 
  
Use Figure mock-up 1 for the following the x-axis should track through 76 hours: 
Figure 1.1: Plot of Mean Pain Intensity Score (VAS) vs Time through 72 hours – Efficacy Analysis Set  
Figure 1.2: Plot of Mean Pain Intensity Score (VAS) vs Time through 72 hours – Per-protocol Analysis Set  
 
Use Figure mock-up 2 for the following (the x-axis should track through 100 hours): 
Figure 2.1: Plot of Mean Pain Intensity Score (VAS) vs Time through 96 hours – Efficacy Analysis Set  
Figure 2.2: Plot of Mean Pain Intensity Score (VAS) vs Time through 96 hours – Per-protocol Analysis Set 
 
Use Figure mock-up 3 for the following (use actual hours since the end of surgery and not scheduled hours, 
include all VAS scores collected, the x-axis should track through 76 hours): 
Figure 3: Plot of Individual Subject Pain Intensity Score (VAS) vs Time through 72 hours – Efficacy 
Analysis Set  
 
Use Figure mock-up 4 for the following (use actual hours since the end of surgery and not scheduled hours, 
include all VAS scores collected, the x-axis should track through 100 hours): 
Figure 4: Plot of Individual Subject Pain Intensity Score (VAS) vs Time through 96 hours – Efficacy 
Analysis Set